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Whooping cough, or pertussis, is a highly contagious respiratory disease that is caused by 
the gram-negative bacterium Bordetella pertussis. B. pertussis was discovered and isolated 
by Bordet and Gengou in 1906 [1]. It is a strictly human pathogen and all age groups can be 
infected. However, infants are the main risk group. Diagnosis of pertussis is often difficult 
in the early stage with only a mild cough, and fever is uncommon. Later, the severity of the 
disease increases with pneumonia, vomiting and increased coughing that in infants can 
lead to death [2]. The most profound characteristic of pertussis is the “whooping” sound 
during coughing. In patients with severe disease, the cough can last for a long period, which 
made the Chinese call pertussis the “100 day cough”. Diagnostics of pertussis is performed 
indirectly with serology or direct bacterial detection in sputum by culturing or PCR [3]. For 
serological diagnosis IgG antibodies against pertussis toxin (Ptx) are used [4].
B. pertussis contains many virulence factors (proteins associated with pathology) that are 
regulated by the Bordetella virulence regulon (Bvg) [5]. These virulence factors have different 
locations and functions in the bacterium (Figure 1A). During colonization, B. pertussis excretes 
Ptx and other toxins, such as adenylate cyclase toxin (Act), dermonecrotic toxin (Dnt), and 
tracheal cytotoxin (Tct). Moreover, the bacterial membrane contains virulence factors, such 
as BrkA, filamentous hemagglutinin (FHA), pertactin (Prn), fimbriae 2 and 3 (Fim 2 and 3) and 
Vag8. These virulence factors facilitate adhesion of the bacteria in the respiratory tract. Some 
virulence factors arm B. pertussis with immune evasive strategies that increase the chances 
of bacterial survival in the respiratory tract [6]. The virulence factor expression depends on 
the state of the bacteria, i.e. colonizing or resting, but also varies among B. pertussis isolates 
probably because of host defense induced selection [7].
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Pertussis vaccines and vaccination
Pertussis is a vaccine-preventable disease. However, B. pertussis is endemic around the world 
and epidemic cycles occur every 2 to 5 years [8] (Figure 2A-B). Vaccination against B. pertussis 
in the 1940s resulted in an impressive decrease of pertussis cases worldwide (Figure 2A). 
Global pertussis vaccine coverage among infants that received three doses was estimated at 
86% (115 million infants) in 2014. However, low vaccination coverage is observed in some low-
income countries (Figure 2C). Vaccination has resulted in the prevention of almost 700,000 
























Figure 1 - B. pertussis and different pertussis vaccines. Schematic illustration of (A) B. pertussis, (B) acellular 




Antibodies are essential for protection against pertussis. Antibodies have therefore been 
marked as potential correlates of protection against B. pertussis [10, 11]. Anti-Ptx IgG antibody 
serology is commonly used for epidemiological screening of protection [12]. However, the 
contribution of antigen-specific T-cells is not to be underestimated [13, 14]. Currently two 
types pertussis vaccine are marketed, the whole-cell and acellular pertussis vaccine, and at 
least two vaccine concept are under development, a live attenuated vaccine and a vaccine 
based on outer membrane vesicles, that are discussed below.
Whole cell pertussis vaccines (wPVs)
The first pertussis vaccines on the market were the cellular vaccines, also known as whole-cell 
pertussis vaccines (wPVs). Currently, still 75% of the world population receives these vaccines. 
These vaccines contain dead B. pertussis bacteria that are physically (heat) or chemically 
(formaldehyde) inactivated. The wPVs contain lipopolysaccharide (LPS), acting as an intrinsic 
adjuvant, as well as other pathogen-associated molecular patterns (PAMPs). Some wPVs 
contain colloidal aluminium salts (alum) as an added adjuvant. As wPVs contain the whole 
bacteria, a diverse range of virulence factors, particularly membrane bound proteins, such as 
FHA, Prn, Fim2, and Fim3, are present in the vaccine. However, the composition of wPVs may 
< 50% (6 countries or 3%)
50-79% (23 countries or 12%)
80-89% (34 countries or 18%)
















































































































































B Pertussis reports The Netherlands
Figure 2 - Pertussis incidence and DTP3 vaccination coverage. (A) The number of pertussis cases registered 
each year in the USA in the period 1922-2014. Figure adapted from www.cdc.gov, accessed July 2016. (B) 
The absolute number of pertussis reports in The Netherlands for each month in the period January 1989 – 
September 2015. Source: Pertussis reports in Osiris, adapted by RVP-EPI-RIVM. (C) The global immunization 
coverage among infants that received three vaccinations with DTP3 according to the WHO in 2012. The colors 
illustrate the coverage per nation. Illustration adapted from www.who.int, accessed July 2016.
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vary depending on the type of strain, culture conditions, and type of inactivation. This variation 
in production leads to vaccines with a varying efficacy [15]. The use of wPV is associated with 
mild adverse effects, such as local swelling and fever after vaccination [15, 16]. The adverse 
effects tend to increase with the number of vaccinations and the age. Therefore, wPV is not 
recommended for vaccination of adolescents and adults. The suspected correlation between 
wPV and serious acute neurological illness in children [17, 18] has led to a call for safer pertussis 
vaccines.
Acellular pertussis vaccines (aPVs)
The need for safer and better-defined pertussis vaccines stimulated the development of 
the acellular pertussis vaccines (aPVs). These were first developed and introduced in Japan 
[19] and slowly afterwards in other developed countries [20, 21]. The marketed aPVs contain 
purified proteins from B. pertussis that are adsorbed onto colloidal aluminium salts and vary in 
antigen composition (Figure 1B). They contain one to five antigens, i.e. FHA, Fim 2, Fim 3, Prn 
and/or Ptx. In the Netherlands, a trivalent aPV (FHA, Prn, Ptx) is used, whereas in Denmark a 
monovalent Ptx vaccine is used. The high cost of aPVs limits their widespread use in developing 
countries.
Live-attenuated pertussis vaccine (BPZE1)
One of the vaccines under development is a live attenuated B. pertussis strain, BPZE1 [22]. 
This strain is genetically attenuated by altering or removing three virulence factors involved 
in pertussis pathogenesis. Dermonecrotic toxin (Dnt) was completely removed, whereas 
the ability to secrete pertussis toxin (Ptx), and tracheal cytotoxin (Tct) was reduced. Similar 
as wPV, BPZE1 also consists of a broad range of antigens and PAMPs. In contrast to other 
pertussis vaccines, BPZE1 is administered intranasally and is still able to replicate in the upper 
and lower respiratory tract. A single nasal dose provides protection in mice [22] with long-term 
immunity [23, 24]. BPZE1 is in early clinical development. A phase 1 study revealed no safety 
issues in healthy adults [25]. Moreover, increased B-cell responses were detected, indicating 
that BPZE1 is immunogenic [26].
Outer membrane vesicle pertussis vaccines (omvPVs) 
Many gram-negative bacteria produce outer membrane vesicles (OMVs) [27, 28]. Naturally, 
they serve as transport system between bacteria and function as decoy for the host immune 
system [27, 28]. Also B. pertussis releases OMVs [29]. These OMVs are a potential vaccine 
candidate. Outer membrane pertussis vaccine (omvPV) confers protection in mice after 
parenteral immunization [30] with long-lasting immunity [31]. The omvPV mainly consists 
of outer membrane proteins, lipids, phospholipids and LPS (Figure 1C). In addition, proteins 
may be present that are encapsulated during the OMV formation. The composition of omvPV 




during cultivation. Constructing high-blebbing mutants can increase the yield of OMVs. Often 
membrane-destabilizing agents, such as EDTA and non-ionic detergents, are used to obtain 
high yields.
Vaccination against B. pertussis
Despite the high vaccine coverage, pertussis still ranks in the top 10 of vaccine-preventable 
diseases according to the WHO. Many countries experience resurgence of B. pertussis [33, 
34]. In addition to infants, older age groups are increasingly affected [35, 36]. Adaptation of 
circulating strains is one of the causes of this resurgence [37]. This selection may be vaccine 
induced. The current increased circulation of Prn-deficient strains is an example of vaccine-
induced strain adaptation that leads to antigen-mismatch [38, 39]. Although current licensed 
vaccines induce high antibody levels, the potential correlate of protection for pertussis 
[10, 11], the duration of protection is with 4-12 years relatively short [40, 41]. Increasing the 
number of immunizations with aPV does not solve this [42]. Studies in baboons [43] have 
demonstrated that the aPVs prevent the disease, but in contrast to wPVs, they are incapable 
to prevent transmission of B. pertussis [44]. Healthy aPV-vaccinated people can carry and 
transmit pertussis to very young, still unprotected children. The most recent strategy to 
prevent pertussis in this vulnerable group, is maternal vaccination with aPV [45]. Maternal 
immunization allows protection of the newborn in the period between birth and primary 
vaccination by placental transfer of antibodies from the mother to the child. This strategy 
significantly reduces the risk of death among the main target group, infants [46]. However, 
the problem of strain adaptation and protection of other target groups require additional 
measures. The switch from aPV back to wPV is highly unlikely in high-income countries because 
of the safety issues with wPV. However, wPVs remain the first choice for many low-income 
countries because of their high efficacy and low cost.
The current state of knowledge with respect to immunity to B. pertussis is that the induction 
of specific IgG antibodies and T-helper (Th) 2 cells is sufficient for short-term protection. 
However, the presence of Th1 and Th17 cells may be beneficial. Additionally, mucosal immunity 
may contribute to better protection  based on the results after local administration of BPZE1 
or a natural infection. Interestingly, infection-induced immunity in humans is estimated 
to last 4-20 years [40] or even up to 50 years [41] which is longer than by vaccination with 
marketed pertussis vaccines [40, 41]. This indicates the possibility to improve vaccine-induced 
pertussis immunity. An unbiased and comprehensive investigation in infection-induced and 
vaccine-induced immune responses could provide insight in molecular signatures that enables 
vaccinologists to improve pertussis vaccines. This thesis describes the findings of a systems 
vaccinology approach in pertussis research and the molecular signatures that were discovered 




Vaccine development has reached a point where the ‘easy’ vaccines have been developed. 
Still no effective vaccines are available for some diseases, i.e. AIDS and tuberculosis, while 
some pathogens require improved vaccines, i.e. B. pertussis. Moreover, the development of 
vaccines against new emerging diseases requires immediate action, yet the lack of in-depth 
knowledge on the pathogen and immunity often leads to hampered development [47]. This 
situation calls for innovative strategies in vaccine development. Systems vaccinology is a new 
approach that provides comprehensive insight in immune responses induced by the pathogen 
or vaccine candidates [48, 49]. Systems vaccinology is a part of systems biology. According 
to Alan Adrem the definition of systems biology is a “comprehensive quantitative analysis 
of the manner in which all the components of a biological system interact functionally over 
time that is executed by an interdisciplinary team of investigators” [50]. In analogy, systems 
vaccinology could be defined as a “comprehensive quantitative analysis of the manner in 
which all the components of the immune system interact functionally over time during 
progression of the response to infection or vaccination”. Systems vaccinology can potentially 
fill the gap for vaccine development by contributing in-depth knowledge on vaccine-induced 
responses, which will be described hereafter.
Systems vaccinology aims at in-depth understanding how vaccines work, or why some 
vaccines do not work. A biological system can vary from the human body to a single cell. 
An important first task for a systems vaccinologist is setting boundaries on the system. 
In this case, this thesis was mainly limited to the host immune system. However, vaccine 
composition was not neglected and characterized for better understanding of the interaction 
of vaccine components with the host immune systems. The immune system consists of many 
different layers, such as organs, tissue, cells, proteins and genes that interact with each other. 
These biological processes have different kinetics, which makes time an essential parameter 
of the investigation. Information on the immune status can be acquired by analysis of gene 
expression (transcriptomics), protein synthesis (proteomics), lipid secretion (lipidomics), and 
production of metabolites (metabolomics), or change in cellular composition and morphology. 
To study the relationship and interaction between all distinct levels of a biological system, a 
comprehensive analysis is required using analytical techniques (Figure 3).
Systems vaccinology can be applied at many stages of vaccine R&D (Table 1). The pioneer 
studies in the field demonstrated the advantage of systems vaccinology to identify molecular 
signatures that predict vaccine efficacy in an early stage after i.e. yellow fever and influenza 
vaccination [51-53]. The yellow fever vaccine has a high efficacy and the correlates of 
protection, antigen-specific CD8+ T-cells and antibody titers, are known. Whereas regular 





























































Figure 3 – Systems vaccinology approach. Data, preferably obtained during a time course of the same 
subject are combined for further analysis. Network analysis (e.g. Cytoscape) is performed to determine co-
expression profiles, indicating interdependence. Functional analysis is executed in public databases, e.g. 
DAVID (www.david.ncifcrf.gov), STRING (www.string-db.org), BioGPS (www.biogps.org), and Interferome 
(www.interferome.org). Combined data form a response profile for a vaccine. Vaccine profiles can be 
compared to other vaccine or infection profiles and used for multiple applications as mentioned in Table 1. 
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molecular signatures were retrieved from the gene expression profiles in blood obtained 1, 
3, and 7 days after vaccination. These studies with clinical data facilitate in further clinical 
development and post-marketing surveillance. Unfortunately, this predictive approach is 
only applicable for vaccines with well-known correlates of protection. For many vaccines, 
including all new vaccines, the correlates of protection are not known [54].
Nevertheless, systems vaccinology can be deployed for multiple other applications to assist 
vaccine R&D (Table 1). Systems vaccinology can assist in better understanding of adjuvants 
like MF59, alum, CpG ODN, and α-GalCer [61, 62]. Furthermore, the safety of vaccines can be 
explored by investigating adverse effects like fever, seizures, and decreased body weight 
[60, 64, 65]. Moreover, vaccine development may benefit from detailed insight into infection-
induced responses as was done for respiratory syncytial virus (RSV) [66], tuberculosis [67], 
and influenza [68, 69]. This provides insight in the host-pathogen responses and isolation of 
potential targets for vaccine development. Finally, datasets from vaccine responses against 
different pathogens in combination with integrative network modeling can reveal detailed 
insight in critical or universal signatures [58-60]. Li et al. compared molecular signatures, 
induced by five different human vaccines against specific bacterial or viral infections, which 
could predict antibody responses [59]. These universal markers can be used as benchmark 




Table 1. Actual and potential use of systems vaccinology
Aim, deliverables Benefits Examples
Predicting responses
Clinical development, post-marketing 
surveillance
[48, 49, 51, 53, 55, 56]
Understand mode of action of 
vaccines
Risk mitigation: less late stage failure [52, 56, 57]
Identify universal vaccine 
signatures
Improve vaccine development [58-60]
Select new immune modulators 
and delivery systems
Risk mitigation: less early stage failure
Better vaccines
[61-63]
Assess vaccine safety and 
adverse effects
Clinical development, post marketing 
surveillance
[60, 64, 65]




Risk mitigation: less early stage failure
Facilitates regulatory acceptance
N.A.
Development of animal models
Improved early development





Thesis scope and outline
The scope of this thesis is the implementation of a systems vaccinology approach to aid 
the development of better vaccines against Bordetella pertussis. This includes the following 
sub-aims:
• Develop a systems approach for pertussis vaccine research
• Explore the infection-induced immunity and use B. pertussis infection as benchmark for 
vaccination studies
• Investigate vaccine-induced responses of different pertussis vaccines
• Connect innate and adaptive immunity with vaccine-induced responses.
• Examine the change in vaccine-induced responses with respect to different routes of 
administration and/or adjuvants.
• Compare and connect the different datasets to obtain a comprehensive overview of the 
molecular signatures involved in pertussis immunity
In this thesis, we investigate and compare the immunogenicity of different pertussis vaccines 
concepts, with emphasis on omvPV, with respect to vaccine composition and administration 
route. Important aspects are the inclusion of B. pertussis infection as benchmark and multiple 
time points of evaluation. The challenge experiments and vaccine production in this thesis 
are performed with the B1917 strain, a clinical isolate from The Netherlands [70]. All concepts 
are tested in a mouse challenge model [14].
In Chapter 2, a systems approach was applied on a primary B. pertussis infection in a murine 
model. We investigate the immune response on transcriptomic and functional level with 
respect to cytokine profile, antibody levels, and cellular responses to create a comprehensive 
overview of innate and adaptive responses after intranasal infection.
Mice develop sterilizing immunity in the lungs after infection. Chapter 3 describes the 
immunological signatures of infection-induced immunity that contribute to sterilizing 
immunity in the lungs of mice. The pulmonary and systemic environments are investigated 
in protected mice with infection-induced immunity in comparison with non-immunized 
unprotected mice following a B. pertussis challenge.
Whole-cell and OMV vaccines are not well-defined biologicals, as they contain many 
bacterial proteins. Most antibodies induced by B. pertussis infection and whole-cell and OMV 
vaccines used in this thesis are not directed against antigens present in acellular vaccines. 
In Chapter 4, a method is developed for immunoproteomic profiling of humoral responses 
to identify immunogens. This method combines protein separation by two-dimensional 




antisera of infected or immunized mice, together with mass spectrometry. The antibody 
specificity and antibody subclass distribution elicited by aPV, omvPV, wPV, and B. pertussis 
infection are assessed.
In Chapter 5 vaccine-induced responses of a candidate omvPV are compared with those elicited 
by a classical wPV after systemic immunization. This comparison includes an assessment of 
bacterial lung clearance and immunological signatures in both immunized groups following 
a B. pertussis challenge.
It was previously shown that addition of a non-toxic TLR4 ligand, Lpxl1, to a licensed aPV 
adjuvanted with colloidal alum, leads to a distinct distribution of T-helper subsets in mice [71]. 
In Chapter 6 we investigate the molecular signatures of these isolated CD4+ T-cells of mice 
that were immunized with aPV or aPV+Lpxl1.
In Chapter 7 we investigate the effect of administration route on protection and the immune 
responses underlying this immunity. To that end, pulmonary administration of an omvPV 
is compared with traditional subcutaneous administration. Innate and adaptive immune 
responses are compared on systemically (blood, spleen) and locally (lung, draining lymph 
nodes). Analyses are done and on transcriptomic, proteomic, and cellular level.
An in silico comparison is made in Chapter 8 by using datasets of the pulmonary transcriptome 
following B. pertussis challenge of non-immunized unprotected mice and mice with infection-
induced immunity from Chapter 3 together with the mice immunized systemically with 
omvPV or wPV from Chapter 5.
The findings of these studies are summarized in Chapter 9. Moreover, the perspectives of 
systems vaccinology in pertussis research are discussed.
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Abstract
Worldwide resurgence of pertussis necessitates the need for improvement of pertussis 
vaccines and vaccination strategies. Since natural infections induce a longer-lasting 
immunity than vaccinations, detailed knowledge of the immune responses following natural 
infection can provide important clues for such improvement. The purpose was to elucidate 
the kinetics of the protective immune response evolving after experimental Bordetella 
pertussis (B. pertussis) infection in mice. Data were collected from (i) individual analyses, 
i.e. microarray, flow cytometry, multiplex immunoassays, and bacterial clearance; (ii) twelve 
time points during the infection; and (iii) different tissues involved in the immune responses, 
i.e. lungs, spleen and blood. Combined data revealed detailed insight in molecular and 
cellular sequence of events connecting different phases (innate, bridging and adaptive) 
of the immune response following the infection. We detected a prolonged acute phase 
response, broad pathogen recognition, and early gene signatures of subsequent T-cell 
recruitment in the lungs. Activation of particular transcription factors and specific cell 
markers provided insight into the time course of the transition from innate towards adaptive 
immune responses, which resulted in a broad spectrum of systemic antibody subclasses and 
splenic Th1/Th17 memory cells against B. pertussis. In addition, signatures preceding the 
local generation of Th1 and Th17 cells as well as IgA in the lungs, considered key elements 
in protection against B. pertussis, were established. In conclusion, molecular and cellular 
immunological processes in response to live B. pertussis infection were unraveled, which 
may provide guidance in selecting new vaccine candidates that should evoke local and 




The Gram-negative bacterium Bordetella pertussis, the causative agent of whooping cough 
(pertussis), accounted for high mortality rates among infants in the pre-vaccine era. Whole-
cell and acellular vaccines have drastically decreased the number of cases [1]. However, 
recently resurgence of pertussis in the vaccinated population has been observed in the 
USA [2, 3] and in European countries [4, 5]. Currently pertussis is still endemic, ranking in 
the top-ten of vaccine preventable diseases worldwide, according to the WHO. Next to 
improved diagnostics and public awareness, also strain adaptation and waning immunity 
are thought to be responsible for this increase in disease cases [6]. Thus, a call for vaccines 
with improved efficacy is evident.
As a main feature of the innate immune response upon B. pertussis infection in mice 
the recognition of lipopolysaccharide (LPS) by TLR4 has been acknowledged [7, 8]. This 
activation of TLR4 by B. pertussis leads to upregulation of cytokine gene expression 
and recruitment of neutrophils into the lungs [9, 10]. It was found in animal models that 
B. pertussis infection results in formation of T helper (Th) 1 and Th17 cells [11-13]. Since 
immunity induced by natural infections provides faster clearance upon reinfection and 
is longer lasting compared to both acellular and whole-cell pertussis vaccination [14, 15], 
immune mechanisms induced upon infection or vaccination have been compared. In 
human and murine studies, immunization with whole-cell or acellular pertussis vaccines 
results predominantly in a Th1 or a Th2 response, respectively [11, 16]. In addition, in both 
the intramuscular (human) or subcutaneous (mice) administered acellular and whole cell 
pertussis vaccines, the humoral response is characterized by systemic IgG antibodies [17, 
18], while mucosal immune responses seem absent. Despite the absence of direct evidence 
for correlates of protection against B. pertussis, both Th1 and Th17 type of CD4+ T-cells as well 
as IgA-producing B-cells seem to play an important role in a protective immune response 
against B. pertussis [12, 15, 19-22]. Since these responses are not induced by the currently 
available vaccines [23], but more resemble responses induced by infection, a better 
understanding of the immune response induced in the host following B. pertussis infection 
is needed. Despite knowledge on particular elements of the immune response generated 
by a B. pertussis infection, little is known about the kinetics and sequential relation of these 
elements. For this, systems biology can be an important tool, as was shown for tuberculosis 
and influenza infection [24-26].
Here, systems biology was applied to elucidate molecular and cellular events in the different 
phases of the immune response after primary B. pertussis infection in a murine model. To 
this end, innate and adaptive immune responses were investigated over a period of 66 days 
post infection. Gene expression profiles in spleen and lungs, cytokine profiles in sera, and 
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cellular composition of the spleen were determined at twelve time points. Furthermore, 
cellular and antibody mediated immune responses against B. pertussis were investigated. 
Herewith, we revealed a chronological cascade of immunological processes consisting of 
recognition, processing, presentation and clearance of B. pertussis. The extensive insights 
into the immune response upon B. pertussis infection generated in this study may serve as a 




Lung clearance of infected mice
The presence of B. pertussis in lungs of mice was examined during a period of 28 days 
post infection (p.i.), providing the benchmark for this study (Figure 1A). Therefore, mice 
were intranasally infected with B. pertussis using a dose of 105 colony forming units (cfu). 
Approximately 13% of the intranasal dose was traceable in the lungs of mice 2 hours p.i. The 
number of bacteria remained fairly constant for one day, and increased from the second day 
to a maximum 7 days p.i. (107 cfu). Subsequently, a decrease in the number of bacteria was 
observed and complete clearance in 2 out of 3 mice was achieved 28 days p.i. To determine 
whether single intranasal infection with B. pertussis leads to protection, mice were reinfected 
56 days after primary infection (Figure 1B). A similar number of viable bacteria was detected 
4 hours p.i. in lungs of both reinfected and naive mice. Reinfected mice were able to clear 
B. pertussis from the lungs within 2 days p.i., whereas naive mice showed a similar pattern 
as observed before. In conclusion, naive mice can clear B. pertussis from the lungs in about 
28 days. Furthermore, mice previously infected with B. pertussis had developed sterilizing 










































Figure 1 - Lung clearance of naive and reinfected mice after B. pertussis infection. (A) Number of colony 
forming units (cfu) in challenge culture (C.C.) was confirmed before challenge. All other cfu were determined 
in lung of challenged mice (mean n = 3). A large fraction of the original infection dose was traceable in the lungs 
of mice 2 hours p.i. Bacteria were able to colonize and multiply approximately 100-fold at 7 days p.i. After one 
week, the mice were able to clear bacteria, which resulted in cleared lungs (2 out of 3 mice) at the last time 
point (day 28 p.i.). (B) Reinfection was performed at 56 days after primary infection and the number of cfu 
were counted after 4 hours p.i. While reinfected mice were able to clear B. pertussis from the lungs within 2 
days p.i., naive mice showed a similar pattern as observed in Figure 1A.
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Gene expression in lung tissue
The gene expression in lung tissue of infected mice was monitored over a period of 28 days. 
In total, 558 genes of the genome were differentially regulated (p-value ≤ 0.001, fold ratio 
(FR) ≥ 1.5): 446 genes were upregulated and 112 genes were downregulated (Figure 2). A 
complete list of gene names is given in Table S1. Gene expression profiles changed already 4 
hours p.i. with largest differences at 14 days p.i. (377 responsive genes). The number of genes 
with an altered expression had declined 21 and 28 days p.i. However, the expression of many 
genes had not yet returned to naive basal levels. Principal component analysis confirmed the 
largest differences at 14 days p.i. and the decline at 21 and 28 days p.i. (Figure 3). Interestingly, 
the time point with the least changes in gene expression (2 days p.i.) preceded the increase 
in cfu in the lungs (Figure 1).
Figure 2 - Pulmonary gene expression profiles as function of time after B. pertussis infection. Fold changes 
in expression were calculated compared to naive mice and significant gene expression results (p-value ≤ 
0.001, FR ≥ 1.5) are visualized as heatmap (mean of n = 3). In total, 558 genes were found to be differentially 
regulated, divided in 446 upregulated genes (red) and 112 downregulated genes (green). Genes not exceeding 
a fold change of 1.5 are depicted as basal level (black). Results are divided in 5 clusters representing up-/
downregulation and time of involvement including corresponding GO-BP terms and KEGG pathways.
Chemotaxis (mmu04062 / GO:0006935)
Antigen processing and presentation (mmu04612 / GO:0019882)
Immunoglobulin mediated immune response (GO:0016064)
Humoral immune response (GO:0006959)
B-cell mediated immunity (GO:0019724)
B-cell receptor signaling pathway (mmu04662)
Adaptive immune response (GO:0002250)
T-cell / B-cell activation (GO:0042110 / GO:0042113)
Phagocytosis (mmu04666 / GO:0006909)
Hemopoiesis (GO:0030097)
Natural killer cell mediated cytotoxicity (mmu04650)
Innate immune response (GO:0045087)
Acute inflammatory response (GO:0002526)
Chemotaxis (GO:0006935)
Phagocytosis (GO:0006909)
Adaptive immune response (GO:0002250)
Antigen processing and presentation (mmu04612 / GO:0019882)
B-cell mediated immunity (GO:0019724)
Intestinal immune network for IgA production (mmu04672)
Cytosolic DNA-sensing pathway (mmu04623)
Complement (mmu04610 / GO:0006956)
Immune response (GO:0006955)
Acute inflammatory response (GO:0002526)
Chemotaxis (mmu04062 / GO:0006935)
Hypothetical genes
Cell adhesion (GO:0007155)
Response to endogenous stimulus (GO:0009719)






























To determine which biological processes were involved, functional analysis of all 558 genes 
was performed using DAVID. Over-representation analysis (ORA) (Benjamini-corrected 
p-value ≤ 0.05) in GO-BP and KEGG databases resulted in respectively 122 terms and 20 
pathways significantly enriched. A selection of these terms is presented in Figure 4. The 
selection is based on immunological relevance and by exclusion of overlapping terms. Acute 
phase response and chemotaxis were observed right after infection (4 hours p.i.) (Figure 
2). Subsequently, innate immune response, phagocytosis, antigen processing and antigen 
presentation were initiated (7 days p.i.). Involvement of B-cell mediated immunity in this 
stage is mainly demonstrated by the expression of complement related genes. Eventually, 
the gene expression showed initiation of the adaptive immune response, such as activation 
of B-cells and T-cells, B-cell receptor (BCR) signaling, humoral immune response (complement 
activation) and immunoglobulin-mediated immunity from 10 until 28 days p.i.
The gene expression data was compared with the BioGPS database to identify the influx, 
presence or activation of particular immunological cells in the lungs (Figure S1). Sixty-one 
genes, which are predominantly expressed in macrophages, suggest two events: (i) triggering 
of alveolar macrophages 4 hours p.i. and (ii) recruitment of macrophages in the lungs 7 days 
p.i. The influx of macrophages was observed on cellular level using fluorescence microscopy 
[27]. In addition, the increased expression of 29 genes was attributed to the presence of 
neutrophils in the lungs 4 days p.i. Moreover, data suggests altered expression of 32, 48, and 
17 genes of B-cells, dendritic cells (DCs) and mast cells, respectively, 7 days p.i., and 19 T-cell 




















Figure 3 - Principal component analysis of pulmonary gene expression. An evolving gene expression profile 
was indicated after B. pertussis infection of naive mice (mean of n = 3), illustrated as principal- component 
analysis (PCA). PCA is a mathematical algorithm [117], which describes data based on (dis)similarity. Therefore, 
a greater distance between points in the plot corresponds to a greater dissimilarity. In this figure, the similarity 
of the 10 time points are compared based on the expression profiles of the 558 differentially expressed 
genes. Results indicate that 81% and 9% of the variance between time points could be addressed by principal 
component 1 (PC1) and PC2, respectively. The next principle components contribute for the residual variances. 
The plot revealed a notable change in gene expression at 2 days p.i. compared to 4 hours p.i., and largest 
differences at 14 days p.i. The gene expression at 28 days p.i. was still far from the naive state.
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Differentially regulated genes in lung tissue after the infection with B. pertussis were 
classified according to function, pathway and cell type. For eleven different groups details 
are described below.
(1) Cytokines. Twenty-one cytokine-encoding genes were differentially expressed in the lungs 
during B. pertussis infection (Figure 5). Sixteen cytokines are associated with a chemotactic 
function. The other five genes (Flt3l, Ifng, Il17a, Il17f, Il16) reflect cytokines involved in the 
activation of T-cells, such as Th1 and Th17 cells.
(2) Membrane receptors. Forty-six membrane receptors were identified with altered gene 
expression (Figure 5). The receptors were divided in eight groups: cytokine receptors, 
C-type lectins (CLRs) [28], Fc-receptors, epithelial cell specific receptors, including the IgA 
transporter (Pigr), myeloid-associated immunoglobulin-like receptors, semaphorins [29], 
Figure 4 - Functional annotation of pulmonary gene expression data after B. pertussis infection. Over-
representation analysis (Benjamini- corrected p-value ≤ 0.05) in GO-BP and KEGG databases of pulmonary gene 
expression data resulted in respectively 122 terms and 20 pathways significantly enriched. A selection of terms 
and pathways, based on immunological relevance and exclusion of overlapping terms, is given in this figure. 
GO-BP terms were divided in mother terms (dark blue) and corresponding daughter terms (light blue). For 





10 20 30 40 50 60 70 80 90 1000
Leukocyte transendothelial migration (mmu04670)    6.49E-03
Fc gamma R-mediated phagocytosis (mmu04666)    4.54E-03
Fc epsilon RI signaling pathway (mmu04664)    4.38E-03
Primary immunodeficiency (mmu05340)    1.78E-03
Intestinal immune network for IgA production (mmu04672)    1.32E-04
Asthma (mmu05310)    1.30E-04
Complement and coagulation cascades (mmu04610)    1.71E-05
Cytokine-cytokine receptor interaction (mmu04060)    1.32E-05
Cell adhesion molecules (CAMs) (mmu04514)    9.24E-07
Natural killer cell mediated cytotoxicity (mmu04650)    4.99E-07
B cell receptor signaling pathway (mmu04662)    2.00E-07
Antigen processing & presentation (mmu04612)    1.96E-10
Chemokine signaling pathway (mmu04062)    8.45E-11
Pathway
Phagocytosis (GO:0006909)    5.94E-03
Response to bacterium (GO:0009617)    1.74E-03
Hemopoiesis (GO:0030097)    3.18E-04
Immune system development (GO:0002520)    3.84E-05
B cell activation (GO:0042113)    1.82E-02
T cell activation (GO:0042110)    5.14E-03
Lymphocyte activation (GO:0046649)    6.40E-06
Cell activation (GO:0001775)    7.22E-10
Immunoglobulin mediated immune response (GO:0016064)    1.07E-13
B cell mediated immunity (GO:0019724)    2.00E-14
Lymphocyte mediated immunity (GO:0002449)    3.08E-14
Immune effector process (GO:0002252)    1.82E-14
Chemotaxis (GO:0006935)    7.46E-15
Antigen processing & presentation (MHC class I) (GO:0002474)    6.92E-09
Antigen processing & presentation (MHC class II) (GO:0002495)    7.93E-11
Antigen processing & presentation (peptide) (GO:0048002)    4.34E-19
Antigen processing & presentation (GO:0019882)    6.28E-15
Acute inflammatory response (GO:0002526)    1.55E-09
Inflammatory response (GO:0006954)    8.98E-22
Response to wounding (GO:0009611)    1.36E-22
Defense response (GO:0006952)    1.33E-23
Complement activation, classical  pathway (GO:0006958)    2.52E-06
Complement activation (GO:0006956)    1.04E-06
Humoral immune response (GO:0006959)    6.51E-07
Innate immune response (GO:0045087)    6.86E-04
Adaptive immune response (GO:0002250)    1.67E-14
Immune response (GO:0006955)    3.93E-41
10 20 30 40 50 60 70 80 90 1000
Number of genes in GO-BP mother term
Number of genes in GO-BP daughter term
Percentage of total GO-BP term population
Number of genes in KEGG term
Percentage of total KEGG term population




Figure 5 - Gene expression profiles of pulmonary cytokines and membrane receptors after B. pertussis 
infection. Results (mean of n = 3) for cytokines and membrane receptors include expected source and known 
corresponding receptors, target cells and receptor ligands. Membrane receptors are divided in eight different 




















Gene / Synonym  Source   Target cells/receptor
CXCL2 / MIP-2  Macro 
CXCL17 / DMC  Epithelial   DCs/Mono
CCL20 / MIP-3a     CCR6+ Th17
CXCL1 / KC  Macro/Epithelial  Neutro
CXCL5 / LIX  Epithelial   Neutro
CXCL9 / Mig     CXCR3+ T-cells
CXCL10 / IP-10  Mono   CXCR3+ T-cells
CXCL13 / BLC     CXCR5+ B-cells
CCL8 / MCP-2     T-cells/NK/Eos
CCL5 / RANTES     T-cells/Eos/Bas
CXCL11 / IP-9     CXCR3+ T-cells
XCL1 / LTN  T-cells/NK/NKT  DCs
IFNG   NK/NKT/Th1/CTL 
CXCL12    
CCL19 / MIP-3b     CCR7+ DCs/B-cells/T-cells
CCL21A / SLC     CCR7+
CCL21C / SLC     CCR7+
IL17A   Th17 
IL17F   Th17 
FLT3L   T-cells   CD135 DCs
IL16 / LCF   CD4+ cells
Gene / Synonym  Source   Ligand   
CCR6 / CD196  Th17   CCL20
CX3CR1 / GPR13  NK/mono/T-cells  CX3CL1
CXCR3 / CD183  DC/NK/T-cell  CXCL9, 10, 11
CXCR5 / CD185  B-cell/CD4  CXCL13
CXCR6 / CD186  T-cell 
IL2RB / CD122     IL2
IL10RA / CDW210A     IL10
TSPAN1   
CD177   Neutro 
CD74 / HLADG  APC (MHC-II) 
TYROBP / DAP12  DCs/Macros/NK 
PROM1 / CD133  Hematopoietic stem cell 
LAIR1 / CD305  NK/T-cells/B-cells 
CSF2RB / CDw131  Mast cells/Macro/Neutro GM-CSF
SIGLECH   pDCs 
ITGB2 / CD18/MAC-1 Macro/Neutro/DCs  C3 
CEACAM10   
LY6G5B   
GPR65 / TDAG8  
TREM2   
SELPLG / CD162  NK/DC/Neutro/T-cells 
CD209F / Signr8  DCs/Macro 
CD209G / Signr7  DCs/Macro 
CLEC10A /  CD301a/MGL1  Macro's/ DCs 
CLEC4A3 / Dcir3  APC/Neutro
FCGR4 / CD16-2  Mono/Macro/Neutro  IgG2a/b
FCGR3 / CD16  Mono/Macro/Neutro  IgG1, IgG2a/b
FCGR1 / CD64  Mono/Macro 
FCGR2B / CD32  B-cell/Mast cell/T-cell 
FCER1G / CD23  Mast cell/Macro  IgE
FCAMR / CD351  Macro/B-cells  IgM/IgA
PIGR   Epithelial cells  IgA
CLDN2   Epithelial cells
CD300LF/ LMIR3/MAIR-V Myeloid cells 
AF251705 / LMIR2/MAIR-II Myeloid cells
SEMA4D / CD100  T-cells   CD72
SEMA4A   DCs   TIM2
CD274 / PD-L1  DCs/IgA Plasma cells 
LILRB3 / PirB  B-cells 
LY86 / MD-1  B-cells   LPS
CD72 / Lyb-2  B-cells 
CD79A / IGA  B-cells 
CD22   B-cells 
ITGB7 / LY69     Th1 T-cells
CD4   T-cells 



































lymphocyte receptors (e.g., Pdl1) [30, 31] and the mucosal-homing receptor (Itgb7). Other 
membrane receptors are collected in one group (Figure 5). Gene expression profiles of 
both cytokines and cytokine receptors enabled early prediction of immune cell recruitment 
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Figure 6 - Pulmonary gene expression representing immunological pathways as function of time after B. 
pertussis infection. Details on pulmonary gene expression profiles (mean of n = 3) indicated expression of anti-
microbial peptides, acute phase proteins, pathogen recognition, phagocytosis, both classical and alternative 
pathways of complement cascade, transcription factors, antigen presentation via both MHC-I and MHC-II, 
B-cell receptor (BCR) signaling ,and immunoglobulin related genes.
towards the lungs on transcriptomic level in this study. Increased expression of Cxcl13 and 
Ccl20 was followed by the upregulation of receptors Cxcr5 and Ccr6. These chemokines lead 
to the recruitment of CXCR5+ B-cells, CXCR5+ T-cells, CCR6+ DCs and CCR6+ Th17 cells into 
the lungs [32-34]. Likewise, the expression of Cxcl9, Cxcl10 and Cxcl11, induced by interferon 
gamma (IFNγ), is associated with recruitment of CXCR3+ T-cells or CXCR3+ pDCs [35].
(3) Antimicrobial peptides (AMPs). AMPs have defensive properties against bacterial 
infections, recruit immune cells and model subsequent immune responses [36]. Gene 
expression of four AMPs was elevated for 21 days p.i. (Figure 6). These four AMPs recruit 
neutrophils or protect against respiratory pathogens [37-40]. Interestingly, the chemokine 
Cxcl17, primarily expressed in the lungs, was described as an antimicrobial mucosal chemokine 
that recruits DCs and CD14+ monocytes and protects against pathogenic bacteria [41, 42].
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(4) Acute phase response. Primary reaction to an infection is the acute phase response, which 
leads to the release of pro-inflammatory cytokines and activation of inflammatory cells. 
Strong upregulation of 19 genes involved in the acute phase response was detected at 4 
hours p.i. Remarkably, the gene expression of the acute phase response remained highly 
expressed at least until day 28 p.i. (Figure 6).
(5) Pathogen recognition. Enhanced gene expression suggested activation of TLR4, TLR9, DAI 
and CLR signaling pathways, implying pathogen recognition by several ligands of B. pertussis 
(Figure 6). The induction of Md-1 and transcription factor Irf5 genes suggested TLR4 signaling 
upon sensing of LPS [43]. Upregulation of Ctsk and the downstream transcription factor Irf7 
assumes activation of TLR9 by sensing of unmethylated CpG sequences in bacterial DNA [44]. 
In addition, the cytosolic DNA sensor (DAI) was induced [45]. Elevated gene expression of 
several CLRs was noticed, such as Mgl1 and the mouse DC-SIGN-related proteins Signr7 and 
Signr8 [46]. Mgl1 recognizes N-acetylgalactosamine (GalNAc), which is present in B. pertussis. 
Mgl1 has recently been linked to B. pertussis mast cell interaction [47].
(6) Transcription factors. Ten transcription factors were differentially expressed in the lungs 
(Figure 6). These include genes of factors Pu.1, Shp-1, Nfil3, Syk, Irf5, Irf7, and Irf8. All of 
these transcription factors have been designated as regulators of immunological processes, 
thereby defining the direction of the host immune response upon bacterial infection [48-54].
(7) Phagocytosis. Six genes representing subunits of NADPH oxidase (NOX) were activated 
between 4 hours and 28 days p.i. (Figure 6). The activation suggests the production of 
reactive oxygen species, which are involved in a phagocyte respiratory burst to assist in the 
killing of bacteria during phagocytosis [55].
(8) Antigen presentation. Twenty-eight genes representing antigen presentation were 
upregulated between 7 and 28 days p.i. (Figure 6). Results indicate that both antigen 
presentation via MHC class I and class II were included. This suggests antigen presentation to 
both CD4+ T-cells and cytotoxic CD8+ T-cells (CTLs). In line with these findings, the upregulation 
of Cd4 and Ctsw gene expression in lung tissue was observed, which may indicate presence of 
CD4+ T-cells [56] and CTLs [57], respectively (Figure S1).
(9) Complement activation. Twelve genes of the complement system were more abundantly 
expressed between 7 and 28 days p.i. (Figure 6). Increased gene expression was observed for 
the complement components C1 and C4, which belong to the classical pathway. In contrast, 
reduced gene expression of the C1-inhibitor (Serping1) was observed day 4 p.i. Furthermore, 
strong up-regulation of Cfb suggests activation of the alternative complement pathway.
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(10) BCR signaling. Fifteen genes of the BCR signaling pathway were upregulated between 7 
and 28 days p.i. (Figure 6). BCR activation was detected by elevated gene expression of eight 
downstream proteins (Blnk, Card11, Grb2, Pik3cd, Plcg2, Prkcb, Rac2, and Vav1). Furthermore, 
the gene expression of the BCR signaling pathways indicates a balanced B-cell response 
because of an interplay of stimulation by Cd79a and Ifitm1, and inhibition by FcgrIIb, Lilrb3 
(Pirb), Cd22, Cd72, and Shp-1. These co-inhibitors prevent overstimulation of B-cells [58].
(11) Immunoglobulins. Gene expression associated with antibody formation was observed 
after 4 days p.i. and was increased up to 28 days p.i. (Figure 6). The microarray data revealed 
gene expression of seven kappa (κ) light chain genes, heavy chain Ig alpha chain C (Ihg-vj558), 
Ighm and Ighg, indicating  the formation of IgA, IgM and IgG antibodies.
In summary, approximately 40% of the genes expressed in the lungs could be annotated 
according to function. The chronology of immunological processes comprises broad 
pathogen recognition, prediction of cell recruitment by cytokine and receptor expression, 
MHC class I and II antigen presentation, and markers for both antibody and cell-mediated 
immunity.
Cytokine profiles in mouse sera
The concentrations of thirty-three cytokines were determined in mouse sera by ELISA and 
multiplex immunoassay (MIA). B. pertussis infection induced nine cytokines: CCL11, CCL20, 
CXCL9, CXCL10, G-CSF, IL-1α, IL-6, IL-9 and IL-17A (Figure 7). The pro-inflammatory cytokines, 
IL-1α and IL-6, are both involved in the acute phase response. The concentration of IL-
1α was significantly increased 1 day p.i. Enhanced concentrations of IL-6 were detected at 
three different time points: 2 hours (not significant), 4 days, and 7 days p.i. (Figure 7A-B). 
Remarkably, IL-6 concentrations returned to basal level 6 hours p.i. Production of IL-1α by 
epithelial cells was most likely a result of LPS or tracheal cytotoxin (TCT) exposure [59]. The 
enhanced concentration of IL-6 2 hours p.i. was most likely caused by lung-resident immune 
cells, such as macrophages and mast cells. These cells are the first to recognize bacterial 
infection [13]. Elevated concentrations of chemokines CXCL9 (MIG) and CXCL10 (IP-10) 
were measured between 14–28 days p.i. (Figure 7D and G), which suggests a Th1 response 
[60]. CCL11 (Eotaxin) was enhanced at 14 days p.i. (Figure 7C). Eotaxin is involved in allergic 
inflammation and is chemoattractive for eosinophils [61] and CCR3+ Th2 cells [62]. IL-9 was 
increased 7 days p.i. (Figure 7F). IL-9 is mainly produced by T-cells and originally associated 
with Th2 responses [63]. However, there is evidence that IL-9 is produced by a specific Th 
subset: Th9 cells [64] and Th17 cells [65]. A Th17 response was identified by markers, such 
as IL-17A, CCL20 (MIP-3a) and granulocyte colony-stimulating factor (G-CSF) [34]. Enhanced 
concentrations of IL-17A and CCL20 were determined in mouse sera 14 days p.i. (Figure 7E,H 
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Figure 7 - Serum cytokine concentrations as function of time after B. pertussis infection. The concentrations 
of (A) IL-1α, (B) IL-6, (C) CCL11, (D) CXCL9, (E) IL-17A, (F) IL-9, (G) CXCL10, (H) CCL20, and (I) G-CSF in serum 
were analyzed over time. Results indicated that after the acute phase response (IL-1α and IL-6) a multi-flavored 
immune response with Th1 (CXCL9 and CXCL10), Th2 (CCL11 and IL-9), and Th17 (G-CSF, CCL20, IL-9, and IL-
17A) was induced. Data represented as mean concentrations including individual values (n = 3). p-values were 
determined by one-way ANOVA with multiple comparison compared to naive mice, * p ≤ 0.05, ** p ≤ 0.01, *** 
p ≤ 0.001 and **** p ≤ 0.0001).
was produced between 4 and 28 days p.i. G-CSF is important for recruitment, differentiation 
and proliferation of neutrophils [66] and is linked to a Th17 response [67]. No significant 
changes in concentrations were detected for the other twenty-four cytokines.
In conclusion, serum cytokine profiles indicate the induction of an acute phase response (IL-
1α and IL-6) followed by a multi-flavored immune response with Th1 (CXCL9 and CXCL10), Th2 
(CCL11 and IL-9) and Th17 signatures (G-CSF, CCL20, IL-9 and IL-17A).
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Cellular composition of the spleen
The cellular composition of the spleen was examined (Figure 8A and Figure S2) by 
flowcytometry with a panel of fluorescence-labeled monoclonal antibodies binding to cell-
specific membrane markers (Figure S3 and Figure S4). Results indicate that in the naive 
situation, the majority of splenocytes consist of B-cells and T-cells (approximately 40% each). 
Upon B. pertussis infection, the ratio between B-cells and T-cells changed, since an increased 
percentage of T-cells and decreased percentage of B-cells was observed on day 2–4 p.i. 
However, this ratio was restored on day 7 p.i. The distribution of minor cell populations in 
the spleen, such as DCs, neutrophils and CD14+ cells, changed over time upon B. pertussis 
infection. Here, we observed an early increased percentage of CD14+ cells (day 1 p.i.) and DCs 
(day 1 and day 7–14 p.i.). Furthermore, a gradual increased percentage of neutrophils from day 
4 until day 21 p.i. was observed. Importantly, enlargement of the spleen was observed during 
the course of infection (not quantified), suggesting influx or proliferation of cells. This might 
explain the observed changes in cellular distribution. In conclusion, cellular composition of 
the spleen indicates fluctuations over time upon B. pertussis infection.
Gene expression in the spleen
Gene expression in the spleen of infected mice was determined by microarray analysis. The 
study identified 798 genes of the whole genome that were differentially regulated (p-value ≤ 
0.001, FR ≥ 1.5): 342 genes were upregulated, 425 genes were downregulated, and 31 genes 
that were initially downregulated and subsequently upregulated (Figure 8B). All involved 
genes are listed in Table S2. A limited set of genes showed altered gene expression between 
4 hours and 7 days p.i. However, large changes in gene expression were observed 21 days p.i., 
while the gene expression was almost back to the original values 28 days p.i. Only eight genes 
still showed altered expression. ORA of the 798 differentially expressed genes in the spleen 
revealed 66 GO-BP terms and two KEGG pathways. A selection of 16 terms and 2 pathways 
is presented in Figure 9, which are involved in transcription, cell cycle, chromatin assembly 
and a number of immunological processes. The corresponding proteins are involved in 
proliferation, differentiation or activation of immune cells in the spleen. Downregulated 
genes encode proteins that are involved in transcription, adaptive immune responses, 
antigen processing, antigen presentation and chemokine signaling (Figure 8B and Figure 10). 
Downregulation of these genes suggests suppression of the immune response or migration 
of immune cells.
(1) Immune response. Forty-one immune response genes were identified (Figure 10), 13 of 
which are associated with the adaptive immune response. Interestingly, downregulation of 
genes involved in T-cell activation, B-cell activation, antigen processing and presentation, and 
the subsequent BCR signaling pathway were observed 21 days p.i. (Figure 10). Upregulation 
of genes encoding immunoglobulin heavy chains Ighg, Igha and Igh-vj558 indicate production 
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Figure 8 - Splenic cellular composition and gene expression profiles as function of time after B. pertussis 
infection. (A) The distribution of the splenic cellular composition illustrated as pie charts at a selection of time 
points during the B. pertussis infection. FACS was used to determine the percentage (mean of n = 3) of B-cells 
(CD19+), CD4+ T-cells, CD8+ T-cells, neutrophils (Gr-1+), macrophages (CD11b+), dendritic cells (33D1+), NK cells 
(DX5+), and CD14+ cells in splenocytes. (B) Fold changes of expression were calculated compared to naive mice 
and significant gene expression results (p-value ≤ 0.001, FR ≥ 1.5) were visualized as a heatmap (mean of n = 
3). This test was performed for each gene at each time point. In total, 798 genes were differentially regulated 
(p-value ≤ 0.001, FR ≥ 1.5) compared to naive mice, divided in 342 upregulated (red) and 425 down-regulated 
genes (green). Additionally, a distinct group of 31 genes showed downregulation between 4 hours and 4 days 
p.i., but were upregulated between 10 and 21 days p.i. Genes not exceeding a fold change of 1.5 are depicted 
as basal level (black) at this time point. Results are divided in 3 clusters representing up/down-regulation and 
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of immunoglobulins IgG and IgA by B-cells (Figure 10). Downregulation of the Ighm gene 
suggests a suppressed IgM production or a class-switch to IgG or IgA.
(2) Membrane receptors. Upregulation of genes encoding myeloid cell membrane markers, 
Fc-receptors and membrane attack complex (MAC) inhibitory proteins (Cd59a/Cd59b) 
suggests increased presence of myeloid cells, such as neutrophils, between 10 and 21 days p.i. 
(Figure 10). The induction of the MAC-inhibitory genes suggests inhibition of MAC formation, 
which is part of the complement cascade. In addition, BioGPS analysis (Figure S5) revealed 
the presence of myeloid cell markers that are expressed on neutrophils (Trem3 and Clec4e) 
or macrophages (Clec4e). Downregulated gene expression of membrane markers of B-cells 
(Cd22, Cd72, Cd74, and Siglecg) and T-cells (Sema4d, Tcra) implies decreased presence of 
lymphocytes 21 days p.i. (Figure 10).
(3) Transcription. Ninety-five genes that were differentially regulated in the spleen turned out 
to be involved in transcription (Figure 9), of which 70 genes were downregulated (data not 
shown).
(4) Cell cycle. Most of the genes involved in the cell cycle process (31 out of 45) were 
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Figure 9 - Functional annotation of splenic gene expression data after B. pertussis infection. Over-
representation analysis (Benjamini- corrected p-value ≤ 0.05) of all 798 differentially expressed genes in the 
spleen in GO-BP and KEGG databases, This resulted in respectively 66 terms and 2 pathways significantly 
enriched of which a selection, based on immunological relevance and exclusion of overlapping terms, of 16 
terms and 2 pathways are presented. GO-BP terms were divided in mother terms (dark blue) and corresponding 
daughter terms (light blue). For each term the amount of genes, the percentage of the total term population 

































































































































































































Gene / Synonym Source      Ligand
IL1F9  Macro/Neutro 
CCL6 / MRP-1  
CCL21A / SLC       CCR7+
Gene / Synonym Source      Ligand
CD59A  Mast cells/Macro 
CD59B  Mast cells/Macro 
CLEC4E  Macro/Neutro 
TREM3  Neutro 
ITGB3BP   
FCER1A  Mast cells/B-cells     IgE
FCGR3 / CD16 Mono/Macro/Neutro       IgG1, IgG2a/b
FCGR4 / CD16-2 Mono/Macro/Neutro     IgG2a/b
FCGR2B / CD32 B-cell/Mast cell/T-cell
CD74 / HLADG APCs (MHC-II)
CD72 / Lyb-2 B-cells
CD22  B-cells
SIGLECG  B-cells
CX3CR1 / GPR13 NK/Mono/T-cells      CX3CL1
SEMA4D / CD100 T-cells                       CD72
TCRA  T-cells 
TREML2   
CD247 / PD-L1 IgA Plasma cells












































































Figure 10 - Splenic gene expression profiles of specific processes as function of time after B. pertussis 
infection. Expression profiles (mean of n = 3) are summarized for immune response, cell cycle, regulation 
of apoptosis, T-cell activation, B-cell activation, immunoglobulin, B-cell receptor (BCR) signaling, antigen 
processing, cytokines and membrane receptors in spleen.
(5) Regulation of apoptosis. Apoptosis was characterized by upregulation of 12 genes 
(between 7 and 21 days p.i.) and downregulation of 24 genes (21 days p.i.) (Figure 10). The 
role of apoptosis is especially interesting because of the recently described link between 
apoptotic markers and influenza vaccine responsiveness [68]. However, no overlap was 
found between the markers from the study of Furman et al. and the current study.
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In summary, most prominent differences in gene expression in the spleen were found around 
21 days p.i. These differences point to downregulation of immunological processes. After 28 
days p.i. the expression profiles returned to basal level, at the same moment that the bacteria 
were almost cleared from the lungs. Interestingly, when combining cellular composition 
(Figure 8A) with gene expression profiles (Figure 8B and Figure S5), the increase in neutrophils 
(10–21 days p.i.) was observed with both techniques. However, changes in the distribution of 
B-cells and T-cells on day 2 and 4 p.i. were not detected on gene expression level. Overall, 
these findings suggest that gene expression profiles cannot directly be translated in cellular 
fluctuations in the spleen.
Overlap of transcriptomic responses in lungs and spleen
A comparison of transcriptomic datasets was made to determine the related biological 
processes that occurred in both spleen and lungs (Figure S6). Seventy-two genes were 
differentially expressed in spleen and lungs, which were divided in four groups: (i) 20 genes 
that were upregulated in both tissues, (ii) 42 genes that were upregulated in lungs and 
downregulated in the spleen, (iii) 2 genes that were downregulated in lungs and upregulated 
in the spleen, and (iv) 8 genes that were downregulated in both tissues. Fifteen genes of 
the second group were involved in the immune response, such as leukocyte activation, BCR 
signaling pathway, antigen processing and presentation, and chemotaxis. Remarkably, the 
immunoglobulin-mediated immune response was the only process upregulated in both 
tissues, suggesting local and systemic antibody production.
In summary, both tissues showed activation of antibody-mediated immunity upon a B. pertussis 
infection. In addition, most differentially expressed genes representing immunological 
processes were observed upregulated in the lungs and downregulated in the spleen.
B. pertussis-specific IgM, IgG and IgA antibody responses
Antibody isotypes, IgM, IgG and IgA against B. pertussis were analyzed for a period of 28 
days p.i. The formation of IgM against B. pertussis antigens present in outer membrane 
vesicles (OMV) was not observed during the course of infection (Figure 11A). Contrarily, 
anti-B.pertussis IgG in mouse sera was detectable from 10 days p.i. and the responses were 
progressively increased until 28 days p.i. (Figure 11B). Notably, no IgG titers were detectable 
against the individual purified B. pertussis antigens pertactin (Prn), pertussis toxin (Ptx), 
filamentous hemagglutinin (FHA) or fimbria type 2 and 3 (Fim2/3) (Figure S7). However, anti-
OMV IgG was significantly increased at 14, 21 and 28 days p.i. (Figure 11C) and consisted of IgG1, 
IgG2a and IgG2b subclasses, but not IgG3. (Figure 11D–G), Remarkably, IgG1 levels dropped 
significantly at 28 days p.i. compared to 21 days p.i. In addition, significantly increased anti-
OMV IgA responses were measured in sera (Figure 11H) as well as in lung lysates (Figure 11I) 
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Figure 11 - Antibody profiling after B. pertussis infection. (A-H) Antibody responses were determined in mouse 
sera after intranasal infection by whole-cell B. pertussis ELISA or MIA and expressed as OD450 or Fluorescent 
Intensity (F.I.), respectively (mean of n = 3). (A) IgM antibodies against OMV B1917 were absent. (B) Whole-
cell B. pertussis ELISA indicated IgG antibody formation 10-14 days p.i., which increased until day 28 days p.i. 
(C-G) Levels of total IgG antibodies and individual subtypes (IgG1, IgG2a, IgG2b, and IgG3) against OMV B1917 
indicated presence of multiple subclasses. (H) Anti-OMV IgA antibodies in serum were induced after 14-28 days 
p.i. (I) In lung lysates, anti-OMV IgA antibodies were detected 14 and 28 days p.i. p-values were determined by 
one-way ANOVA with multiple comparison compared to naive mice, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, and 
**** p ≤ 0.0001.
In conclusion, intranasal infection leads to a broad spectrum of systemic antibody subclasses 
against outer membrane proteins of B. pertussis within 14 days p.i., but responses against 
purified virulent antigens Ptx, Prn, FHA and Fim2/3 remain undetectable until 28 days p.i. 
Moreover, B. pertussis-specific anti-OMV IgA antibodies were secreted in the lungs.
CD4+ T-cell responses after B. pertussis infection
Cytokine profiles of antigen-specific memory CD4+ T-cells in the spleen were determined 
66 days p.i. Splenocytes of naive and infected mice were stimulated for 8 days with Ptx, 
FHA or Prn, important virulence factors present in the acellular pertussis vaccine. Cytokine 
profiling on single cell level was established by using intracellular cytokine straining (ICS), 
while cytokine concentrations in splenic culture supernatants were determined by using a 
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Figure 12 - Systemic memory Th cytokine profiles. (A-C) Splenocytes of naive and infected mice were collected 
66 days p.i. and in vitro restimulated with Prn, FHA, or Ptx for 8 days. The percentages of IFNγ-, IL-17A-, and IL-
5-producing CD4+CD44+ T-cells were determined using ICS (mean of n = 6). (D-F) Cytokine levels in supernatant 
after 7 days of stimulation were determined by using a MIA. Results (mean of n = 6) are corrected for the 
background level in the presence of medium as control. Statistical differences between the groups were 
detected for the ICS with a non-parametric Mann-Whitney test and for the MIA with a Student t-test on the 
log-transformed data. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.
MIA. CD44 expression was used to focus on activated CD4+ T-cells. Results of ICS indicate 
a significant increase in IFNγ- and IL-17A-producing Prn-, FHA-, and Ptx-specific CD4+CD44+ 
T-cells after infection (Figure 12A-B). Except for FHA-stimulation, no evidence was found for 
specific IL-5-producing CD4+CD44+ T-cells (Figure 12C). Cytokine profiles in culture supernatant 
revealed a significant increase in TNFα production by splenocytes of infected mice after 
FHA stimulation and IL-17A production after Prn, Ptx, or FHA stimulation (Figure 12D-F). No 
changes were observed in IFNγ production in culture supernatants (Figure 12D-F). Notably, 
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FHA stimulation induced besides Th1 and Th17 cytokines an increase in IL-5, IL-13, IL-4, and IL-
10 production by splenocytes of infected mice (Figure 12E). IL-5 and IL-13 production occurred 
also after Prn stimulation (Figure 12D). This might indicate that these three B. pertussis 
antigens induce a mixed Th response, of which Th1 and Th17 are the major components. While 
ICS specifically focuses on CD4+CD44+ T-cells, multiple cell types can produce the accumulated 
cytokines present in the splenic culture supernatants after stimulation. The production of IL-
17A is exclusive for Th17 cells [69]. Besides Th1 cells, IFNγ could also be produced by CTLs and 
NK cells. The high levels of IFNγ produced by splenocytes of naive mice after Ptx stimulation 
may be explained by TLR4 activation on innate cells by Ptx [70]. A high background of Prn-
responding IL-17A+CD4+CD44+ T-cells and IL-17A in supernatant was seen in two out of six 
naive mice, indicating Prn-activated IL-17A production in unprimed splenocytes.
In summary, CD4+ memory T-cell analysis revealed that infection with B. pertussis primarily 
generates specific Th1 and Th17 responses, regarded essential in protection against a B. 
pertussis infection [12, 20, 21].
Figure 13 (Right) - Overview of immune response evolving after B. pertussis infection. Merging data from a 
wide array of functional analyses reveals a comprehensive overview of the immune response of mice upon B. 
pertussis infection. (i) Innate phase, (ii) bridging phase and (iii) adaptive phase are indicated in the response 
facing variable levels of B. pertussis present in the initial inoculum, the exponential growth phase, and in 
the clearance phase, respectively. Highlights of the study are given, based on lung clearance, relative gene 
expression levels (lungs), cytokine profiles (serum), cellular response (spleen) and pertussis-specific responses 
in serum and spleen as depicted in the figure legend.
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An integrated systems biology approach was applied to investigate the evolving immune 
response of mice following a primary intranasal B. pertussis infection, considered capable 
of inducing sterilizing immunity. Data sets from individual analytical platforms, such as 
microarray, flow cytometry, multiplex immunoassays, and colony counting, addressing 
different biological samples taken at multiple time points during the immune response were 
merged. Altogether, a comprehensive overview of immunological processes occurring upon 
primary infection of mice with B. pertussis was constructed in three consecutive phases, as 
shown in Figure 13: (i) the innate phase, (ii) the bridging phase, and (iii) the adaptive phase.
Highlights featured in this study are: (i) a protracted acute phase response, as part of the 
innate phase, lasting for at least 28 days, which co-occurred with prolonged antigen exposure; 
(ii) the recognition of several B. pertussis pathogen-associated molecular patterns (PAMPs), 
i.e. LPS, DNA, and GalNac, (iii) early signatures for recruitment of adaptive immune cells 
e.g. the cytokine CCL20 that attracts CCR6+ Th17 cells, (iv) expression of specific membrane 
markers (e.g. DAP12) and transcription factors that determine the strength and direction of 
the adaptive immune response. Furthermore, features of adaptive immunity consisted of: 
(v) IgA secretion in the lungs; (vi) a broad systemic antibody response; (vii) a Th1 and Th17-
mediated response in the lungs and systemic formation of specific memory Th1 and Th17 cells.
Various signatures, associated with the induced protective immune response as presented 
in Figure 13, are discussed in detail hereafter. The innate phase was characterized by the 
presence of AMPs, acute phase proteins and chemotactic cytokines as detected by microarray 
analysis and MIA (Figure 5–7). Expression of the involved genes is most likely initiated by 
activation of TLR2 and TLR4 by LPS of B. pertussis [8, 10]. Upregulated gene expression of 
four AMPs (Chi3l1, Cxcl17, Lcn2, and Spli) was found in the lungs during the whole course of 
infection. These AMPs contribute to innate protection as was shown for other respiratory 
pathogens [38-40, 42]. In addition, these AMPs have the capacity to recruit immune cells, such 
as neutrophils, DCs, and monocytes [37, 41] and are therefore important for the induction of 
subsequent immune responses [36].
Furthermore, the expression of particular cytokines on gene and protein level in the innate 
phase (Figure 5 and Figure 7), in combination with increased gene expression of cytokine 
receptors and the change in cellular composition of the spleen (Figure 5 and Figure 8A), gave 
detailed insight into the immunological processes during the course of infection, as depicted 
in Figure 13. For example, the gene expression levels of the cytokine Cxcl1, Cxcl2, Cxcl5, and 
Cxcl17 was in agreement with the recruitment of neutrophils and DCs towards the site of 
infection [41, 71, 72]. Furthermore, the gene expression of the cytokines Cxcl9, Cxcl10, Cxcl11 
and Ccl20 was increased early after infection. CXCL9, CXCL10 and CXCL11 are known to be 
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involved in the recruitment of CXCR3+ Th1 cells, and CCL20 in the recruitment of CCR6+ Th17 
cells [32, 33, 60]. The upregulation of Ccr6 and Cxcr3 genes was observed at day 14 p.i. in the 
lung (Figure 13).
Remarkably, gene expression of cytokines, acute phase proteins, and AMPs was temporary 
suppressed at 2 days p.i. Simultaneously, the proliferation of bacteria started in the lungs. 
These results indicate temporary suppression of the immune system by B. pertussis. Several 
immune evasion strategies of B. pertussis have been described in literature [73-77]. The evasion 
is attributed to virulence factors, such as adenylate cyclase toxin (ACT), Ptx, TCT, and FHA. 
These investigators demonstrated enhanced production of IL-10 and regulatory T-cells, delay 
of neutrophil recruitment, and inhibition of early chemokine production in mice in relation 
to secretion of B. pertussis virulence factors. In the present study, these immunosuppressive 
properties of B. pertussis might explain the suppression of the differential gene expression 
observed 2 days p.i. In addition, secretion of OMVs occurs during bacterial colonization 
[78]. These OMVs are thought to serve as decoy for the host immune response and their 
immunomodulatory properties support survival of the bacteria [79, 80].
During the bridging phase, the number of bacteria in the lungs increased (Figure 1). The 
highest number of bacteria in the lungs was found at 7 days p.i. followed by a decrease, 
suggesting that day 7 is the turning point in the progress of the infection. Simultaneously, 
microarray analysis suggests the presence of neutrophils, macrophages, and DCs in the lungs 
based on BioGPS analysis (Figure S1). These cells are likely responsible for (i) phagocytosis, 
(ii) pathogen recognition, (iii) antigen presentation, and (iv) differentiation by expression of 
cell receptors in the period between 4-10 days p.i. (Figure 13).
The innate immune cells appeared to cause the initial decrease in numbers of bacteria in the 
lungs from 7 days p.i., because a strong antibody response (IgM, IgG, IgA) (Figure 11) and 
CD4+ T-cell response were not yet present. Based on gene expression of neutrophil markers, 
the neutrophil invasion in the lungs probably occurred from 4 days p.i., which is observed on 
cellular level by McGuirk et al. [81]. This influx of cells is most likely orchestrated by IL-17A and 
G-CSF [66, 67, 69]. In the present study, both cytokines were enhanced in the sera of infected 
mice. Furthermore, genes involved in phagocytosis were found to be upregulated (Figure 6) 
which is important for protection against B. pertussis [55, 82].
This study demonstrated also that B. pertussis infection activates different pattern recognition 
receptor (PRR) pathways, such as TLR4, TLR9, DAI, and several CLRs (Figure 6). Bacterial 
ligands, e.g. LPS, DNA, and GalNAc trigger these signaling pathways [8, 45, 47]. Upregulation 
of genes involved in TLR4-signalling (Md-1, Irf5) is probably caused by detection of bacterial 
LPS [8, 10, 43]. Bacterial DNA recognition occurred through the TLR9 pathway (Ctsk, Irf7) 
and the cytosolic DNA sensor (Dai). The receptor DAI recognizes both host DNA, upon tissue 
damage, and bacterial DNA, which leads to an innate immune response [45]. Furthermore, 
increased gene expression of the CLRs, Signr7, Signr8, and Mgl1 was observed, which are 
50
Chapter 2
predominantly expressed on DCs [28, 83]. The enhanced expression of mouse DC-SIGN-
related genes Signr7 and Signr8 during the B. pertussis infection is a novel finding. Despite 
indications of sensing of 6-sulfo-sialyl Lewis(x) oligosaccharide by Signr7, the exact ligands 
and role of these receptors remains to be discovered [46]. Recognition of GalNAc via Mgl1 
has recently been associated with mast cell activation by B. pertussis [47]. An important 
conclusion is that ligands of B. pertussis activate multiple PPRs during the infection. This may 
be important for the induction of a broad adaptive immune response, including Th1 as well as 
Th17 cells, mucosal IgA and systemic IgG.
During the bridging phase, upregulation of MHC class I and II genes were measured, enabling 
antigen presentation to both CD4+ Th cells and cytotoxic CD8+ T-cells (CTLs). Several studies 
focused on the role of Th cells because of their important contribution to protect against B. 
pertussis [12, 20, 21]. Nevertheless, the CTLs seem also important for protection against B. 
pertussis, indicated by CTL infiltration, based on upregulation of Ctsw, in lungs in our study by 
formation of FHA-specific IFNγ-producing CTLs upon B. pertussis infection in other studies in 
mice and humans [81, 84].
In addition, the bridging phase was characterized by simultaneous gene expression of several 
receptors on innate immune cells in the lungs and spleen. Interestingly, this included MAIRs, 
TREMs, semaphorins, and DAP12, which is the first evidence that these receptors might play 
a role in B. pertussis infection. Especially DAP12, which is abundantly expressed in lungs, 
interacts with other membrane receptors and influences cytokine expression [85]. Coupled 
to MAIR-II, DAP12 is an inhibitor of B-cell responses [86]. Together with TREM2, DAP12 
downregulates TLR and FcR expression [87]. Overall, these former receptors function as an 
important bridge between innate and adaptive immune responses, determining the strength 
and direction of the adaptive immune response by the successive activation of lymphocytes, 
such as CTLs, Th cells, and B-cells [29, 88-91]. Since the exact role of these receptors in the 
protection against B. pertussis remains unresolved, additional research is needed to find 
whether targeting of these receptors might be a viable strategy to elicit desired immune 
responses. In summary, the bridging phase suggests the presence of APCs and myeloid cells, 
such as DCs and neutrophils based on gene expression of membrane markers. However, this 
was not validated by histological data.
Finally, the adaptive phase was recognized by the formation of T and B-cell responses and a 
broad antibody response (Figure 13). In this same period, the naive mice were able to clear B. 
pertussis from their lungs. Gene expression, cytokine secretion and cellular analysis revealed 
presence of activated CD4+ T-cells. The highest number of CD4+ T-cells was detected at 14 days 
p.i., which is in agreement with a study showing the largest influx of Th17 cells in the lungs 
after B. pertussis infection at 14 days p.i. [12]. Phenotyping of CD4+ T-cells, based on cytokine 
profiles in serum (protein) and lung (genes) and expression of specific transcription factors 
or membrane markers, suggests a broad Th response in the present study. The Th1 response 
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in the lungs was characterized by Ifng and Stat1 expression [92]. Gene expression of the 
mucosal homing receptor Ccr6, Card11, Ccl19, Ccl21a, Ccl21c, and signature cytokines Il17a and 
Il17f might indicate Th17 cells in the lungs [32, 69, 93-96]. Upon re-stimulation of splenocytes 
with purified B. pertussis antigens, Prn- and FHA-specific Th1 and Th17 type CD4+ T-cells could 
be detected in the memory phase (66 days p.i.) (Figure 12). In addition, enhanced IL-9 levels 
in serum suggest activation of Th9 cells and Th17 cells as these cells produce large amounts 
of IL-9 [64, 65]. However, Tregs, NKT-cells and mast cells are also sources of IL-9. In summary, 
the different phases of T-cell development were mapped; the expansion phase of naive 
T-cells in the spleen (2 days p.i.), the effector phase in the lungs (14 days p.i.), contraction 
phase in the spleen (21 days p.i.) and finally the specific memory T-cells (66 days p.i.) (Figure 5, 
8A, 10 and 12). Data from this study suggests generation of local specific Th1/Th17 cells in the 
lungs. Th1 cells, which produce IFNγ are important for clearance of B. pertussis. Postponed 
clearance was shown in IFNγ-depleted mice [97]. Th17 cells have been indicated as key cells 
to control bacterial infections at mucosal sites [98]. Recent studies revealed that Th17 cells 
increase the clearance of B. pertussis after an intranasal infection in animals [12, 13, 99].
Infection with B. pertussis induces also B-cell and antibody mediated immunity. Microarray 
analysis showed increased gene expression of the BCR in the lungs. In addition, gene 
expression of IgM, IgG, and IgA was observed in lungs and spleen. Whereas, most genes for 
antibody isotypes were found upregulated in both tissues, IgM was downregulated in the 
spleen (Figure 6 and Figure 10). This was confirmed by the detection of IgA and IgG (IgG1, 
IgG2a and IgG2b) antibodies after 14 days p.i. However, IgM antibodies were not found 
systemically (Figure 11). In mice, IgG1 is associated with a Th2-like response, while IgG2a (in 
Balb/c mice) and IgG2b suggest induction of a Th1 response [100]. IgG2b is also linked to Th17 
lymphocytes [101]. All antibody responses in the present study were directed against whole-
cell B. pertussis and outer membrane vesicles, but not against the B. pertussis antigens that 
are typically present in acellular vaccines: Ptx, Prn, FHA and Fim2/3. However, memory Th1/
Th17 cells were detected upon re-stimulation with Prn and FHA (Figure 12). The polymeric 
immunoglobulin receptor (pIgR) was highly expressed during the whole course of B. pertussis 
infection in the lungs. pIgR is essential for the transport of IgA into the mucus and is seen 
as a bridge between innate and adaptive mucosal responses [102, 103]. The expression of 
pIgR was drastically enhanced 14 days p.i., leading to secretion of mucosal IgA in the lungs 
(Figure 5 and Figure 11). Interestingly, the increased pIgR expression coincided with IL-17A 
production in the lungs and sera (Figure 5 and Figure 7), which is in agreement with the 
finding that Th17-mediated responses influence the local humoral response by inducing pIgR 
expression and elevating secretory IgA levels [104]. Therefore, the transport of IgA to the 
mucosa, which is orchestrated by IL-17A via the induction of pIgR, supports an important 
role for local immunity. In summary, B. pertussis infection induces a broad humoral response, 
which was observed by gene and protein expression.
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Our study also contains several conceptual points for discussion. First, altered gene 
expression in the spleen caused by B. pertussis infection was modest, except for 21 days 
p.i. Two possible reasons can be given: (i) the infection initiated a local immune response in 
the lungs and (ii) gene expression is required to be rather strong to exceed the significance 
threshold. After the lungs and the draining lymph nodes, the spleen is the third organ in 
line involved in the generation of the immune response. Therefore, gene expression effects 
could be less abundant. Furthermore, the spleen consists of many cell types with different 
gene expression profiles, so changes in expression levels in a single cell type might not have 
been detected. Cell sorting of individual cell types and subsequent gene expression profiling 
could overcome this problem. Second, specific antibody and T-cell responses were only 
measured for a limited set of available purified antigens. The inclusion of other antigens, 
such as outer membrane proteins, would perhaps have allowed a more detailed analysis. 
Third, in this study we propose murine infection-induced immune signatures as a benchmark 
to be used in the development of improved human pertussis vaccines. Since B. pertussis 
is not a natural pathogen for mice, translation of the results obtained in this study to the 
human situation remains to be interpreted with caution. Nevertheless, using a (naive) murine 
model has several advantages. It is regarded an important small animal model for pertussis 
vaccine development [105] and enables to dissect the local and systemic immune response 
in great detail, as shown in this study, rather than using blood or nasal washes from humans 
undergoing a B. pertussis infection. Furthermore, the role of individual gene signatures and 
products could be assessed in future research in mice by using knock-in or knock-out strains, 
or by functional interventions. Encouraging is that many observations made in this study, 
such as the rapid clearance upon reinfection and involvement of Th17 and Th1 responses, are 
in line with recent studies on B. pertussis infection in baboons, which resemble the human 
situation more closely [13, 15]. Translation of biomarkers from mouse to man however should 
be performed with care.
Overall, our study describes the molecular and cellular sequence of events that eventually 
lead to the induction of protective immunity to B. pertussis, including local immunity in the 
lungs, which is not induced by current vaccines. Especially the inductions of Th1 and Th17 
cells and IgA antibodies in the lungs are regarded key elements in superior immunity. Our 
data can be used to select vaccine concepts that resemble infection, with respect to e.g. 
administration route and prolonged antigen exposure, and immune signatures elicited. Local 
delivery of vaccines may be an important advancement for improved protection as was 
previously demonstrated with a live attenuated pertussis vaccine [106]. Also adjuvants could 
be selected and optimized that can steer host immunity of inactivated vaccines towards an 
infection-like immune response with minimal adverse effects. The molecular and cellular 
fingerprint of the local immune response discovered in B. pertussis infected mice thus can 
provide a strong guidance for developing improved pertussis vaccines.
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The independent ethical committee for animal experimentations ‘Dierexperiment Commissie 
(DEC)’ of the National Institute for Public Health and the Environment (RIVM) reviewed the 
animal experiments in this study according to the guidelines provided by the Dutch Animal 
Protection Act. The committee approved documents with the identification numbers 
‘DPA201100230’ and ‘DPA201100348’.
Materials
Bordetella pertussis strain B1917 [107] was isolated in The Netherlands in 2000 and was kindly 
provided by Frits Mooi. Bordet-Gengou agar plates with 15% sheep blood were purchased from 
BD (Cat. No. 254400, BD, The Netherlands). Verweij medium was obtained from Bilthoven 
Biologicals (BBio, Bilthoven, The Netherlands). PBS (pH 7.2) and Roswell Park Memorial 
Institute Media 1640 (RPMI) were purchased from Invitrogen (Gibco, Invitrogen). All RPMI 
media used in this experiment were supplemented with 10% fetal calf serum (FCS, Hyclone, 
New Zealand), 100 units penicillin, 100 units streptomycin, and 2.92 mg/ml L-glutamine (p/s/g; 
Invitrogen). Shockbuffer for splenocyte isolation consisted of 8.3 g/L NH4CL, 1 g/L NaHCO3, 
and 5000 IE/L Heparine dissolved in dH2O (pH 7.4; ice cold) and was filtered (0.22 µm) before 
use. FACS buffer consisted of PBS pH 7.2 supplemented with 0.5% BSA (A3803, Sigma Aldrich, 
Germany) and 0.5 mM EDTA (ICN Biomedicals). Horseradish peroxidase (HRP) labelled goat-
anti-mouse IgG and R-Phycoerythrin (RPE)-conjugated goat-anti-mouse IgM, IgA, IgG, IgG1, 
IgG2a, IgG2b, and IgG3 were obtained from Southern Biotech (Southern Biotech, United 
States). Fluorescently labeled antibodies for flow cytometry, anti-CD3-Pacific blue (17A2), 
anti-CD4- Pacific blue (GK1.5), anti-IA-IE-PerCP-Cy5.5 (M5/114.15.2), anti-33D1-APC (33D1), and 
anti-IL-5-APC were purchased from Biolegend (ITK, The Netherlands). Fluorescently labeled 
antibodies, anti-CD4-APC (RM4-5), anti-CD8a-PerCP (53 6.7), anti- CD69-FITC (H1.2 F3), anti-Gr-
1-PE (RB6-8C5), anti-CD19- FITC (1D3), anti-CD14-PE (rmC5-3), anti-DX5-APC (DX5), anti-CD11b-
PE (M1/70), anti-CD40-FITC (HM40-3), anti-CD44-FITC (IM7), and anti-IFNγ-PE were purchased 
from BD (BD Biosciences, The Netherlands). Fluorescently labeled antibodies CD11c-PE-Cy7 
(N418) and anti-IL-17A-PerCP-Cy5.5 were obtained from eBioscience (eBioscience, Austria). 
Live/dead staining was purchased from Invitrogen (LIVE/DEAD Fixable Aqua Dead Cell Stain 
Kit; Invitrogen). Anti-CD16/CD32 was purchased from BD (BD, The Netherlands).
Cultivation of B. pertussis
B. pertussis strain B1917 was grown on Bordet-Gengou agar plates for 4 days at 35⁰C. 
Subsequently, multiple colonies were transferred onto new plates and grown for 24 hours 
at 35⁰C, which was repeated 3 times. Colonies on each plate were harvested in 1.5 ml 
Verweij medium [108] and the suspensions were pooled. After centrifugation (30 min, 1932 
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g), cells were washed with 15 ml Verweij medium. Subsequently, bacterial suspensions of 
approximately 2x1010 cfu/ml were resuspended in Verweij medium containing 15% glycerol 
(v/v) and aliquots of 0.25 ml were flash frozen in ethanol and dry ice and stored at -80⁰C.
Challenge culture
A stock of B. pertussis B1917 was diluted with Verweij medium to a final concentration of 5x106 
cfu/ml. The number of cfu was confirmed by plating 100 µl of the infection suspension (1:2000 
in Verweij medium) on Bordet-Gengou agar plates. Plates were incubated for 4 days at 35⁰C 
and cfu were counted by using a colony counter (ProtoCOL, Synbiosis, Cambridge, United 
Kingdom).
Animal experiment
Female BALB/c mice (Harlan, The Netherlands), 8-weeks-old, were divided in groups of three 
animals and housed in cages (macrolon III including filter top). Three healthy mice were 
euthanized at day 0 and considered as naive group. Other mice were intranasally infected 
under anesthesia (isoflurane/oxygen), with 2x105 cfu B. pertussis B1917 in 40 µl Verweij medium 
at day 0. Groups of animals (n = 3) were euthanized after 2, 4, 6 hours, and after 1, 2, 4, 7, 10, 
14, 21, and 28 days of infection, respectively. At 56 days p.i. five groups of primary infected 
animals and five groups of naive animals (n = 3) were infected as previously described and 
euthanized after 4 hours, and after 2, 7, 10, and 14 days of infection. In addition, six infected 
and six healthy mice were euthanized at day 21 and day 66 for the analysis of CD4+ T-cell 
responses. Mice were bled, under anesthesia (isoflurane/oxygen), by orbital bleeding and 
sacrificed by cervical dislocation. Whole blood from each mouse was collected in a blood 
collection tube (MiniCollect 0.8 ml Z Serum Sep GOLD, Greiner Bio-One, Austria). After 
coagulation (10 min at room temperature), sera were taken after centrifugation (10 min, 3000 
g) and stored at -80⁰C. Lung lobes were excised. The right lobe was placed in 900 µl Verweij 
medium and kept at room temperature. The left lobe was placed in 1 ml RNAlater (Qiagen), 
incubated overnight at 4⁰C and stored at -80⁰C. The spleen was excised and divided in two 
equal parts. One piece was placed in 5 ml of RPMI medium and kept on ice. The other piece 
was placed in 1 ml RNAlater (Qiagen), incubated overnight at 4⁰C and stored at -80⁰C. For 
the analysis of CD4+ T-cell responses, whole spleen was collected and placed in 5 ml of RPMI 
medium and kept on ice.
Colonization assay
Lung tissue in 900 µl Verweij medium was homogenized for 15 seconds using a Labgen 7 
Homogenizer (Cole Palmer, Schiedam, The Netherlands). Homogenizer was sanitized 
between samples with ethanol (80%) and water. Lung homogenates were serially diluted 
(undiluted, 1:10, 1:100 or 1:1000) in Verweij medium depending on the expected number of 
cfu. Suspensions of 100 µl were plated on Bordet-Gengou agar plates and incubated for 4 
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days at 35⁰C. The numbers of colonies were counted by using a colony counter (ProtoCOL, 
Synbiosis, Cambridge, United Kingdom) and calculated as cfu per mouse.
RNA isolation
Lung and spleen tissues were homogenized by using a Labgen 7 Homogenizer (Cole 
Palmer, Schiedam, The Netherlands) in 700 and 2100 µl Qiazol (Qiagen Benelux, Venlo, The 
Netherlands), respectively. RNA isolation was performed using a miRNeasy Mini Kit with 
DNAse treatment (Qiagen Benelux, Venlo, The Netherlands) according to the manufacturer’s 
protocol.  RNA concentrations were determined by UV spectroscopy (Tech3 module, Synergy 
Mx, BioTek, Winooski, United States). RNA quality was determined by using electrophoresis 
(RNA nano 6000 kit, 2100 Bioanalyzer, Agilent Technologies, Amstelveen, The Netherlands). 
Results were given as RNA integrity numbers (RIN) between 1 and 10 (manual Bioanalyzer). 
Samples with a RIN of 7 or higher were used for microarray analysis. For microarray analysis of 
lung tissue, RNA concentrates of individual mice were analyzed for the following time points: 
naive, 4 hours, 2 days, 4 days, 7 days, 10 days, 14 days, 21 days, and 28 days post infection (p.i.). 
For spleen tissue, samples of individual mice were analyzed for the following time points: 
naive, 4 hours, 1 day, 2 days, 4 days, 7 days, 10 days, 14 days, 21 days, and 28 days p.i.
Microarray analysis
Amplification, labeling and hybridization of RNA samples to microarray chips was carried out 
at the Microarray Department of the University of Amsterdam, The Netherlands, as described 
previously [109].
Briefly, 500 ng total RNA of each sample was amplified (aRNA) according to the Agilent 
QuickAmp kit manual (Agilent technologies). A common reference sample for either lung 
or spleen tissue was made by pooling equimolar amounts of aRNA from individual samples 
of the respective tissues. Cy3 and Cy5 monoreactive dyes (GE Healthcare) were used to 
label individual samples and the common reference sample, respectively. Labeling was 
performed with 10 ml of CyDye solution and incubated for 1 hour before the reaction was 
quenched by adding 5 ml 4 M hydroxylamine (Sigma-Aldrich). Purification was performed by 
using a clean-up kit (E.Z.N.A. MicroElute RNA Clean Up Kit, Omega Bio-Tek, Norcross, United 
States). The yields of amplified RNA and incorporation of CyDye were determined by using a 
spectrophotometer (NanoDrop ND-1000, NanoDrop products, Wilmington, United  States).
Hybridization mixture was prepared by adding a dried mixture (1:1) of sample (Cy3) and 
common reference (Cy5) together with sample tracking control (STC, Roche NimbleGen) 
and hybridization cocktail (NimbleGen Arrays User’s Guide - Gene Expression Arrays Version 
5.0, Roche NimbleGen). Samples were incubated successively for 5 min at 95⁰C and 5 min 
at 42⁰C. Hybridization was performed  by loading a sample onto a microarray (NimbleGen 
126135 k Mus musculus, Roche, Germany) containing probes for 44,170 genes with 3 spots per 
target probe. Hybridization was performed with a NimbleGen Hybridization System 4 (Roche 
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NimbleGen) for 20 hours at 42⁰C. After washing (NimbleGen Arrays User’s Guide - Gene 
Expression Arrays Version 5.0), slides were scanned in an ozone-free room with a microarray 
scanner (Agilent DNA microarray scanner G2565CA, Agilent Technologies). Each microarray 
corresponded to labeled RNA from specific tissue (lung or spleen) from one individual 
mouse. Feature extraction was performed with NimbleScan v2.5 (Roche NimbleGen) 
resulting in a table containing individual probe signal intensities for both dyes. Complete raw 
and normalized microarray data and their MIAME compliant metadata from this publication 
have been submitted to the GEO database (www.ncbi.nlm.nih.gov/geo) and assigned the 
identifier GSE53294.
Data analysis of gene expression
Quality control was performed on raw data by means of Cy3-Cy5 scatter plots, and by 
comparing signal average and distribution across slides. All slides passed quality control. Raw 
microarray data for gene-coding probes were normalized in R (www.r-project.org), by using 
a four step approach [109]: (1) natural log-transformation, (2) quantile normalization of all 
scans, (3) correcting the sample spot signal for the corresponding reference spot signal and 
(4) averaging data from replicate probe spots. Further analysis of normalized data of 44,170 
probes was performed in R and Microsoft Excel.
Genes differentially expressed between experimental groups (naive and various time points 
p.i.) were identified by using ANOVA. Fold ratio induction or repression of individual genes was 
calculated by comparing mean gene expression levels of infected groups to the group with 
naive mice. Data are presented as the average normalized gene expression levels of three 
mice per group. Probes were considered differentially expressed if they met the following 
two criteria: (i) a p-value ≤ 0.001 (ANOVA), which corresponds to a Benjamini-Hochberg False 
discovery rate (FDR) [110] of < 5%; and (ii) an absolute fold ratio ≥ 1.5 (infected compared to 
naive mice) for at least one time point. If multiple probes corresponding to the same gene 
were significant, their data were averaged to remove redundancy for further analysis. Gene 
expression of each group was compared with the group of naive mice. Differences in gene 
expression were visualized in heat maps (GeneMaths XT, Applied Maths, St-Martens-Latem, 
Belgium). Genes were arranged according to similar expression patterns in time at which 
genes exceeded the fold ratio cut-off of 1.5. To facilitate visual interpretation of heat maps, 
only induction (red) and repression (green) of gene expression levels with fold ratios ≥ 1.5 are 
visualized, therefore presenting fold ratios < 1.5 as naive level (black).
Functional enrichment with an over-representation analysis (ORA) was carried out by using 
DAVID [111] based on Gene Ontology Biological Processes (GO-BP) and Kyoto Encyclopedia of 
Genes and Genomes (KEGG). Cell-specific or tissue-specific gene sets were obtained by using 
data from BioGPS [112, 113]. For each cell type or tissue, gene expression data were compared 
to the average of all tissues included in the data set. The top 100 genes, which had the highest 
tissue-specific expression and were included on the NimbleGen array, were selected. If the 
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BioGPS dataset included multiple entries for the same cell type (e.g., CD4+ and CD8+ T-cells), 
the resulting sets were combined in our subsequent analysis.
Whole-cell B. pertussis ELISA
Immunoglobulin G responses against B. pertussis were determined in sera by an ELISA. 
Therefore, B. pertussis B1917 was heat-inactivated for 45 min. at 56⁰C, after which ELISA plates 
(Immunolon 2HB, Thermo Scientific) were coated overnight at room temperature with 100 µl/
well whole-cell B. pertussis (OD590 nm = 0.1 in PBS). Plates were washed with 0.03% (v/v) Tween 
80 in water. Then, plates were incubated for 1 hour at 37⁰C with 100 µl/well serial dilutions 
of serum samples in PBS, pH 7.2 (Gibco) with 0.1% (v/v) Tween 80. Plates were washed twice 
and incubated (1 hour, 37⁰C) with 100 µl/well of HRP-conjugated goat-anti-mouse IgG (1:5000) 
in PBS with 0.1% (v/v) Tween 80 and 0.5% (w/v) Protifar (Nutricia). After washing twice, 100 
ml/well peroxidase substrate (4.2 mM Tetra Methyl Benzidine and 0.012% H2O2 in 0.11 M 
sodium acetate buffer, pH 5.5.) was added, plates were incubated at room temperature and 
the reaction terminated after 10 min by adding 100 µl/well, 2 M H2SO4 (BBio, Bilthoven, The 
Netherlands). Finally, the absorbance was recorded at 450 nm with a plate reader (BioTek 
reader EL808, Bio-Tek, USA) and antibodies against whole-cell B. pertussis are presented in 
OD450 signal, because a reference is not available.
Multiplex immunoassay (MIA) for antibody response
Responses of IgM, IgA, total IgG, and the IgG subclasses (IgG1, IgG2a, IgG2b and IgG3) against 
B. pertussis antigens P.69 pertactin (P.69 Prn), filamentous hemagglutinin (FHA), pertussis 
toxin (Ptx), combined fimbria type 2 and 3 antigens (Fim2/3), and outer membrane vesicles 
B1917 (OMV B1917) were determined in sera by using a MIA. Outer membrane vesicles from 
B. pertussis B1917 were produced as previously described [114] with additional changes. 
Conjugation of antigens and OMVs to beads was performed as described previously [115]. 
Serum was diluted 1:100 in PBS containing 0.1% Tween 20 and 3% bovine serum albumin and 
mixed 1:1 with conjugated beads. After incubation with R-Phycoerythrin (RPE)-conjugated 
anti-mouse IgM (1:100), IgA (1:100), IgG (1:200), IgG1 (1:200), IgG2a (1:40), IgG2b (1:200), and 
IgG3 (1:200), samples were analyzed by using a Bio-Plex system (Bio-Plex 200, BioRad). Total 
IgG titers (U/ml) against B. pertussis antigens were calculated from mean fluorescent intensity 
(MFI) by using a reference from  the National Institute for Biological Standards and Control 
(Code 99/520, NIBSC, England) in the Bio-Plex Manager software (Bio-Rad Laboratories). 
Results for IgM, total IgG, IgG subclasses, and IgA antibodies against OMV B1917 are presented 
in fluorescent intensity (F.I.), because a reference is not available.
Lung lysate preparation and IgA antibody assay
The lung lysates used for the colonization assay were centrifuged (10 min, 2000 g) and 
filtered (0.22 µm Millex-GV, Merck KGaA, Darmstadt, Germany) to remove cell debris and 
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bacteria. Filtrates were stored at -80⁰C. Prior to analysis, lung lysates were diluted 1:10 in PBS 
containing 0.1% Tween 20 and 3% bovine serum albumin. Analysis of IgA antibodies in the lung 
lysate was performed against B. pertussis antigens (Ptx, Prn, FHA, and Fim2/3) and OMV B1917 
as described in the section multiplex immunoassay (MIA) for antibody response.
Splenocyte isolation
Spleen tissue was forced through a 70-µm cell strainer (BD Falcon, BD Biosciences, USA) and 
washed two times with 5 ml medium (RPMI, FCS, p/s/g) to obtain a single cell suspension. After 
centrifugation (5 min, 550 g), 1 ml shock buffer was added to cell pellet to lyse erythrocytes. 
After one minute, shock incubation was stopped by adding 25 ml medium. For cell count 
(CASEY model TT, Innovatis, Roche, Germany), cells were centrifuged and resuspended in 1 
ml medium.
Cellular composition of spleen
Splenocytes were transfered to each well of a V-bottom 96-wells plate. After centrifugation (3 
min, 400 g), pellets were washed with 100 µl FACS buffer. Fc-specific receptors on cells were 
blocked with anti-CD16/CD32 in FACS buffer (2%, v/v) by 5 min. incubation on ice to prevent 
aspecific binding of labeled antibodies to cells. Cells were stained after centrifugation by 
using a mixture (100 µl) of labeled antibodies (30 min, 4⁰C). To determine the number and 
identity of cells, three different panels of labeled antibodies were used to prevent overlapping 
fluorescence spectra. Panels consisted of 1) total T-cell population (CD3), CD4 T-cell (CD4), 
CD8 T-cell (CD8), early activated T-cell (CD69), and neutrophil (Gr-1); 2) T-cell (CD3), B-cell 
(CD19), monocyte (CD14), and natural killer cell (DX5); 3) T-cell (CD3), macrophage (CD11b), 
DC (33D1, CD11c), MHC class II (IA/IE), and activation marker (CD40). Data acquisition was 
performed with a FACSCanto II (BD Biosciences, USA) and data analysis was done by using 
FlowJo software (Tree Star Inc., USA). Debris and dead cells were excluded by using forward/
side scatter characteristics and live/dead staining, respectively.
Stimulation of splenocytes
Splenocytes were resuspended in the culture medium IMDM (Gibco) + 8% FCS + p/s/g + 20 
µM β-mercaptoethanol (Sigma) and cultured (24-wells plate; 6x106 cells/well) for 7 days at 
37⁰C in a humidified atmosphere containing 5% CO2. Culturing was in the presence of either 
the culture medium, or the culture medium supplemented with Prn P.69 (in house expressed 
and purified as described previously [116]), heat-inactivated (15 min. at 95⁰C) Ptx (Kaketsuken, 
Japan) or FHA (Kaketsuken, Japan), at a final concentration of 1 µg/ml. Supernatants were 
collected after 7 days for cytokine analysis. Subsequently, cells were transferred to U-bottom 
96-wells plates (5x106 cells/well) and stimulated overnight by using the same antigens and 
conditions and used for intracellular cytokine staining.
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Intracellular cytokine staining
The intracellular cytokine staining was performed on 8-days stimulated splenocytes by using 
a Cytofix/Cytoperm Fixation/ Permeabilization Solution Kit (BD Biosciences, USA). Briefly, 
cells were incubated during the last 5 hours of stimulation with 10 µg/ ml Golgiplug (BD 
Biosciences), 1 µg/ml αCD28 (BD Pharmingen), and 1 µg/ml αCD49d (BD Pharmingen). Cells 
were stained after washing with FACS buffer with anti-CD4-Pacific blue, anti-CD44-FITC, and 
live/dead staining. Subsequently, the cells were fixed, permeabilized, and stained with anti-
IFNγ-PE, anti-IL-5-APC and anti-IL-17A-PerCP-Cy5.5. Data from fluorescence-activated cells 
were acquired on FACS Canto II (BD Biosciences) and analyzed with FlowJo software (Tree 
Star Inc., USA). CD44 was used to distinguish between naive and antigen experienced T- cells. 
IL-5 was used as a Th2 cytokine, IFNγ as a Th1 cytokine, and IL-17A as a Th17 cytokine.
Multiplex immunoassay (MIA) for cytokines
Cytokine (IL-4, IL-5, IL-10, IL-13, IL-17A, TNFα, and IFNγ) concentrations (pg/ml) were 
determined in culture supernatants of 7-days stimulated splenocytes of individual mice by 
using a MIA (Milliplex mouse cytokine 7-plex luminex kit; Merck KGaA, Darmstadt, Germany). 
Cytokine (Eotaxin, G-CSF, GM-CSF, IFNγ, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17A, IL-1α, 
IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IP-10, KC, LIF, LIX, M-CSF, MCP-1, MIG, MIP-1α, MIP-
1β, MIP-2, RANTES, TNFα, VEGF) concentrations (pg/ml) present in serum were determined 
by using a MIA (Milliplex MAP Mouse Cytokine/ Chemokine - Premixed 32 Plex; Merck 
KGaA, Darmstadt, Germany) according to the manufacturer’s instructions. Briefly, serum/
supernatant (25 µl) was diluted in supplied assay buffer (1/ 1; v/v), mixed with 25 µl conjugated 
beads and incubated overnight at 4⁰C on a plate shaker. Subsequently, beads were washed 
twice with washing buffer by using a Bio-Plex handheld magnetic washer (BioRad, USA) and 
incubated with 25 µl detection antibodies (1 hour, 20-25⁰C) followed by incubation with 25 µl 
streptavidin-phycoerythrin (30 min, 20-25⁰C). After washing twice with 200 µl washing buffer, 
beads were resuspended in 150 µl PBS. Samples were analyzed using a multiplex system (Bio-
Plex 200, BioRad, USA). In total, 50 beads per region were analyzed in 100 µl sample volume. 
Mean fluorescence intensity (MFI) of each cytokine was converted into pg/ml by using a 
dilution series of a standard (3.2–10,000 pg/ml) and Bio-Plex Manager software 5.0 (Bio-Rad, 
USA).
MIP-3α (CCL20) cytokine ELISA
Serum concentration of Macrophage Inflammatory Protein 3α (MIP3α/CCL20) was determined 
by ELISA (Mouse MIP-3α ELISA kit, RAB0061, Sigma-Aldrich, Germany) according to the 
manufacturer’s manual. In short, serum (50 µl) was diluted in assay buffer A (1/1; v/v) and 
incubated in an antibody-coated ELISA plate (overnight, 4⁰C, gentle shaking). After washing 
four times with 300 µl wash buffer, wells were incubated with 100 µl biotinylated antibody (1 
hour, room temperature, gentle shaking). After washing four times with 300 µl wash buffer, 
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wells were incubated with 100 µl streptavidin solution (45 min, room temperature, gentle 
shaking). After washing four times, wells were incubated with 100 µl TMB one-step substrate 
reagent (30 min, room temperature) and reaction stopped with 50 µl stop solution. Finally, 
the absorbance was recorded at 450 nm with a plate reader (BioTek reader EL808, Bio-Tek) 
and converted to MIP-3α concentration by using a dilution series of a standard (2.06–1,500 
pg/ml) and Gentech 5 software (BioTek).
Statistical analysis
Cellular composition of spleen, antibody titers and cytokines levels were analyzed by using 
a one-way ANOVA with multiple comparisons of all time points post infection vs. naive mice 
followed by a Dunnett t-test. ICS data was analyzed by using a Mann-Whitney t-test. For 
cytokine profiling after re-stimulation of splenocytes, MIA data was first log-transformed 
before t-test analysis. In all corresponding figures, p-values are represented as * p ≤ 0.05, ** 
p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001.
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Figure S1 - Cell type comparison analysis for lung gene expression. Data (mean of n = 3) represent gene 
profiles in the lung per cell type or tissue extracted from BioGPS. Results from B-cells, mast cells, T-cells, 
dendritic cells, neutrophils, and lung-specific genes are depicted.
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Figure S2 - Cellular composition of the spleen as function of time after B. pertussis infection. The percentage 
of (A) CD14+ cells (CD14+), (B) NK cells (DX5+), (C) macrophages (CD11b+), (D) neutrophils (Gr-1+), (E) T-cells 
(CD3+, CD4+CD8-, and CD8+CD4-), (F) B-cells (CD19+), and (G) dendritic cells (33D1+) in splenocytes were 
analyzed over time. p-values were determined by one-way ANOVA with multiple comparison compared to 
naive mice, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, and **** p ≤ 0.0001 (mean of n = 3). An increased percentage 
of CD14+ cells (monocytes, DCs and macrophages) was found 1 day p.i., followed by natural killer (NK) cells and 
macrophages at 2 days p.i. There was a gradual increase in the percentage of neutrophils in the spleen until 7 
days p.i. Furthermore, an increased percentage of T-cells, distinguished by the CD3 marker, was found 2 and 
4 days p.i. A similar increase was observed for both CD4+CD8- and CD8+CD4- T-cell subsets, indicating that this 
increase was not specific for either T helper or cytotoxic T-cells. The CD4+ cells increased significantly 21 days 
p.i. and remained constant until at least 28 days p.i. B-cells decreased during two periods: 2-4 and 10-14 days 
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Figure S3 - Flow cytometric-gating strategy for CD14+, Gr-1+, CD19+, and CD11b+ cell population analysis in 
splenocytes. Each FACS plot shows results from one mouse of the group. Per cell type, the change in numbers 
of cells is visible over time for CD14+, Gr-1+, CD19+, and CD11b+ cell populations. Time points 2 hours, 6 hours 
and 10 days p.i. were excluded in this figure. (*) FACS plot for CD14+ cells at day 4 and day 7 p.i. were manually 
adapted by BiExponential transformation in FlowJo for better visualization without influencing the gating.
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Figure S4 - Flow cytometric-gating strategy for CD3+, CD4+, CD8+, DX5+ and 33D1+ cell population analysis in 
splenocytes. Each FACS plot shows results from one mouse of the group. Per cell type, the change in numbers 
of cells is visible over time for CD3+, CD4+, CD8+, DX5+, and 33D1+ cell populations. Time points 2 hours, 6 hours, 
and 10 days p.i. were excluded in this figure. (*) FACS plot for 33D1+ cells at day 1, day 7, and day 14 p.i. were 










































































































































































































Figure S5 - Splenic gene expression profiles of cell types and tissues extracted from BioGPS databases. Data 
(mean of n = 3) represent gene profiles of the following cell types or tissues: B-cells, neutrophils, mast cells, 
T-cells, macrophages, dendritic cells (DCs), lung, lymph nodes, and spleen.
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Figure S6 - Genes differentially regulated in both lung and spleen. Comparison of transcriptomic data in lung 
and spleen (mean of n = 3) revealed an overlap of 72 genes differentially regulated in both tissues. Genes 
divided in 4 groups based on expression pattern. Functional annotation showed that genes in group 2 were 
mostly involved in immunological processes.
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Figure S7 - IgG antibody response in serum against Ptx, Prn, FHA, and Fim2/3 after B. pertussis infection. 
IgG antibody titers against four purified B. pertussis antigens; (A) pertussis toxin (Ptx), (B) pertactin (Prn), 
(C) filamentous hemagglutinin (FHA), and (D) Fimbriae 2 and 3 (Fim2/3) were determined using a multiplex 
immunoassay (mean of n = 3). The antibody titers were determined in mouse sera 14, 21, and 28 days after an 
intranasal infection with B. pertussis. No antibodies were detected for Ptx, Prn, and Fim2/3. For FHA, 1 out of 3 
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Table S1 - Full list of genes expressed in the lungs. This supplementary table can be found in the online version 
at http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0104548. This table contains the full list of 
significantly expressed genes obtained by microarray analysis of the lungs, which can be used for additional 
in-depth information for each gene. In total 558 genes were significantly altered compared to naive mice. The 
expression pattern for each gene is given including the fold changes at each time point. In addition to the 
official gene symbol (obtained from the Nimblegen array), the full gene name, synonyms and gene ID are given. 
Synonyms are not given for all genes but only for genes that were included in detail in the manuscript. Gene ID is a 
linked to gene information on the NCBI website. Subsequently, there are three columns with gene information 
obtained in databases; (i) BioGPS, (ii) Gene Ontology - Biological Processes (GO-BP), (iii) KEGG pathways. Pull-
down menus can be used to search for specific information in the full gene list. For BioGPS, information about 
cell and tissue specific gene expression is given for the following databases; B-cells (B), dendritic cells (DC), lung 
(Lu), lymph node (LN), mast cells (MC), macrophages (MF), neutrophils (N), spleen (Sp) and T-cells (T). For GO-
BP the following biological processes were included; ‘acute inflammatory response’, ‘acute-phase response’, 
‘antigen processing and presentation’, ‘cell activation’, ‘chemotaxis’, ‘defense response’, ‘immune response’, 
‘inflammatory response’, ‘intracellular signaling cascade’, ‘phagocytosis’, ‘regulation of apoptosis’, ‘response 
to bacterium’, and ‘transcription’. For KEGG the following pathways were included; ‘Antigen processing and 
presentation’, ‘Apoptosis’, ‘B-cell receptor signaling pathway’, ‘Cell adhesion molecules (CAMs)’, ‘Chemokine 
signaling pathway’, ‘Complement and coagulation cascades’, ‘Cytokine-cytokine receptor interaction’, 
‘Endocytosis’, ‘Leukocyte transendothelial migration’, ‘MAPK signaling pathway’, ‘NOD-like receptor signaling 
pathway’, and ‘Toll-like receptor signaling pathway’.
Table S2 - Full list of genes expressed in the spleen. This supplementary table can be found in the online 
version at http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0104548. This table contains the 
full list of significantly expressed genes obtained by microarray analysis of the spleen, which can be used for 
additional in-depth information for each gene. In total, 798 genes were significantly altered compared to naive 
mice. The expression pattern for each gene is given including the fold changes at each time point. In addition 
to the official gene symbol (obtained from the Nimblegen array), the full gene name, synonyms and gene ID are 
given. Synonyms are not given for all genes but only for genes that were included in detail in the manuscript. 
Gene ID is a linked to gene information on the NCBI website. Subsequently, there are three columns with 
gene information obtained in databases; (i) BioGPS, (ii) Gene Ontology – Biological Processes (GO-BP), (iii) 
KEGG pathways. Pull-down menus can be used to search for specific information in the full gene list. For 
BioGPS, information about cell and tissue specific gene expression is given for the following databases; B-cells 
(B), dendritic cells (DC), lung (Lu), lymph node (LN), mast cells (MC), macrophages (MF), neutrophils (N), 
spleen (Sp) and T-cells (T). For GO-BP the following biological processes were included; ‘acute inflammatory 
response’, ‘antigen processing and presentation’, ‘cell activation’, ‘chemotaxis’, ‘chromatin assembly’, 
‘defense response’, ‘hemopoiesis’, ‘immune response’, ‘inflammatory response’, ‘intracellular signaling 
cascade’, ‘regulation of apoptosis’, ‘response to bacterium’ and ‘transcription’. For KEGG the following 
pathways were included; ‘Antigen processing and presentation’, ‘Apoptosis’, ‘B-cell receptor signaling 
pathway’, ‘Cell adhesion molecules (CAMs)’, ‘Chemokine signaling pathway’, ‘Complement and coagulation 
cascades’, ‘Cytokine-cytokine receptor interaction’, ‘Endocytosis’, ‘Leukocyte transendothelial migration’, 
‘MAPK signaling pathway’, ‘NOD-like receptor signaling pathway’ and ‘Toll-like receptor signaling pathway’.
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Abstract
Effective immunity against Bordetella pertussis is currently under discussion following the 
stacking evidence of pertussis resurgence in the vaccinated population. Natural immunity 
is more effective than vaccine-induced immunity. This indicates that much is still to be learnt 
from infection-induced immune memory and the mechanisms at work during the control 
of challenge inoculum to improve vaccination strategies. We applied a systems biology 
approach comprising microarray, flow cytometry and multiplex immunoassays to unravel 
the molecular and cellular signatures in unprotected mice and protected mice with infection-
induced immunity, around a B. pertussis challenge. Pre-existing systemic memory Th1/Th17 
cells, memory B-cells, and mucosal IgA specific for Ptx, Vag8, Fim2/3 were detected in the 
protected mice 56 days after an experimental infection. In addition, pre-existing high activity 
and reactivation of pulmonary innate cells such as alveolar macrophages, M-cells and goblet 
cells was detected. The pro-inflammatory responses in the lungs and serum, and neutrophil 
recruitment in the spleen upon an infectious challenge of unprotected mice were absent in 
protected mice. Instead, fast pulmonary immune responses in protected mice led to efficient 
bacterial clearance and harbored potential new gene markers that contribute to immunity 
against B. pertussis. These responses comprised of innate makers, such as Clca3, Retlna, 
Glycam1, Gp2, and Umod, next to adaptive markers, such as CCR6+ B-cells, CCR6+ Th17 cells and 
CXCR6+ T-cells as demonstrated by transcriptome analysis. In conclusion, besides effective 
Th1/Th17 and mucosal IgA responses, the primary infection-induced immunity benefits 
from activation of pulmonary resident innate immune cells, achieved by local pathogen-
recognition. These molecular signatures of primary infection-induced immunity provided 




The resurgence of pertussis in the vaccinated population prompts the necessity of more 
knowledge on effective immunity against Bordetella pertussis [1, 2]. This global health 
problem occurs after vaccination with acellular pertussis vaccines (aPV) and whole-cell 
pertussis vaccines (wPV) as recent data point out [3]. aPV-vaccinated individuals face waning 
immunity early after vaccination, since the vaccine-induced immunity lasts for only 4-12 years 
[4, 5] despite multiple booster vaccinations [6]. Moreover, research in baboons revealed 
that aPV-vaccinated animals are protected against disease, but still harbor viable bacteria 
resulting in continuation of pathogen transmission [7]. These findings indicate that even aPV-
vaccinated individuals may act as an important resource for the transmission of B. pertussis 
[8, 9]. Hence, the present situation necessitates the reevaluation of pertussis immunity and 
vaccination strategies.
The immunity induced by a B. pertussis infection may provide crucial information for improving 
vaccine-induced immunity, since it provides important advantages compared to immunity 
induced by aPV or wPV. Infection-induced immunity continues for a longer period [4, 5] and 
it leads to sterilizing immunity in mice and baboons [7, 10]. Infection as well as aPV and wPV 
vaccination induces strong systemic responses, but infection induces a mucosal immune 
response at the site of pathogen entry in addition. As others and we recently showed, this 
immunity includes pulmonary IgA, systemic IgG [10] and specific Th1/Th17 responses [10-12]. 
The lungs are naturally exposed to pathogens and therefore equipped with a large number 
of immune cells and an epithelial layer. The lung epithelial cells offer a first line of defense by 
secretion of anti-microbial peptides and pathogen recognition, but also by interaction with 
the local innate immune cells [13]. These innate immune cells include mucin-secreting goblet 
cells [14], alveolar macrophages [15] and the upper layer of the bronchus-associated lymphoid 
tissue (BALT) [16], that act in the same way as microfold (M)-cells [17], harbor functions, such 
as pathogen recognition and antigen-uptake. These pulmonary innate cells orchestrate the 
specific adaptive immune responses, such as mucosal IgA production and activation of tissue-
resident B-cells and T-cells in the BALT [16].
In this study, we further explored the molecular and cellular events underlying infection-
induced protective immune responses. To this end, pulmonary transcriptomic profiles were 
characterized around the challenge of mice protected by primary infection-induced immunity, 
in comparison to events in unprotected counterparts. Additionally, pulmonary and systemic 
cytokine profiles as well as cellular and antibody mediated immune responses against B. 
pertussis were studied. Markers for pulmonary immunity included both trained innate and 
adaptive signatures. M-cells, alveolar macrophages and epithelial cells characterized the 
former, and CCR6+ B-cells, CCR6+ Th17 cells, CXCR6+ T-cells and mucosal IgA the latter. These 
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extensive insights into the signatures of infection-induced immunity involving important 
pulmonary components may be used for the development of improved pertussis vaccines 




Pre-existing immunological signatures in protected mice before B. pertussis 
challenge.
Recovery from a B. pertussis infection in BALB/c mice is associated with sterilizing immunity. 
A challenge with B. pertussis bacteria showed that the lungs were cleared within two days 
in these protected mice, whereas this takes approximately 28 days in unprotected mice 
[10]. To understand infection-induced protection in more detail we designed a systems 
biology approach to study pre- and post-challenge immune responses in unprotected and 
Figure 1 - Design and baseline parameters of a B. pertussis challenge model in protected and naive 
unprotected mice. (A) Schematic diagram of animal pre-treatment, sacrifice, sampling and systems analysis 
on 4 hours and 2, 7, 10 and 14 days p.c. in a B. pertussis challenge model in protected and unprotected BALB/c 
mice. Pulmonary transcriptomic profile, percentage of splenic Gr1+ cells (neutrophils), serum and lung cytokine 
profiles, serum and lung antibody profiles, and specific splenic CD4+CD44+ T-cells were assessed at the given 
time points in protected and unprotected mice. (B) Study parameters at baseline (D0) of naive unprotected 
mice and protected mice, 56 days after primary infection, including time frames of lung clearance, systemic 
T-helper subsets, serum IgG profile, mucosal IgA, and pulmonary transcriptomic profile as obtained from data 
in the current study and data adapted from our previous study [10]. 320 genes are differential expressed in 
protected mice compared to naive (D0 unprotected) mice. (C) An overrepresentation analysis was performed 
using DAVID for Keywords, KEGG-pathways, and gene ontology biological pathways (GO-BP) to determine the 
function of the 320 genes. For each term, the number of upregulated (red) and downregulated (green) genes 
are depicted.
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protected mice, recovered from a primary infection received 56 days before (Figure 1A). 
Before the receiving the challenge inoculum (D0), protected mice showed enhanced levels 
of B. pertussis-specific serum IgG, mucosal IgA in the lungs, and Th1/Th17 cells in the spleen, 
which were absent in naive (D0 unprotected) mice (Figure 1B). When comparing levels of 
pulmonary gene expression, 320 genes were still differentially expressed, mostly upregulated, 
in the lungs of protected compared to naive (D0 unprotected) mice. An overrepresentation 
analysis (ORA) was performed using DAVID [18] to ascribe the functional group to which 
the 320 corresponding proteins belong (Figure 1C). The data analysis indicated that the 
pulmonary gene expression of protected mice was enriched with 33 and 27 genes involved 
in immune response and defense response, respectively. Upregulated genes were further 
involved in antigen processing, the innate response and several terms indicating B-cell 
mediated immunity. Notably, a large number of both downregulated and upregulated genes 
were related to alternative splicing. In conclusion, these results indicated that the protected 
mice with infection-induced immunity contain a large variety of adaptive and additionally still 
some innate markers to resist a new B. pertussis challenge as compared to their unprotected 
naive counterparts.
Pulmonary transcriptome of protected and unprotected mice receiving a B. 
pertussis challenge.
To gain more insight into gene transcription patterns associated with fast clearance of B. 
pertussis and protection, we subsequently assessed the pulmonary transcriptome over a 
period of 14 days post challenge (p.c.) in protected and post infection (p.i.) in unprotected 
mice in comparison to naive non-challenged mice (unprotected D0) (Figure 2A). In total, 786 
genes were differentially regulated (p-value ≤ 0.001, fold ratio (FR) ≥ 1.5). These genes were 
divided in six clusters (I - VI) based on differential expression in unprotected and protected 
mice (Figure 2). Cluster I: differential expression in unprotected mice, absent in protected 
mice; cluster II: differential expression in both unprotected mice and protected mice; cluster 
III: differential expression in unprotected mice and in protected mice pre- or post-challenge; 
cluster IV: differential expression in unprotected mice and additional differential expression 
post-challenge in protected mice; cluster V: absent in unprotected mice but differential 
expression in protected mice; cluster VI: absent in unprotected mice but differential 
expression pre- and post-challenge in protected mice. 
The individual fold ratios (FR) of 786 differentially expressed genes were plotted for each 
time point after being analyzed in protected and unprotected mice (Figure S1A). Before 
the challenge (D0), already 320 genes were differentially regulated in the protected mice if 
compared to the unprotected mice. Furthermore, this analysis revealed that on 2 days p.c. 
the largest number of genes was differentially expressed between both groups, namely 
212 genes of which 108 genes were upregulated and 104 were downregulated. Since the 
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[10], signatures underlying this immunity could be detected on 2 days p.c. in protected mice. 
Therefore, the transcriptomic profiles of the 786 genes were investigated in detail on 2 days 
p.c. (Figure 2B). Subsequent to the comparison of both datasets to naive mice, the fold ratios 
of each gene was calculated between the datasets of unprotected versus protected mice 
obtained 2 days p.c. (FR ≥ 1.5 or ≤ 0.67, red triangles) (Figure 2B). The scatter plot was divided 
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in eight different fractions that were significantly upregulated (1-4) or downregulated (5-8) 
in protected mice compared to unprotected mice 2 days p.c. The genes of these fractions 
were shown as heatmaps (Figure S1B). Many genes are involved in innate (e.g. A2m, Saa3, 
C3, Reg3g, Umod) and adaptive (e.g. Cd4, Ighg, Cxcr6, Ccr6, Cd22) immune responses were 
upregulated in protected mice.
An ORA for KEGG pathways and GO-BP terms was performed on all 786 genes. In total, 97 
terms were enriched (Benjamini ≤ 0.05). The number of upregulated and downregulated 
genes and the kinetics for a subset of these terms was determined (Figure 2C-D). Enriched 
terms contained genes involved in immune response (79 genes) including innate immune 
functions such as acute phase (9 genes), antigen presentation (20 genes), chemotaxis (29 
genes), and pathogen recognition through the NOD-like receptor (11 genes). Moreover, terms 
incorporated in the adaptive immune response (16 genes) involved antibody response (16 
genes), IgA responses (13 genes) and T-cell activation (13 genes) (Figure 2D). The expression 
kinetics were determined by averaging the FR for each time point for a selection of these 
enriched terms (Figure 2C). This analysis showed that post-challenge in protected mice the 
immunoglobulin-mediated immune response remained high (4h-D14). The complement 
response, antigen-presentation, and T-cell activation were still moderately enhanced in 
protected mice. Furthermore, genes belonging to acute phase, cytokine responses, apoptosis 
and cell division were expressed to a lesser extent upon challenge in protected mice than in 
unprotected mice.
Figure 2 (Left) - Pulmonary gene expression profiles in protected and unprotected mice following a B. 
pertussis challenge. (A) Fold changes in gene expression of both unprotected and protected mice were 
calculated compared to naive mice (D0 unprotected). The expression results (FR ≥ 1.5, p-value ≤ 0.001) are 
visualized as heatmap (mean of n = 3). Genes not exceeding a fold change of 1.5 are depicted as basal level 
(black) at this time point. In total, 786 genes were found to be differentially regulated. Genes were divided in 
six clusters (I-VI) based on their expression profiles (color coding for these clusters is depicted in an additional 
table): cluster I (Differential expression in unprotected mice, absent in protected mice), Cluster II (Differential 
expression in unprotected mice and protected mice), Cluster III (Differential expression in unprotected mice 
and in protected mice before and after challenge), Cluster IV (Differential expression in unprotected mice and 
additional differential expression as result of challenge in protected mice), Cluster V (Absent in unprotected 
mice but differential expression in protected mice) and Cluster VI (absent in unprotected mice but differential 
expression pre- and post-challenge in protected mice). (B) Transcriptomic profiles obtained on 2 days p.i. in 
unprotected and 2 days p.c. protected mice were compared by plotting all 786 genes in a scatter plot and 
divide the genes in different fractions based on co-expression. The black solid lines are the thresholds for the 
significant FR (FR ≥ 1.5 or ≤ 0.67) compared to naive mice (D0 unprotected) for both unprotected and protected 
mice. Black dots represent genes that are not significantly regulated compared to naive mice (D0 unprotected) 
in both groups. The red solid lines represent the threshold for the significant FR (FR ≥ 1.5 or ≤ 0.67) of both 
unprotected 2 days p.i. and protected mice 2 days p.c. All red triangles represent genes that show significant 
differential expression (FR ≥ 1.5 or ≤ 0.67) between unprotected  2 days p.i. and protected mice 2 days p.c. In 
total, 212 genes were differentially expressed between both groups of which 108 genes were upregulated and 
104 were downregulated. These genes were divided in eight fractions that are significantly up-regulated (1-4) or 
downregulated (5-8) in protected mice compared to unprotected mice and are further specified as heatmaps 
in Figure S1B. Dots with other colors (orange, green, brown, and blue) represent genes that are significantly 
regulated in unprotected and/or protected mice compared to naive mice (D0 unprotected) but these genes are 
not differentially regulated between unprotected 2 days p.i. and protected mice 2 days p.c. (C-D) A selection of 
eight terms (KEGG-pathways and GO-BP terms) found enriched in the ORA of the 786 genes and the kinetics 
over time of indicated terms is depicted. (C) Kinetics was determined by averaging the FR for each term at each 
time point and is expressed on LN-scale. (D) For each enriched term, the Benjamini score and the number of 
upregulated (red) and downregulated (green) genes in the protected mice and unprotected mice is shown.
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While the ORA gave an insight in several functions involved upon challenge of protected as 
well as unprotected mice, a large number of genes that were differentially regulated in our 
dataset were not annotated. To obtain in depth information on the function of these genes, 
we performed additional text mining on all individual genes using BioGPS, GeneRifs, and the 
literature (Pubmed). Based on this information, selected genes could be grouped according 
to function such as T-cell-related responses, B-cell-related responses, membrane receptors 
and secreted proteins, as is described in more detail hereafter.
Gene expression of membrane receptors and secreted proteins
The gene expression profiles of membrane receptors and secreted proteins indicated the 
involvement of specific cell types and biological processes. Therefore, the expression of 
all genes encoding for membrane proteins and secreted proteins was further investigated 
(Figure 3) and divided in four groups (Group A-D), based on their involvement during the first 
two days following challenge. 
Genes in group A were mainly upregulated in unprotected mice 7-14 days p.i., but unaltered 
in protected mice. Therefore, this gene expression is essential for a first encounter with B. 
pertussis, but it is not required for protected mice. In group A, membrane marker genes 
were in general related to myeloid cells (Cd300lf, Fcgr4, Gp49a, Cd200r1, Cd302, Lair1, Sirpb1a). 
Other membrane marker genes are specific, for example for neutrophils (Cxcr2, Fpr1, Fpr2) 
or for macrophages, such as Il1rn, killer-cell lectin-like receptors (Klra2, Klra17), C-type lectins 
(Clec4a2, Clec4a3, Clec4b1, Clec4d) and membrane-spanning four-domains, subfamily A 
(Ms4a6c, Ms4a6d, Ms4a4a, Ms4a4c). Moreover, the expression of Cd1d1 and Cd1d2, involved 
in MHC Class I antigen presentation, C3ar1 (APCs, Macrophages, T-cell activation), Clmp (cell-
cell adhesion molecule), and Chl1 was only upregulated in unprotected mice. In addition, 
expression of some T-cell-related genes (Art2b, Cd48) were found. Art2b is constitutively 
expressed on T-cells, whereas Cd48 is expressed on multiple immune cells playing a major 
role in T-cell activation. Finally, podoplanin (Pdpn) which is a lung injury marker and serves 
as a CD4+ effector T-cell inhibitor [19], was only expressed in unprotected mice. Among the 
genes encoding secreted proteins, expression of a number of acute inflammatory genes 
was altered in unprotected mice (Cp, Fn1, Il1a, Il1b, Il6, Ptx3, Saa1, S100a9, S100a8), but not 
in protected mice. Some genes are involved in blood vessel formation (Fn1, Vegfc, Vegfd) or 
LPS-binding (Crispld2). Furthermore, the genes of a Th17-specific cytokine (Il17f), and mucosal 
chemokines attracting IgA plasmablasts (Ccl28) and CCR7+ lymphocytes (Ccl21b) were only 
upregulated in unprotected mice.
The genes in group B were not expressed until 7 days p.i. in unprotected mice. However, in 
protected mice, these genes were already upregulated between 4 hours and 2 days p.c. Here, 
higher activity of microfold cells (M-cells) was suggested by enhanced gene expression of 
Gp2 and Umod. Moreover, macrophage-related genes (Basp1, Mpeg1, Ms4a7), innate-specific 
receptors such as Fc-receptors (Fcgr2b, Fcer1g, Fcgr3) and genes important for function 
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of multiple innate cells (Fnbp1, Parm1, Cdhr1) were expressed earlier in protected mice. 
Additionally, gene expression of membrane markers (Vcam1, Cd22, Cd72, Cd4, Cd3g, Cxcr6, 
Ccr6, Art2a-ps) demonstrated earlier adhesion of immune cells in the lungs of protected 
mice. It indicated early presence of adaptive immune cells such as B-cells (Cd22, Cd72, Ccr6) 
and T-cells (Cd4, Cd3g, Cxcr6, Ccr6, Art2a-ps). In total, 16 genes encoding secreted proteins 
were still upregulated in protected mice before challenge, whereas seven genes were 
reactivated following the challenge. These genes included many chemoattractants (Ccl8, 
Cxcl9, Cxcl12, Cxcl13, Ccl19, Glycam1, Gm12407, Gm2023, Gm1987). Some genes are associated 
with attracting specific cells, such as B-cells (Cxcl13), CXCR4+ lymphocytes (Cxcl12), CCR7+ 
lymphocytes (Ccl19), CD62l+ lymphocytes (Glycam1), CXCR3+ T-cells (Cxcl9), and CCR5+ cells 
(Ccl8). In addition, upregulation was detected for genes associated with antibodies (Ighg), 
complement (C1qa, C1qb, C1qc), activated macrophages (Aif1), Peyer’s patches (Pglyrp1), 
matrix metalloproteinases (Mmp3, Mmp12) and an MMP inhibitor (Timp4), increased mucus 
production by goblet cells (Agr2, Clca1, Clca3, Clca4) and genes related to lipid metabolism 
(Apod, Pla2g2d). Expression of Pla2g2d in DCs and macrophages is related to induction of anti-
inflammatory lipid mediators [20].
Most genes in group C were upregulated early (4 hours) after challenge in protected and 
unprotected mice. Analyzing the membrane markers, the expression of 12 genes was 
still upregulated prior to the challenge of protected mice, while the other 13 genes were 
reactivated post-challenge. The membrane marker genes in group C included a neutrophil 
specific marker (Cd177), for which the expression was earlier and more intense in protected 
mice. A similar observation was found for Pigr, which traffics IgA across the epithelial barrier. 
The C-type lectins (Clec4e, Clec4n), found on DCs, were detected in unprotected mice till 7 
days p.i., but were only expressed in protected mice 4 hours p.c. The early expression of 
Cd14 suggests LPS binding in both protected and unprotected mice, whereas Tlr2 is involved 
in pathogen recognition. Additionally, markers for antigen presentation (Cd74, H2-d1), 
macrophages (Msr1), regulation of anti-inflammatory activities in murine airways (Adam8) 
[21], epithelial cells (Pigr, Rab11b, Retnla), DCs (Cd209f), and the endothelial marker Plvap, 
which enables lymphocytes to enter the lungs [22], were detected in this group of genes. 
Among the genes encoding secreted proteins, a selection of acute phase genes (Saa3, Reg3g, 
Lcn2) were highly upregulated in protected and unprotected mice. However, the expression 
went down after 2 days p.c. whereas this continued in unprotected mice. In protected mice, 
Cxcl5 remained highly upregulated while Cxcl1, Cxcl2, and Cxcl3 were expressed for a limited 
amount of time. The chemokines encoded by Cxcl1, Cxcl2, Cxcl3 and Cxcl5 are involved in 
CXCR2+ leukocyte recruitment. Expression of Ccl20, the chemokine attracting CCR6+ cells, 
was increased more intensely in protected mice than in unprotected mice. In addition, genes 
involved in the complement system (Cfb, C3, C4b), cytokine expression (Ccl2, Ccl7, Ccl17, 
Cxcl17), mucosal tissue repair (Tff2), epithelial cells (Cyr61), and mast cells (5730469M10RIK / 


















































































































































































































































Figure 3 - Pulmonary gene expression profiles of membrane proteins and secreted proteins in protected 
and unprotected mice following B. pertussis challenge. Expression profiles of genes in the lungs encoding 
membrane proteins (left panel) and secreted proteins (right panel) were selected according to GO-BP terms, 
KEGG pathways and text mining. Each list is divided in four groups (A-D) based on their expression profile 
on 4 hours and 2 days p.c. Group A contains genes that are significantly upregulated in unprotected mice, 
but unaltered in protected mice. Group B covers genes that are not upregulated on 4 hours and 2 days p.i. 
in unprotected mice, but are directly activated in protected mice. Group C comprehends genes that are 
upregulated on 4 hours and/or 2 days p.c. in both protected and unprotected mice. Group D includes genes 
that are significantly regulated from 7 days p.c. in both protected and unprotected mice. In addition, the color 
codes of the six clusters from Figure 2 are added.
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Figure 4 - Pulmonary gene expression profiles of genes related to T-cells, B-cells, MHC-I and II and novel genes 
in protected and unprotected mice following B. pertussis challenge. Expression profiles of genes in the lungs 
related to (A) T-cells, (B) B-cells, (C) and antigen presentation by MHC-I and MHC-II were selected according 
to GO-BP terms, KEGG pathways and text mining. In addition, genes with unknown or poorly understood 
function that showed interesting gene expression profiles in protected mice were listed as (D) novel genes. 
Additionally, the color codes of the six clusters from Figure 2 are added.
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Genes in group D were mainly up-regulated in protected and unprotected mice between 7 and 
14 days p.c. The expression of these genes returned faster to basal level in protected mice than 
in unprotected mice. Based on the membrane-related genes in group D, this phase indicates 
innate and adaptive immune cells interacting with each other (Clec9a, Clec10a, Clec12a, Il7r, Thy1, 
Trav3n-3). For example, genes were detected related to T-cells (Il7r, Thy1, Trav3n-3), DCs (Clec9a, 
Clec10a, Clec12a), leukocytes (Lilrb4), macrophages (Igsf6) and lymphocytes or myeloid cells 
(Cd52). Group D also contained the upregulated gene Spp1. The corresponding protein of Spp1 
is also known as osteopontin (OPN), which is produced by many different immune cells and 
possesses many immunological functions [23]. However, the expression of this gene was not 
different between protected and unprotected mice.
B-cell and antibody-related signatures
The enhanced gene expression for the B-cell chemoattractant Cxcl13, detected 7 days p.i., 
suggested recruitment of B-cells towards the lungs of unprotected mice (Figure 4A). In 
protected mice, the expression of Cxcl13 had raised earlier at 2 days p.c. Increased expression 
of antibody-related genes indicated B-cell recruitment to the lungs 14 days p.i. in unprotected 
mice. Higher and earlier expression of the immunoglobulin-related genes (i.e. Igj, Igk, Ighm, Igkc) 
was observed in protected mice than in unprotected mice (Figure 4A). These immunoglobulin-
related genes indicated the formation of IgM, IgG and IgA by these B-cells in the lung. Notably, 
a small decrease in expression of antibody-related genes occurred 2 days p.c. in protected 
mice. Furthermore, genes of the classic complement pathway were co-expressed with the 
immunoglobulin-related genes. Genes of B-cell inhibitory receptors (Cd22, Cd72, Fcgr2b) were 
expressed slightly earlier in protected mice compared to unprotected mice. Moreover, the co-
stimulatory receptor Ifitm1 was earlier and more constant in protected mice. The upregulation of 
Ccl28 in unprotected mice 14 days p.i. indicated homing of IgA producing B-cells to the mucosa. 
However, the expression of Ccl28 was absent in protected mice. The upregulation of Pigr, the 
IgA transporter on epithelial cells, suggested an increase of IgA in the mucosa of protected and 
unprotected mice.
T-cell-related signatures
Gene expression of T-cell-related markers (Cd3g, Cd4) indicated the presence of T-cells, most 
likely T-helper (Th) cells, in the lungs of unprotected mice around 14 days p.i. (Figure 4B). 
The upregulation of Cd3g and Cd4 is still present in protected mice prior to the challenge. The 
enhanced RNA levels remain high during challenge of these mice. In addition, multiple T-cell-
related genes (Il7r, Cxcr6, Thy1) were upregulated 14 days p.i. in unprotected mice. The expression 
in protected mice was observed earlier at 7 days p.c., indicating a faster recall of memory T-cell 
responses. Expression of the IL-7 receptor gene (Il7rI) indicated the presence of memory T-cells. 
The Th17 specific cytokine gene (Il17f) was significantly upregulated in unprotected mice, but 
unaffected in protected mice. Resistin-like alpha (Retnla) was earlier expressed by epithelial 
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cells in protected mice, and the expression was already diminished 7 days p.c. Resistin-like alpha 
stimulates Th17 responses [24].
Antigen presentation
Genes related to MHC class I and II were upregulated in unprotected mice following the 
challenge (Figure 4C). Whereas enhanced MHC-I expression was observed during the whole 
course of the challenge, MHC-II expression was found upregulated 7-14 days p.i. In protected 
mice, genes related to both antigen-presenting pathways were expressed at every time point 
and decreased 14 days p.c.
Genes not previously described in the context of immunity against B. pertussis
Some genes showed increased expression in response to B. pertussis challenge, but limited or 
no information is available about their function (Figure 4D). The expression of most of these 
genes was induced during the adaptive phase in unprotected mice and persisted in protected 
mice after challenge. Therefore, these genes may play an important role in immunity against 
B. pertussis. These genes include members of the SPEER-family (4930572o03rik, Speer7-ps1, 
Speer4b, Speer4c, Speer4e, Gm5862, Gm9758), chloride channel calcium activated channels 
(Clca1, Clca3, Clca4), microRNAs (Mir142, Mir147, Mir5117), a transcription factor (Akna), and 
X-linked lymphocyte-regulated genes (Xlr4a, Xlr4b). Significant expression of cell proliferation 
marker Ki-67 was found in unprotected mice, but unaffected in protected mice. Moreover, the 
expression of M-cell specific genes (Gp2, Umod), an effector protein of CD4+CD25+ regulatory 
T-cells (Pla2g2d) [25], and of Glycam1, Pglyrp1, and Retnla were expressed earlier or to a stronger 
extent in protected mice compared to unprotected mice yet their involvement is not previously 
described in the context of immunity against B. pertussis.
Modulated cytokine levels in lung tissue extract
The protein concentrations of 32 cytokines in the lungs were analyzed. The concentrations 
of thirteen cytokines significantly changed following a B. pertussis challenge in protected and 
unprotected mice (Figure 5). CCL4 was decreased in protected mice 10 days p.c. (Figure 5A). 
CCL11 decreased in unprotected mice until 14 days p.i. and in protected mice until 2 days p.i. 
(Figure 5B). Moreover, a significant decrease occurred for VEGF in unprotected mice between 
2-7 days p.i., which was less dramatic in protected mice (Figure 5C). In unprotected mice, G-CSF 
concentrations were elevated 7 days p.i. In protected mice, higher concentrations of G-CSF were 
found already at 4 hours and 2 days p.c. (Figure 5D). Both CXCL1 and CXCL2 were enhanced in 
unprotected mice, whereas only CXCL1 was significantly increased 4 hours p.c. in protected mice 
(Figure 5E-F). CXCL5 was significantly induced in unprotected mice and remained elevated until 
7 days p.i. (Figure 5G). CXCL9, CXCL10 and IL-17A were elicited 14 days p.i. in unprotected mice, 
but they were absent in protected mice (Figure 5H-J). IL-5, TNFα and M-CSF were produced in 
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Figure 5 - Cytokine profiles in the lungs following B. pertussis challenge in unprotected and protected mice. 
Pulmonary concentrations of (A) CCL4, (B) CCL11, (C) VEGF, (D) G-CSF, (E) CXCL1, (F) CXCL2, (G) CXCL5, (H) 
CXCL9, (I) CXCL10, (J) IL-17A, (K) IL-5, (L) TNFα and (M) M-CSF were analyzed before and after a B. pertussis 
challenge in unprotected (lighter blue bars) and protected (dark blue and red bars) mice, as indicated. Data 
represented as mean concentrations of individual values (n = 3). Significant values were calculated by one-way 
ANOVA with multiple comparison compared to the pre-challenge level (D0) of unprotected mice or protected 
mice (* = p ≤ 0.05, ** = p ≤ 0.01, and *** = p ≤ 0.001, **** = p ≤ 0.0001).
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Figure 6 - Serum cytokine profiles and percentage of splenic 
neutrophils following B. pertussis challenge in unprotected 
and protected mice. (A) The serum concentrations of 33 
cytokines were analyzed before and after a B. pertussis 
challenge in unprotected (lighter blue bars) and protected 
(dark blue and red bars) mice, as indicated. Concentrations of 
CXCL13, CCL11, CXCL1, G-CSF, IL-6, CXCL10, and IL-13 serum were 
significantly altered and represented as mean concentrations 
of individual values (n = 3). Significant values were calculated 
by one-way ANOVA with multiple comparison compared to 
the pre-challenge level (D0) of unprotected mice or protected 
mice (* = p ≤ 0.05, ** = p ≤ 0.01, and *** = p ≤ 0.001). (B) The 
percentage of Gr1+ cells (neutrophils) was determined over 
time in the spleen of unprotected and protected mice by using 
Flow cytometry (* = p ≤ 0.05).
Enhanced cytokine levels in mouse serum
The concentrations of 33 cytokines were analyzed in serum of protected or unprotected mice 
before and following the B. pertussis challenge. Only for seven of these, significant alterations in 
their levels were found upon challenge (Figure 6A). The concentrations of CXCL1 (KC) and CCL11 
(Eotaxin) were increased 4 hours p.i. in unprotected mice. Higher concentrations of both IL-6 
and G-CSF were detected 7 days p.i. in unprotected mice. A decrease in both CXCL10 and IL-13 
occurred between 7-14 days p.i. in protected mice. B lymphocyte chemoattractant (BLC) CXCL13 
was elevated 14 days p.i. in unprotected mice and unaltered in protected mice. Overall, serum 
cytokines present during infection of unprotected mice are unaltered during the challenge of 
protected mice. In conclusion, these results indicate that systemic signals for pro-inflammatory 
cytokines (CXCL1 and IL-6) and recruitment of B-cells (CXCL13), T-cells (CCL11 and CXCL10) and 




In unprotected mice, neutrophils (Gr1+) play an important role in the clearance of bacteria 
from the lungs and are often used as marker of disease. This process is characterized by a 
gradually increased percentage of neutrophils in the spleen between 4 and 21 days p.i. [10]. 
Analysis of the percentage Gr1+ cells in the spleen following challenge in protected mice 
indicated that this recruitment of granulocytes did not occur 14 days p.c. whereas the drastic 
increase of granulocytes in unprotected mice was again observed (Figure 6B). Together, 
these results show that recruitment of circulating granulocytes/neutrophils occurs only in 
unprotected mice after a challenge. 
B. pertussis-specific antibody responses in serum and lung tissue extract
Levels of IgA, IgG, and IgG subclasses were determined just before and after 14 days challenge 
in sera of unprotected and protected mice (Figure 7A-E) B. pertussis outer membrane vesicles 
(OMV) and purified antigens (Prn, Ptx, FHA, and Fim2/3) were used as coating antigen. Only 
anti-OMV antibodies were induced in unprotected mice 14 days p.i., while antibodies against 
purified antigens could not be detected. Antibodies specific for all five purified antigens were 
observed in protected mice before challenge (D0).
After the challenge, anti-Ptx IgG and IgA levels dropped in protected mice, whereas the 
anti-OMV and anti-FHA IgG levels remained high. Moreover, the anti-Prn IgG1 and IgA levels 
decreased, while IgG2a and IgG2b levels increased. Notably, serum IgA levels against Fim2/3 
were only detected in protected mice 14 days p.c. In addition to systemic antibody levels, the 
local formation of IgA antibodies was determined in lung lysates (Figure 7F). Challenge in 
unprotected mice elicited mainly anti-OMV IgA, which was detected 14 days p.i.
In protected mice, anti-OMV IgA antibodies were present before challenge (D0) and were 
further increased 14 days p.c. Anti-Prn and anti-Fim2/3 IgA remained elevated, while anti-Ptx 
IgA decreased. Combined data of all time points showed a gradual increase of pulmonary 
anti-OMV IgA levels post-challenge in protected mice (Figure 7G). Western blotting and mass 
spectrometry was used to determine the antigen specificity of the anti-OMV IgA antibodies in 
protected mice before (D0) and after the challenge (D14) (Figure 7H). The IgA antibodies on 
D0 were solely directed against Vag8. Notably, challenge of protected mice led to strong anti-
LPS IgA antibody formation, whereas the level of anti-Vag8 antibodies remained unaltered 
(Figure 7H).
Specific CD4+ T-cell response in the spleen
After challenge, the presence and type of B. pertussis antigen-specific memory CD4+CD44+ 
T-cells in the spleen were determined. The cytokine production of CD4+ T-cells was analyzed 
according to the study design depicted in Figure 8A on single cell level and in culture 
supernatants after stimulation of splenocytes with Ptx, FHA, or Prn.  The CD4+ T-cell response 
was determined after primary infection of unprotected mice 10 days and 66 days p.i. (-D46 
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Unprotected mice (D0)
Unprotected mice 14 days p.i.
Protected mice (D0)







































































































































































































































































Figure 7 - Serum and pulmonary antibody profiles in unprotected and protected mice following B. pertussis 
challenge. Serum IgA, IgG, and IgG subclass responses specific for (A) OMV, (B) Ptx, (C) Prn, (D) FHA, and (E) 
Fim2/3 were determined by using a MIA. Data were obtained in naive mice and protected mice prior to challenge 
(D0) and 14 days post infection (p.i.) or 14 days post-challenge (p.c.) (n = 3 / time point). (F) Pulmonary IgA 
responses against these antigens were determined on the same time points. * = p ≤ 0.05 experimental group 
versus unprotected group (D0), + = p ≤ 0.05 protected group (D0) versus protected group (14 days p.c.). (G) The 
kinetics of the anti-OMV IgA antibody formation in lung lysates were analyzed at more time points (n=3/time 
point) and expressed in fluorescence intensity (F.I.). **** = p ≤ 0.0001, challenged unprotected or protected 
group versus unprotected or protected group (day 0), ++ and +++ = p ≤ 0.01 and p ≤ 0.001 unprotected group 
versus protected group (for each time point). (H) Western blot on separated B. pertussis B1917 proteins was 
performed with pooled lung lysates (1:50) of unprotected and protected mice prior to challenge (D0), and of 
protected mice 14 days p.c. with IR800-labeled secondary antibody. Left panel shows whole protein range 
(260kDa-<10kDa) of B. pertussis lysate. Right panel shows more detailed separation of the 110-60kDa protein 
range. Antigen identification for Vag8 and LPS is depicted.
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Figure 8 - Systemic T-cell responses in unprotected and protected mice. (A) Study design is depicted for the 
collection of splenocytes in two different experiments (-D46 and D10). The first experiment (-D46) included 
unprotected mice 10 days p.i. and naive mice. The second experiment (D10) included unprotected mice 66 days 
p.i., protected mice 10 days post-secondary challenge, and naive mice. Splenocytes were in vitro restimulated 
with Prn, FHA or Ptx for 8 days. (B) The percentages of IFNγ-, IL-5-, and IL-17A-producing CD4+CD44+ T-cells 
were determined using ICS (n = 6). (C) Cytokine levels of IL-4, IL-5, IL-10, IL-13, IL-17A, IFNγ, and TNFα in 
supernatant after 7 days of stimulation were determined by using a MIA. Results (mean of n = 6) are corrected 
for the background level in the presence of medium as control. Statistical differences between the groups 
were detected for the ICS with a non-parametric Mann-Whitney test and for the MIA with a Student t-test on 
the log-transformed data. * = p ≤ 0.05 experimental group versus naive group, # = p ≤ 0.05 protected group 
(D10) versus unprotected group (D10).
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and D10, respectively). Primary infection led to increased percentages of IFNγ- and IL-17A-
producing Prn-specific CD4+ T-cells on 10 days p.i. (-D46), which percentages significantly 
increased 66 days p.i. (D10). In addition, IFNγ- and IL-17A-producing FHA-specific CD4+CD44+ 
T-cells could be detected on this time point (Figure 8B). Protected mice received an intranasal 
B. pertussis challenge 56 days after the primary infection (D0) and showed increased 
percentages of IFNγ- and IL-17A-producing Prn-specific CD4+CD44+ T-cells on 10 days p.c. 
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compared to the percentage in naive mice. Notably, the percentage IL-17A-producing Prn-
specific CD4+CD44+ T-cells in these challenged protected mice 10 days p.c. was increased 
compared to the percentage in the unprotected mice on that time point (Figure 8B).
Cytokine levels in culture supernatant revealed that 10 days p.i. (-D46) splenocytes showed a 
moderate production of IL-5 and IFNγ after stimulation with Ptx and FHA, respectively (Figure 
8C). In unprotected mice that were sacrificed 66 days p.i. (D10), Prn-stimulation resulted in 
enhanced production of IL-5, IL-13, and IL-17A while production of IL-17A was also observed 
after Ptx stimulation. FHA stimulation caused production of IL-4, IL-5, IL-13, TNFα, IL-17A, and 
IL-10. Data obtained in protected mice 10 days p.c. revealed the induction of IL-5, IL-13 and IL-
17A after Prn-stimulation, increase in IFNγ- and IL-17A after Ptx-stimulation, and production of 
IL-5, IL-13, IFNγ, TNFα, IL-17A and IL-10 after FHA-stimulation. In conclusion, infection-induced 
T-cell responses were Th1 and Th17 mediated. Additionally, challenge of protected mice did 
not result in a dramatic booster of the CD4⁺ T-cell response, since only a higher percentage 




A Bordetella pertussis infection in mice or baboons causes sterilizing immunity [7, 10]. There 
are strong indications that the Th1/Th17 responses and mucosal IgA are major contributors 
to this superior protection [10-12]. Nevertheless, many immunological responses caused 
upon a B. pertussis infection are still not discovered. In the current study, protected and 
unprotected mice were challenged intranasally with B. pertussis after which innate and 
adaptive immunological signatures were identified associated with the infection-induced and 
excellent immunity in mice.
Protected mice had high levels of B. pertussis-specific serum IgG, mucosal IgA in the lungs 
and Th1/Th17 cells in the spleen, whereas unprotected mice have not. In addition, pulmonary 
molecular signatures in the protected mice revealed unique markers of B-cells, T-cells, and 
immunoglobulins, implying the presence of tissue-resident adaptive immune cells in the lungs. 
Moreover, molecular signatures of myeloid and mucosal-specific cells, such as mast cells and 
goblet cells were present. Interestingly, 320 genes were still differentially expressed before 
the challenge in protected mice as result of the first infection, as compared to unprotected 
mice before challenge. Since bacteria were cleared from the lungs 28 days after primary 
infection [10], the question was raised what is the source responsible for this upregulation. 
Possibly, a change in the cellular composition of the lungs due to residence of new innate 
and adaptive immune cells result an aberrant gene expression profiles. Importantly, the 
overall transcriptomics data indicate not only a relatively persistent and broadly altered 
adaptive pulmonary immune status but also maintained innate changes in protected mice in 
comparison to their naive counterparts.
Pathogenesis of pertussis in non-vaccinated individuals is characterized by prolonged 
bacterial presence and severe lung tissue distress and damage [26]. It is hypothesized that 
immune evasion strategies of B. pertussis [27] extend residence time. Ideally, pre-existing 
immunity induced by vaccination should provide fast clearance of pertussis bacteria and 
long-lasting immunity to avert bacterial transmission [7] and limit respiratory tissue damage. 
The absence of pro-inflammatory responses and neutrophil circulation may be signs of less 
severe disease. Protected mice, in contrast to unprotected mice, had reduced systemic serum 
cytokine secretion, including the pro-inflammatory cytokine IL-6 and neutrophil attractants 
(CXCL1 and G-CSF), and no induction of neutrophils in the spleens. Additionally, selective 
innate molecular signatures were absent in the lungs of protected mice following the B. 
pertussis challenge. This included genes encoding pro-inflammatory cytokines such as Il1a, 
Il1b, Il6 and Saa1 as part of the acute phase response. Moreover, enhanced gene expression 
of the KLR and CLEC-family, was not detected in protected mice. KLR and CLEC genes may 
harbor similar functions [28], which are specifically found on myeloid cells [29] and play an 
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important role in tissue infiltration of neutrophils following inflammation [30]. This lack of 
expression in protected mice implies that myeloid cells expressing these membrane markers 
are not required for the sterilizing immunity. Finally, the enhanced cell proliferation in the 
lungs of unprotected mice, based on the high expression of Ki-67, was absent in protected 
mice. Overall, the altered transcriptomes in the lungs of protected mice suggest that these 
mice are able to control the challenge locally without alarming systemic pro-inflammatory 
signals.
The acquired immune status of the protected mice enables an alternative solution for fast 
bacterial clearance with limited systemic recruitment of immune cells from the circulation. 
Specific markers (IL-5, TNFα and M-CSF) were exclusively present in the protected mice, 
which may contribute to the sterilizing immunity. Secretion of IL-5 indicates the presence 
of antigen specific Th2-cells in the lungs. However, no B. pertussis-specific Th2-cell formation 
was detected in the spleen of protected mice. Therefore, IL-5 could be produced by innate 
lymphoid cells (ILCs). The presence of ILCs is indicated by gene expression of Thy1 and Il7r 
[31]. While pulmonary innate immune cells still play a role during the challenge of protected 
mice, some of these cells signatures (i.e. Gp2, Umod, Pglyrp1, Clca3) were also highly active 
prior to the challenge. The pulmonary expression of Gp2 and Umod was increased in 
protected mice prior and post-challenge. Glycoprotein 2 (GP2) and uromodulin (Umod) are 
expressed on microfold cells (M-cells) [32]. M-cells facilitate the uptake of antigens at the 
mucosal site and the subsequent transportation across the epithelial barrier. GP2 serves as a 
receptor for mucosal antigen and binds adhesins on Fim+ bacteria [33], such as B. pertussis. 
Simultaneously, expression of peptidoglycan recognition protein 1 (Pglyrp1) was detected, 
which at the intestinal mucosal site is found in Peyer’s patches co-localized with M-cells [34]. 
This indicates that the M-cells are either increased in number or more active in protected mice 
prior and post-challenge. At the pulmonary site, M-cells are commonly found in the Bronchus-
Associated Lymphoid Tissue (BALT) [35] gathered with tissue-resident adaptive cells, such 
as B-cells and T-cells, facilitating a more efficient antigen presentation. This suggests that 
the local pulmonary immunity induced by a primary B. pertussis challenge is a result of not 
only the induction of acquired immunological memory, but also increased innate activity and 
subsequent interplay between of innate and acquired immune cells in the BALT. Enhanced 
expression of genes specific for goblet cells (mucus-producing cells), such as chloride 
channel calcium activated channels (Clca1, Clca3 and Clca4) and anterior gradient 2 (Agr2) [36] 
suggests that these cells are more active during the challenge in protected mice. Goblet cells 
can also orchestrate local immune responses. For instance, IL-17 and CXCL1 induction in the 
lungs and leukocyte recruitment are modulated by CLCA3 in mucus cells [37].
Myeloid cells play an important role in clearance of B. pertussis. For instance, a large 
neutrophil influx into the lungs occurs during the challenge of unprotected mice [10, 38]. 
Neutrophils are essential for phagocytosis and may serve as a marker for disease like white 
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blood cell counts for baboons and young infants [39, 40]. Myeloid cells expressing membrane 
markers of the KLRs, CLECs and the MS4A family [28, 29, 41] were absent in the protected 
mice after the challenge. However, the enhanced gene expression of the neutrophil-specific 
Cd177 and macrophage-specific Mpeg1 suggests involvement of other subsets of myeloid 
cells during the challenge in protected mice. The expression of CD177 on neutrophils is 
enhanced in the presence of G-CSF [42] which was also detected in the lungs of protected 
mice. These signatures could be related to changes in the pulmonary cell composition as a 
result of the first infection. For example, opsonization of bacteria by pre-existing specific 
antibodies and the subsequent phagocytosis by different myeloid cells enables an enhanced 
clearance of bacteria. In addition, the outgrowth of bacteria is absent in protected mice 
after challenge. Hence, the total number of phagocytes required for removal of bacteria is 
expected to be lower. Finally, the infection-induced immunity might result in signatures of 
airway specific cells, such as was detected for alveolar macrophages. Both GC-CSF and M-CSF 
play an important role in proliferation and differentiation of alveolar macrophages [43]. In 
addition, pulmonary secretion of M-CSF was detected exclusively in protected mice 4 hours 
p.c. This change in lung environment enables formation of specific alveolar macrophages 
with a very high antigen-presenting capacity [44]. The contribution of alveolar macrophages 
[45] and mast-cells [46] with respect to immunity against B. pertussis has previously been 
demonstrated.
Together these findings demonstrate that the infection-primed immunity resulted in the 
enhanced activity of pulmonary innate cells, such as alveolar macrophages, M-cells, and ILCs. 
This may indicate that these innate cells have trained innate immunity [47] that provides an 
altered pulmonary innate homeostasis [48]. This different status of innate cells may contribute 
to the local immunity in protected mice. Therefore, pulmonary innate cells are interesting 
targets for optimizing pertussis vaccination strategies, e.g. by pulmonary vaccination.
Infection-induced immunity comprised of a Th1/Th17-mediated response, as was 
demonstrated by the systemic analysis of B. pertussis-specific T-cells in the spleen. After the 
challenge, these responses were recalled fast in the protected mice. Despite the upregulated 
pulmonary gene expression of Cxcl9, protein secretion of CXCL9 and CXCL10 was not 
detectable in lung lysates and serum of protected mice, indicating reduced recruitment of 
CXCR3+ T-cells. However, gene expression showed that molecular signatures of T-cells (i.e. 
Cd3g, Cd4, Thy1) were further enhanced in protected mice post-challenge. This indicates 
the presence of tissue-resident memory CD4+ T-cells. This assumption is emphasized by the 
enhanced expression of the memory T-cell marker Il7r (Cd127). Moreover, gene expression of 
the chemokines Ccl20 and Cxcl12 and their corresponding receptors Cxcr6 and Ccr6 implied 
recruitment of different types of T-cells, such as CCR6+ Th17-cells [49] and CXCR6+ T-cells [50] 
in the lungs. Lee et al. showed that the presence of pulmonary CXCR6+ T-cells correlated with 
local protective immunity against Mycobacterium tuberculosis [50]. Furthermore, CCR6 is 
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an important mediator of mucosal immunity [51], indicating a potential role for pulmonary 
CXCR6+ and CCR6+ T-cells in immunity against B. pertussis. Strong B. pertussis-specific Th17 
responses occur during infection in unprotected mice, which remain present for a long period 
[10]. Moreover, the Resistin like alpha (Retnla) was found to stimulate Th17 responses [24]. 
However, the secretion of IL-17A and expression of Il17f in the lungs was absent after the 
challenge of protected mice. This indicates either that we missed this expression due to a 
change in expression kinetics or that the effector function of the Th17 cells had changed.
Protected mice had high levels of B. pertussis-specific IgG in the serum. In addition, protected 
mice expressed genes encoding for B-cell markers and antibody production in their lungs. 
This was confirmed by the presence of mucosal IgA in the lungs. We demonstrated that this 
pulmonary IgA in protected mice is directed against Ptx, Fim2/3, and Vag8. The inclusion 
of Fim2 or Vag8 in pertussis vaccines may improve efficacy. IgA plays an important role in 
protection against B. pertussis [52]. Therefore, the induction of mucosal IgA by mucosal 
vaccination might be a big advantage, especially because IgA induction is completely absent 
after immunization with current pertussis vaccines [53]. Induction of B-cell-related gene 
expression after a challenge of protected mice shows a recall response leading to increased 
antibody production. Here, CCR6 expression may be important for memory B-cells to mount 
a recall response [54]. The antibody-related gene expression showed co-expression with 
components of the classical complement pathway and seven genes of the SPEER-family 
with unknown function, suggesting the expression of these genes occurring in the B-cells. 
Overall, these findings demonstrate the presence of both systemic and pulmonary humoral 
responses primarily directed against Ptx, Fim2/3 and Vag8. This is where the results obtained 
in this study may contribute to understanding and optimizing immunity against B. pertussis. 
Pertussis vaccines, such as the acellular (aPV), whole-cell (wPV) and outer membrane vesicle 
(omvPV) vaccines, substantially different T-helper cell polarization [11, 55] and humoral 
immunity based on subclass responses and antigen specificity [53]. All vaccines provide 
enhanced bacterial clearance in mice as compared to non-vaccinated mice, indicating that 
multiple types of immunity can achieve protection against pertussis. Nonetheless, sterilizing 
immunity in the lungs that is seen for infection induced-immunity [7, 10] is not provided by 
subcutaneous vaccination [7].
In conclusion, the comprehensive comparison of responses between protected mice 
and unprotected mice resulted in detailed insight in characteristics of protective immune 
responses against pertussis. The unprotected mice are largely depending on recruitment of 
phagocytic cells into the lungs to remove the bacteria, whereas the acquired immunity in the 
protected mice enables fast recognition and neutralization of the bacteria. The presence of 
memory Th1/Th17 cells, memory B-cells, and mucosal IgA characterized this effective immunity 
against B. pertussis. Here, CCR6+ B-cells, Th17 cells and CXCR6+ T-cells play an important role 
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in the B. pertussis infection-induced pulmonary immunity. Moreover, high activity of ‘trained’ 
pulmonary innate immune cells, such as alveolar macrophages, M-cells and goblet cells, was 
observed in the lungs of protected mice. Hence, induction of pulmonary immunity e.g. achieved 
by local immunization will improve the efficacy of pertussis vaccines, perhaps also on the long 
term. A single dose of intranasally administered live-attenuated pertussis vaccine shows that 
such an approach induces good protection in mice [56] with longer lasting immunity [57] and 
also through a Th1/Th17-mediated response [58]. In conclusion, the present study showed 
that the use of a systems approach enables to unravel infection-induced responses in more 
detail, including the interplay between innate and acquired immune responses.
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An independent ethical committee for animal experimentations (DEC) of Intravacc reviewed 
the animal experiments according to the guidelines provided by the Dutch Animal Protection 
Act. The committee approved documents with the identification number ‘DPA201100348’.
B. pertussis challenge culture
Cultivation of Bordetella pertussis B1917 and preparation of the challenge culture was 
performed as previously described [10].
Animal experiments
Thirty female, 8-weeks-old, BALB/c mice (Harlan, The Netherlands) were divided in ten groups 
of three animals and housed in cages (macrolon III including filter top). Six groups of naive 
mice (n = 3 mice/group) were intranasally infected under anesthesia (isoflurane/oxygen), 
with 2x105 CFU B. pertussis B1917 in 40µl Verweij medium and left 56 days to recover. 56 
days p.i. (D0), five groups of these protected mice with infection-induced immunity and five 
groups of naive (D0 unprotected) mice (n = 3) of the same age were challenged intranasally 
as described above for the primary infection and euthanized at 4 hours, and 2, 7, 10 and 14 
days after challenge, according to the study design in Figure 1. Additionally, 30 mice were 
included for two individual experiments analyzing CD4+ T-cell responses (Experiment design 
in Figure 8A). On 10 days p.i. (-D46), six primary-infected and six complete naive mice were 
euthanized. On day 10 p.c., six mice that had encountered two infectious doses (-D56 and 
D0), six primary-infected mice (66 days p.i.), and six complete naive mice were euthanized. 
Mice from all groups were bled under anesthesia (isoflurane/oxygen) by orbital bleeding 
and euthanized by cervical dislocation. Collection of whole blood, lungs and spleen were 
performed as described before [10].
Microarray analysis
RNA isolation from lung tissue, determination of RNA concentrations, and RNA integrity 
was executed as described before [10]. Amplification, labeling and hybridization of RNA 
samples to microarray chips was carried out at the Microarray Department of the University 
of Amsterdam, The Netherlands, as described previously [59]. Complete raw and normalized 
microarray data and their MIAME compliant metadata from this publication have been 
submitted to the GEO database (www.ncbi.nlm.nih.gov/geo) and assigned the identifier 
GSE75438.
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Data analysis of gene expression
Statistical analysis of gene expression data was done in R according to methods described 
before [10]. Further functional interpretation, was performed using resources such as DAVID 
[18], Gene Ontology, KEGG, and BioGPS. Data visualization was done in R as well as GeneMaths 
XT software (Applied Maths, Sint-Martens-Latem, Belgium).
Antibody levels in serum and lung lysate
Levels of pulmonary total IgA and serum total IgA, IgG and IgG subclass (IgG1, IgG2a, IgG2b and 
IgG3) specific for B. pertussis antigens P.69 pertactin (P.69 Prn), filamentous hemagglutinin 
(FHA), pertussis toxin (Ptx), combined fimbria type 2 and 3 antigens (Fim2/3) and outer 
membrane vesicles B1917 (OMV B1917) were determined using a multiplex immunoassay 
(MIA) as described previously [10].
Western Blotting using IgA from lung lysate
Infrared labeling (IR800) of goat-anti-mouse IgA (Southern Biotech), protein separation by 
SDS-PAGE, and immunoproteomic profiling by Western blot (1:50 dilution) and MS-MS were 
performed as described previously [53]. For improved separation of the 80kD-110kD range, a 
4-12% Bis-Tris protein gel (NuPAGE Novex, 1.0mm 10wells, Invitrogen) was used.
Splenic Gr-1+ cell analysis
Determination of the percentage Gr-1+ cells in isolated splenocytes was carried out as 
described before [10].
Stimulation of B. pertussis-specific T-cell from spleens
Splenocytes were isolated and stimulated with 1 µg/ml Prn, Ptx or FHA in IMDM complete 
medium (IMDM medium (Gibco) supplemented with 8% FCS, 100 units penicillin, 100 units 
streptomycin, 2.92 mg/ml L-glutamine, and 20 μM β-mercaptoethanol (Sigma)), or only 
medium, as described previously [10]. Supernatants were collected after 7 days for cytokine 
analysis. After overnight stimulation with the same conditions, intracellular cytokine staining 
was executed splenocytes that were stimulated for 8 days to identify CD4+CD44+ T-cells 
producing IL-5, IFNγ or IL-17A.
Multiplex immunoassay (MIA) for cytokines
A mouse cytokine 7-plex luminex kit (Milliplex; Merck KGaA, Darmstadt, Germany) was used 
to determine concentrations (pg/ml) of IL-4, IL-5, IL-10, IL-13, IL-17A, TNFα, and IFNγ in culture 
supernatants of 7 days stimulated splenocytes of individual mice in a MIA.
A mouse cytokine/chemokine 32-plex luminex kit (Milliplex MAP Mouse Cytokine/Chemokine 
- Premixed 32 Plex; Merck KGaA, Darmstadt, Germany) was used to determine concentrations 
(pg/ml) of Eotaxin, G-CSF, GM-CSF, IFNγ, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17A, 
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IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IP-10, KC, LIF, LIX, M-CSF, MCP-1, MIG, MIP-1α, 
MIP-1β, MIP-2, RANTES, TNF-α, and VEGF, in serum and lung lysates in a MIA (according to 
the manufacturer’s instructions and as described previously [10]). Measurements and data 
analysis were performed with Bio-Plex 200, using Bio-Plex Manager software (version 5.0, 
Bio-Rad Laboratories).
BLC (CXCL13) cytokine ELISA
Serum concentration of B lymphocyte chemoattractant (BLC/CXCL13) was determined 
by ELISA (Mouse BLC ELISA kit, RAB0046, Sigma-Aldrich, Germany) according to the 
manufacturer’s manual. In short, serum (50 µl) was diluted in assay buffer A (1/1; v/v) and 
incubated in an antibody-coated ELISA plate (overnight, 4°C, gentle shaking). After washing 
four times with 300 µl wash buffer, wells were incubated with 100 µl biotinylated antibody (1 
hour, room temperature, gentle shaking). After washing four times with 300 µl wash buffer, 
wells were incubated with 100 µl streptavidin solution (45 min., room temperature, gentle 
shaking). After washing four times, wells were incubated with 100 µl TMB one-step substrate 
reagent (30 min., RT) and reaction stopped with 50 µl stop solution. Finally, the absorbance 
was recorded at 450 nm with a plate reader (BioTek reader EL808, Bio-Tek) and converted to 
BLC concentration by using a dilution series of a standard (1.37 – 1,000 pg/ml) and Gentech 5 
software (BioTek).
Statistical analysis
Serum and pulmonary cytokines levels were analyzed by using a one-way ANOVA with multiple 
comparisons compared to the pre-challenge level (D0) of unprotected mice or protected 
mice followed by a Dunnett t-test. ICS data was analyzed by using a Mann-Whitney t-test. 
For cytokine profiling after re-stimulation of splenocytes, cellular composition of spleen, and 
antibody levels, data was first log-transformed before t-test analysis. In all corresponding 
figures, p-values are represented as * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001 and **** = p ≤ 
0.0001.
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Figure S1 - Comparison of pulmonary transcriptomic profiles between unprotected and protected mice per time 
point. (A) The fold ratios (FR) of all 786 differentially regulated genes compared to non-infected naive mice for 
both unprotected and protected mice were portrayed as scatter plot at all five time points. At each time point, 
for each gene, the FR was calculated between unprotected and unprotected mice. All genes that were differently 
expressed (FR ≥ 1.5 or ≤ 0.67) were depicted in red. The number of upregulated and downregulated genes is 
given for each comparison. (B) The 212 genes that were found differently expressed (FR ≥ 1.5 or ≤ 0.67) between 
unprotected and protected mice 2 days p.c. in Figure 2D were divided in in eight fractions based on upregulation 
(1-4) or downregulation (5-8). These genes are depicted as heatmap per fraction with additional information on 
the FR of these genes in unprotected mice and protected mice compared to non-infected naive mice.
Supplementary information
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Abstract
The current resurgence of whooping cough is alarming and improved pertussis vaccines are 
thought to offer a solution. Outer membrane vesicle vaccines (omvPV) are potential vaccine 
candidates, but omvPV-induced humoral responses have not yet been characterized in 
detail. The purpose of this study was to determine the antigen composition of omvPV and 
to elucidate the immunogenicity of the individual antigens. Quantitative proteome analysis 
revealed the complex composition of omvPV. The omvPV immunogenicity profile in mice was 
compared to those of classic whole-cell vaccine (wPV), acellular vaccine (aPV) and pertussis 
infection. Pertussis-specific antibody levels, antibody isotypes, IgG subclasses, and antigen 
specificity were determined after vaccination or infection by using a combination of multiplex 
immunoassays, 2-dimensional immunoblotting and mass spectrometry. The vaccines and 
infection raised strong antibody responses, but large quantitative and qualitative differences 
were measured. The highest antibody levels were obtained by omvPV. All IgG subclasses 
(IgG1/IgG2a/IgG2b/IgG3) were elicited by omvPV and in a lower magnitude by wPV, but not 
by aPV (IgG1) or infection (IgG2a/b). The majority of omvPV-induced antibodies were directed 
against Vag8, BrkA and LPS. The broad and balanced humoral response makes omvPV a 
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The resurgence of whooping cough in the vaccinated population [1-4] demands improved 
pertussis vaccines. Two types of pertussis vaccines are marketed: whole-cell (wPV) and 
acellular vaccines (aPV). Other types are under development, such as live attenuated and 
outer membrane vesicle pertussis vaccines (omvPV) [5, 6]. These vaccines differ largely in 
their composition. The first marketed vaccines were wPVs, which are inactivated bacteria 
that are naturally adjuvated with bacterial components, such as lipopolysaccharide (LPS) [6-
8]. Despite an acceptable vaccine efficacy, wPVs were found to be reactogenic due to the 
presence of endotoxins. This lead to the development of alum-adjuvated aPVs containing one 
to five purified pertussis antigens: pertussis toxoid (Ptd), filamentous hemagglutinin (FHA), 
pertactin (Prn), and fimbriae types 2 and 3 (Fim2 and Fim3). Despite low reactogenicity of 
aPVs, waning immunity [9, 10] and persistent transmission of Bordetella pertussis [11] call 
for reevaluation of aPVs. To retain high vaccine compliance, the target product profile of an 
improved pertussis vaccine should include better efficacy compared to aPV while maintaining 
a low reactogenicity.
Currently, antibodies are used as correlates of vaccine-induced immunity for most commercial 
vaccines [12], including pertussis vaccines [13, 14]. The protective role of pertussis antibodies 
was supported by passive immunization studies in naive mice [15, 16], though cellular 
responses may also contribute to protection, at least during infection [17, 18]. Antibody 
responses can be characterized by several parameters, including (i) antigen specificity, (ii) 
titer, (iii) isotype and subclasses, and (iv) avidity. The IgG antibody subclass profile reflects 
the T-helper (Th) cell environment [19, 20]. For instance, vaccination with aPV results in the 
formation of IgG1 antibodies and Th2 cells [21, 22]. Contrarily, vaccination with wPV generates 
a Th1/Th17 response [23] which is thought to be important for protection against B. pertussis 
[17, 18, 23]. The functionality of the antibodies is determined by antigen specificity, avidity 
and antibody subclass. This determines the ability of antiserum to kill bacteria directly or 
by opsonophagocytic killing through activation of Fc-receptors (FcRs) on phagocytes, 
with an important role for FcγRs in the clearance of B. pertussis [24, 25]. For aPV vaccines, 
antibodies against pertussis toxin (Ptx) and Prn are considered to be protective against a B. 
pertussis infection [13, 26, 27]. For wPV, many immunogenic proteins have been identified 
by 2D-electrophoresis and western blotting [8, 28, 29]. The humoral immune response 
generated by omvPV is not well defined, although some major antigens were identified [30] 
and long-lasting immunity observed [31].
In this study, the systemic humoral response after immunization of mice with an experimental 
omvPV was compared with the response elicited by classic vaccines, aPV and wPV. Multiplex 
immunoassays, gel electrophoresis, immunoblotting and mass spectrometry were used to 
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identify the immunogenic antigens and the subclass profiles they induced. Because mice 
develop sterilizing immunity after a pertussis infection [18], antisera from B. pertussis-infected 





B. pertussis B1917 was heat-inactivated (30 min, 56°C) in PBS to produce wPV. Outer membrane 
vesicles from B. pertussis B1917 (omvPV) were produced as previously described [32] with 
minor changes. Both wPV and omvPV were diluted in PBS to a final concentration of 4 μg total 
protein per vaccine dose (300 μl). One human dose of a tetanus-diphtheria-3-component (25 
μg pertussis toxoid, 25 μg filamentous hemagglutinin, and 8 μg pertactin) acellular pertussis 
vaccine (TDaP, Infanrix, GSK) was diluted in PBS (aPV) to a final concentration of 0.25 μg Ptd, 
0.25 μg FHA, and 0.08 μg Prn per vaccine dose (300 μl).
Dynamic Light Scattering (DLS)
Particle size was determined by analyzing 0.5 ml of vaccine stock solutions diluted in PBS 
(1:100) at 25°C using a Zetasizer Nano-ZS (Malvern Instruments). For each sample, three 
records of 12 scans were obtained. The Z-average particle size and polydispersity index (PdI) 
were calculated using DTS Nano software (Malvern Instruments).
Double stranded (ds) DNA quantitation
Samples were diluted in Tris EDTA (TE) buffer (Invitrogen). Salmon sperm ds-DNA (Invitrogen) 
was used as standard (0 – 2500 ng/ml). In a V-bottom (black) 96-wells plate, 50 µl of each 
sample or standard was incubated with 50 µl of PicoGreen reagent solution (Invitrogen). 
Fluorescence intensity (excitation 480 nm, emission 520 nm) was measured by using a 
SynergyMx (BioTek Instruments, USA). Concentration of dsDNA was calculated based on the 
standard curve.
LPS analysis
LPS concentration was determined by analyzing fatty acid composition with a modified gas 
chromatography method [33]. The peak height of C14:0-3OH was used to quantify LPS, while 
C12:0-2OH was used as the internal standard. The molecular weight (4057 g/mol [34]) of B. 
pertussis LPS was used to calculate the LPS-concentrations.
Challenge culture 
A stock suspension of B. pertussis strain B1917 was diluted with Verweij medium (BBio, 
Bilthoven, The Netherlands) to a final concentration of 5x106 colony-forming units (cfu)/ml. 
The cfu concentration was confirmed by plating 100 μL of the bacterial suspension (after 
2000-fold dilution in Verweij medium) on Bordet-Gengou agar plates (Cat. no. 254400, BD, 
The Netherlands). Plates were incubated for 4 days at 35°C and the number of colonies was 
counted by using a ProtoCOL colony counter (Synbiosis, Cambridge, United Kingdom). 
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Animal experiment
An independent ethical committee for animal experimentations of the Institute for Translational 
Vaccinology (Intravacc) approved the animal experiment. Female BALB/c mice (Harlan, The 
Netherlands), 8-week-old, were divided in five groups of ten animals and housed in cages 
(macrolon III including filter top). Group 1 remained naive. Groups 2, 3 and 4 were vaccinated 
twice with 300 µl omvPV (4 µg total protein), 300 µl wPV (4 µg total protein) and 300 µl aPV 
(1:100 HD in PBS), respectively, on day 0 and day 28. Vaccinations with omvPV, wPV, and aPV 
were administered subcutaneously in the left groin for primary vaccination, followed by booster 
vaccination in the right groin. Group 5 was intranasally infected under anesthesia (isoflurane/
oxygen), with 2x105 CFU B. pertussis B1917 in 40 µl Verweij medium on day 0. Mice in all groups 
were bled, under anesthesia (isoflurane/oxygen), by orbital bleeding and euthanized by cervical 
dislocation on day 56. Whole blood was collected in blood collection tubes (MiniCollect 0.8ml 
Z Serum Sep GOLD, Greiner Bio-One, Austria). After coagulation (10 min. at room temperature 
(RT)), sera were collected by centrifugation (10 min., 3000 g) and stored at -80°C for further use.
Multiplex immunoassay
Serum total IgA, IgG, and IgG subclasses (IgG1, IgG2a, IgG2b and IgG3) levels against pertactin 
(Prn), filamentous hemagglutinin (FHA), pertussis toxin (Ptx), combined fimbriae type 2 
and 3 antigens (Fim2/3), and outer membrane vesicles B1917 (OMV B1917) were determined 
using a multiplex immunoassay (MIA). Conjugation of OMVs and purified antigens to beads 
was performed as described previously [35]. Serum was diluted 100-fold or 1250-fold in 
PBS containing 0.1% Tween 20 and 3% bovine serum albumin and mixed 1:1 (v/v) with 25 μl 
conjugated beads (4,000 beads/region/well). After incubation with R-Phycoerythrin (RPE)-
conjugated anti-mouse IgA (1:100), IgG (1:200), IgG1 (1:200), IgG2a (1:40), IgG2b (1:200) and 
IgG3 (1:200) (Southern Biotech), samples were analyzed by using a Bio-Plex system (Bio-
Plex 200, BioRad). Results for antibody levels were illustrated with GraphPad Prism 6.04 
(GraphPad Software Inc., USA), and presented in fluorescent intensity (F.I.).
Protein digestion by proteinase K treatment 
For protein digestion, 5 µg B. pertussis B1917 was incubated (Overnight (ON), 56°C) with 5 
µl (20 mg/ml) proteinase K (Proteinase K, recombinant, PCR Grade, Roche). Incubation was 
terminated by heating the sample for 5 minutes at 100°C.
Sample preparation
Protein concentrations were determined using a bicinchoninic acid (BCA) assay (Pierce). For 
SDS-PAGE, B. pertussis B1917 (100 µg) was denatured in a total volume of 100 µl 8 M urea (GE 
Healthcare) in 500 mM bicarbonate (Merck) solution (pH 8.5, 1 h, RT). For 2DE, B. pertussis 
B1917 (100 µg) was centrifuged (1 min., 16200 g) and the pellet was dissolved and denatured 




IR680 label (15 µg) (Pierce) and IR800 label (100 µg) (Licor) were reconstituted in 100 µl and 
25 µl water, respectively. For conjugation of IR800 label to secondary antibodies, 100 µl goat-
anti-mouse IgG, IgG1, IgG2a, IgG2b, IgG3 or IgA (Southern Biotech) was mixed with 1 µl (4 µg) 
IR800 label. For IR680 labeling of B. pertussis proteins, 100 µg denatured proteins were mixed 
with 10 µl IR680 label with optimized concentrations. For 1DE gels and corresponding western 
blots, a 1:10 and 1:100 dilution of IR-680 stock (0.15 µg/ml) were used, respectively. For 2DE, an 
undiluted and 1:20 dilution of IR-680 stock (0.15 µg/ml) were used for gels and western blot, 
respectively. All samples were incubated for 1 hour (RT, in the dark). Subsequently, unbound IR 
label was removed from samples by using a ZEBA spin desalting column (Pierce) (2 min, 1500 g).
Isoelectric focusing (IEF)
After sample preparation and IR-labeling, samples for 2DE (25 µg B. pertussis proteins) were 
incubated (60 min., RT) in a total volume of 115 µl DeStreak Rehydration Solution plus 10 µl 
250 mM DTT and 0.62 µl (0.5%) IPG Buffer pH 3-10NL (GE Healthcare). Immobiline DryStrip pH 
3-10NL, 7 cm (GE Healthcare) were rehydrated (ON, RT) with protein sample in an IPGbox (GE 
Healthcare). Isoelectric focusing (IEF) was performed in an Ettan IPGphor 3 IEF system (GE 
Healthcare) according to the following conditions: 0.5 h at 300 V, 0.5 h at 1000 V, 1 h at 2000 V, 1 h 
at 3000 V, 1 h at 4000 V, and 1 h at 5000 V. After IEF, strips were equilibrated in 3 ml equilibration 
buffer (75 mM Tris-HCl pH 8.8, 6 M urea, 30% glycerol, 2% SDS, and bromophenol blue) with DTT 
(65 mM) for 15 min. at RT, followed by 3 ml equilibration buffer with iodoacetamide (54 mM) 
for 15 min. at RT.
Gel electrophoresis
For SDS-PAGE, 10 µg B. pertussis (B1917) lysate, 1 µg of Prn P.69 (in house prepared [36]), Ptx 
(Kaketsuken, Japan), FHA (Kaketsuken, Japan), or Fim2/3 (Sanofi) were incubated (10 min., 
100°C) with 3.3 µl reducing sample buffer (250 mM Tris, 8% SDS, 400 mM DTT, 40% Glycerol, 0.04% 
bromophenol blue) and loaded on a 10% NuPAGE bis tris 1.0-mm precast gel (Invitrogen). For 
2DE, the equilibrated strip was placed on a 4-12% NuPAGE Novex bis-tris ZOOM gel (Invitrogen) 
and sealed with agarose sealing buffer (Bio-rad). Proteins were separated (SDS-PAGE, 45 min., 
200 V) (2DE, 50 min., 200 V) with MES running buffer (Invitrogen) in a Xcell surelock minicell 
electrophoresis system (Invitrogen). Gels were washed in water and either stained with 
Coomassie (Imperial protein stain, Thermo Scientific), used for western blot or scanned using 
an Odyssey infrared imager (Westburg).
Western blotting
Nitro-cellulose membrane (Biorad), filters (Biorad) and gel were equilibrated in transfer buffer 
(48 mM Tris, 39 mM glycine, 20% methanol in 1 liter water). Subsequently, proteins were 
transferred (60 min., 60 mA) (TE77 semidry pwr transfer unit, Amersham Biosciences) from 
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the acrylamide gel to the nitro-cellulose membrane. Blot was blocked in block buffer (0.5% 
protifar in TBS-T, 20 mM Tris, 150 mM NaCl, 0.5% Tween-20 in 1 liter water) (ON, 4°C). Blot was 
incubated (2 h, RT) with pooled murine sera (100-fold diluted in block buffer) or a monoclonal 
anti-LPS antibody (Mab 88F3) (1:200) followed by frequent washing with TBS-T. Subsequently, 
secondary antibody incubation (1 h, RT) was performed using goat-anti-mouse IgG, IgG1, IgG2a, 
IgG2b, IgG3 or IgA (Southern Biotech) labeled with IR800 (Licor) (1:5000 diluted in block 
buffer), which was followed by frequent washing with TBS-T. Blots were scanned using an 
Odyssey infrared imager.
Delta2D analysis
Image warping and spot detection on 2DE gels and western blots were done by using Delta2D 
software (Version 4.5) (Decodon, Germany). Images of 2DEWB using five distinct sera (omvPV, 
wPV, aPV, infection and control) were merged by using the Delta2D group warping strategy for 
IgA, IgG and IgG subclasses individually. Subsequently, spot detection was performed and the 
intensities were measured in grey values.
In-gel protein digestion for LC-MS/MS analysis
Spots were manually excised from the acrylamide gel. In-gel digestion was performed according 
to a protocol based on Yan et. al [37]. Briefly, individual gel spots were cut in pieces of about 1 
mm3 and washed three times with water, followed by washings with 50% acetonitrile and 100% 
acetonitrile for dehydration. Trypsin (Promega) digestion (pH 8.5, ON, 37°C) was performed 
in 50 mM triethyl ammonium bicarbonate. Peptides were extracted with three sequential 
steps of 5% formic acid solution and extracts were dried in a vacuum concentrator. Peptides 
were dissolved in formic acid/dimethyl sulfoxide (DMSO)/water (0.1/5/94.9% v/v) for LC-MS/MS 
analysis.
Protein digestion for LC-MS/MS analysis
Samples (omvPV or wPV) were diluted in a denaturation buffer containing 1 M guanidine 
hydrochloride (Gnd-HCl) and 50 mM triethyl ammonium bicarbonate, pH 8.5, to a final 
concentration of 0.5 mg/ml protein. For digestion, 100 µg of protein was digested with 2 µl 
of 0.25 µg/µl endoproteinase Lys-C (Roche) followed by incubation (4h, 37°C). Subsequently, 
digests were incubated (ON, 37°C) with 2 µl of 0.5 µg/µl trypsin (Promega). The samples were 
stored at –20 °C before dimethyl labeling. A common reference was prepared by mixing 
equal volumes of both omvPV and wPV digests. The samples and common reference were 
dimethylated by treatment with formaldehyde (CH2O) and d2-formaldehyde (CD2O) and sodium 
cyanoborohydride, respectively, and subsequently pooled in a 1:1 w/w ratio [38]. Solid-phase 
extraction was performed to remove excess reagents using C18 Sep-pack cartridges according 
to the manufacturer’s protocol. Peptides were dried in a vacuum concentrator. Peptides were 
dissolved in formic acid/DMSO/water (0.1/5/94.9% v/v) for LC-MS/MS analysis.
120
Chapter 4
Peptide identification by LC-MS/MS analysis
Samples were analyzed by nano-scale reversed-phase liquid chromatography electrospray 
mass spectrometry, according to the method by Meiring et al. [39]. The analysis was 
performed on LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Germany). 
Analytes were loaded on a trapping column (Reprosil-Pur C18-AQ 5 µm (Dr. Maish, Germany); 
23 mm long x 100 µm inner diameter) with solvent A (0.1% (v/v) formic acid in water) in 10 
min. at 5 µl/min. The analytes were separated by reversed-phase chromatography on an 
analytical column (Reprosil-Pur C18-AQ 3 µm (Dr. Maish, Germany); 36.2 cm long x 50 µm 
inner diameter) at a flow rate of 100-150 nl/min. A gradient was started with solvent B (0.1% 
(v/v) formic acid in acetonitrile): 6% to 28% in 130 min, 28% to 38% in 10 min and 90% for 10 min. 
After the gradient, the columns were equilibrated in 100% solvent A for 20 min at 100-150 nl/
min. The peptides were measured by data-dependent scanning; comprising a MS-scan (m/z 
300 – 1500) in the orbitrap with a resolution of 60,000 (FWHM), followed by collision-induced 
dissociation (LTQ) of the ten most abundant ions of the MS spectrum. The threshold value 
for these precursor ions was set at 1000 counts. The normalized collision energy was set at 
35% and isolation width at 2.0 Da, activation Q to 0.250 and activation time to 30 ms. The 
maximum ion time (dwell time) for MS scans was set to 250 ms and for MS/MS scans to 1000 
ms. Precursor ions with unknown and +1 charge states were excluded for MS/MS analysis. 
Dynamic exclusion was enabled (exclusion list with 500 entries) with repeat set to 1 and an 
exclusion duration of 15s. The background ion at 391.28428 was used as lock mass for internal 
calibration.
Data handling for total vaccine protein digests
Proteome Discoverer software (version 1.4.1.14, Thermo) was used for peak area determination, 
identification and relative quantification of the LC-MS/MS raw data. Identification of peptides 
was performed by searching MS/MS spectra against the protein database of B. pertussis 
Tohama (NCBI 257313) (3261 entries) and B. pertussis B1917 (3513 entries) [40] using the 
SEQUEST HT mode. Asparagine deamidation and methionine oxidation were set as variable 
modifications and lysine dimethylation (light) as a fixed modification. The data were searched 
with full trypsin cleavage specificity, allowing 2 miscleavages. Precursor ion and MS/MS 
tolerances were set to 5 ppm and 0.6 Da, respectively. Peptides were filtered to 1% FDR using 
Perculator (Proteome Discoverer, Thermo). Relative protein concentrations were calculated 
using the quantification module of Proteome Discoverer using default settings (light: 28.013 
Da, heavy 32.055 Da). The molar concentration of proteins was estimated according to 
Silva et. al. [41], except that the peptides were dimethyl-labeled in our method. The molar 
concentrations were converted to mass concentrations by multiplying with the molecular 
masses of the proteins. The percentage of protein abundance for each individual protein 
relative to the total sum of all identified proteins was used to determine an estimated protein 
amount in one vaccine dose (4 μg total protein) of wPV and omvPV. 
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Data handling for in-gel protein digests
Proteome Discoverer software was used for identification of the LC-MS/MS raw data for in-
gel digested proteins almost in a similar way as described in data handling for total vaccine 
protein digests. Asparagine deamidation and methionine oxidation were set as variable 
modification. The data were searched with full trypsin cleavage specificity, allowing 2 
miscleavages. Precursor ion and MS/MS tolerances were set to 5 ppm and 0.6 Da, respectively. 
Peptides were filtered to 1% FDR using Perculator.
Bioinformatics
Functional enrichment with an over-representation analysis (ORA) of the detected B. pertussis 
proteins was carried out by using DAVID [42] based on Gene Ontology Biological Processes 




Characteristics and composition of pertussis vaccines 
The outer membrane vesicle vaccine (omvPV), heat-inactivated whole-cell vaccine (wPV), 
and acellular vaccine (aPV) were characterized with respect to particle size, DNA content, 
LPS concentration and protein composition (Table 1). OMVs were about ten times smaller 
in diameter (114 nm) than the inactivated bacteria in the wPV (1156 nm). Further, the omvPV 
contained a small amount of DNA per vaccine dose (0.2 µg) when compared to wPV (1.2 µg), 
whereas aPV contained undetectable levels of DNA. In addition, the LPS concentration was 
slightly lower in omvPV compared to wPV.
Characteristic omvPV wPV aPV
Dose 4 µg B. pertussis proteins
4 µg B. pertussis 
proteins
0.25 µg FHA, 
0.25 µg Ptx,












(µg ± SD) 0.18 ± 0.02 1.19 ± 0.15 0
LPS2,3 
(µg) 1.0 1.5 N/M
Number of proteins 268 332 3
Additional Adjuvant - - Al(OH)3
1 N/M = Not measured.
2 Based on the vaccine dose of 4 µg total protein for omvPV and wPV.
3 Analysis n = 1 (All other analysis n = 3)
Table 1. Characteristics of the vaccines studied. 
LC-MS analysis was performed to characterize total vaccine protein composition of omvPV 
and wPV. In total, 268 and 332 proteins were identified and quantified in omvPV and wPV, 
respectively (Table S1). Obviously, these numbers do not cover the identification of all 
proteins present in both vaccines, as B. pertussis has more than 3500 genes. However, this 
LC-MS method identified and quantified the most abundant proteins present in the vaccines. 
The quantity of different proteins differed remarkably between omvPV and wPV. For both 
vaccine formulations, the top 25 of most abundant proteins is shown in Figure 1A. The 25 
proteins that are most abundant in omvPV cover 86% of the total protein content in omvPV. 
Autotransporters Vag8 (34%) and BrkA (24%) are the major antigens. The other proteins of 
the top 25 contributed each less than 5% of the total protein amount. For wPV, the top 25 of 
proteins of this vaccine covered 67% of the total protein content. GroEL (17%) and FHA (11%) 
were the most abundant proteins in wPV.
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Figure 1 - Protein composition wPV and omvPV. (A) Proteins in omvPV and wPV were determined by 
quantitative LC-MS-analysis. Protein abundance is expressed as percentage of total detected protein content. 
The top 25 proteins cover 86.0% of the total protein content in the omvPV, compared to 67.2% in wPV. (B) 
For each individual protein, the amount in wPV was compared to omvPV and expressed as percentage as 
shown in the scatter plot. For instance, 50% - 50% indicate equal presence of a protein in both vaccines. Sum 
of percentages in omvPV and wPV is in principle 100%. Functional analysis indicates enrichment of proteins 
involved in translation, DNA binding and the cell inner membrane in wPV, while the outer membrane proteins 
and lipoproteins are enriched in the omvPV. Three technical replicates of both vaccines were characterized.
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Next, the relative amounts of each individual protein present in omvPV and wPV were 
compared between both vaccines (Figure 1B). In addition, functional analysis using DAVID [42] 
revealed that nuclear, cytoplasmic and inner membrane proteins were more abundant in wPV, 
whereas omvPV was enriched for outer membrane proteins and lipoproteins. Periplasmic 
proteins were present in similar amounts in both vaccines. The protein composition of aPV 
was not investigated, since it is specified by the manufacturer (one human dose contains 25 
µg FHA, 25 µg Ptx and 8 µg Prn).
By using 2-dimensional electrophoresis (2DE), 182 spots were visualized in omvPV and 270 in 
wPV (Figure 2A and 2B, respectively). The most intense spots were isolated and the proteins 
present identified by LC-MS after in-gel protein digestion. The 25 most abundant proteins in 
omvPV as determined by total vaccine protein LC-MS analysis could also be recovered from 
the 2DE gels. For wPV, five proteins (bpH1, bpH2, cspA, rplC, BP3037) (see Figure 1) were not 
found by 2DE, presumably because their isoelectric point (pI) was outside the range (3-10) of 
the IPG-strip.
Serum levels and subclass distribution of antibodies against antigens in OMVs 
and aPV.
Serum IgG levels against purified antigens (Prn, Ptx, FHA and Fim2/3) as well as B. pertussis 
OMVs were determined in mice vaccinated subcutaneously with omvPV, wPV or aPV at day 
0 and day 28. In addition, a group of mice was intranasally infected with B. pertussis at day 0. 
Vaccination with omvPV induced the highest concentration of anti-OMV IgG, followed by wPV 
and intranasal infection, whereas anti-OMV IgG was absent after aPV vaccination (Figure 3A 
Figure 2 - Protein fingerprint of wPV and omvPV by 2-dimensional gel electrophoresis. Total protein lysates 
(25 µg total protein) of omvPV (A) and wPV (B) were separated by 2-dimensional gel electrophoresis. Gels 
were Coomassie stained and scanned on an Odyssey infrared imager (680 nm, Int. 5.0). Numbers in the 
gels correspond with the 25 most abundant proteins identified by LC-MS/MS analysis in either omvPV or 
wPV. Different colors correspond with proteins that are present in both vaccines (green), only present in 
omvPV (red), and only present in wPV (blue), respectively. For each vaccine, three technical replicates were 
characterized and one representative gel is presented.
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Figure 3 - Immunoproteomic profiling by multiplex immunoassay of different pertussis vaccines. 
(A-G) Antibody profiles against OMV, Prn, Ptx, FHA and Fim2/3 antigens (indicated at x-axes) were 
analyzed in serum of mice (n = 10). Each group of mice was either untreated (naive), received a different 
pertussis vaccine (omvPV, wPV, aPV), or underwent an intranasal infection. The intensity of all antibody 
concentrations is expressed in fluorescence intensity (F.I.). (A) The antibody levels were determined in 
1:100 diluted sera. (B) Samples exceeding the detection limit were further analyzed by using a 1:1250 serum 
dilution. In addition, the antibody concentrations of IgG-subclasses (C) IgG1, (D) IgG2a, (E) IgG2b and (F) 
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and 3B). As expected, vaccination with aPV induced antibodies against all components present 
in the vaccine: Prn, Ptx and FHA. Anti-Prn IgG antibodies were also detected upon omvPV 
and wPV vaccination. Anti-FHA IgG was measured after immunization with wPV, but not after 
vaccination with omvPV. B. pertussis infection resulted in high anti-Ptx IgG and moderate IgG 
levels against Prn and FHA. In addition, upon infection antibodies against Fim2/3, antigens that 
are present in certain other aPVs, were present in serum (Figure 3A).
Subsequently, IgG subclass (IgG1, IgG2a, IgG2b and IgG3) and IgA serum levels were determined 
(Figure 3C-G). Vaccination with omvPV and wPV generated antibodies of all IgG subclasses 
(IgG1, IgG2a, IgG2b and IgG3). However, the magnitude of the responses was lower in case 
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Figure 4 (Left) - 1-Dimensional immunoproteomic profiles of pertussis vaccines. (A) B. pertussis B1917 
proteins labeled with IR-680 were separated by SDS-PAGE (lane 2, P) (680 nm, Int. 5.0). Subsequently, blots 
were incubated with pooled serum of ten mice either vaccinated with omvPV (lane 3-8), wPV (lane 9-14), or 
aPV (lane 15-20), mice that underwent an intranasal infection (lane 23-28) or untreated mice (lane 29-34). 
Immunostaining was performed with six different IR-800-labeled goat-anti-mouse secondary antibodies (IgG, 
IgG1, IgG2a, IgG2b, IgG3 or IgA). Results for total IgG (G) are shown as dual staining (680 nm, Int. 5.0, 800 
nm, Int. 8.0) with B. pertussis proteins in red and IgG antibodies in green. Blots with IgG subclasses and IgA 
display single staining for antibodies in grey/black. The 22 unique bands detected on one or more blots are 
marked on a Coomassie stained gel with B. pertussis B1917 proteins (P, lane 21 & 35). (B) Purified pertussis 
antigens (FHA, Prn, Ptx, Fim2/3) (1 µg) were individually separated on SDS-PAGE (Lane 1). Blots were incubated 
with serum of naive mice (lane 2), mice vaccinated either with omvPV (lane 3), wPV (lane 4), or aPV (lane 
5) or mice that underwent an intranasal infection (lane 6-7). Subsequent IR800-labeled goat anti-mouse IgG 
incubation (1:5000) indicated IgG formation against FHA, Prn and Ptx in aPV vaccinated mice. In addition, 
anti-Prn was detected in omvPV and wPV vaccinated mice as well as infected mice. Both IgG (Lane 6) and 
IgA (lane 7) formation against Ptx was observed in serum upon intranasal infection. No antibody formation 
was observed against Fim2/3. (C) Coomassie stained B. pertussis B1917 proteins were untreated (-) (lane 2) 
or digested (+) (lane 3) with proteinase K. Western blot was performed with both treated and untreated B. 
pertussis by incubation with serum (1:100) of mice vaccinated either with omvPV (lane 4-5) or wPV (lane 6-7), 
or mice that underwent an intranasal infection (lane 8-9). Treatment with IR800-labeled anti-IgG (1:5000) (800 
nm, Int. 7.0) showed that proteinase K treatment leads to diminished immunostaining in all sera except for the 
band at approximately 7kD. Anti-LPS incubation (1:200) showed a similar band (lane 10-11) (800 nm, Int. 4.0). 
Blue color in lanes 4 and 6 indicates saturation of signal obtained by the Odyssey scanner. For each condition, 
experiments were performed three times with pooled serum of 10 mice resulting in similar outcomes, and one 
representative blot is presented.
of wPV vaccination with the exception of IgG1. Vaccination with aPV induced antibodies 
solely of the IgG1 subclass. An intranasal infection induced predominantly IgG2a and IgG2b 
antibodies and was the only condition inducing measurable serum IgA antibodies (Figure 
3G). After the infection of mice, high levels of serum IgA antibodies were detected binding to 
pertussis OMVs. In addition, IgA against Fim2/3, Prn or Ptx could be measured in some mice. 
No pertussis-specific antibodies were measured in serum of naive mice (Figure 3A-G).
Heterogeneity of antigen specificity and anti-LPS antibodies identified by using 
immunoblotting
A combination of 1-dimensional gel electrophoresis and western blotting (1DEWB) was used 
in order to identify the antigen-specificity of the antibody isotypes or subclasses elicited by 
the different vaccines (Figure 4). 1DEWB unraveled staining against 22 bands in a B. pertussis 
lysate, as marked in lane 21 and 35 (Figure 4A). The most intense staining was obtained 
with sera from omvPV-vaccinated mice. In addition, it was observed that antibody subclass 
formation is antigen specific in some cases. For instance, antibodies against band 16 were only 
formed upon omvPV vaccination and were exclusively of the IgG2a subclass. A broad subclass 
induction was observed in these sera for the other antigens (Figure 4A, lane 3-8). These results 
for IgG subclasses are in line with those of the MIA measurements, as are the results found for 
wPV (Figure 4A, lane 9-14), aPV (Figure 4A, lane 15-20), and infection (Figure 4A, lane 23-28). 









































































Figure 5 - 2-Dimensional immunoproteomic profiling. B. pertussis B1917 proteins were separated by 
2-dimensional gel electrophoresis followed by western blot analysis with serum of mice that underwent 
vaccination with (A) omvPV, (B) wPV, or (C) aPV, or (D) a B. pertussis infection. Immunogenic proteins were 
detected (800 nm, Int. 8.0) with IR800-labeled anti-IgG and identified by LC-MS-analysis. For each condition, 
experiments were performed three times with pooled serum of 10 mice resulting in similar outcomes. One 
representative total IgG blot is presented.
Since concentrations of Ptx, Prn, and Fim2/3 were low in the B. pertussis B1917 lysate used on 
the blot, the pools of serum of vaccinated mice were analyzed on blotted purified antigens 
(i.e. Ptx, Prn, Fim2/3 and FHA) (Figure 4B). This analysis revealed that the anti-Ptx antibodies 
detected upon both aPV vaccination (IgG) and infection with B. pertussis (IgG and IgA) were 
only directed against Ptx subunit 1 (Ptx S1) (Figure 4B). In addition, results revealed high anti-
Prn, anti-FHA and anti-Ptx antibody formation after aPV vaccination, whereas these antibodies 
were not detectable or low in serum of mice vaccinated with omvPV or wPV. These results are 
in line with the observations made by MIA.
Since western blot analysis was performed on both untreated B. pertussis proteins and 
proteins digested with proteinase K, one non-proteinaceous band could be identified as LPS 
by using an anti-LPS monoclonal antibody (Figure 4C). Thus, a substantial fraction of the IgG 
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elicited by omvPV and wPV was directed against LPS (Figure 4C). Antibodies against LPS were 
mainly of the IgG3 subclass (Figure 4A, lane 7, 13 and 27), but were also of the IgG1 subclass 
(Figure 4A, lane 4, 10 and 24). After a B. pertussis infection, less anti-LPS IgG antibodies were 
found but in addition IgA antibodies were formed against LPS (Figure 4A, lane 28).
Identification of the antibody-inducing antigens
A combination of 2-dimensional gel electrophoresis, western blot analysis (2DEWB) and LC-MS 
was performed on a B. pertussis lysate (Figure 2B) to identify the immunogenic proteins and 
the subclass specificity of the serum antibodies from vaccinated or infected mice (Figure 5A-
D). We detected 16, 9, 3, and 5 antibody-inducing proteins in serum from omvPV, wPV and aPV-
vaccinated mice, or infected mice, respectively. The immunogenic proteins were identified 
and quantified by LC-MS (Table 2). Highest staining intensities for IgG after omvPV vaccination 
were found directed against Vag8 and BrkA. Moderate antibody binding was measured 
against atpA, bfrD, BvgA, glcB, HtpG, katA, maeB, purH, Tcf and three unidentified proteins 
(U1-3). Anti-Tcf antibodies were only detected upon omvPV vaccination (Figure 5A), although 
similar concentrations of Tcf are present in wPV (Figure 6). The humoral response induced 
by wPV was mainly characterized by antibodies against BrkA, GroEL and Vag8 (Figure 5B). In 
addition, immunostaining of EfTu, gdhA, gltA, Pnp, and thiG was observed. It was confirmed 
that vaccination with aPV induced antibodies directed against FHA, Prn and Ptx (Figure 5C). 
Anti-Ptx antibodies were directed against a single spot, whereas anti-Prn and anti-FHA were 
detected as multiple spots, most likely indicating degradation (change in size), deamination 
or post-translational modifications (change in pI). Although FHA was present in both wPV 
and omvPV, only aPV elicited detectable anti-FHA antibodies. B. pertussis infection resulted in 
moderate antibody levels against BrkA, EfTu, GroEL, Ptx and Vag8 (Figure 5D). Western blot 
analysis of serum of naive mice revealed the presence of antibodies against the 50S ribosomal 
protein L7/L12 (Q7W0S0) (Figure 6).
The results of 2DEWB analyses are summarized in heatmaps (Figure 6). Vaccination with 
omvPV induced antibodies of all IgG subclasses against Vag8 and BrkA. The formation of IgG3 
against Vag8 and BrkA and IgG2a against Tcf was only detected upon omvPV vaccination. All 
vaccines generated IgG1 against multiple antigens. However, the staining intensities were 
the strongest upon aPV and wPV vaccination. The aPV elicited only antibodies of the IgG1 
subclass against FHA, Prn, and Ptx. The wPV-induced antibodies against BrkA, Pnp and EfTu 
were only of the IgG1 subclass, while antibodies against Vag8 consisted of both IgG1 and IgG2a 
subclasses. Western blots revealed that anti-GroEL antibodies formed upon wPV vaccination 
and after pertussis infection were predominantly IgG1 and to a lesser extent IgG2b. The 
infection induced IgG2a and IgG2b antibodies against Vag8 and BrkA. However, the highest 
staining intensities of BrkA were found to be IgG1. Finally, serum IgA was exclusively measured 
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This study demonstrates that vaccination with three different pertussis vaccines (omvPV, wPV 
or aPV) elicited distinct differences in humoral responses, not only with respect to antigen–
specificity and antibody levels, but also with respect to antibody isotypes and IgG subclasses. 
Characterization of complex vaccines by immunoproteomic profiling enabled us to identify 
and quantify immunogenic proteins in omvPV and wPV. Vaccine protein composition was 
determined by quantitative proteomics using LC-MS. The immunogenic proteins of the B. 
pertussis B1917 proteome were identified by 2-dimensional immunoblotting and subsequent 
LC-MS analysis.
To our best knowledge, this is the first time that immunoproteomic profiles of different 
pertussis vaccines were extensively compared. This study will be useful for understanding 
host-pathogen interaction and for vaccine design, since complete subclass profiling, especially 
regarding IgG2b and IgG3, is often absent [15, 43]. Distinct variances in IgG subclass response 
were seen in mice receiving different pertussis vaccines or B. pertussis infection (Figure 3, 4 
and 6). Vaccination with omvPV and wPV resulted in antibodies of all IgG subclasses, although 
the wPV elicited a subclass response that was dominated by IgG1. Vaccination with aPV solely 
induced IgG1 antibodies, while a B. pertussis infection led to the formation of mainly IgG2a 
and IgG2b antibodies. The formation of antibody-producing B-cells can occur either through a 
T-cell dependent or independent way. In the case of T-cell involvement, the type of cytokines 
secreted, e.g. IFNγ, IL-4, IL-5, and IL-17, determines the IgG subclass production by B-cells [19, 
20, 44]. In mice, Th1 type responses promote the production of IgG2a, whereas Th2 responses 
stimulate the formation of IgG1 [19, 44]. In addition, production of IgG2b seems to be linked 
to a Th17 type response [20]. Whereas all types of T-cell help stimulate the secretion of IgG3 
[19, 44], the highest IgG3 formation is achieved by T-cell independent antibody responses by 
B-cells, i.e. against LPS [45].
The differences in IgG subclass responses observed in the mice upon vaccination with 
different pertussis vaccines are likely influenced by the vaccine characteristics, such as (i) 
particle size, (ii) vaccine composition or (iii) presence of adjuvants, along with (iv) the route 
of administration. For instance, OMVs are ten times smaller in diameter than whole bacteria. 
This may increase the exposure to different cell types because there are more particles 
present in the omvPV or affect the uptake by different cell types with respect to efficiency in 
uptake and routing within the cells [46]. In addition, OMVs may reach immune cells deeper in 
the tissue, which are less accessible for the whole bacteria or the large alum particles [47], or 
drain faster (unprocessed) to the lymph nodes [46], thereby affecting the immune responses 
induced.
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Further, the presence of natural immune potentiators or co-administered adjuvants is known 
to influence the type of immune response. No adjuvants were added to the omvPV and wPV 
vaccines. However, these vaccine formulations do contain LPS and bacterial DNA, which are 
agonists for TLR4 and TLR9, respectively [48]. Activation of these pathogen recognition 
receptors stimulates and directs the humoral immune response in a T-cell dependent or 
independent way [49]. The higher concentrations of LPS and especially DNA detected in wPV, 
when compared to omvPV, might partly explain the different subclass responses. In addition, 
LPS-recognition by TLR4 in synergy with the B-cell receptor may also lead to direct T-cell 
independent anti-LPS antibody formation, especially IgG3, by B-cells [45]. In the case of aPV, 
the presence of aluminum hydroxide leads to a Th2 biased response [50] and subsequently 
the formation of IgG1 against purified pertussis antigens [22], as was also found in this study. 
Interestingly, it was shown that this Th2 response caused by aluminum-containing vaccines 
could be steered towards a Th1 response by addition of TLR ligands that induce strong 
Th1 responses, such as an LPS derivate (TLR4 ligand) [51] or CpG (TLR9-agonist) [52]. This 
indicates that the sum of all interactions within and between activated pathways determines 
the environmental conditions in which the B-cells reside, and consequently the outcome of 
the humoral response.
The intranasal infection resulted in production of IgG2a and IgG2b, which is thought to be 
related to a Th1/Th17 response [18, 20]. An enhanced IgG2a antibody formation, relative to 
IgG1, was also found upon intranasal administration of live attenuated pertussis vaccine [5]. 
A bacterial infection results in colonization and protein secretion of the bacteria leading to 
prolonged antigen exposure [18] when compared to vaccination. The intranasal route of 
administration of the infection, compared to subcutaneous vaccination with omvPV, wPV or 
aPV, at least partly explains the exclusive presence of serum IgA antibodies in infected mice 
[18].
Antibody subclasses determine the functionality of antibodies, since IgG subclasses may 
have a different bactericidal and opsonophagocytic activity [53]. Recently, it was suggested 
that for B. pertussis, antibodies with opsonophagocytic killing functionality might be more 
important compared to direct serum bactericidal killing [54]. For B. pertussis, Fc-receptors 
play an important role in opsonophagocytic killing in the respiratory tract in mice [24, 25]. 
IgG subclasses have a different affinity and selectivity towards FcRs [55]. In mice, IgG1 
predominantly targets FcγRIII (CD16) [56]. FcγRIV (CD16-2) exclusively binds IgG2a and IgG2b 
that both have the highest affinity for this receptor but are able to bind all FcRs [57]. Finally, 
murine IgG3 has a high affinity for FcRn and low affinity for FcγRI (CD64). Fc-receptors are 
present on several cell types such as B-cells and NK-cells, but predominantly on phagocytes, 
such as neutrophils and macrophages [55]. The neutrophils seem essential to protect against 
B. pertussis, since neutrophil depletion resulted in impaired lung clearance, especially in 
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immunized mice [58]. Because multiple immune cells, such as neutrophils, B-cells and 
macrophages, express different FcγRs [55], a certain IgG subclass cannot predict the involved 
type of FcγR-expressing cells. However, the humoral response with multiple antibody 
subclasses after omvPV vaccination might result in the involvement of different FcγR-
expressing cells resulting in a broad immune response. In contrast, selective IgG1 induction 
by aPV suggests mainly involvement of FcγRIII-expressing cells. A broad subclass distribution 
against surface exposed antigens, such as Vag8, BrkA, Prn and FHA should therefore lead to 
addressing a variety of FcγR-containing cells. The involvement of multiple FcγR-containing 
cells might result in increased phagocytosis. Antibodies against secreted antigens, such as 
Ptx, are less involved in direct phagocytosis of the bacteria. However, Ptx inhibits neutrophil 
recruitment [59]. Therefore, antibody-mediated neutralization of Ptx might prevent the 
impaired recruitment of neutrophils, increasing phagocytosis of bacteria in the respiratory 
tract.
The present study showed the essence of characterization of complex vaccines for 
understanding antibody profiles. In another study describing the antigenic composition of an 
omvPV, Ptx and Fim2 were reported to be present in that vaccine [30]. However, this was not 
observed in our study using a different omvPV. The differences in vaccine composition might 
be explained by the use of different B. pertussis strains, culture conditions, OMV extraction 
methods [38], vaccine dose, and methods of analysis. Though some antigens that were most 
abundant induced the highest antibody responses (such as Vag8 and BrkA in omvPV), other 
abundant proteins (such as FHA and Prn in omvPV and wPV) did not induce that high antibody 
responses, whereas some less abundant proteins (Pnp, BvgA) induced higher responses than 
expected based on the quantity present. In addition, some proteins present in equal amounts 
in omvPV and wPV (Tcf, EfTu) induced different antibody levels.
While many immunogenic proteins are present in omvPV and wPV, little is known about 
their protective capacity. Some indications have been reported, for example, using a mouse 
intracerebral protection assay it was shown that in combination with non-protective levels 
of anti-Ptx, Vag8 induced protective activity [60]. In addition, when administered as a single 
component vaccine, recombinant Vag8 could induce a protective response in the lung [16]. 
For another autotransporter, BrkA, human antibodies against this protein were shown to 
have bactericidal activity [61]. In addition, a three-component acellular vaccine with BrkA, 
Ptx and FHA was shown to induce a protective immune response in mice [62]. However, 
vaccination with recombinant BrkA as a single component did not protect against B. pertussis 
infection [62]. The tracheal colonization factor (Tcf) is a virulence factor and aerosol challenge 
of mice with a Tcf-deficient B. pertussis strain resulted in a 10-fold decrease in trachea 
colonization compared to a WT strain, indicating an important role for Tcf during colonization 
[63]. This might suggest a protective function for anti-Tcf antibodies in the respiratory tract. 
Indeed, intranasal administration of Tcf, carried by an attenuated strain of Vibrio cholerae, 
135
Immunoproteomic profiling of pertussis vaccines
4
resulted in clearance of B. pertussis in the trachea, but not in the lungs of vaccinated mice 
[64]. The GroEL protein is a conserved protein, found in many species of bacteria as well 
as in humans and therefore probably less suitable as a vaccine antigen [65]. In this study, 
anti-GroEL antibody formation was found upon wPV vaccination and B. pertussis infection. 
Active immunization with GroEL induced only little protection against a B. pertussis infection 
[65]. In the present study, anti-LPS antibodies were detected at high levels in mice vaccinated 
with omvPV or wPV and to a lesser extent in infected mice. Others have demonstrated 
that anti-LPS antibodies in mice [66], rats [67], and humans [68] have bactericidal activity 
and reduce bacterial colonization in the respiratory tract. In addition, anti-LPS antibodies 
might lead to diminished pro-inflammatory cytokine production by binding LPS, leading to 
reduced endotoxic effects of an infection. Immunization with LPS-based oligosaccharide 
conjugates induced bactericidal antibodies, indicating the potential for improving immunity 
by implementing pertussis LPS in a vaccine [69].
The question remains whether omvPV provides protective immunity by eliciting a humoral 
immune response. Based on the protective capacity of antibody induction against antigens, 
such as BrkA, LPS, Tcf and Vag8 described in literature [61, 64, 69, 70], the omvPV antibody 
profile in our study suggests potential induction of protective humoral immunity in mice. 
Other studies have shown that omvPV confers protection similar to aPV when studying the 
short-term responses [6, 31]. More importantly, it was shown that omvPV could also provide 
long-lasting immunity. This was also achieved by a commercial aPV but only at a high dose 
(1/10 Human Dose) in mice [31]. In addition, omvPV protects against different strains [31]. 
The broader response against multiple relevant antigens by omvPV, instead of selective 
antigens by aPV, may prevent impaired immunity due to strain adaptation. Future studies 
should demonstrate the relationship between the immunoproteomic profiles determined for 
different pertussis vaccines and the presence of long lasting-immunity. These studies should 
provide us with important new insights into the role of the humoral response and protection.
In order to maintain high vaccine compliance after introducing an improved pertussis 
vaccine, first a better efficacy but not more reactogenicity of omvPV compared to aPV should 
be established.
In conclusion, the humoral immune response elicited by omvPV is distinct from that induced 
by classic pertussis vaccines, such as wPV and aPV. The omvPV elicits high serum antibody 
levels that consist of a broad subclass response in mice against multiple antigens. The study 
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Abstract
Resurgence of whooping cough demands better understanding of the mode of action of 
pertussis vaccines. A systems biology approach was applied to investigate the immunogenicity, 
potency, and potential adverse effects in mice of a candidate outer membrane vesicles 
pertussis vaccine (omvPV) and a whole-cell pertussis vaccine (wPV) as comparator. To this 
end, responses were compared after (i) subcutaneous immunization and (ii) an intranasal 
Bordetella pertussis challenge. Both vaccines stimulated a mixed systemic response of Th1/
Th2/Th17 cells. Remarkably, omvPV, as compared to wPV, evoked higher serum IgG levels, 
lower systemic pro-inflammatory cytokine responses, higher numbers of splenic neutrophils, 
and enhanced gene expression in the spleen. The transcriptome comprised gene signatures 
of the IFN-signaling pathway, anti-inflammatory signatures that attenuate LPS responses, 
anti-inflammatory metabolic signatures, IgG responses, and confirmed the presence of 
neutrophils. Upon intranasal challenge, mice immunized with omvPV or wPV were equally 
efficient in clearing B. pertussis from the lungs. Both immunized groups evoked diminished 
pulmonary and splenic gene transcription and pulmonary cytokine secretion as compared to 
challenged non-immunized mice. In conclusion, omvPV and wPV provide equal protection 
to bacterial colonization and induce a similar mixed Th1/Th2/Th17 response, while omvPV 
induced higher IgG levels. Moreover, omvPV elicited less pro-inflammatory cytokines, but 
more anti-inflammatory signatures. Therefore, milder inflammatory responses are observed 
in mice upon immunization with omvPV compared to wPV. These results emphasize the 
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Introduction
The efficacy of the pertussis vaccines on the market, whole-cell pertussis vaccine (wPV) and 
acellular pertussis vaccine (aPV), is under scrutiny because of the resurgence of whooping 
cough, despite high vaccination coverage [1, 2]. The current view on immunity to B. pertussis 
is that T-helper 1 and T-helper 17 (Th1/Th17) responses [3, 4] and specific antibody responses 
are preferred for protection. wPV induce a predominant Th1/Th17 response [4-6] and a broad 
systemic antibody repertoire [7], but wPV is associated with mild adverse effects [8, 9]. The 
suspected correlation between wPV and serious acute neurological illness in children [10, 
11] has finally led to the call for safer pertussis vaccines. This resulted in the introduction of 
better-defined aPVs in many countries. The aPVs evoke high IgG1 antibody titers and mainly 
a Th2 response, which provides protection against disease, however, with a relatively short 
duration. Recent findings for aPV suggest waning immunity in children [12] and impaired 
prevention of transmission in baboons [13]. It is thought that the breadth of the antibody 
response [7] and the type of T-cell response induced by aPVs are suboptimal [14]. This 
situation calls for improved pertussis vaccines.
Outer membrane vesicles from B. pertussis are a potential vaccine candidate (omvPV). The 
protection in mice induced by omvPV is comparable to that of aPV, based on lung colonization 
data after B. pertussis challenge [15, 16]. Nevertheless, the omvPV elicits a broader humoral 
immunity compared to aPV [7]. To match the high short-term efficacy and good safety profile 
of current aPVs, a more comprehensive insight into omvPV-induced responses is required to 
unravel the type of immunity and assist in future vaccine registration. For this, an unbiased 
and detailed systems biology approach may be suitable. The application of systems biology 
in vaccine research has provided a better understanding of immune mechanisms and has 
been useful for the prediction of vaccine efficacy based on correlating biomarkers both for 
yellow fever and influenza [17-19]. Moreover, systems biology can be applied for comparing 
molecular signatures induced by distinct vaccines [20, 21] and for gaining insight into vaccine 
safety [22]. Previously we used a systems approach in mice to study B. pertussis infection-
induced responses [23].
Here, a systems vaccinology approach is implemented to investigate the potency of omvPV 
in mice. In addition, wPV is included in the study as a benchmark. Furthermore, markers for 
vaccine safety are measured with respect to pro- and anti-inflammatory cytokine secretion 
and splenic transcriptome. Finally, immunized mice were subjected to a B. pertussis challenge 




OmvPV provides slightly better protection than wPV against B. pertussis 
challenge
The composition of both omvPV and wPV, in terms of proteins, DNA, and LPS as well as 
particle size [7], was determined before mice were immunized twice with a four-week interval 
as illustrated in Figure 1. Vaccine efficacy was assessed by determining lung colonization in 
omvPV-immunized mice (omvPV-mice) compared to wPV- and non-immunized mice (wPV-
mice and N.I.-mice, respectively) upon an intranasal challenge with B. pertussis (Figure 2A). 
As observed before [23], N.I.-mice showed extensive colonization and lungs were not cleared 
at day 77, the end of the observation time (21 days post challenge). The lungs of immunized 
mice were cleared faster. The lungs of omvPV-mice were cleared as fast as those of wPV-
mice. Though omvPV-mice seemed to be even faster, no significant differences were found. 
In conclusion, this indicates that omvPV provides slightly better protection than wPV against 
B. pertussis challenge.
Figure 1 - Study design of the systems approach on omvPV- and wPV-induced responses. BALB/c mice 
were subcutaneously immunized with 4 μg omvPV (red) or wPV (blue) on day 0 and day 28. Subsequently, 
the vaccine-induced responses of both vaccines were characterized over a period of 56 days at 10 different 
time points. Additionally, an intranasal B. pertussis challenge (2x105 cfu/mouse) was performed on day 56 in 
immunized groups and in non-immunized mice (green). Both vaccine- and infection-induced responses were 

























































Systems vaccinology of whole-cell versus outer membrane vesicle vaccine
5
Figure 2 - Lung colonization and vaccine-induced adaptive responses in omvPV- and wPV-immunized mice. 
(A) Non-immunized, omvPV-immunized, and wPV-immunized mice were intranasally challenged with 2x105/40 μl 
cfu B. pertussis. The number of cfu in 1 ml challenge culture (c.c.) was confirmed before challenge. Subsequently, 
the cfu/ml in the lungs of mice was determined 4 hours and 2, 7, 14, and 21 days after challenge (day 56(4h)-
77). * and ** = p ≤ 0.05 and p ≤ 0.01 for immunized group vs. non-immunized group. (B-C) Splenocytes were 
obtained post booster immunization (day 49) of mice that were naive (black), omvPV-immunized (red), or 
wPV-immunized (blue). Concentrations of IL-4, IL-5, IL-13, IFNγ, TNFα, IL-17A and IL-10 were determined in the 
culture supernatants after 7 days of stimulation with (B) 5 µg/ml OMVs or (C) 5 µg/ml B. pertussis whole-cells. 
Results for each mouse are corrected for medium stimulation. Data presented as mean ± SD (n = 4). * = p ≤ 0.05 
for immunized group vs. naive group. (D-H) The kinetics of serum (D) anti-OMV IgM, (E) anti-OMV IgG and (F) 
anti-B. pertussis IgG formation was determined for a period of 56 days after omvPV and wPV immunization. 
Data are presented as mean ± SD (n = 4). For (D), *, **, *** and **** = p ≤ 0.05, p ≤ 0.01, p ≤ 0.001 and p ≤ 0.0001 
for day 28-56 vs. naive, # and ## = p ≤ 0.05 and p ≤ 0.01, for day 28(4h)-56 vs. day 28, + and ++ = p ≤ 0.05 and p ≤ 
0.01 for omvPV-mice vs. wPV-mice. For (E-F), *, **, *** and **** = p ≤ 0.05, p ≤ 0.01, p ≤ 0.001 and p ≤ 0.0001 for 
naive vs. day 28, #, ##, ### and #### = p ≤ 0.05, p ≤ 0.01, p ≤ 0.001 and p ≤ 0.0001 for day 28 vs. day 56, + and ++ = 
p ≤ 0.05 and p ≤ 0.01 for omvPV-mice vs. wPV-mice. The significance in (E) and (F) between day 28(4h)-49 is not 
depicted. (G) Subclass distribution was determined at day 56 in serum of mice immunized with omvPV or wPV 
by calculating the ratio of the level for each subclass from the sum of the levels all subclasses. (H) To determine 
antigen-specificity, the immunoproteomic profiles of serum antibodies (pooled sera, n = 4) following primary 
immunization (day 28) and booster immunization (day 56) were obtained. The band positions of Vag8, BrkA 



























































































































































































































































OmvPV and wPV induce a mixed Th1/Th2/Th17 response
To investigate the vaccine-induced systemic T-cell responses, the levels of seven cytokines 
related to Th-responses were determined in culture supernatants from stimulated 
splenocytes harvested three weeks after the second immunization (Figure 2B-C). Stimulation 
with B. pertussis OMVs or whole-cells resulted in enhanced production of Th1 (IFNγ), Th2 (IL-5 
and IL-13), and Th17 (IL-17A) cytokines and IL-10 in omvPV-mice and wPV-mice, compared to 
naive mice. TNFα was not observed, while IL-4 (Th2) was only detected after OMV stimulation 
of splenocytes from omvPV-mice. Upon stimulation of splenocytes with purified antigens, 
pertussis toxin (Ptx), filamentous hemagglutinin (FHA), and pertactin (Prn), hardly any 
cytokines were produced, with the exception of  IL-17A after FHA stimulation of splenocytes 
from wPV-mice and IL-5 after Prn stimulation of splenocytes from omvPV-mice (Figure S3A-C, 
left panels). In conclusion, the cytokine profiles indicate that immunization of mice with 
omvPV and wPV generated a mixed repertoire of Th1/Th2/Th17 cells.
OmvPV induces higher serum IgG antibody responses
The IgG and IgM levels in mouse sera were monitored for 56 days (Figure 2D-F). omvPV 
induced IgM specific for OMV proteins and reached highest IgM levels on day 32 (Figure 2D). 
wPV also stimulated IgM production specific for OMV proteins, but at a slower rate and with 
a maximum level on day 49 (Figure 2D). Moderate IgG levels were detected 28 days after the 
primary immunization with either omvPV or wPV, detected by both a multiplex immunoassay 
(MIA) against OMVs and a whole-cell ELISA (Figure 2E-F). Booster immunization resulted 
in a strong increase of IgG production, with omvPV-mice developing higher IgG levels than 
wPV-mice. No IgG or IgM antibodies were found directed against purified antigens (Ptx, 
FHA, Prn, and Fimbriae 2 and 3 (Fim2/3)) (data not shown). The subclass distribution and 
immunoproteomic profiles of serum IgG antibodies were compared for both vaccines on 
day 28 and 56 (Figure 2G-H). The subclass distribution on day 28 was dominated by IgG1 for 
both omvPV and wPV (Figure 2G). However, booster immunizations with wPV and to a much 
larger extent with omvPV, stimulated production of IgG3 antibodies on day 56 (Figure 2G). As 
described previously, most of the IgG3 antibodies induced by omvPV and wPV immunization 
were shown to be specific for LPS [7]. Confirmed here, higher levels of anti-LPS IgG antibodies 
were detected after omvPV immunization compared to wPV immunization (Figure 2H). 
Moreover, these anti-LPS IgG antibodies were observed solely on day 56, indicating that 
these antibodies were elicited by the booster immunization. Additionally, both vaccines 
mainly induced antibodies specific for Vag8 and BrkA (Figure 2H).
Less pro-inflammatory cytokine induction in serum by omvPV compared to wPV
A MIA was performed on mouse sera to measure the vaccine-induced cytokine responses 
elicited by immunization with omvPV or wPV (Figure 3). Cytokine levels were mainly affected 
4 hours after booster immunization (day 28(4h)), when the concentrations of CXCL10, G-CSF, 
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IL-1α, IL-6 and CCL4 were significantly enhanced in omvPV-mice and wPV-mice compared to 
pre-immunization levels. In omvPV-mice, all these cytokine concentrations were significantly 
lower than in wPV-mice. Moreover, concentrations of CXCL1, CCL2, IL-1β, IL-5, and IL-13 were 
only significantly elicited by the wPV booster immunization. These results indicate that the 
induction of pro-inflammatory cytokine levels is less intense after booster immunization with 
omvPV compared to wPV.
Transcriptomic profiles in the spleen induced by immunization with omvPV or 
wPV
Gene expression profiles were obtained in the spleen over a period of 28 days (day 28-56) 
to reveal the effects of immunization with omvPV or wPV. In total, 423 and 185 genes were 
identified that were differentially regulated compared to naive mice (day 0) (p-value ≤ 0.001, 
Fold Ratio (FR) ≥ 1.5) in omvPV-mice and wPV-mice, respectively (Figure 4A). Of these genes, 
160 (132 upregulated, 28 downregulated) overlapped between both immunized groups. 
Additionally, differential expression of 263 genes (180 upregulated, 83 downregulated) was 
exclusively detected in omvPV-mice, whereas 25 genes (21 upregulated, 4 downregulated) 
were only differentially regulated in wPV-mice (Figure 4A).
Figure 3 - Serum cytokine secretion following omvPV or wPV immunization. Concentrations of 32 cytokines 
were determined in serum at multiple time points after immunization with omvPV or wPV. Levels of CXCL10, 
G-CSF, CXCL1, IL-1α, IL-6, IL-5, IL-13, IL-1β, CCL4, and CCL2 were significantly altered and are depicted here. The 
different stages of primary immunization and booster immunization are depicted in the panels. Data represent 
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Figure 4 - Transcriptomic profiles in the spleen following omvPV and wPV booster immunization. (A) Fold 
changes of differentially expressed genes were calculated compared to naive mice (FR ≥ 1.5, p-value ≤ 0.001). 
In total, 448 differentially expressed genes were found divided over both vaccine responses, as depicted in 
a Venn-diagram with total number of genes (black) and both upregulated (red) and downregulated genes 
(green). (B) Overrepresentation analysis on all 448 genes revealed the involvement of specific GO-BP 
terms and KEGG pathways with corresponding upregulated (red) and downregulated (green) genes. (C) All 
differentially upregulated (red) and downregulated (green) genes are portrayed as heatmap (mean of n = 4). 
Genes not surpassing a FR of 1.5 are shown as basal level (black) at this time point. Gene clustering is based 
on up/downregulation, time of involvement, and presence in the immunization group. The overlap and the 
exclusive presence of differentially expressed genes in either the omvPV or wPV groups are further depicted 
next to the heatmap. Booster immunization-induced responses were divided in three phases: early phase (day 
28(4h)-32), middle phase (day 35-42) and late phase (day 49-56) as calculated in Figure S1A. Selections of genes 
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To gain insight into the molecular pathways regulated by immunization, an overrepresentation 
analysis (ORA) was performed using DAVID. This analysis revealed enrichment of 77 gene 
ontology biological pathways (GO-BP) terms and 2 KEGG pathways (Benjamini ≤ 0.05) in the 
dataset of omvPV-mice and/or wPV-mice. The pathways related to immunity are shown in 
Figure 4B. The terms Immune response, Defense response, and Cell cycle contained more 
genes upregulated in omvPV-mice than in wPV-mice. Both groups have an equal number of 
genes related to Phagocytosis and B-cell mediated immunity (Figure 4B).
Genes were clustered based on (i) co-expression over time and (ii) overlap between both 
immunized groups (Figure 4C). Additionally, based on hierarchical clustering (Figure S1A), 
the time points in the vaccine-induced response could be divided in three phases; early phase 
(day 28(4h)-32), middle phase (day 35-42) and late phase (day 49-56) (Figure 4C). Based on 
the clustering of genes, 7 groups were identified that were further investigated in-depth 
using text mining and are described below.
Group 1 consists of genes that were detected exclusively in the early phase of the omvPV-
induced response. This group comprised genes related to pathogen recognition, such as 
formyl peptide receptor 1 (Fpr1) and genes involved Toll-like receptor (TLR) 3 (Tlr3, Mlkl) and 
TLR7 (Tlr7, Treml4, Lgmn, Trex1) mediated signaling. Trex1 limits the pro-inflammatory signals 
following TLR7 activation in macrophages [24], whereas Siglece represses TLR-signaling in 
general [25]. Moreover, members of the Bcl family, (Bcl2a1a, Bcl2a1b, Bcl2a1c, Bcl2a1d, Bcl3), 
paired-Ig-like receptors (Pira1, Pira2, Pira4, Pira6, Pira11, Lilrb3), IFN-induced transmembrane 
proteins 1 and 2 (Ifitm1, Ifitm2) and IL-1 receptor antagonist (Il1rn) were detected. In addition, 
enhanced expression was detected of the liver X receptor (Nr1h3), which is involved in lipid 
metabolism and an important mediator of inflammation in macrophages. Genes related to 
processing of LPS included Bst2, the macrophage scavenger receptor 1 (Msr1) that inhibits 
LPS-stimulated IL-6 secretion [26], and PKR (Eif2ak2), which is essential for LPS-induced iNOS 
production [27]. Finally, neutrophil-related genes (Pram1, Fgr), the C-type lectin receptor DCIR 
(Clec4a2), and two cytokines (Ccl2, Saa3) were found.
Group 2 genes were exclusively upregulated in the middle phase of the omvPV-induced 
response. This group contained genes related to myeloid cells (Mcpt8, Clec12a, Chi3l3) 
and more specifically neutrophil markers, including late stage neutrophil differentiation 
marker [28], lactotransferrin (Ltf), a neutrophil activation marker (Clec1b), Cd177, Ngp, 
and Cebpe. Moreover, the neutrophil-secreted lipocalin 2 (Lcn2), elastase (Elane), matrix 
metalloproteinase-9 (Mmp9), cathelicidin antimicrobial peptide (Camp), and ficolin B (Fcnb) 
were detected. Similar gene expression profiles were observed for Rgs18, Mgmt, and integrin 
alpha 2 (Itga2b).
Group 3 includes antibody-related genes, such as Igkc, Igj, Igk, and Ighg, which showed higher 




Group 4 genes were upregulated in the early phase of immunization in omvPV-mice, but were 
not or hardly upregulated in wPV-mice. In addition, most of these genes were differentially 
expressed in omvPV-mice during the middle phase, while the expression in wPV-mice was 
























































































































































































































































































































Figure 5 - Selected splenic transcriptome profiles and the involvement of Gr1+ cells following omvPV and 
wPV booster immunization. (A) The splenic transcriptome profiles of genes related to antibodies, pathogen 
recognition receptors (PRRs), interferon regulatory factors (IRFs), IL-1 signaling, LPS sensing, and lipid 
metabolism are depicted. (B) Transcriptomic profiles from spleen tissue of omvPV-mice and wPV-mice were 
compared with BioGPS databases. In total, 46 genes found following immunization showed overlap with the 
Mac+Gr1+ granulocytes dataset, which are depicted as heatmap. (C) Flow cytometry was subsequently used to 
determine the percentage of Gr1+ cells in the spleen following omvPV and wPV immunization. Data presented 
as mean ± SD (n = 4). * and ** = p ≤ 0.05 and p < 0.01 for immunized mice vs. naive mice (day 0), ++ = p ≤ 0.01 
for omvPV-mice vs. wPV-mice.
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and Steap4 that decreases the inflammatory effect by repressing IL-6 production [30]. 
Moreover, genes involved in LPS responsiveness were upregulated, such as the secretory 
leukocyte peptidase inhibitor (Slpi) that suppresses responses to LPS [31], heme oxygenase 
1 (Hmox1), Stfa3 with a member of the same family Stfa2l1, and angiopoietin-like 4 (Angptl4) 
that is induced by LPS in the acute phase response [32]. Notably, Angptl4 has multiple 
functions, e.g. inflammation and lipid metabolism [33]. Genes involved in metabolism (Hk3, 
Tbxas1) and more specifically the lipid metabolism (Angptl4, Lpl, Hpgds) were found in this 
group. Furthermore, this group comprised Pf4/Cxcl4 that induces phagocytosis [34], myeloid 
cell specific genes (Lilrb4, Ms4a3, Serpina3g), danger-associated molecular patterns (DAMPs) 
(S100a9, S100a8), IFN-induced genes Slfn4 and Ifitm6, and Fcgr4 that binds IgG2a and IgG2b. 
Moreover, genes were detected encoding proteins expressed on or secreted by neutrophils, 
such as myeloperoxidase (Mpo), proteinase 3 (Prtn3), a chemoattractant receptor (Cxcr2), 
and Il1f9 [35]. IL-1F9 promotes Th1 formation by binding IL-36R on T-cells [36].
Group 5 genes were increased on day 29 by both vaccines. Some of these genes are involved 
in the type I IFN-signaling pathway. This included Irf7 as well as Oasl1 that inhibits IRF7 [37], 
in addition to other IFN-induced proteins (Ifi44, Ifi204, Ifi202b, Ifi27l2a, Ifit1, Ifit2, Ifit3, Ifih1, 
Ifitm3, Irgm1, H28, Mnda, Oasl2, Tor3a, Lgals3bp, Mx2). Moreover, two genes were detected 
that encode PRRs which involved in sensing cytosolic DNA: DAI (Zbp1) [38] and LPG2 (Dhx58) 
[39]. Furthermore, genes encoding Fc receptors (Fcgr1, Fcer1g), a NOD-like receptor (Nlrp12), 
which is a neutrophil migration marker [40], C-type lectins (Clec4d, Clec4e), and other 
membrane markers (Ly6a, Ms4a6d, Cd300lf, Gp49a) were identified. Moreover, differential 
gene expression was detected for matrix metalloproteinase-8 (Mmp8), hemopoietic cell 
kinase (Hck), LPS-induced gene (Cmpk2), the colony stimulating factor 3 receptor (Csf3r), 
genes involved in apoptosis (Cd5l, Xaf1), two members of the guanylate-binding protein 
gene family (Gbp6, Gbp9) that assist in protection against bacterial infection [41], and two 
genes encoding tripartite-motif proteins (Trim30a, Trim30c) of which TRIM30α inhibits TLR4-
mediated NF-kappaB activation [42].
Group 6 genes were upregulated on day 28(4h) by both vaccines. This group included an 
LPS-induced macrophage gene (Ifi205), the inflammatory chemokine Ccl12, the interleukin 
1 receptor, type II (Il1r2), and protein tyrosine phosphatase 1B (Ptpn1) that controls pro-
inflammatory responses after LPS exposure [43]. Moreover, upregulated genes encoding 
membrane markers were detected that are mainly myeloid-restricted (Cd300e) of which 
some are related to pathogen-recognition, such as dectin-2 (Clec4n) that recognizes high-
mannose ligands, Cd14 commonly expressed on monocytes and involved in LPS binding, and 
other membrane markers (Cd244, Ccr3).
Group 7 genes were merely differentially expressed in the wPV-mice in the early phase 
after immunization. This group included increased gene expression of PDGFC (Pdgfc), IFN 
regulatory factor 9 (Irf9), complement component 4B (C4b), lymphocyte membrane marker 
(Ly6e), an Fc-receptor (Fcgr3), adenosine deaminase (Adar) that represses the effect after 
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bacterial DNA sensing, and PARP-14 (Parp14) that promotes Th2 and Th17 cell formation and 
steers the antibody subclass distribution [44, 45]. In the late phase after wPV immunization, 
ten genes were exclusively expressed including an IgM gene (Ighm), Cd83 an important 
activation marker on B-cell, T-cell, and dendritic cell populations [46], and others (Gnas, Ctso, 
Hspa1a, Acta2, Ctgf, and Odz4).
Based on this text mining, sets of genes involved in antibody formation, pathogen recognition 
receptors (PRRs), interferon regulatory factors (IRFs), IL-1 signaling, LPS sensing and lipid 
metabolism were found (Figure 5A). For further investigation of genes related to IFN-
signaling, the transcriptome of the spleen was matched with the Interferome database to 
identify which vaccine-induced genes were involved in the type I and type II IFN-signaling 
pathways (Figure S2). In total, 91 genes were related to type I IFN, 22 to type II IFN, and 60 
genes to both pathways. The omvPV induced the majority of IFN-related genes of both type 
I and II, whereas only 13 of such genes were found exclusively in wPV-mice. Moreover, the 
type II IFN-signaling pathway was mainly involved in the early phase of the immune responses 
after omvPV and wPV immunization. Genes of the type I IFN-signaling pathway were also 
mainly found in the early phase, but also partly in later phases (Figure S2).
Together, comparison of the splenic transcriptomes after omvPV and wPV immunization 
demonstrated that omvPV conferred a more diverse and more intense gene expression 
compared to wPV. Moreover, omvPV activated genes are involved in pathogen-recognition, 
dampening of LPS-responses, IFN-related genes, lipid metabolism, neutrophils, and antibody 
production.
Higher neutrophil responses elicited by omvPV compared to wPV
Gene expression profiles were compared with BioGPS databases to identify which cell 
types were involved in vaccine-induced immune responses (Figure S1B). According to this 
analysis, 46 genes were associated with MAC+GR1+ granulocytes (neutrophils). All 46 genes 
were detected in omvPV-mice and were mainly activated during the early and middle phase 
of the vaccine-induced response (Figure 5B). In contrast, only 16 of these 46 genes were 
upregulated in the wPV-mice. Flow cytometry confirmed that the percentage of Gr1+ cells in 
the spleen was significantly increased by omvPV and wPV immunization between days 29-42 
(Figure 5C). In line with the enhanced gene expression, the omvPV-induced response was 
characterized by a significant increase in Gr1+ cells in the middle phase on day 42 compared to 
the wPV-induced response.
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Reduced serum and pulmonary cytokine responses in immunized mice following 
B. pertussis challenge
Subsequent to the investigation of vaccine-induced responses, we examined the immune 
responses in omvPV-mice, wPV-mice, and N.I.-mice after B. pertussis challenge by measuring 





































































































































































































































































































































































































































































































































































Figure 6 - Serum and pulmonary cytokine secretion following B. pertussis challenge in mice immunized with 
omvPV or wPV and non-immunized mice. (A-B) The concentrations of 32 cytokines were determined prior to 
and at multiple time points post challenge with B. pertussis in non-immunized mice (green) or mice immunized 
with omvPV (red) or wPV (blue). Only cytokines that were significantly altered in (A) serum and (B) lung lysate 
are depicted. Data are presented as mean ± SD for immunized groups (n = 4) and non-immunized groups (n = 
3). * = p ≤ 0.05 for challenged groups vs. day 56, # = p ≤ 0.05 for immunized groups vs. non-immunized group, 
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First, concentrations of 32 cytokines were determined in serum and lung lysate (Figure 6A-B). 
In sera of N.I.-mice, IL-1α, IL-1β, CXCL2, CCL3, IL-13, and G-CSF were significantly increased mainly 
between days 63-77. Notably, no significant cytokine secretion was observed in sera of omvPV-
mice (Figure 6A). The concentrations of IL-1α, IL-1β, IL-5, IL-6, IL-10, IL-12(p70), IL-13, CCL3, CCL4, 
CCL5, CXCL1, CXCL2, and CXCL10 were significantly higher in the sera of wPV-mice compared 
to omvPV-mice, mainly on day 63. However, the cytokine levels of wPV-mice were not induced 
upon challenge, as no significant differences were found after challenge compared to day 56, 
except for CCL3 (Figure 6A). Analysis of the pulmonary cytokine profiles demonstrated that 
IL-17A, G-CSF, CXCL9, CCL4, and CXCL10 were significantly increased in lung tissue of N.I.-mice, 
between day 63-77 (Figure 6B). These cytokines were not elevated in either of the immunized 
groups, except for G-CSF in wPV-mice between day 56(4h)-63. These results demonstrate that 
both omvPV and wPV immunization prevented pulmonary cytokine secretion following a B. 
pertussis challenge. However, the systemic cytokine responses in wPV-mice appeared more like 
those in N.I.-mice, but different in omvPV-mice.
Transcriptomic profiles in the spleen following B. pertussis challenge
Splenic transcriptomes of immunized mice were compared to those of N.I.-mice at 5 timepoints 
after an intranasal challenge. In total, 402 genes were differentially expressed in the spleen 
of immunized mice or N.I.-mice (p-value ≤ 0.001, FR ≥ 1.5) (Figure 7A). Differential expression 
of 87, 7, and 59 genes was exclusively detected in the challenged omvPV-mice, wPV-mice, 
and N.I.-mice, respectively. 120 genes (70 upregulated, 50 downregulated) were found in all 
three groups (Figure 7A). The ORA on infection-induced responses in the spleen revealed 
enrichment of 24 gene ontology biological pathways (GO-BP) terms and 2 KEGG pathways 
(Benjamini ≤ 0.05) in omvPV-mice, wPV-mice, and N.I.-mice (Figure 7B). In omvPV-mice, several 
of the downregulated genes are involved in Cell cycle (33 genes) and Cell division (18 genes). 
The terms Immune response and Defense response comprised a small number of genes that 
were differentially regulated in omvPV-mice, but in higher numbers in wPV-mice and N.I.-
mice. Genes were clustered based on (i) co-expression over time and (ii) overlap between 
both experimental groups (Figure 7C). Hierarchical clustering on the three challenged groups 
indicated that the infection-induced response was distinct in immunized mice compared to the 
Figure 7 (Left) - Transcriptomic profiles in the spleen following B. pertussis challenge in omvPV-, wPV-, 
and non-immunized mice. (A) Fold changes in expression and significant gene expression were calculated 
compared to naive mice (FR ≥ 1.5, p-value ≤ 0.001). In total, 402 differentially expressed genes were found 
divided over the three groups in a Venn-diagram with total number of genes (black), upregulated genes (red), 
and downregulated genes (green). (B) Overrepresentation analysis on all 402 genes revealed the involvement 
of specific GO-BP terms and KEGG pathways with corresponding upregulated (red) and downregulated 
(green) genes. (C) All differentially upregulated (red) and downregulated (green) genes are portrayed as 
heatmap (mean of n = 3 for immunized groups, n = 1 (pool of 3 mice for non-immunized group)). Genes not 
surpassing a FR of 1.5 are shown as basal level (black). Gene clustering is based on up/downregulation, time of 
involvement, and presence in different groups. Infection-induced responses were divided in phases according 




challenged N.I.-mice (Figure S1C). The infection-induced response of N.I.-mice was divided 
in three phases: early phase (day 56(4h)-58), middle phase (day 63), and late phase (day 70-
77). In omvPV-mice, a faster response was observed compared to N.I.-mice and was divided 
in two phases: early phase (day 56(4h)) and middle phase (day 58). The later time points 
(day 63-77) were similar to the expression levels prior to challenge (day 56). In wPV-mice, a 
slightly slower response compared to omvPV was seen and could be divided in an early phase 
(day 58), middle phase (day 63), and late phase (day 70) (Figure 7C and S1C). A selection of 
genes in nine (1-9) areas in the heatmap is depicted. BioGPS analysis revealed induction of 38 
genes in challenged N.I.-mice that are usually expressed in MAC+GR1+ granulocytes (Figure 
8A). In immunized mice, neutrophil involvement after challenge was much less pronounced 
as only 10 and 22 genes were found in omvPV-mice and wPV-mice, respectively. Additional 













































































































































Figure 8 - Cell specific transcriptomic profiles and the involvement of Gr1+ cells after challenge of omvPV-, 
wPV-, and non-immunized mice. (A) Transcriptomic profiles from spleen tissue of omvPV-, wPV-, and non-
immunized mice following a B. pertussis challenge were compared with BioGPS databases. In total, 38 
differentially regulated genes matched with the Mac+Gr1+ granulocytes dataset and are depicted as heatmap. 
(B) Flow cytometry was used to determine the percentage of Gr1+ cells in the spleen after challenge of 
immunized and non-immunized mice. Data are presented as mean ± SD (n = 3). * and ** = p ≤ 0.05 and p ≤ 0.01 
for challenged groups vs. day 56, # and ## = p ≤ 0.05 and p ≤ 0.01 for immunized groups vs. non-immunized 
group.
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neutrophils, was significantly increased in N.I.-mice on day 70 (Figure 8B). In contrast, the 
fraction of Gr1+ cells in omvPV-mice and wPV-mice was enhanced on day 63 and day 63-77, 
respectively. The Gr1+ cell fraction in immunized mice was significantly lower between days 































































































Figure 9 - Pulmonary transcriptomic profiles following B. pertussis challenge in omvPV- and wPV-and non-
immunized mice. (A) Fold changes in expression and significant gene expression were calculated compared 
to naive mice (FR ≥ 1.5, p-value ≤ 0.001). In total, 3269 differentially expressed genes were found divided 
over the three groups in a Venn-diagram with total number of genes (black), upregulated genes (red), and 
downregulated genes (green). (B) All differentially upregulated (red) and downregulated (green) genes 
are portrayed as heatmap (mean of n = 3 for immunized groups, n = 1 (pool of 3 mice for non-immunized 
group)). Genes not surpassing a FR of 1.5 are shown as basal level (black). Gene clustering is based on up/
downregulation, time of involvement, and presence in the different groups. Infection-induced responses were 
divided in phases according to the hierarchical clustering calculated in Figure S1D.
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B. pertussis demonstrated less intense gene expression profiles in omvPV-mice and wPV-mice 
than in N.I.-mice. These responses were even lower in omvPV-mice than in wPV-mice.
Pulmonary transcriptomic profiles following B. pertussis challenge
To determine the effect of immunization on the murine host response in the lung following 
B. pertussis challenge, pulmonary transcriptomic profiles of challenged immunized mice 
were compared to those of challenged N.I.-mice. In total, 3269 genes were differentially 
expressed in lungs of immunized mice or N.I.-mice (p-value ≤ 0.001, FR ≥ 1.5) (Figure 9A). 
Exclusive differential expression of 578, 156, and 90 genes was detected in challenged 
omvPV-mice, wPV-mice, and N.I.-mice, respectively. In total, 1702 genes (695 upregulated, 
1007 downregulated) were found in all three groups (Figure 9A). Genes were clustered 
based on (i) co-expression over time and (ii) overlap between both experimental groups 
(Figure 9B). Hierarchical clustering on the pulmonary transcriptome of the three challenged 
groups demonstrated a distinct infection-induced response in immunized mice compared to 
challenged N.I.-mice (Figure S1D). The infection-induced response of N.I.-mice was divided in 
three phases: early phase (day 56(4h)-58), middle phase (day 63 and day 77) and late phase 
(day 70), as seen before [23]. In omvPV-mice, the response was less diverse compared to day 
56 and was divided in two phases; early phase (day 56(4h)) and middle phase (day 70). In 
wPV-mice, the response compared to day 56 was more diverse and developed slower than in 
omvPV-mice with an early phase (day 63-70) and middle phase (day 77) (Figure 9B and S1D). 
The pulmonary transcriptome in omvPV-mice on day 56 prior to challenge differs a lot from 
the naive basal gene expression level. Moreover, omvPV-mice show less change in pulmonary 
gene expression as compared to wPV-mice and N.I.-mice after challenge. Together, these 
results demonstrate that a B. pertussis challenge evokes fewer effects on gene expression 
levels in omvPV-mice than wPV-mice and N.I.-mice.
Adaptive recall responses in omvPV-mice and wPV-mice following B. pertussis 
challenge
Prior to the challenge (day 56), no vaccine-induced anti-OMV IgA could be detected in the 
lungs of omvPV-mice and wPV-mice (Figure 10A). However, after intranasal B. pertussis 
challenge, anti-OMV IgA antibodies were detected in a similar amount in wPV-mice and N.I.-
mice on day 63-77, yet not in omvPV-mice. Serum IgG levels specific for pertussis OMV or 
whole-cells were unaltered in wPV-mice and were slightly decreased in omvPV-mice after the 
intranasal challenge, whereas IgG levels in N.I.-mice were rising between day 63-77 (Figure 
10B-C). The specificity of IgG antibodies, as determined by immunoblot, did not change in 
omvPV-mice after a challenge, except for the disappearance of the band at 15 kDa (Figure 
10D). The challenge of wPV-mice led to the formation of additional antibodies directed 
against GroEL (60 kDa) and an unknown antigen of 20 kDa.
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Th-responses were determined post challenge, by analyzing the levels of seven cytokines in 
culture supernatants after antigen-specific stimulation of splenocytes from challenged omvPV-
mice, wPV-mice, and N.I.-mice, with those of non-challenged naive mice as control, harvested 
on day 77 (Figure 10E-F and S3). After stimulation with OMVs, Th1 (TNFα), Th2 (IL-5 and IL-13), 
and Th17 (IL-17A) cytokines were altered in challenged omvPV-mice, wPV-mice, and N.I.-mice 
compared to naive mice. IL-5 and IL-17A levels were higher in immunized mice compared to 





























































































































































































Figure 10 - Humoral and cellular adaptive recall responses following B. pertussis challenge in omvPV- and wPV-
immunized mice as compared to control mice before and after challenge. (A-C) Kinetics of (A) pulmonary anti-
OMV IgA, (B) serum anti-B. pertussis IgG, and (C) serum anti-OMV IgG levels were determined for a period of 21 
days following intranasal challenge in immunized mice (n = 4) and non-immunized mice (N.I.) (n = 3). Data are 
presented as mean ± SD. Statistical significance of differences in (A), (B) and (C): *, **, *** and **** = p ≤ 0.05, 
p ≤ 0.01, p ≤ 0.001 and p ≤ 0.0001 for vs. day 56 per group, + and ++ = p ≤ 0.05 and p ≤ 0.01 for omvPV vs. wPV, #, 
##, ### and #### = p ≤ 0.05, p ≤ 0.01, p ≤ 0.001 and p ≤ 0.0001 for immunized groups vs. non-immunized group. 
(D) Immunoproteomic profiles of serum IgG antibodies (pooled sera, n = 4) before (day 56) and 21 days post 
challenge (day 77) were obtained on a B. pertussis lysate. (E-F) Concentrations of IL-4, IL-5, IL-13, IFNγ, TNFα, 
IL-17A and IL-10 were determined in the culture supernatants after 7 day stimulation with (E) 5 µg/ml OMVs, 
or (F) 5 µg/ml B. pertussis whole-cells. Splenocytes were obtained from naive mice (black) and post-challenge 
(day 77) of mice that were omvPV- (red), wPV- (blue) or non-immunized (green). Results for each mouse are 
corrected for medium stimulation. Data in (E) and (F) presented as mean ± SD (n = 4). Statistical significance 
of differences in (E) and (F): * = p ≤ 0.05 for challenged groups vs. naive, + = p ≤ 0.05 for omvPV group vs. wPV 
group, # = p ≤ 0.05 for immunized group vs. non-immunized group.
162
Chapter 5
(IFNγ), Th2 (IL-5 and IL-13) and Th17 (IL-17A) cytokines in omvPV-mice, wPV-mice, and N.I.-
mice compared to naive mice. The levels of these cytokines were overall higher in immunized 
mice compared to N.I.-mice. Moreover, production of IL-10 was only observed in immunized 
mice (Figure 10F). IFNγ and TNFα were both high in naive control mice after stimulation with 
B. pertussis OMVs and whole-cells, most likely caused by LPS. Nevertheless, omvPV-mice and 
wPV-mice showed a similar result post challenge on day 77 as after immunization on day 49. 
Stimulation with Prn resulted in increased concentrations of IL-13 and IL-17A in challenged 
immunized and N.I.-mice compared to the non-challenged naive group (Figure S3A, right 
panel). These IL-17A levels were significantly higher in both immunized groups compared 
to the N.I.-mice. Furthermore, significantly higher IL-5 production was observed in omvPV-
mice and N.I.-mice than in wPV-mice. After Ptx stimulation, IL-17A production was exclusively 
observed in wPV-mice (Figure S3B, right panel). IL-5, IL-13 and IL-17A production was evoked 
by FHA stimulation in immunized and N.I.-mice. Moreover, enhancement of IFNγ, TNFα, and 
IL-10 was detected in wPV-mice (Figure S3C, right panel). In conclusion, the cytokine profiles 
showed enhanced Th1/Th2/Th17 ex vivo recall responses in challenged omvPV-mice and wPV-
mice compared to challenged N.I.-mice.
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Discussion
Introduction of an improved third generation pertussis vaccine requires in-depth knowledge 
on vaccine-induced responses in comparison to current pertussis vaccines especially in terms 
of efficacy and safety profile. To that end, we applied a systems biology approach to compare 
comprehensive immune responses in a murine model induced by an OMV-based pertussis 
vaccine (omvPV) or a classical whole-cell pertussis vaccine (wPV).
Parenteral injection of wPV has been related to adverse effects [8, 9] and suspected 
correlation with serious acute neurological illness in children [10, 11] mainly as a result of 
circulating pro-inflammatory cytokines such as IL-1β, TNFα, and IL-6 [11, 47]. This has been 
a key reason for the development of aPVs that are safer and better defined. Our in vivo 
study demonstrated that omvPV in comparison to wPV, with an equal total protein dose, 
elicited reduced concentrations of serum pro-inflammatory cytokines (IL-1α, IL-1β, and IL-
6), chemokines (CXCL1 and CXCL10), and G-CSF. Especially, the reduced IL-1β secretion by 
omvPV may be beneficial given its involvement in the suspected acute neurological illness 
[11]. Activation of Toll-like receptors (TLRs) [48] by pathogen-associated molecular patterns 
(PAMPs), like lipopolysaccharide (LPS) and bacterial DNA, result in the secretion of these 
cytokines. Previously we showed that the omvPV contains less TLR activating LPS and DNA 
per amount protein than wPV [7]. An additional hypothesis might be that omvPV contains 
mostly membrane-associated LPS and less free LPS compared to wPV thus resulting in lower 
cytokine induction. Less pro-inflammatory cytokine production was also seen when LPS is 
adsorbed to alum [49], which demonstrates that free LPS might be more pyrogenic than 
bound LPS. On the other hand, LPS in omvPV seems more immunogenic than LPS in wPV 
(Figure 2H). The lower concentrations of LPS and DNA in omvPV may therefore lead to less 
activation of TLR4 and TLR9 and contribute to the attenuated pro-inflammatory cytokine 
response by omvPV compared to wPV.
The splenic transcriptome measured after booster omvPV and wPV immunization 
demonstrated that omvPV induced a larger number of genes than wPV. This was an 
unexpected observation in light of the attenuated pro-inflammatory cytokine signatures. 
The triggering of anti-inflammatory responses, diminished PRR responses, and expression of 
modifiers that dampen inflammatory LPS responses in omvPV-mice may explain why omvPV 
elicited low amounts of pro-inflammatory cytokines. OmvPVs activated genes encoding 
anti-inflammatory formyl peptide receptors FPR1 and FPR2. These PRRs bind many different 
signal peptides of bacteria [50] which are important for rapid neutrophil recruitment [51]. 
Furthermore, the response induced by omvPV may repress pro-inflammatory responses 
following LPS recognition due to enhanced gene expression of FPR2, SPLI, STEAP4, PTPN1, 
and MSR1, which correspond to proteins that are attenuators of LPS responses [26, 29-31, 43]. 
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Finally, omvPV stimulated genes encoding proteins with a dual function in lipid metabolism 
and anti-inflammatory responses, namely ANGPTL4 [32, 33], HPGD2S [52], and LXRα. These 
metabolic signatures may have been activated by lipid mediators induced by omvPV and 
may subsequently contribute to the anti-inflammatory response that is less prominent in the 
wPV-induced response. Despite the lower content of genomic DNA in omvPV [7], two genes 
encoding PRRs sensing cytosolic DNA, DAI [38], and LPG2 [39], were upregulated by both 
vaccines. Interestingly, only omvPV immunization led to enhanced gene expression of TLR3 
and TLR7, intracellular sensors for viral and bacterial nucleotides. Activation of TLRs leads to 
induction of IFN-signaling pathways. For instance, we found induction of transcription factor 
IRF7, a factor downstream of TLR7, by both vaccines. IRF7 is an important mediator of type I 
IFN-signaling [53]. Overall, a large number of genes of the type I IFN-signaling pathway were 
induced by omvPV and wPV, which were more profound in the omvPV response. Type I IFN-
signaling can affect a broad range of immune mediators, including both innate and adaptive 
immune cells [54]. With respect to CD4 T-cells, the pathway is important for the regulation 
of Th1 and Th17 responses [55]. Additionally, both vaccines induced many genes involved 
in the type II IFN-signaling pathway. IFNγ is the only member of the type II IFN family, for 
which upregulation of associated genes was again more profound in the omvPV response. 
Therefore, induction of both types of IFN-signaling pathways by omvPV and wPV seems to 
contribute to Th1/Th17 responses that are thought to be important for protection [3, 4, 23].
TLR4 activation by LPS is one of the pathways that can direct the cellular responses towards 
Th1 and Th17 responses [5, 6]. Thus, it is important to evaluate whether the reduced TLR4-
signaling by omvPV does not affect the ability of omvPV to induce B. pertussis-specific Th1 
and Th17 responses. Cytokine profiles of stimulated splenocytes revealed that omvPV and 
wPV both induce mixed systemic Th1/Th2/Th17 responses, in contrast to the Th2-biased aPV-
induced response [4, 14]. This indicates that despite lower LPS concentration and TLR4-
signaling, the omvPV still induced a similar Th response as wPV. This may suggest that the 
LPS concentration in omvPV is sufficient for the induction of Th1/Th17 responses or that other 
signaling, such as TLR2 [56], promote Th17 responses.
The concentrations of aPV components (Prn, FHA, and Ptx) are low in the omvPV and wPV 
used in this study, except for FHA in wPV [7]. Therefore, it was not surprising that antibody 
and T-cell responses specific for these antigens were low following immunization with omvPV 
and wPV. However, high levels of antibodies against other B. pertussis-specific antigens were 
detected that were more strongly induced by omvPV when compared to wPV. Especially the 
booster immunization induced a strong antibody response that was mainly directed against 
BrkA, Vag8 and LPS, in line with our previous study [7]. This broad humoral response conferred 
by both omvPV and wPV might limit the risk of driving B. pertussis adaptation as a result 
of vaccine-induced selection pressure. As Prn-deficient B. pertussis strains are increasingly 
circulating, especially in aPV-immunized populations, it has been hypothesized that this might 
be the result of pathogen adaptation [57, 58]. Since omvPV contains more BrkA and Vag8 [7], 
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higher antibody levels were induced against these antigens. Remarkably, despite the lower 
LPS concentrations measured in omvPV, the omvPV booster immunization induced higher 
anti-LPS IgG3 antibody levels than wPV. This indicates that the LPS in omvPV was processed 
in a different way by the immune system during the first immunization compared to booster 
immunization. Since anti-LPS IgG3 antibodies are mostly produced in a T-cell independent 
manner [59], this may indicate that omvPV evokes a more efficient T-cell independent B-cell 
response than wPV. Furthermore, mucosal B. pertussis-specific IgA induction in the lungs 
was absent after immunization with omvPV and wPV, as expected. Mucosal IgA is produced 
after natural infection [23, 60] and contributes most likely to a faster lung clearance during 
B. pertussis challenge. Presumably, direct involvement of the respiratory tract through 
intranasal or pulmonary vaccine administration may result in more effective immunity.
Mice immunized with omvPV or wPV showed rapid clearance of B. pertussis from the lungs 
after challenge when compared to N.I.-mice. Whereas no significant differences were 
observed between both immunized groups, lungs of omvPV-mice tended to be cleared 
slightly faster perhaps because of the higher serum IgG levels. Previously, intraperitoneal 
immunization with alum-adjuvated omvPV and wPV derived from a B. pertussis Tohama 
strain also demonstrated equal protection [15]. The B. pertussis challenge was utilized to 
elucidate the pre-existing immunity in omvPV-mice and wPV-mice. The immune responses of 
challenged immunized mice were characterized by (i) adaptive recall responses, (ii) a change 
in pulmonary environment by reduced cytokine secretion and transcriptome expression, (iii) 
altered systemic cytokine responses, and (iv) reduced splenic transcriptome expression in 
comparison to challenged N.I.-mice. The presence of high serum IgG levels and the strong 
recall of Th1/Th2/Th17 responses enabled a rapid clearance in both immunized groups. In 
contrast to the vaccine-induced responses, the responses after challenge of immunized 
and N.I.-mice were characterized by detectable Th cytokines after stimulation with purified 
proteins, which indicates significant specific T-cell activation as a result of prolonged exposure 
to these antigens after B. pertussis challenge [23]. Furthermore, immunized mice responded 
less vigorous on an infection with respect to the splenic and pulmonary transcriptome, 
pulmonary and serum cytokine responses, and number of splenic neutrophils. The N.I.-mice 
showed the largest changes in gene expression in the lungs 14 days after challenge, which 
is in line with our previous study [23]. These responses were overall lower in omvPV-mice 
than wPV-mice. Finally, no IL-17A was secreted after ex vivo Ptx stimulation of splenocytes, 
and no antigen-specific IgA was detected in the lungs of challenged omvPV-mice, while 
these were present in both wPV-mice and N.I.-mice. This Ptx exposure occurred during B. 
pertussis colonization, as Ptx is absent in both omvPV and wPV used in this study [7]. Since 
the responses after B. pertussis challenge of wPV-mice and N.I.-mice show more similarities 
compared to those of omvPV-mice, this may indicate that omvPV-mice controlled the B. 
pertussis challenge more effectively than wPV-mice.
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In summary, we demonstrated that in comparison to wPV, omvPV confers equal protection 
with higher IgG levels and a comparable Th1/Th2/Th17 response. Additionally, the systems 
approach provided detailed insight into the molecular signatures of the vaccine as well as 
challenge-induced responses. The inflammatory responses elicited by omvPV were milder, as 
reflected by reduced levels of pro-inflammatory cytokines. Probably, inflammatory responses 
are attenuated by the enhanced anti-inflammatory responses, i.e. ANGPTL4, FPR2, PTPN1, 
SPLI, and STEAP4. Therefore, it is tempting to speculate that the decreased inflammatory 
responses induced by omvPV reflect a better safety profile. In conclusion, our collective 
findings emphasize the potential of omvPV as a third-generation pertussis vaccine.
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Methods
Vaccines and challenge culture
OmvPV from B. pertussis B1917 were produced as previously described [61]. For production 
of wPV, B. pertussis B1917 was heat-inactivated (30 min, 56°C) in PBS. Both omvPV and wPV 
were diluted in PBS to a final concentration of 4 μg total protein per immunization dose 
(300 μl). Vaccine characterization included particle size, protein composition, and LPS and 
DNA content [7]. For the challenge culture, stock suspension of B. pertussis strain B1917 was 
diluted with Verweij medium (BBio, Bilthoven, The Netherlands) to a final concentration of 
5x106 colony-forming units (cfu)/ml.
Animal experiment
An independent ethical committee of the Institute for Translational Vaccinology (Intravacc) 
approved the animal experiment with identifier 201200073. 8 week old female BALB/c mice 
(Harlan, The Netherlands) were subcutaneously immunized with 4 μg total protein in 300 μl 
of either omvPV or wPV on day 0 (left groin) and day 28 (right groin). Mice were challenged 
intranasally under anesthesia (isoflurane/oxygen), with 2 × 105 cfu of B. pertussis B1917 in 40 
μL of Verweij medium on day 56. Non-immunized (N.I.) mice were used as a control.
For the determination of gene expression in spleen, cytokine responses and antibody 
responses, mice (n = 4) were sacrificed on day 28 after primary immunization. In addition, 
mice (n = 4) were euthanized after booster immunization on day 28 + 4 hours (day 28(4h)), 
and day 29, 30, 32, 35, 38, 42, 49 and 56. Finally, mice (n = 4 per group) were sacrificed 4 hours 
after challenge and on day 58, 63, 70, and 77 to measure bacterial load in the respiratory tract, 
antibody responses and cytokine responses. For the investigation of Th subsets, mice (n = 
4) were sacrificed on day 49 and 84. Naive mice (n = 4) were included as additional control 
group on each time point. Mice were bled under anesthesia (isoflurane/oxygen) by orbital 
bleeding and sacrificed by cervical dislocation for further sample collection. An overview of 
the study design is depicted in Figure 1A.
Sample collection and preparation
For investigation of cytokine and antibody responses in serum, whole blood from each mouse 
was collected in a blood collection tube (MiniCollect 0.8 ml Z Serum Sep GOLD, Greiner Bio-
One, Austria). After coagulation (10 min. at room temperature) and centrifugation (10 min., 
3000 g), sera were taken and stored at -80°C. For the colonization assay, the right lung lobe 
was placed in 900 ml Verweij medium at room temperature. To determine pulmonary cytokine 
and antibody responses, the lung lysates used for colonization assays were filtered (Millex GV 
Filter unit 0.22 μm, Millipore) and stored at -80°C. For characterization of pulmonary gene 
expression, the left lung lobe was placed in 1 ml RNAlater (Qiagen), incubated overnight at 
4°C, and stored at -80°C. In addition, the spleen was excised and divided in two equal parts. 
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For gene expression analysis, one piece was placed in 1 ml RNAlater (Qiagen), incubated 
overnight at 4°C and stored at -80°C. For detection of Gr1+ cells, the other piece was placed in 
in 5 ml RPMI-1640 medium (Gibco) supplemented with 10% FCS (Hyclone), 100 units penicillin, 
100 units streptomycin, and 2.92 mg/ml L-glutamine (Invitrogen), hereafter called RPMI 
complete medium, and kept on ice. For the analysis of Th responses, the whole spleen was 
placed in 5 ml of RPMI medium and kept on ice. Splenocytes were isolated by homogenization 
of spleens using a 70-μm cell strainer (BD Falcon, BD Biosciences) in RPMI complete medium.
Colonization assay
The numbers of cfu in lung tissue were determined as previously described [23].
RNA isolation and microarray analysis
Isolation and determination of concentration and integrity of RNA obtained from lung and 
spleen tissue were performed as described before [23]. For spleen tissue of both omvPV-mice 
and wPV-mice, individual RNA concentrates of individual mice (n = 3) were analyzed for all 16 
time points (naive, and day 28, 28(4h), 29, 30, 31, 32, 35, 42, 49, 56, 56(4h), 58, 63, 70, and 77 
post primary immunization). For lung tissue, samples of individual mice were analyzed for 
the following time points: day 56(4h), 58, 63, 70, and 77 post primary immunization. For the 
non-immunized mice after challenge, samples of lung and spleen tissue were pooled (n = 3). 
Amplification, labeling and hybridization of RNA samples for either lung or spleen tissue to 
microarray chips (NimbleGen 126135 k Mus musculus, Roche, Germany) was carried out at 
the Microarray Department of the University of Amsterdam, The Netherlands, as described 
previously [23].
Data analysis of gene expression
Quality control and normalization of raw microarray data was performed as described before 
[23]. To identify differentially expressed genes between experimental groups (naive and 
various time points post immunization or challenge) an ANOVA was applied. The induction 
or repression of individual genes was expressed as fold ratio (FR) by comparing mean gene 
expression levels of experimental groups to the naive mice. Average normalized gene 
expression levels contain data of three mice per immunized group. The data of challenged 
non-immunized mice are individual samples of pooled RNA of three mice. The dataset of 
challenged non-immunized mice (n = 3) of our previous study [23] was incorporated in the 
analysis to increase the statistical power. Probes were considered differentially expressed 
if they met the following two criteria: (i) a p-value < 0.001 (ANOVA), which corresponds to 
a Benjamini-Hochberg False discovery rate (FDR) [62] of < 5%; and (ii) an absolute FR ≥ 1.5 
(experimental groups compared to naive mice) for at least one time point. If multiple probes 
corresponding to the same gene were differentially expressed, their data were averaged to 
remove redundancy for further analysis. GeneMaths XT (Applied Maths, St-Martens-Latem, 
169
Systems vaccinology of whole-cell versus outer membrane vesicle vaccine
5
Belgium) was used to visualize differences in gene expression in heatmaps and perform 
the hierarchical clustering using Euclidean distance (linear scaling) with UPGMA clustering. 
Genes were arranged according to similar expression patterns in time at which genes 
exceeded the FR cut-off of 1.5. To facilitate visual interpretation of heatmaps, only induction 
(red) and repression (green) of gene expression levels with fold ratios ≥ 1.5 are visualized, 
therefore presenting fold ratios ≤ 1.5 as naive level (black). Functional enrichment with an 
over-representation analysis (ORA) based on Gene Ontology Biological Processes (GO-BP) 
and Kyoto Encyclopedia of Genes and Genomes (KEGG) by using DAVID and the detection of 
cell-specific or tissue-specific gene expression based on BioGPS datasets was performed as 
described previously [23]. Involvement of type I and II IFN-signaling pathway was performed 
by using the Interferome database (http://www.interferome.org/interferome/home.jspx) 
[63]. Additional text mining on gene function was performed in PubMed.
Multiplex immunoassay (MIA) and ELISA for antibody response
Levels of pulmonary IgA and serum IgM, IgA, total IgG and IgG subclasses (IgG1, IgG2a, 
IgG2b and IgG3)  specific for B. pertussis antigens Prn, FHA, Ptx, combined fimbria type 2 
and 3 antigens (Fim2/3) and outer membrane vesicles B1917 (OMV B1917) were determined 
as described previously [23] and are presented as fluorescent intensity (F.I.). Whole-cell B. 
pertussis ELISA for total serum IgG was performed as described before [23].
Immunoproteomic profiling of serum IgG antibodies
Antigen specificity of B. pertussis-specific serum IgG antibody responses were determined by 
SDS-PAGE and subsequent Western blotting as described before [7].
Gr1+ cells in the spleen
After treatment with erythrocyte lysis buffer (8.3 g/L NH4CL, 1 g/L NaHCO3, 5000 IE/L Heparin in 
dH20; pH 7.4), the percentage of Gr1
+ cells in the spleen was determined with flow cytometry 
as described before [23].
Isolation and in vitro restimulation of splenocytes
After treatment with erythrocyte lysis buffer, splenocytes were cultured in 24-well plates at 
6 × 106 cells/well for 7 days at 37°C in a humidified atmosphere containing 5% CO2 in IMDM 
medium (Gibco) supplemented with 8% FCS, 100 units penicillin, 100 units streptomycin, 
2.92 mg/ml L-glutamine, and 20 µM β-mercaptoethanol (Sigma). The cells were either left 
unstimulated (medium control) or stimulated with 1 µg/ml, 1 µg/ml Ptx, 1 µg/ml FHA, 5 µg/ml 
OMV, or 5 µg/ml heat-killed B. pertussis. B. pertussis antigens Ptx and FHA were obtained from 
Kaketsuken (Japan), Prn and Fim2/3 were kindly provided by Betsy Kuipers (National Institute 
for Public Health and the Environment, Bilthoven, the Netherlands). On day 7, supernatant 
was collected for cytokine analysis.
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Cytokine profiling using multiplex technology
Concentrations (pg/ml) of 32 cytokines (Eotaxin, G-CSF, GM-CSF, IFNγ, IL-10, IL-12 (p40), IL-12 
(p70), IL-13, IL-15, IL-17A, IL- 1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IP-10, KC, LIF, LIX, M-CSF, 
MCP-1, MIG, MIP-1α, MIP-1β, MIP-2, RANTES, TNFα, VEGF) present in serum and lung lysates 
were determined by using a MIA (Milliplex MAP Mouse Cytokine/ Chemokine - Premixed 32 
Plex; Merck KGaA, Darmstadt, Germany) following the manufacturer’s protocol.
The concentration of various Th cytokines (IL-4, IL-5, IL-10, IL-13, IL-17A, TNFα, and IFNγ) 
was determined in culture supernatant using a Milliplex mouse cytokine 7-plex luminex kit 
(Millipore), according to the manufacturer’s protocol. Measurements and data analysis 
were performed with Bio-Plex 200, using Bio-PlexManager software (version 5.0, Bio-Rad 
Laboratories). Results were corrected for the background (medium control) per mouse per 
stimulation per cytokine and calculated in pg/ml.
Statistical analysis
Data of the antibody, cytokine, and colonization assays were log-transformed after which 
a t-test was performed. P-values ≤ 0.05 were considered to indicate significant differences.
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Figure S1 - Hierarchical clustering and BioGPS comparison of splenic transcriptome. (A) Hierarchical clustering 
of the omvPV-induced splenic transcriptome dataset to identify which time points showed a similar response. 
The response was divided in four parts illustrated by the different colors. (B) Transcriptomic profiles from 
spleen tissue of omvPV-mice and wPV-mice were compared with BioGPS databases. The numbers of genes 
detected in the different BioGPS databases are listed. (C-D) Hierarchical clustering on the (C) splenic and (D) 
pulmonary transcriptome datasets of challenged N.I.-mice, omvPV-mice and wPV-mice to identify which time 
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Figure S2 - IFN-induced genes in spleens of omvPV- and wPV-immunized mice. Genes induced by omvPV 
and wPV in the transcriptome of the spleen were matched with the Interferome database (http://www.
interferome.org/interferome/home.jspx). A Venn diagram shows the total number of genes (black) induced 
by type I IFN, type II IFN, or both. Genes that were found exclusively in the omvPV-mice (red), wPV-mice (blue) 
or overlapped in both groups (orange) are depicted. The individual genes involved in type I IFN, type II IFN, or 























































































































































































































































































































































































































































Figure S3 - Splenic cytokine responses after antigen restimulation in omvPV- and wPV-immunized mice before 
and after challenge as compared to naive control mice before and after challenge. (A-C) Concentrations of IL-
4, IL-5, IL-13, IFNγ, TNFα, IL-17A and IL-10 were determined in the culture supernatants after 7 day stimulation of 
splenocytes with 1 µg/ml (A) Prn, (B) Ptx, or (C) FHA. Splenocytes were harvested post booster immunization 
(day 49, left panel) of mice immunized with omvPV (red) or wPV (blue). Post-challenge (day 77, right panel), 
same groups were included with an additional group of non-immunized mice that received a challenge (green). 
In both experiments, complete naive mice (black) were used as control. Results for each mouse are corrected 
for medium stimulation. * = p ≤ 0.05 for immunized group and challenged group vs. naive group, # = p ≤ 0.05 for 
omvPV group vs. wPV group, + = p ≤ 0.05 for challenged immunized group vs. challenge non-immunized group.
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Abstract
Current acellular pertussis (aPV) vaccines promote a T-helper 2 (Th2)-dominated response, 
while Th1/Th17 cells are protective. As our previous study showed, after adding a non-toxic 
TLR4 ligand, LpxL1, to the aPV in mice, the Bordetella pertussis-specific Th2 response is 
decreased and Th1/Th17 responses are increased as measured at the cytokine protein level. 
However, how this shift in Th response by LpxL1 addition is regulated at the gene expression 
level remains unclear. Transcriptomics analysis was performed on purified CD4+ T-cells of 
control and vaccinated mice after in vitro restimulation with aPV antigens. Multiple key 
factors in Th differentiation, including transcription factors, cytokines, and receptors, were 
identified within the differentially expressed genes. Upregulation of Th2- and downregulation 
of follicular helper T-cell-associated genes were found in the CD4+ T-cells of both aPV- and 
aPV+LpxL1-vaccinated mice. Genes exclusively upregulated in CD4+ T-cells of aPV+LpxL1-
vaccinated mice included Th1 and Th17 signature cytokine genes Ifng and Il17a respectively. 
Overall, our study indicates that after addition of LpxL1 to the aPV the Th2 component is not 
downregulated at the gene expression level. Rather an increase in expression of Th1- and 




Pertussis or whooping cough, caused by the gram-negative bacterium Bordetella pertussis, 
remains endemic even in highly vaccinated populations [1-3]. This resurgence has been 
ascribed to multiple causes, including suboptimal programming of the adaptive immune 
response by second generation acellular pertussis (aPV) vaccines. This has been supported by 
several studies in different models, namely mice, baboons, and humans, which have revealed 
that a mixed T-helper 1 (Th1) and Th17 type of CD4+ T-cell response is induced by B. pertussis 
infection [4-7]. Moreover, these Th subsets have been shown, by both the mice and baboon 
models, to be crucial in the protection against B. pertussis [4, 7]. In contrast, the CD4+ T-cell 
response induced by current aPV is rather Th2-dominated [4, 8-10].
Th subsets are mainly identified by the production of Th subset signature cytokines, such as 
IFNγ (Th1), IL-4, IL-5, and IL-13 (Th2), IL-17A (Th17), IL-10 and TGFβ (regulatory T-cells (Treg)), 
and IL-21 (follicular helper T-cells (Tfh)). CD4+ T-cell differentiation has several underlying 
processes. After activation through their T-cell receptors, the functional programming of CD4+ 
T-cells is initiated by differentiation cytokines produced in the priming microenvironment, 
such as IL-12, interacting with their cognate receptors. This results in the activation of signal 
transducer and activator of transcription (Stat) proteins [11], which induce the expression of 
master transcription factors. Each Th subset can be defined by the expression of Stat proteins 
and master transcription factors, namely Stat4/Stat1/Tbet (Th1), Stat5/Stat6/Gata3 (Th2), 
Stat3/Rorγt (Th17), Stat5/FoxP3 (Treg), and Stat3/Bcl6 (Tfh) [11-13]. These master transcription 
factors subsequently induce expression of many Th subset-associated genes and silence 
genes expressed in other Th subsets. These genes include chemokine and cytokine receptors, 
which also can be used to discriminate between Th subsets. Th1 cells are characterized by 
CCR1/CCR5/CXCR3 expression, Th2 cells by CCR3/CCR4/CCR8 expression, Th17 cells by CCR4/
CCR6 expression, Treg cells by CD25 expression, and Tfh cells by CXCR5 expression [14].
Recently, the programming of aPV-induced CD4+ memory T-cells was investigated using 
genome-wide gene expression profiling of human CD4+ T-cells [15]. This approach revealed co-
expression of both Th2- and Th1-associated gene modules in reactivated CD4+ memory T-cells 
generated after aPV vaccination in children. This raised the question of how these in principle 
antagonistic gene modules can establish a predominantly functional Th2 type of CD4+ T-cell 
outcome. These gene modules, it was suggested, may exist in a dynamic equilibrium, and 
depending on ongoing response, the intensity of module components may tip the balance 
in Th subset outcome towards a Th1 or Th2 response. As several preclinical studies have 
demonstrated, steering the aPV-induced Th2-dominated response towards a more favorable 
Th1 and Th17 type of response at the cytokine protein level through the use of adjuvants is 
feasible, for example through replacement of the currently used adjuvant alum in the aPV 
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with TLR2 or TLR9 ligands [4, 16]. We recently showed that also adding the TLR4 ligand 
LpxL1, a non-toxic Neisseria meningitidis LPS derivative, to an alum-containing aPV skewed 
the vaccine-induced CD4+ T-cell response towards a Th1/Th17 type of CD4+ T-cell response 
at the cytokine level [10]. Yet, how the Th subset outcome in the aPV-induced B. pertussis-
specific CD4+ T-cell response by LpxL1 as adjuvant is regulated at the level of gene expression 
remains unclear. This insight is necessary to understand shortcomings and improvement of 
current aPV vaccination.
Therefore, in the present study we compared, in mice, gene expression profiles of B. pertussis-
specific CD4+ T-cells induced by aPV or LpxL1-adjuvanted aPV vaccination. Short stimulation 
of splenocytes of vaccinated mice with B. pertussis antigens activated the B. pertussis-specific 
CD4+ T-cells, after which microarray analysis was performed on RNA from isolated CD4+ 
T-cells. Distinct profiles in CD4+ T-cells were found that are potentially useful in the evaluation 





































Figure 1 - Visualization of differences in gene expression in CD4+ T-cells of control, aPV-, and aPV+LpxL1-
vaccinated mice by principle component analysis. (A) Principal component analysis, based on the differentially 
expressed genes, showing (dis)similarities in gene expression in samples stimulated with the Ptx, FHA, and Prn 
combination (dark colors, n = 5 per group) and medium controls (light colors, n = 3 per group) in all vaccination 
groups (PBS (blue), aPV (red), aPV+LpxL1 (green)) are shown. (B) Venn diagram showing the amount of 
overlap between up- (red) and downregulated (green) genes in 24 hour B. pertussis antigen-stimulated CD4+ 
T-cells of aPV- and aPV+LpxL1-vaccinated mice, as compared to control mice, based on averaged normalized 
gene expression levels of groups.
 
B. pertussis-specific CD4+ T-cell transcriptome of aPV- or aPV+LpxL1-vaccinated 
versus control mice
To determine how addition of LpxL1 to the aPV regulates the Th subset outcome of the 
vaccine-induced B. pertussis-specific CD4+ T-cells on the molecular level, gene expression 
profiles of these responding CD4+ T-cells were investigated. Splenocytes from control, aPV- 
and aPV+LpxL1-vaccinated mice were shortly stimulated with B. pertussis antigens, Ptx, 
FHA, and Prn, after which microarray analysis was performed on RNA from isolated CD4+ 
T-cells. The gene expression profiles of unstimulated CD4+ T-cells of all groups were taken 
as a baseline, to establish whether there is an intrinsic difference between the groups. No 
Figure 2 (Right) - Gene expression profiles of B. pertussis-specific CD4+ T-cells of aPV- and aPV+LpxL1- 
vaccinated mice. The heatmaps depict differential up- (red) or downregulation (green) of genes observed in 
24 hour B. pertussis antigen-stimulated CD4+ T-cells of vaccinated compared to control mice (FR ≥ 1.5). (A) 247 
genes were differentially expressed in CD4+ T-cells of both aPV- and aPV+LpxL1-vaccinated mice. (B) 137 genes 
were differentially expressed in CD4+ T-cells of exclusively aPV-vaccinated mice. (C) 111 genes were differentially 
expressed in CD4+ T-cells of exclusively aPV+LpxL1-vaccinated mice. Expression data shown are averages from 
the samples of 5 mice per group. 
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significant differentially expressed genes could be identified between these unstimulated 
samples (criteria: p-value ≤ 0.001, fold ratio (FR) ≥ 1.5). Nevertheless, to exclude small intrinsic 
non-significant differences, the expression intensities of the antigen-stimulated samples 
were corrected for the average expression intensities of unstimulated samples of their 
corresponding group. In total, 1876 differentially expressed genes (p-value ≤ 0.001, FR ≥ 1.5) 
were identified between averaged unstimulated samples and antigen-stimulated samples of 
the control, aPV-, or aPV+LpxL1-vaccinated groups. A principal component analysis on these 
genes showed differences in gene expression profiles between unstimulated and stimulated 
samples of all groups, including control mice, suggesting an effect of the stimulation on naive 
CD4+ T-cells (Figure 1A). However, distinct gene expression profiles between stimulated 
samples of all groups were still observed, revealing functionally differently programmed B. 
pertussis-specific CD4+ T-cells (Figure 1B). After comparing the B. pertussis antigen-stimulated 
samples of vaccinated mice with those of control mice, differential expression (FR ≥ 1.5) of 
384 and 358 genes was identified in the CD4+ T-cells of, respectively, aPV- and aPV+LpxL1-
vaccinated mice. Overlap comparison showed that 247 genes were differentially expressed 
in CD4+ T-cells of both aPV- and aPV+LpxL1-vaccinated mice, 137 genes were exclusively 
differentially expressed in CD4+ T-cells of aPV-vaccinated mice and 111 genes were exclusively 
differentially expressed in CD4+ T-cells of aPV+LpxL1-vaccinated mice (Figures 1 and 2).
Over-representation of immune- and metabolism-related terms after aPV- and 
aPV+LpxL1- vaccination
To provide more insight in the differentially expressed genes, functional annotation and over-
representation analysis (Benjamini-corrected p-value ≤ 0.05) in GO-BP and KEGG databases 
were performed using DAVID [17]. Analysis of the overlapping 247 differentially expressed 
genes in CD4+ T-cells from both aPV- and aPV+LpxL1-vaccinated mice showed that 74 GO-
BP terms and 8 KEGG pathways were enriched. Based on exclusion of overlapping terms/
pathways and their relevance, a selection of these terms/pathways is shown in Figure 3A. 
The enriched terms/pathways are mainly involved in the regulation of the adaptive immune 
response, as indicated by terms as regulation of lymphocyte activation (GO:0051249), 
proliferation (GO:0050670), and differentiation (GO:0045597), and cytokine signaling, 
including chemotaxis (GO:0006935) and Jak-STAT signaling pathway (mmu4630). Moreover, 
the enrichment of the asthma pathway (mmu05310) indicates the presence of Th2-associated 
genes. Further, terms involved in metabolic processes are enriched, including positive 
regulation of macromolecule metabolic process (GO:0010604) and positive regulation of 
protein metabolic process (GO:0051247).
Functional annotation and over-representation analysis (Benjamini-corrected p-value ≤ 
0.05) of the 137 genes differentially expressed in CD4+ T-cells of exclusively aPV-vaccinated 
mice revealed enrichment of 9 GO-BP terms. Five relevant terms are depicted in Figure 3B, 
which includes immune response-related terms, such as immune response (GO:0006955) 
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Figure 3 - Functional annotation and pathway enrichment of differentially expressed genes in B. pertussis-
specific CD4+ T-cells of aPV- and aPV+LpxL1-vaccinated mice. Over-representation analysis (Benjamini-
corrected p-value ≤ 0.05) in GO-BP and KEGG databases was performed using genes differentially expressed 
in B. pertussis antigen-stimulated CD4+ T-cells of vaccinated compared to control mice. Functional annotation 
and pathway enrichment are depicted from genes differentially expressed in CD4+ T-cells of both aPV- and 
aPV+LpxL1 vaccinated mice (A), in CD4+ T-cells of exclusively aPV-vaccinated mice (B), and in CD4+ T-cells of 
exclusively aPV+LpxL1-vaccinated mice (C). The amount of up- or downregulated genes per term/pathway and 
the percentage of the genes in the total term/pathway population are shown.
and regulation of cytokine production (GO:0001817), and metabolism-related terms such 
as oxidation-reduction process (GO:0055114) and regulation of nitric oxide biosynthetic 
process (GO:0045428). Functional annotation and over-representation analysis of the 111 
genes solely altered in CD4+ T-cells of aPV+LpxL1-vaccinated mice showed enrichment of 9 
GO-terms, including inflammatory response (GO:0006954), chemotaxis (GO:0006935), and 
phagocytosis (GO:0006909) (Figure 3C).
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Differential expression of cytokine-encoding genes in vaccine-induced CD4+ 
T-cells
Our previous study investigated the type of CD4+ T-cell response at the protein level by 
determining the percentage of B. pertussis antigen-specific IL-5-, IFNγ-, and IL-17A-positive CD4+ 
T-cells using flow cytometry and by supernatant analysis. It showed that addition of LpxL1 to 
the aPV skews the CD4+ T-cell response of a Th2-dominated to a mixed response, dominated 
by Th1/Th17 [10]. Therefore, we investigated in more detail the expression of cytokine-
encoding genes. Some Th subset signature cytokine-encoding genes could be identified 
which were upregulated in the CD4+ T-cells of both aPV- and aPV+LpxL1-vaccinated mice, such 
as Il4, Il5, Il13, Il21, and Il10 (Figure 4A). No signature cytokine-encoding genes were found to 
be differentially expressed in the CD4+ T-cells of solely aPV-vaccinated mice, while both Ifng 
and Il17a were found to be upregulated exclusively in those of aPV+LpxL1-vaccinated mice 
(Figure 4C). In addition to the Th subset signature cytokines-encoding genes, other cytokine 
genes were differentially expressed of which 19 were found in CD4+ T-cells of aPV- as well as 
aPV+LpxL1-vaccinated mice. Genes Il3, Il9, Ccl1, Ccl17, and Ccl24 were upregulated, whereas 
downregulation was found for genes encoded for chemokines, Cxcl1, Ccl2, Cxcl2, Cxcl5, Cxcl3, 
Ccl3, and Csf3, and pro-inflammatory cytokines, Il1b, Il6, Tnf, and Il18 (Figure 4A). Five genes 
encoding other cytokines were detected in the CD4+ T-cells of exclusively aPV-vaccinated 
mice, which included downregulation of Cxcl10, IL12a, Il1a, and Tnfsf12 and upregulation of 
Flt3l (Figure 4B). Three upregulated genes were found only in those of aPV+LpxL1-vaccinated 
mice, namely Cxcl9, Ccl5, and Cxcl16 (Figure 4C). Together, these results indicate substantial 
overlap in the expression of cytokine-encoding genes, including Th2 signature cytokines, 
after both aPV- and aPV+LpxL1- vaccination, while expression of genes encoding Th1 and Th17 
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Figure 4 - Gene expression profile of cytokine encoding genes 
in B. pertussis-specific CD4+ T-cells of aPV- and aPV+LpxL1-
vaccinated mice. Genes encoding cytokines differentially 
expressed in B. pertussis antigen-stimulated CD4+ T-cells of 
both aPV- and aPV+LpxL1-vaccinated mice (A), in CD4+ T-cells 
of exclusively aPV-vaccinated mice (B), and in CD4+ T-cells of 
exclusively aPV+LpxL1-vaccinated mice (C). Expression data 
shown are averages from the samples of 5 mice per group.
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Differential expression of transcription factor-encoding genes in vaccine-
induced CD4+ T-cells
Important in the differentiation of CD4+ T-cells to different Th subsets are the master 
transcription factors, T-bet, Gata3, Rorγt, Bcl6, and FoxP3 [11-13]. Within the CD4+ T-cells 
of both aPV- and aPV+LpxL1-vaccinated mice, Gata3, the gene encoding the Th2 master 
transcription factor was found upregulated whereas Bcl6, the gene encoding the Tfh master 
transcription factor was found downregulated (Figure 5A). Genes encoding other known 
master transcription factors were not found differentially expressed. The expression of 
master transcription factors is regulated by different Stat proteins [11]. Upregulation of only 
one Stat gene, namely Stat5a, which is involved in the differentiation of Th2 and Treg cells, 
was detected within CD4+ T-cells of both aPV- and aPV+LpxL1-vaccinated mice (Figure 5A). 
In addition, five genes encoding other transcription factors were identified as differentially 
expressed in the CD4+ T-cells of both aPV- and aPV+LpxL1-vaccinated mice, including 
upregulation of Pparg, Xbp1, and Ikzf3 and downregulation of Nrld2 and Cebpd (Figure 5A). 
Transcription factors Spic and Tgif1 were found downregulated only in the CD4+ T-cells of 
the aPV-vaccinated mice (Figure 5B), while transcription factors Atf3, Mafb and Batf3 were 
found upregulated only in the CD4+ T-cells of aPV+LpxL1-vaccinated mice (Figure 5C). Based 
on expression of Th differentiating transcription factors, both aPV and aPV+LpxL1 vaccination 
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Figure 5 - Gene expression profile of transcription factor 
encoding genes in B. pertussis-specific CD4+ T-cells of aPV- and 
aPV+LpxL1-vaccinated mice. Genes encoding transcription 
factors differentially expressed in B. pertussis antigen-stimulated 
CD4+ T-cells from both aPV- and aPV+LpxL1-vaccinated mice (A), 
in CD4+ T-cells of exclusively aPV-vaccinated mice (B), and in CD4+ 
T-cells of exclusively aPV+LpxL1-vaccinated mice (C). Expression 
data shown are averages from the samples of 5 mice per group.
Differential expression of receptor- and cell surface molecule-encoding genes 
in vaccine-induced CD4+ T-cells
Another way to characterize CD4+ T-cell subsets is by the expression of certain receptors 
and cell surface markers. Upregulation of markers Ccr1 and Ccr3 was detected in the CD4+ 
T-cells of aPV- and aPV+LpxL1-vaccinated mice (Figure 6A). Remarkably, higher expression of 
the Th2-associated Ccr3 was seen in aPV+LpxL1 samples than in aPV samples (Figure 6A). In 
addition to the markers used to characterize Th subsets, differential expression was found of 
genes encoding other receptors and cell surface molecules. Of these genes, 24 were found in 
CD4+ T-cells of aPV- and aPV+LpxL1-vaccinated mice, and of these, 19 genes were upregulated, 
including as Il4ra, and 5 genes were downregulated, including Cxcr2 (Figure 6A). Within the 
CD4+ T-cells of aPV-vaccinated mice, 36 receptor- and cell surface marker-encoding genes were 
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downregulated, including Ly6a, and multiple genes encoding for proteins involved in pattern 
recognition, like Tlr2, Tlr13, Clec4a, Clec4n, and Cd14 (Figure 6B). The 26 upregulated receptor- 
and cell surface marker-encoding genes in the CD4+ T-cells of aPV+LpxL1-vaccinated mice 
included Havcr2, Itga1, and genes encoding proteins involved in the innate immune response, 
such as Tlr4, Clec7a, C3ar1, Fcgr1, Fcgr3, and Fcgr4 (Figure 6C). The 4 downregulated receptor- 
and cell surface marker-encoding genes in samples of aPV+LpxL1-vaccinated mice were Ackr3, 
Ltf, Trbv14, and Trav12-3. Together, these results suggest that aPV+LpxL1 vaccination induces 
expression of genes encoding receptors and cell surface markers associated with Th2 (Ccr3 
and Il4ra), Th1 (Havcr2), and Th17 (Il13ra1) subsets, while aPV vaccination only induced genes 
associated with the Th2 (Ccr3 and Il4ra) subset. 
Differential expression of genes encoding proteins involved in metabolism in 
vaccine-induced CD4+ T-cells
Recent studies have revealed that a shift in metabolism from oxidative phosphorylation 
toward aerobic glycolysis is important in the activation of T-cells [18]. Moreover, the 
production of IFNy in effector T-cells requires aerobic glycolysis [19]. For this reason, we 
also analyzed the expression of genes involved in these metabolic pathways. Only one 
gene encoding a protein involved in the oxidative phosphorylation was found differentially 
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Figure 6 - Gene expression profile of genes 
encoding receptors and cell surface markers 
in B. pertussis-specific CD4+ T-cells of aPV- and 
aPV+LpxL1-vaccinated mice. Genes encoding 
receptors and cell surface markers differentially 
expressed in B. pertussis antigen-stimulated 
CD4+ T-cells of both aPV- and aPV+LpxL1-
vaccinated mice (A), in CD4+ T-cells of exclusively 
aPV-vaccinated mice (B), and in CD4+ T-cells 
of exclusively aPV+LpxL1-vaccinated mice (C). 
Expression data shown are averages from the 
samples of 5 mice per group.
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aPV+LpxL1-vaccinated mice (Figure 7A). Additionally, six genes encoding for proteins with a 
function in the glycolytic process could be identified in the CD4+ T-cells (Figure 7B). Four genes 
were found upregulated in both vaccinated groups, namely Aldoc, Il3, Pfkm, and Pfkp. The Ier3 
gene was downregulated in CD4+ T-cells of aPV-vaccinated mice, while Igf1 was upregulated in 
those of aPV+LpxL1-vaccinated mice. In addition, a recent study has shown that regulation of 
glucose uptake induced by Notch signaling is important in the survival of memory CD4+ T-cells 
[20]. However, no genes involved in this pathway were found to be differentially expressed 
in the CD4+ T-cells of aPV- and aPV+LpxL1-vaccinated mice. Overall, these data suggest that 
there is no difference in the expression of genes involved in metabolic pathways in CD4+ 
T-cells of aPV- and aPV+LpxL1-vaccinated mice.
Distinct Th subset-associated gene modules expressed after aPV and aPV+LpxL1 
vaccination
Based on literature from human and murine studies, a network analysis was performed to 
visualize the expression patterns of genes associated with different Th subsets that were 
observed in the CD4+ T-cells of aPV- and aPV+LpxL1-vaccinated mice (Figure 8). In addition to 
genes encoding the previously mentioned master transcription factors, signature cytokines, 
and surface markers, other differentially expressed genes associated with the main Th subsets 
were found. Mainly Th2-associated genes, such as the Th2 subset signature cytokines (Il4, Il5, 
and Il13), Gata3, Il3, Nabp1, and Slc37a3, were found upregulated in the CD4+ T-cells of both 
aPV- and aPV+LpxL1-vaccinated mice. Interestingly, another Th2-associated gene, Socs3, was 
downregulated in the CD4+ T-cells of exclusively aPV+LpxL1-vaccinated mice. Th1-associated 
genes were upregulated in CD4+ T-cells of aPV+LpxL1-vaccinated mice, including Havcr2 and 
chemokines Cxcl9 and Ccl5, while downregulation of Th1-associated genes Scl11a1 and Il12a is 
observed in those of aPV-vaccinated mice. Further, upregulation of Th17-associated genes 
Dse, Il13ra1, and Il17a was only observed in the CD4+ T-cells of aPV+LpxL1-vaccinated mice. 
Differential expression of Treg-associated genes was found in the CD4+ T-cells of aPV- as 
well as aPV+LpxL1-vaccinated mice, namely Il10 and Stat5a. However, other Treg-associated 
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Figure 7 - Gene expression profile of genes encoding proteins involved 
in metabolism in B. pertussis-specific CD4+ T-cells of aPV- and aPV+LpxL1-
vaccinated mice. Heatmaps depict genes involved in oxidative phosphorylation 
(A) and glycolytic process (B) that are differentially expressed in B. pertussis 
antigen-stimulated CD4+ T-cells of aPV- and aPV+LpxL1-vaccinated mice 
compared to control mice. Expression data shown are averages from the 
samples of 5 mice per group.
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Figure 8 (Right) - Network analysis of Th subset-associated genes differentially expressed in B. pertussis-
specific CD4+ T-cells of aPV- and aPV+LpxL1-vaccinated mice. A gene-function network analysis showing the 
Th subset-associated genes differentially expressed in B. pertussis antigen-stimulated CD4+ T-cells of aPV- and 
aPV+LpxL1-vaccinated was performed using Cytoscape to visualize the patterns of Th subset-associated genes 
induced by the different vaccines. Association of genes with the gene modules (blue rectangles) was based on 
literature from mouse (bold blue lines) and human (thin blue lines) studies. The interactions between genes 
(grey lines) were determined using the STRING database. The shape of the gene nodes indicate whether genes 
were differentially expressed in CD4+ T-cells of both vaccination groups (circles), had the highest fold-change in 
either the CD4+ T-cells of aPV-vaccinated mice (diamonds) or in those of aPV-LpxL1-vaccinated mice (triangles). 
The color intensity of the gene nodes indicate whether genes were differentially expressed in CD4+ T-cell of 
both aPV- and aPV+LpxL1-vaccinated mice (light green and red) or in CD4+ T-cells of exclusively aPV-vaccinated 
mice or in those of exclusively aPV+LpxL1-vaccinated mice (dark green and red).
Tfh-associated genes were found in our study, Bcl6 and Il21, which were respectively down- 
and upregulated in CD4+ T-cells of both the aPV- and aPV+LpxL1-vaccinated mice. Moreover, 
genes involved in glycolysis were found in CD4+ T-cells of both vaccination groups of which 2 
genes are associated with the Th2 subset, namely Pgkp and Il3. Based on this gene expression 
network, our results suggest that aPV vaccination induces mainly Th2 and Treg gene modules, 
while addition of LpxL1 to the aPV induces a shift towards Th1 and Th17 gene modules.
Enrichment of transcription factor-binding sites within the gene set of 
differentially expressed genes in CD4⁺ T-cells of aPV- or aPV+LpxL1-vaccinated 
mice
To further provide insight in the concerted regulation of the differentially expressed genes 
in CD4⁺ T-cells of aPV and aPV+LpxL1 mice, a transcription factor-binding site (TFBS) analysis 
was performed. This analysis revealed enrichment of binding sites for SPIB, RELA, and IRF2 
within the promoter regions of upregulated genes in the CD4⁺ T-cells of aPV-vaccinated 
mice and ELF5, SPI1, Klf4, SPIB, RELA, REL, ELK1, NF-kappaB, and FEV within the upregulated 
genes in the CD4⁺ T-cells of aPV+LpxL1-vaccinated mice, respectively (Figure S1). Binding 
sites for transcription factors within the downregulated genes in the CD4⁺ T-cells of aPV-
vaccinated mice were NF-kappaB and RELA, while no enrichment of TFBS was found within 
the downregulated genes in the CD4⁺ T-cells of aPV+LpxL1-vaccinated mice (Figure S1). An 
overview of the top 20 transcription factors from each analyzed gene set is given in Table S1. 
These results suggest the involvement of multiple transcription factors that regulate the 
distinct of Th subset-related gene expression observed after addition of LpxL1 to the aP 
vaccine. Whereas SPIB and RELA were found in both groups, SPI1, Klf4, and NF-kappaB were 
only involved after addition of LpxL1.
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Addition of the TLR4 ligand LpxL1 to an aPV was found to dampen the Th2 dominance of 
the antigen-specific CD4+ T-cell response of vaccinated mice and to increase a Th1/Th17 type 
response, based on cytokine analysis [10]. In the present study, this skewing was investigated 
in more detail at the gene expression level. Analysis of the expression of Th subset signature 
cytokine-encoding genes revealed an increased expression of Ifng and Il17a in CD4+ T-cells 
of exclusively aPV+LpxL1-vaccinated mice, which is consistent with our previous findings. 
Most importantly, the Th2 subset signature cytokine genes Il4, Il5, and Il13 showed increased 
expression in the CD4+ T-cells of aPV- as well as aPV+LpxL1-vaccinated mice, suggesting that 
the Th2 component is not downregulated at the gene expression level of Th subset signature 
cytokines after addition of LpxL1 to the aPV.
Other Th1-, Th17-, and Th2-associated genes showed the same trend as the genes encoding 
Th signature cytokines. Genes associated with the Th1 subsets had increased expression 
in the CD4+ T-cells of exclusively aPV+LpxL1-vaccinated mice, including genes encoding 
chemokines (Ccl5 and Cxcl9) and cell surface marker Havcr2 (Tim3). Both Ccl5 and Cxcl9 are 
chemoattractants for Th1 cells and are described to be produced by human CD4+ T-cells [21, 
22]. Havcr2 is a cell surface marker preferentially expressed on Th1 cells and its expression 
is induced by Th1 master transcription factor T-bet [23]. Th17-associated genes that showed 
increased expression solely in the CD4+ T-cells of aPV+LpxL1-vaccinated mice were Il13ra1 and 
Dse. IL-13Rα1 is a functional receptor found on both murine and human Th17 cells while it is 
not expressed on Th0, Th1, Th2, and Treg cells [24]. Binding of IL-13 to this receptor attenuates 
the production of IL-17A [24]. Further, Dse is an intracellular enzyme involved in epitope 
processing and is preferentially expressed in human Th17 cells [25].
Remarkably, several other Th2-associated genes also showed increased expression in CD4+ 
T-cells of both aPV- and aPV+LpxL1-vaccinated mice, of which most genes showed the same 
trend as the expression of the Th2 subset signature cytokine-encoding genes. These other 
Th2-associated genes include Th2 master transcription factor Gata3, Stat protein Stat5a, 
chemokine-receptors Ccr1 and Ccr3, and cytokine-receptor Il4ra, and other genes, namely 
Rab19, Nabp1, Scl37a3, and Pfkp [15]. Interestingly, downregulation of Th2-associated Socs3 
is observed in the CD4+ T-cells of exclusively aPV+LpxL1-vaccinated mice. Socs3, suppressor 
of cytokine signaling-3, is preferentially expressed in Th2 cells [26] and inhibits Th1 and 
Th17 differentiation by suppressing STAT4 and STAT3 activation, respectively [27, 28]. 
Downregulation of Socs3 in CD4+ T-cells of aPV+LpxL1-vaccinated mice suggests reduced 
active suppression of Th1 and Th17 differentiation when LpxL1 is present in the aPV and 
thereby favors Th1 and Th17 differentiation.
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In addition to the involvement of the Th1, Th2, and Th17 subsets, this study in aPV- and 
aPV+LpxL1-vaccinated mice revealed gene expression modules pointing at the induction or 
inhibition of other Th subsets, namely Treg and Tfh. Treg cells were induced by both aPV and 
aPV+LpxL1 vaccination, since increased expression of a Treg subset signature cytokine gene, 
Il10, as well as the Treg-associated Stat gene, Stat5a, was detected in CD4+ T-cells of both 
groups. However, expression of Gzmb, encoding Granzyme B, which has cytolytic functions 
and is expressed in different cells including Tregs [29,30], showed increased expression in the 
CD4+ T-cells of exclusively aPV-vaccinated mice. Together with the increased expression of 
Flt3l, which is involved in the expansion of Treg cells [31], in only the samples of aPV-vaccinated 
mice, this suggests that increased numbers of Treg cells were induced after vaccination with 
the aPV alone. Tfh master transcription factor Bcl6 showed decreased expression in the CD4+ 
T-cells of both aPV- and aPV+LpxL1-vaccinated mice, indicating that differentiation towards 
the Tfh subset was suppressed. This seems contradictory given the increased expression of 
the Tfh subset signature cytokine gene Il21. However, this cytokine can also be produced by 
Th17 cells [32]. Some induction of Th17 cells by aPV vaccination might explain the increased 
expression of Il21. A study of Ross et al. indeed showed that Th17 cells could be detected in 
mice after aPV vaccination [4]. These results are consistent with the increased expression of 
Ikzf3 in CD4+ T-cells of both aPV- and aPV+LpxL1-vaccinated mice, since this gene is specifically 
expressed in Th17 cells [33].
In addition to Th subset associated genes, genes encoding proteins that are involved in 
metabolism were investigated, since a shift in metabolism from oxidative phosphorylation 
toward aerobic glycolysis is important in the activation of T-cells [18]. Only a small number of 
genes involved in oxidative phosphorylation and glycolysis were differentially expressed in 
the CD4+ T-cells of aPV- and aPV+LpxL1-vaccinated mice. The genes encoding proteins involved 
in glycolysis, namely Il3, Pfkp, Aldoc, and Pfkm, showed increased expression in the samples 
of both aPV- and aPV+LpxL1-vaccinated mice. Interestingly, Il3 and Pfkp are also associated 
with Th2 cells [15]. Overall, these results suggest little or no difference in the activation of 
CD4+ T-cells based on metabolism by the different vaccines.
Within the set of genes differentially expressed in CD4+ T-cells of aPV- and aPV+LpxL1-
vaccinated  mice, genes were found encoding proteins with a known function in the innate 
immune system, including cytokines (Il6, Il1b, Tnf, and Il12a), complement components (C1qa, 
C1qb, C1qc, Cd55, Cfb, C3, Cd93, C3ar1, Itgam), Toll-like receptors (Tlr2, Tlr13, and Tlr4), C-type 
lectin receptors (Clec4a, Clec4d, Clec4n, Clec7a, Cd302), and Fc-receptors (Fcgr1, Fcgr3, and 
Fcgr4). It is unlikely that these innate gene signatures can be fully explained by contamination 
of innate immune cells within the CD4+ T-cell fraction, since the purity of the samples was 
>95%. Interestingly, several of these innate immunity genes are known to be expressed in CD4+ 
T-cells, including complement components such as Itgam, C3ar1, and Cd55 [34-36]. Signaling 
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through C3a receptor 1, upregulated gene in aPV+LpxL1 samples, by binding a derivative 
of C3, downregulated gene in aPV samples, has been associated with a Th2 [37] and a Th1 
response [38], and with inhibition of Treg function [39]. Moreover, some TLRs, such as TLR2 
and TLR4, are also expressed on CD4+ T-cells. Signaling via TLR2, which is downregulated in 
aPV samples, has been found to induce IFNγ production by Th1 cells [40] and might even 
inhibit IL-4 production [41]. In addition, TLR2 signaling promotes the differentiation of Tregs 
into Th17 cells in human [42]. Signaling through TLR4 which gene expression is upregulated 
in aPV+LpxL1 samples is reported to provide a signal for proliferation and cell survival and 
seems to regulate persistence of Th lineages [43]. Furthermore, the Fc-gamma receptor Fcgr3 
gene, which was upregulated in aPV+LpxL1 samples, was shown to be expressed on a small 
proportion of CD4+ T-cells with an effector memory phenotype [44] and activated CD4+ T-cells 
expressing IFNγ and T-bet [45]. Together these data indicate that the differential expression 
of innate genes could have a function in CD4+ T-cells.
TFBS analysis indicated enrichment of binding sites for three members of the NF-κB family, 
REL, RELA, and NF-kappaB, in the gene set from the CD4⁺ T-cells of aPV+LpxL1-vaccinated 
mice, while enrichment of binding sites of only one member, RELA, was observed in those 
of aPV-vaccinated mice. Signaling via multiple receptors, including T-cell receptor, TLRs, 
including TLR4, and pro-inflammatory cytokine receptors, can lead to the activation of NF-
κB [46]. Together with the observed upregulation of Tlr4 in the gene set of CD4⁺ T-cells 
of exclusively aPV+LpxL1-vaccinated mice, this suggests that LpxL1 might directly activate 
these transcription factors via TLR4 signaling. Moreover, there is evidence that and RELA 
is associated with Th17 differentiation [47] and REL with Th1 [48] and Th17 differentiation 
[47], although conflicting results are published regarding the association of REL with Th17 
differentiation [49]. In addition, enrichment of binding sites of Klf4 was observed in the gene 
set of CD4⁺ T-cells of exclusively aPV+LpxL1-vaccinated mice, which is also associated with 
Th17 differentiation [50]. Binding sites for SPI1 were also enriched within this gene set, which 
is known to inhibit the expression of Th2 cytokines [51]. Together, the data indicate that LpxL1 
activates several transcription factors associated with Th1 and Th17 differentiation, which 
corroborates our findings of the expression of Th-related genes. Furthermore, the results 
suggest that LpxL1 might activate these transcription factors via TLR4 signaling.
Within the CD4+ T-cells of aPV+LpxL1-vaccinated mice, increased expression of Th1- and 
Th17-associated genes, including the signature cytokine genes Ifng and Il17a, was observed. 
However, no increased expression of the master transcription factors of Th1 and Th17 
cells, Tbx21 and Rorc respectively, was found. An in vitro effect of 24-hour stimulation with 
B. pertussis antigens might underlie this effect, since in our previous study IFNγ and IL-17A 
production by naive CD4+ T-cells was detected after stimulation with the B. pertussis antigens 
[10]. Indeed, in the current study, differently expressed genes found between unstimulated 
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versus antigen-stimulated CD4+ T-cells of control mice were detected, including the Th1 
master transcription factor gene Tbx21 and Th1 Stat gene Stat1. Therefore, we interpret 
the lack of differential expression of Th1 and Th17 master regulators in the samples of the 
vaccinated mice compared to those of control mice to be a result of an increased background 
expression in naive CD4+ T-cells induced by the in vitro B. pertussis antigen stimulation. 
This in vitro activation of naive CD4+ T-cells could also explain why only a few genes were 
found corresponding to proteins involved in metabolism, since the metabolism is altered by 
activation of CD4+ T-cells [18].
Although addition of LpxL1 to the aPV led to a decreased percentage of Th2 cells and 
reduced in vitro Th2 cytokine levels in B. pertussis antigen-stimulated CD4+ T-cell cultures 
from vaccinated mice in our previous study [10], no or only a limited decrease in expression 
of Th2-associated genes was observed in the current study, except for Socs3. This might 
be explained by the duration of in vitro stimulation of the CD4+ T-cells, since in the gene 
expression analysis the duration was shorter (24 hours) than in the functional read-out study 
(8 days). In addition, there might be reduced translation of the Th2 cytokine mRNA due to 
Th1- and Th17-associated miRNA translational repression. Such mechanism was shown for 
Th1-specific miR-135b [52] repressing Th2-associated genes Stat6 and Gata3 mRNA translation 
to protein [53]. Therefore, we propose that the shift towards a mixed Th1 and Th17 response 
is likely due to increased expression of Th1- and Th17-associated gene modules rather than 
downregulation of the Th2-associated gene module. Interestingly, White et al. (2012) also 
found a decisive role for the Th1 gene network module in the outcome of Th responses. 
In their study, extreme Th2 dominance in atopic allergy was associated with the complete 
absence of the Th1 gene network module [15]. A limitation of our study is that the differences 
on gene expression are measured on the total splenic CD4+ T-cell population. Therefore, the 
question remains whether the shifts in gene modules observed at the population level also 
occur within the same cell. In future research, investigating the gene expression on single cell 
level can overcome this limitation, as was described by Chattopadhyay et al. [54].
In summary, this study provides a gene expression network model that may explain why aPV 
vaccination induces Th2 and Treg differentiation of CD4+ T-cells, and why addition of LpxL1 to 
the aPV leads to the induction of Th1 and Th17 cells. Together with our previous data, showing 
a shift from a Th2-dominated response to a mixed Th1/Th17 response at the cytokine protein 
level, this study indicates that only a small change in the balance between the expression 
of Th1/Th17- and Th2-associated genes results in a shift in Th type. Moreover, this model 
can be used in the evaluation of the effects of new adjuvants on vaccination-induced T-cell 





This study was approved by the Committee on Animal Experimentation of the Netherlands 
Vaccine Institute (Bilthoven, The Netherlands) under permit number 201200115. Animal 
handling in this study was carried out in accordance with relevant Dutch national legislation, 
including the 1997 Dutch Act on Animal Experimentation.
Vaccines and antigens
Pertactin P.69 (Prn) was expressed in Escherichia coli, purified as described previously [55] 
and was tested for E. coli LPS impurities using a Limulus Amebocyte Lysate (LAL) test. The 
endotoxin level was < 0.015 EU/ml. Purified filamentous hemagglutinin (FHA) and pertussis 
toxin (Ptx) were obtained from Kaketsuken (Japan) and Ptx was heat-inactivated at 95°C for 
15 minutes before use. The registered combined pentavalent diphtheria, tetanus, and acellular 
pertussis vaccine (Infanrix; aPV) was purchased from GlaxoSmithKline and one human dose 
(HD) contains a minimum of 30 I.E. diphtheria toxoid, a minimum of 40 I.E. tetanus toxoid, 25 
μg FHA, 25 μg Ptx, and 8 μg Prn, all absorbed to aluminumhydroxide. LpxL1, a meningococcal 
LPS derivative, was engineered and obtained as described elsewhere [56].
Mice and immunization
Adult (6-8 weeks old) Balb/c mice (Harlan, The Netherlands) were vaccinated s.c. on day 0 
(right flank) and day 28 (left flank) with 0.3 ml of 1/4 HD aPV, 1/4 HD aPV supplemented with 
1 µg non-adsorbed LpxL1 (aPV+LpxL1), or as a control with PBS, with 5 mice per group. Mice 
were sacrificed on day 38, after which spleens were harvested from each mouse.
Isolation and in vitro restimulation of splenocytes
From each mouse, homogenized splenocytes were treated with erythrocyte lysis buffer 
(8.3 g/L NH4CL, 1 g/L NaHCO3, 5000 IE/L Heparin in dH20; pH 7.4) and transferred to 24-well 
plates (6x106 cells/well). The cells were cultured in IMDM medium (Gibco) supplemented 
with 8% FCS, 100 units penicillin, 100 units streptomycin, 2.92 mg/ml L-glutamine, and 20 μM 
β-mercaptoethanol (Sigma) at 37°C in a humidified atmosphere of 5% CO2. The cells were 
either left unstimulated or stimulated for 24 hours with a combination of Prn, Ptx, and FHA (1 
µg/ml each)(2 replicate wells per condition), after which the cells were harvested and pooled 
per culture condition per mouse.
CD4+ T-cell isolation and purity check
From each cultured splenocyte sample CD4+ T-cells were isolated by positive selection 
using CD4 magnetic microbeads and a magnetic cell separator (Miltenyi Biotech) according 
to the manufacturer’s instructions. The purity of the CD4+ T-cells was determined using 
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flowcytometry. Briefly, the isolated cells were stained with Pacific blue-conjugated anti-CD4 
(Biolegend) in FACS buffer (PBS (pH 7.2) supplemented with 0.5% BSA (Sigma Aldrich) and 
0.5 mM EDTA (ICN Biomedicals). After washing, data were acquired on a FACS Canto II (BD 
Biosciences) and analyzed using FlowJo software (Tree Star). The purity of the isolated CD4+ 
T-cells was >95%.
RNA extraction
From each CD4+ T-cell preparation, cells were lysed in Qiazol (Qiagen) and RNA isolation 
was performed using a miRNeasy Mini Kit with DNAse treatment (Qiagen) according to the 
manufacturer’s protocol. RNA concentrations and quality were determined using respectively 
UV spectroscopy (Tech3 module, Synergy Mx, BioTek) and electrophoresis (RNA nano 6000 
kit, 2100 Bioanalyzer, Agilent Technologies). 
Microarray analysis
Amplification, labeling and hybridization of RNA samples to microarray chips (GeneChip HT 
MG-430 PM Array Plate; Affymetrix) were carried out at the Microarray Department of the 
University of Amsterdam (The Netherlands) according to Affymetrix protocols. Array plates 
were scanned with a Genechip HT array plate scanner and analyzed with the Affymetrix 
HT software suite. Microarray analysis was performed on 3 unstimulated and 5 antigen 
stimulated samples per group.
Data analysis of gene expression
Quality control and normalization of Affymetrix CEL files were performed using the 
ArrayAnalysis website (www.arrayanalysis.org) [57], using the Robust Multichip Average 
(RMA) method [58] and the MBNI custom CDF version 15 [59]. Normalized data consisted 
of Log2 transformed signal values for 17306 genes. All slides passed quality control. Further 
analysis of normalized data was performed in R (www.r-project.org) and Microsoft Excel. 
Genes differentially expressed between the different groups of immunized mice were identified 
by using ANOVA. Fold ratio induction or repression of individual genes was calculated by 
comparing mean gene expression levels of the different immunization groups. Probes were 
considered differentially expressed if they met the following two criteria: (i) a p-value ≤ 0.001 
(ANOVA), which corresponds to a Benjamini-Hochberg False discovery rate (FDR) of 5%; and 
(ii) an absolute fold ratio ≥ 1.5. Heatmaps visualizing differently expressed genes were made 
using GeneMaths XT software (Applied Maths). Hierarchical clustering of the differentially 
expressed genes was performed in GeneMaths XT software using Euclidean distance (with 
variances) as a distance metric and UPGMA linkage. Additional data visualization was done 
by Principal Component Analysis in R. Functional enrichment with an over-representation 
analysis (ORA) was performed using DAVID [17] based on Gene Ontology biological processes 
(GO-BP) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. 
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Transcription factor-binding site analysis
For the transcription factor binding site (TFBS) analysis, the platform oPOSSUM3.0 (http://
opossum.cisreg.ca/oPOSSUM3) was used. To evaluate whether a TFBS is enriched within 
the different gene sets, the software detects known transcription factor binding sites in the 
promoter sequences of the co-expressed genes [60]. Up- and downstream sequences (5000 
bp) of up- or downregulated genes in CD4⁺ T-cells of aPV- or aPV+LpxL1-vaccinated mice were 
analyzed using the default parameters in oPOSSUM 3.0 Single Site Analysis (SSA). A TFBS 
was considered enriched when it met the following criteria, Z-score > 10 and Fischer score > 
7, which are the recommended criteria at the oPOSSUM site.
Gene network analysis
To construct a gene-function network, genes associated with Th subsets and metabolism 
were determined using text mining in murine and human studies.  Interactions between genes 
associated with Th subsets and metabolism were determined using the STRING database 
(http://string.embl.de/) with high confidence (0.700) and using co-occurrence, co-expression, 
experiments, databases, and text mining as types of evidence. The network visualization was 
performed using Cytoscape (version 2.8.3).
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Figure S1 - Over-representation of transcription factor-binding sites. Using the web-based platform 
oPOSSUM3.0 (http://opossum.cisreg.ca/oPOSSUM3) over-representation of transcription factor binding sites 
(TBFS) was analyzed within all upregulated genes in CD4⁺ T-cells of aPV-vaccinated (A) or aPV+LpxL1-vaccinated 
(B) mice, or within all downregulated genes in CD4⁺ T-cells of aPV-vaccinated (C) or aPV+LpxL1-vaccinated (D) 
mice. A TFBS was considered over-represented when it met the following criteria, Z-score > 10 and Fischer 
score > 7, which are the recommended criteria at the oPOSSUM site.
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Top 20 over-represented TFBS within upregulated genes in CD4⁺ T-cells of aPV vaccinated mice (A)
Transcription 
factor








REL MA0101.1 Ig-fold Rel 87 291 17.504 6.387
Pax4 MA0068.1 Helix-Turn-Helix Homeo 3 3 16.198 4.191
IRF2 MA0051.1 Winged Helix-Turn-Helix IRF 14 14 13.414 8.012
Stat3 MA0144.1 Ig-fold Stat 79 227 12.747 4.469
SPIB MA0081.1 Winged Helix-Turn-Helix Ets 140 1449 11.833 10.628
RELA MA0107.1 Ig-fold Rel 65 131 11.748 8.211
FEV MA0156.1 Winged Helix-Turn-Helix Ets 115 693 11.428 3.568
NF-kappaB MA0061.1 Ig-fold Rel 69 172 11.185 5.745
ELK1 MA0028.1 Winged Helix-Turn-Helix Ets 107 478 10.969 6.278
ELF5 MA0136.1 Winged Helix-Turn-Helix Ets 133 959 9.624 9.058
STAT1 MA0137.2 Ig-fold Stat 54 98 9.482 4.676
Pax6 MA0069.1 Helix-Turn-Helix Homeo 17 17 8.211 6.710
Hand1::Tcfe2a MA0092.1 Zipper-Type Helix-Loop-Helix 105 477 8.111 3.784
MEF2A MA0052.1 Other Alpha-Helix MADS 64 121 7.405 8.167
EBF1 MA0154.1 Zipper-Type Helix-Loop-Helix 91 324 6.954 4.987
SPI1 MA0080.2 Winged Helix-Turn-Helix Ets 128 789 6.414 8.651
NFATC2 MA0152.1 Ig-fold Rel 121 726 5.493 6.012
NR3C1 MA0113.1 Zinc-coordinating Hormone-nuclear Receptor 22 28 5.094 3.164
EWSR1-FLI1 MA0149.1 Winged Helix-Turn-Helix Ets 3 3 4.797 2.055
FOXF2 MA0030.1 Winged Helix-Turn-Helix Forkhead 31 51 4.707 2.120
Table S1 – Top 20 TFBS found in gene sets from CD4⁺ T-cells of aPV- or aPV+LpxL1-vaccinated mice.
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Top 20 over-represented TFBS within downregulated genes in CD4⁺ T-cells of aPV vaccinated mice (C)
Transcription 
factor








RELA MA0107.1 Ig-fold Rel 82 160 15.089 7.836
CEBPA MA0102.2 Zipper-Type Leucine Zipper 132 512 13.306 4.313
IRF1 MA0050.1 Winged Helix-Turn-Helix IRF 69 129 12.800 4.975
NF-kappaB MA0061.1 Ig-fold Rel 94 197 11.408 8.238
REL MA0101.1 Ig-fold Rel 104 298 10.831 3.265
Pou5f1 MA0142.1 Helix-Turn-Helix Homeo 35 53 10.466 3.484
SRY MA0084.1 Other Alpha-Helix High Mobility Group 149 900 10.233 2.121
IRF2 MA0051.1 Winged Helix-Turn-Helix IRF 12 13 9.305 3.641
Sox17 MA0078.1 Other Alpha-Helix High Mobility Group 134 633 9.059 1.267
FOXI1 MA0042.1 Winged Helix-Turn-Helix Forkhead 120 436 8.792 2.032
NFATC2 MA0152.1 Ig-fold Rel 155 871 8.686 4.624
Pax4 MA0068.1 Helix-Turn-Helix Homeo 2 2 7.997 1.911
MEF2A MA0052.1 Other Alpha-Helix MADS 67 140 7.877 2.385
AP1 MA0099.2 Zipper-Type Leucine Zipper 168 1090 7.388 5.808
Foxq1 MA0040.1 Winged Helix-Turn-Helix Forkhead 77 190 7.258 1.596
TAL1::TCF3 MA0091.1 Zipper-Type Helix-Loop-Helix 72 138 7.064 2.383
CTCF MA0139.1 Zinc-coordinating BetaBetaAlpha-zinc finger 34 40 7.008 3.675
HLF MA0043.1 Zipper-Type Leucine Zipper 57 93 6.971 3.164
NFE2L2 MA0150.1 Zipper-Type Leucine Zipper 64 98 6.156 4.404
FEV MA0156.1 Winged Helix-Turn-Helix Ets 151 746 6.033 3.577
Top 20 over-represented TFBS within upregulated genes in CD4⁺ T-cells of aPV+Lpxl1 vaccinated mice (B)
Transcription 
factor








REL MA0101.1 Ig-fold Rel 142 427 20.407 10.808
NF-kappaB MA0061.1 Ig-fold Rel 114 270 16.938 10.145
Stat3 MA0144.1 Ig-fold Stat 125 341 16.304 5.797
FEV MA0156.1 Winged Helix-Turn-Helix Ets 192 1036 14.583 8.724
SPIB MA0081.1 Winged Helix-Turn-Helix Ets 222 2152 14.425 14.405
RELA MA0107.1 Ig-fold Rel 103 193 13.908 11.579
Hand1::Tcfe2a MA0092.1 Zipper-Type Helix-Loop-Helix 165 737 13.518 4.257
ELF5 MA0136.1 Winged Helix-Turn-Helix Ets 217 1444 13.409 17.278
STAT1 MA0137.2 Ig-fold Stat 86 150 13.184 6.474
Klf4 MA0039.2 Zinc-coordinating BetaBetaAlpha-zinc finger 181 1006 12.993 15.421
Pax4 MA0068.1 Helix-Turn-Helix Homeo 3 3 11.558 3.002
ELK1 MA0028.1 Winged Helix-Turn-Helix Ets 175 695 11.443 11.310
SPI1 MA0080.2 Winged Helix-Turn-Helix Ets 208 1215 11.341 15.465
TP53 MA0106.1 Zinc-coordinating Loop-Sheet-Helix 1 1 10.490 2.186
EBF1 MA0154.1 Zipper-Type Helix-Loop-Helix 146 491 9.990 7.340
IRF2 MA0051.1 Winged Helix-Turn-Helix IRF 15 15 8.227 4.583
SP1 MA0079.2 Zinc-coordinating BetaBetaAlpha-zinc finger 164 792 8.115 14.017
Pax6 MA0069.1 Helix-Turn-Helix Homeo 22 23 7.843 5.516
MEF2A MA0052.1 Other Alpha-Helix MADS 100 175 7.795 10.702
EWSR1-FLI1 MA0149.1 Winged Helix-Turn-Helix Ets 5 5 7.401 2.985
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Top 20 over-represented TFBS within downregulated genes in CD4⁺ T-cells of aPV+Lpxl1 vaccinated mice (D)
Transcription 
factor








CEBPA MA0102.2 Zipper-Type Leucine Zipper 55 211 8.947 2.472
HNF4A MA0114.1 Zinc-coordinating Hormone-nuclear Receptor 30 57 8.647 2.461
NR3C1 MA0113.1 Zinc-coordinating Hormone-nuclear Receptor 13 17 8.374 2.699
IRF1 MA0050.1 Winged Helix-Turn-Helix IRF 25 53 8.352 1.359
CTCF MA0139.1 Zinc-coordinating BetaBetaAlpha-zinc finger 18 19 7.731 4.622
IRF2 MA0051.1 Winged Helix-Turn-Helix IRF 5 6 7.628 2.094
RELA MA0107.1 Ig-fold Rel 32 61 7.584 2.969
NF-kappaB MA0061.1 Ig-fold Rel 41 80 7.105 5.341
Hand1::Tcfe2a MA0092.1 Zipper-Type Helix-Loop-Helix 61 232 6.954 3.950
Pax4 MA0068.1 Helix-Turn-Helix Homeo 1 1 6.848 1.405
ELF5 MA0136.1 Winged Helix-Turn-Helix Ets 69 454 6.602 2.604
Foxq1 MA0040.1 Winged Helix-Turn-Helix Forkhead 34 81 6.029 1.712
AP1 MA0099.2 Zipper-Type Leucine Zipper 65 454 5.905 1.136
TAL1::TCF3 MA0091.1 Zipper-Type Helix-Loop-Helix 30 59 5.843 1.561
SPI1 MA0080.2 Winged Helix-Turn-Helix Ets 65 383 5.763 2.058
SPIB MA0081.1 Winged Helix-Turn-Helix Ets 74 663 5.619 3.587
MEF2A MA0052.1 Other Alpha-Helix MADS 25 57 4.946 0.794
EBF1 MA0154.1 Zipper-Type Helix-Loop-Helix 47 154 4.936 1.926
znf143 MA0088.1 Zinc-coordinating BetaBetaAlpha-zinc finger 7 8 4.731 1.652
Egr1 MA0162.1 Zinc-coordinating BetaBetaAlpha-zinc finger 25 46 4.661 2.009
About the cover: The Perito Moreno glacier located in the Los Glaciares National Park in Patagonia, Argentina.  Part of the 
Southern Patagonian Ice field which is the third largest reserve of fresh water. The end of the glacier is 5 km wide, with 
an average height of 74 metres and moves 1 - 2 metres each day. In 2016, René attended the 11th International Bordetella 
Symposium that was held in Buenos Aires, Argentina.
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Abstract
Local immune responses in the lungs contribute to protection against B. pertussis infection 
and might improve the vaccine-elicited immunity. Therefore, the effect of the vaccine 
administration route on the degree of protection and the local and systemic immune response 
was investigated. Immunization of mice via the pulmonary route with a novel outer membrane 
vesicle pertussis vaccine (omvPV) led to faster clearance of B. pertussis upon intranasal 
challenge compared to immunization via the subcutaneous route. The local and systemic 
immune responses underlying this difference in protection were analyzed using a systems 
biology approach. Exclusively pulmonary immunization led to the presence of B. pertussis-
specific IgA antibodies, IgA-producing plasma cells and Th17-cells in the lungs. Moreover, 
this route elicited increased levels of systemic specific IgG antibodies, IgG-producing plasma 
cells, memory B-cells, and Th17-cells. In addition, only pulmonary immunization elicited a 
rapid induction of pro-inflammatory cytokines and chemoattractants, e.g. IL-6 and CXCL10, 
observed on transcriptomic and proteomic levels, in the lungs. Distinct cytokine profiles were 
measured in sera, which were overall higher after subcutaneous immunization, e.g. G-CSF and 
IL-5. Transcriptome analysis of lungs and draining lymph nodes revealed differences in innate 
and adaptive responses between both administration routes e.g. the expression of Igha and 
Rorc, supporting the superior IgA, IgG, and Th17 responses detected in pulmonary-immunized 
mice. These results show that by administering the vaccine via the pulmonary as opposed to 
the subcutaneous route, an omvPV can elicit superior local and systemic immunity against B. 
pertussis, resembling immunity after primary infection. The study indicates that pulmonary 




Pulmonary administration of an outer membrane vesicle pertussis vaccines
7
Introduction
Currently, pertussis remains an endemic disease, even in highly vaccinated populations. 
Approaches to increase protection include the improvement of pertussis vaccines and 
vaccination strategies [1, 2]. The whole-cell and acellular pertussis vaccines induce a systemic 
immune response characterized by the formation of IgG antibodies and a T-helper (Th) 
response that is Th1/Th17 or Th2 dominated, respectively [3-6]. In contrast, a B. pertussis 
infection evokes a Th1/Th17 response both systemically and locally in the lungs [5, 7, 8]. 
Outer-membrane vesicle pertussis vaccines (omvPV) might be an improved alternative for 
the currently available vaccines. Subcutaneous immunization of omvPV elicited a systemic 
immune response comparable to that induced by B. pertussis infection, including high serum 
IgG levels against a broad antigen range [9] and a mixed Th1, Th17, and Th2 response [10]. 
Unfortunately, subcutaneous omvPV immunization does not induce local immune responses 
in the lungs that are thought to contribute to a better protection against B. pertussis [10].
Direct vaccine administration in the respiratory tract can lead to better protection compared 
to parenteral administration due to the induction of local immune responses as was shown 
for other respiratory pathogens, such as M. tuberculosis and influenza [11-13]. The feasibility of 
mucosal administration of different pertussis vaccines was proven as intranasal immunization 
provides protection against B. pertussis challenge [14-17]. Nonetheless, direct comparison of 
the local and systemic immune responses induced by parental and mucosal immunization of 
pertussis vaccines is not yet performed.
In the present study, we investigated in detail whether the route of immunization affects 
protection and the quality of the immune response in mice. A systems biology approach was 
used to compare immune responses following pulmonary and subcutaneous immunization 
with omvPV (Figure 1A). Such an approach was previously applied in vaccine research to 
predict vaccine responsiveness [18-21] and to unravel of molecular signatures of mucosal 
adjuvants [22] and respiratory pathogen infections [7, 23]. In our study, the novel omvPV-P93 
with abolished Prn autocleavage was used, since it enables more specific readouts and 
provides better protection in a murine challenge model compared to the WT omvPV, even 
at a lower dose [24]. Besides B. pertussis clearance from the respiratory tract after intranasal 
challenge, gene expression profiles in draining lymph nodes and lungs, and cytokine profiles 
and antibody responses in serum and lungs of immunized mice were determined. Finally, 
specific B-cell and T-cell responses were investigated both locally and systemically. Our 
results demonstrate hallmarks of superior protective immunity to B. pertussis conferred by 





The outer membrane vesicle pertussis vaccine (omvPV) was prepared using a genetically 
modified B. pertussis B1917 strain lacking the autocleavage site in pertactin (Prn), as described 
previously [24]. 1 μg total protein omvPV was diluted in 50 μl and 300 μl PBS (Gibco) for 
pulmonary and subcutaneous immunization respectively. Pertussis antigens Ptx and FHA were 
obtained from Kaketsuken (Japan), Prn and Fim2/3 were kindly provided by Betsy Kuipers 
(National Institute for Public Health and the Environment, Bilthoven, the Netherlands).
B. pertussis challenge culture
The B. pertussis challenge culture was prepared as described in the literature [7], except that 
bacteria were grown in THIJS medium [25].
Ethics statement
An independent ethical committee for animal experimentations of the Institute for 
Translational Vaccinology (Intravacc) approved the animal experiments with identifiers 
201400125 and 201400182. Animal handling in this study was carried out in accordance to the 
guidelines provided by the Dutch Act on Animal Experimentation. 
Immunization and challenge of mice
Female BALB/c mice (Harlan, The Netherlands), 8-week-old, were immunized with 1 μg total 
protein omvPV either pulmonary (P.M.; 50 μl) or subcutaneously (S.C.; 300 μl) on day 0 
and 28. Non-immunized (N.I.) mice were used as a control. Pulmonary administration was 
performed as described by Bivas-Benita et al. [26] using a MicroSprayer aerosolizer (IA-1C; 
Penn-Century, Philadelphia, PA, USA) supplied with a high-pressure syringe (FMJ-250; Penn-
Century). Mice were intranasally challenged under anesthesia (isoflurane/oxygen), with 2 × 
105 colony forming units (cfu) of B. pertussis B1917 in 20 μL of THIJS medium on day 56. 
For gene expression in the lungs and draining lymph nodes (dLN), cytokine responses, and 
antibody responses, mice (n = 4 per group) were sacrificed 4 hours and 2, 7, 14 and 28 days 
after primary immunization. In addition, to investigate gene expression in the dLN, cytokine 
responses, and antibody responses after booster vaccination, mice (n = 4 per group) were 
sacrificed on day 35 and 56. Finally, mice (n = 4 per group) were sacrificed 4 hours after 
challenge and on day 58, 63, 70, and 84 to measure bacterial load in the respiratory tract, 
cytokine responses and antibody responses. For evaluation of B-cell responses, mice (n = 6 
per group) were sacrificed on day 35 and 63 (plasma cells) and on day 56 and 84 (memory 
B-cells). For investigation of T-cell responses, mice (n = 6 per group) were sacrificed on day 
28, 56, and 84. An additional control group (n = 6) of completely naive mice were included for 
B- and T-cell investigation on each time point. Mice were bled under anesthesia (isoflurane/
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oxygen) by orbital bleeding and sacrificed by cervical dislocation for further sample collection. 
An overview of the study design of treatment and sample collection is schematically depicted 
in Figure 1A.
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Figure 1 - Study design and B. pertussis colonization measured in the respiratory tract. (A) BALB/c mice were 
immunized with 1 μg omvPV pulmonary (P.M.; red) or subcutaneously (S.C.; blue) twice on day 0 and day 28. 
Subsequently, for both routes the vaccination-induced responses were characterized over a period of 56 days 
at 7 different time points. Additionally, a B. pertussis challenge (2x105 CFU) was performed on day 56 in both 
vaccinated groups and non-immunized (N.I.) mice (green). Vaccination responses and in vivo recall responses 
were characterized at the transcriptomic, proteomic and cellular level on given time points, as depicted. (B-D) 
The number of colony-forming units (cfu) were determined after B. pertussis challenge (B) in lungs, (C) trachea 





From the lungs, the left lobe was placed in 1 ml RNAlater (Qiagen), incubated overnight at 4°C, 
and stored at -80°C for subsequent microarray analysis. The right lobe was collected in 900 μl 
THIJS medium and was homogenized using a Bio-Gen PRO200 Homogenizer (Pro Scientific 
Inc., Oxford, CT, USA) for the lung colonization assay after the challenge and after filtration 
(Millex GV Filter unit 0.22 μm, Millipore), lysates of all time points were used for pulmonary 
cytokine and antibody analysis. Complete lungs of mice used for T- and B-cell assays were 
collected in 5 ml RPMI-1640 medium (Gibco) supplemented with 10% FCS (Hyclone), 100 units 
penicillin, 100 units streptomycin, and 2.92 mg/ml L-glutamine (Invitrogen), hereafter named 
RPMI complete medium and kept on ice until use. The draining lymph nodes (dLN), bronchial 
LN for P.M. immunization and inguinal LN for S.C. immunization, were isolated and placed in 
5 ml RPMI complete medium and kept on ice until use, for subsequent microarray analysis 
and T-cell analysis by tetramer staining. Whole blood for tetramer staining and analysis of 
B-cell responses was collected in heparin tubes (MiniCollect 1 ml LH Lithium Heparin, Greiner 
Bio-One, Austria). Serum for cytokine and antibody responses was obtained by collecting 
whole blood in a serum collection tube (MiniCollect 0.8 ml Z Serum Sep GOLD, Greiner 
Bio-One, Austria). After coagulation (10 min. at room temperature), sera were taken after 
centrifugation (10 min., 3000 g) and stored at -80°C. Spleens were placed in 5 ml RPMI 
complete medium and kept on ice for subsequent B- and T-cell assays. Trachea were collected 
in 900 μl THIJS medium and were homogenized using the Bio-Gen PRO200 Homogenizer 
for the trachea colonization assay. Nose lavage was obtained by flushing the nose with 1 ml 
THIJS medium after the trachea was removed for nose colonization assay. After filtration 
(Millex GV Filter unit 0.22 μm, Millipore), nose lavages were used to determine nasal antibody 
responses.
Colonization assays
The tissue lysates from lungs and trachea, and lavages of the nose were serially diluted 
(undiluted, 1:10, 1:100, and 1:1000) in THIJS medium. The diluted samples were plated on 
Bordet-Gengou agar plates and incubated for 5 days at 35⁰C. The number of cfu per ml was 
determined by using a colony counter (ProtoCOL, Synbiosis, Cambridge, United Kingdom).
B-cell ELISpot
Wells of filter plates (Multiscreen-HA 96 wells plates, Millipore) were coated (overnight, 
4°C) with 5 µg/ml Prn (Sanofi) or 10 µg/ml wildtype B1917 OMV. As a positive control, wells 
were coated with a mixture of 7 μg/ml purified goat-anti-mouse kappa and 7 μg/ml purified 
goat-anti-mouse lambda (Southern Biotech). As a negative control, wells were left uncoated 
(PBS). After washing 3 times with PBS, the plates were blocked (1h, room temperature (RT)) 
with RPMI 1640 + 2% Protifar (Nutricia) and washed again.
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Spleens and lungs were homogenized using a 70-μm cell strainer (BD Falcon, BD Biosciences) 
and cells were collected in RPMI complete medium. From whole blood, erythrocytes were 
lysed by using RBC lysis buffer (Pharm Lyse, BD Pharmingen). For detection of memory 
B-cells, 5x105 splenocytes per well of a 24 well-plate were stimulated with CpG ODN 1826 
(10 µg/mL, Invivogen), PWM (10 µg/mL), Staphylococcus aureus protein A of Cowan Strain 
(1:5000) and β-mercaptoethanol (1:25000) (all Sigma) in RPMI complete medium for 5 days at 
37⁰C to induce antibody secretion. Cells from blood (0.75x105 cells/well), lungs (0.75x105 cells/
well), spleen (5x105 cells/well) or stimulated splenocytes (5x105 cells/well) were added to the 
coated plates and incubated overnight at 37°C. Plates were washed 7 times with PBS and 3 
times with PBS-T (0.05% Tween-20). Then, the plates were incubated (1h, 37°C) with alkaline 
phosphatase-conjugated goat-anti-mouse IgA or IgG (Southern Biotech; 1:1000). Plates were 
washed 7 times with PBS, 3 times with PBS-T, and 5 times with tap water. Subsequently, 
filtered (0.45 μm) BCIP-NBT liquid substrate (Sigma) was added. Spot development was 
stopped by removing the substrate and extensively rinsing with distilled water. Plates were 
dried and stored at room temperature in the dark. Spots were counted with an AID iSpot 
reader (Autoimmun Diagnostika GmbH). The number of B. pertussis OMV-specific IgG- and 
IgA-secreting cells were indicated as antibody secreting cells (ASC) per 5 x 105 cells.
Antibody measurements
OMV-, Prn-, FHA-, Ptx-, and Fim2/3-specific antibodies were measured using an in-house 
developed mouse multiplex immunoassay, as described previously [27]. Serum samples 
were diluted 1:5000 for IgG (subclass) and 1:100 for IgM and IgA measurements. Lung lysate 
samples were diluted 1:100 and nose lavage samples were not diluted for measuring IgA 
levels. Reporter antibodies were R-PE-conjugated goat-anti-mouse IgA, IgG, IgG1, IgG2a, 
IgG2b, IgG3 or IgM (Southern Biotech). Data were acquired with a Bio-Plex 200, analyzed 
using Bio-Plex Manager software (version 5.0, Bio-Rad Laboratories), and presented as 
fluorescence intensities (FI).
Detection of Prn10-24 -specific CD4
+ T-cells
dLN were homogenized using a 70-μm cell strainer and cells were collected in RPMI complete 
medium. Blood was treated with erythrocyte-lysis buffer (10 g/L NH4CL, 1.25 g/L NaHCO3, 0.125 
mM EDTA in dH20; pH 7.4) for 10 minutes on ice, and then resuspended in RPMI complete 
medium. Cells were stained with APC-conjugated I-Ad tetramers specific for the Prn10-24 T-cell 
epitope [28] (NIH Tetramer Facility, Atlanta, Georgia, USA) in RPMI complete medium for 1 
hour at 37°C. Next, cells were stained with Pacific blue-conjugated anti-CD4 (Biolegend), FITC-
conjugated anti-CD44 (BD Biosciences), and LIVE/DEAD® Fixable Aqua Dead Cell Stain Kit for 
30 minutes at 4°C in FACS buffer (PBS (pH 7.2) supplemented with 0.5% BSA (Sigma Aldrich) 
and 0.5 mM EDTA (ICN Biomedicals). Data were acquired on a FACS Canto II (BD Biosciences) 
and analyzed using FlowJo software (Tree Star). 
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Intracellular cytokine staining (ICS)
Lungs and spleens were homogenized using a 70-μm cell strainer and cells, collected in RPMI 
complete medium, were treated with erythrocyte lysis buffer. The cells were cultured in 24-well 
plates (6x106 cells/well) for 3 days at 37°C in the presence of IMDM complete medium (IMDM 
medium (Gibco) supplemented with 8% FCS, 100 units penicillin, 100 units streptomycin, 2.92 
mg/ml L-glutamine, and 20 μM β-mercaptoethanol (Sigma)). For restimulation of cells, 1 µg/
ml Prn or 1.5 µg/ml wildtype B1917 OMVs was added. On day 3, supernatant was collected for 
cytokine analysis, and the cells were transferred to U-bottom 96-well plates (5x105 cells/well) 
and restimulated overnight using the same antigen conditions.
ICS was performed on restimulated splenocytes and lung cells by using the BD Cytofix/Cytoperm 
Fixation/Permeabilization Solution Kit (BD Biosciences), according to the manufacturer’s 
protocol. Briefly, cells were incubated with 10 μg/ml Golgiplug (BD Biosciences), 1 μg/ml αCD28 
(BD Pharmingen), and 1 μg/ml αCD49d (BD Pharmingen) during the last 5 hours of restimulation. 
Cells were then stained in FACS buffer with Pacific blue-conjugated anti-CD4 (Biolegend), FITC-
conjugated anti-CD44 (BD Biosciences), PE-Cy7-conjugated anti-CD103 (Biolegend; only the 
lung cells), and with LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen). Thereafter, cells 
were fixed, permeabilized, and stained with PE-conjugated anti-IFNγ (BD Biosciences), APC-
conjugated anti-IL-5 (Biolegend), and PerCP-Cy5.5-conjugated anti-IL-17A (eBioscience). Data 
were acquired on a FACS Canto II and analyzed by using FlowJo software.
Multiplex cytokine analysis (MIA)
Concentrations (pg/ml) of 32 cytokines (Eotaxin, G-CSF, GM-CSF, IFNγ, IL-10, IL-12 (p40), IL-
12 (p70), IL-13, IL-15, IL-17A, IL- 1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IP-10, KC, LIF, LIX, 
M-CSF, MCP-1, MIG, MIP-1α, MIP-1β, MIP-2, RANTES, TNFα, and VEGF) present in serum and 
lung lysates were determined by using a MIA (Milliplex MAP Mouse Cytokine/ Chemokine - 
Premixed 32 Plex; Merck KGaA). The concentration of various Th subset cytokines (IL-4, IL-
5, IL-10, IL-13, IL-17A, TNFα, and IFNγ) was determined in splenic culture supernatant using 
a Milliplex mouse cytokine 7-plex luminex kit (Millipore), according to the manufacturer’s 
protocol. Measurements and data analysis were performed with a Bio-Plex 200 and using 
Bio-PlexManager software (version 5.0, Bio-Rad Laboratories). Results of the Th subset 
cytokines were corrected for the background (IMDM complete medium control) per mouse 
per stimulation per cytokine and calculated in pg/ml.
RNA isolation and microarray analysis
Isolation of RNA from lung tissue with additional determination of RNA concentrations and 
integrity was performed as described previously [7]. For isolation of RNA from cells in the dLN, 
the dLN were homogenized using a 70-μm cell strainer (BD Falcon, BD Biosciences) and cells 
were collected in RPMI complete medium and then washed with PBS. By using the MagNA 
Pure LC RNA Isolation High Performance kit (Roche) according to the manufactures protocol, 
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the cells were lysed, in 1 ml lysis buffer, and RNA was isolated with the MagNA Pure System 
(Roche). For lung tissue, samples of naive mice and P.M. vaccinated mice were analyzed as 
individual samples (n=3), whereas the RNA concentrates of S.C. vaccinated mice were pooled 
(n=3) for the following time points: Naive, 4 hours, 2 days, 7 days, 14 days, and 28 days post 
primary vaccination. RNA concentrates from the lymph node suspensions, bronchial for P.M. 
vaccination and inguinal for S.C. vaccination, of individual mice (n=3) were analyzed for eight 
time points (naive, 4 hours, 2 days, 7 days, 14 days, 28 days, 35 days and 56 days post primary 
vaccination). From the naive mice, both bronchial and inguinal lymph nodes were analyzed.
Amplification, labeling and hybridization of RNA samples for either lung tissue or lymph nodes 
for microarray (HT MG-430 PM Array Plates, Affymetrix, Santa Clara, Calif, USA) was carried 
out at the Microarray Department of the University of Amsterdam, The Netherlands.
Transcriptomic data analysis
Quality control and normalization of raw Affymetrix CEL files were performed using the 
ArrayAnalysis website (www.arrayanalysis.org) [29], using the Robust Multichip Average 
(RMA) method [30] and the MBNI custom CDF version 19 [31]. Normalized data consisted of 
Log2 transformed signal values for 17856 genes. Subsequent analysis of normalized data was 
performed in R (www.r-project.org) and Microsoft Excel. To identify differentially expressed 
genes between experimental groups (naive and various time points post vaccination) an 
ANOVA was applied. The induction or repression of individual genes was expressed as fold 
ratio by comparing mean gene expression levels of experimental groups to the naive mice. 
For pulmonary transcriptome analysis, average normalized gene expression levels contain 
individual data of three mice per group (P.M. and naive mice) and  pooled data of 3 mice for 
the S.C. group. For dLN transcriptome analysis, average normalized gene expression levels 
contain individual data of three mice per group. The criteria for differential expression for the 
pulmonary transcriptome analysis were p-value <0.01 (ANOVA) and an absolute fold ratio >2.0 
(experimental groups compared to naive mice). For dLN transcriptome analysis, the criteria 
were set at p-value < 0.001 and fold ratio > 1.5. GeneMaths XT (Applied Maths, St-Martens-
Latem, Belgium) was used to visualize differences in gene expression in heatmaps. Genes 
were arranged according to similar expression patterns in time at which genes exceeded 
the fold ratio cut-off. To facilitate visual interpretation of heatmaps, upregulation (red) and 
downregulation (green) of gene expression levels are only visualized above the fold ratio 
cutoffs and presenting fold ratios below the cutoffs as an unchanged value (black). Additional 
data visualization was done by principal component analysis based on expression profiles of 
all differentially expressed genes in R. Functional enrichment was determined with an over-
representation analysis (ORA) based on Gene Ontology Biological Processes (GO-BP) and 
Kyoto Encyclopedia of Genes and Genomes (KEGG) by using DAVID [32]. Involvement of type I 





To construct a gene-function network, genes associated with five modules, namely acute 
phase, cytokine response, humoral response, pathogen recognition receptor (PRR) signaling, 
and T-cell responses, were determined using the ORA results and additional text mining. 
Interactions between genes were determined using the STRING database (http://string.
embl.de/) with high confidence (0.700) and using co-occurrence, co-expression, experiments, 
databases, and text mining as types of evidence. Gene-function associations and gene-gene 
interactions were combined into one network file. The network visualization was performed 
using Cytoscape (version 2.8.3).
Immunoproteomic profiling
One-dimensional (1D) and two-dimensional (2D) electrophoresis in combination with 
Western blotting (1DEWB, 2DEWB) and LC-MS analysis were performed for the identification 
of antigen specificity of the antibody responses as described in the literature [9]. Acrylamide 
gels were loaded with 10-15 µg protein of a B. pertussis (B1917) lysate for 1D and with 25 µg 
protein of the lysate for 2D electrophoresis and blotted. Blots were treated with diluted sera 
(1:100), diluted lung lysates (1:10-1:50) and diluted nose lavages (1:10) prior to immunostaining 
with two different IR-800-labeled goat-anti-mouse secondary antibodies (anti-IgG or -IgA). 
Blots were scanned using an Odyssey infrared imager (Westburg) and analyzed with Delta2D 
software (Version 4.5) (Decodon, Germany).
Statistics
To determine significance of differences in the outcome of B-cell ELIspot, T-cell ICS, and T-cell 
tetramer analysis between groups, a Mann-Whitney t-test was used. Data of the cytokine, 
antibody, and colonization assays were log-transformed after which a t-test was performed. 
p-values ≤0.05 were considered to indicate significance of differences.
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Figure 2 - B. pertussis OMV-specific B-cell responses induced by P.M. and S.C. immunization with omvPV. 
(A-D) By using MIA, (A) anti-OMV IgG antibody levels, (B) IgG subclass distribution, (C) IgM antibody levels 
were determined in sera and (D) anti-OMV IgA antibody levels in lung lysates. Results are expressed as 
fluorescence intensities (FI) of 4 mice per group per time point. (E) Specificity of serum IgG and pulmonary 
IgA elicited by P.M. and S.C. immunization as determined by 2DEWB. Analysis was performed using pooled 
serum and lung lysates of 4 mice per group. Fluorescence intensities for each spot were obtained from 1 blot 
for IgA and the average of 3 blots for IgG. * p ≤ 0.05 versus naive mice (day 0); # p ≤ 0.05 versus S.C. mice. (F-
G) Numbers of (F) OMV-specific IgG- and IgA-secreting plasma cells in lungs, blood, and spleens and numbers 
of (G) IgG- and IgA-producing memory cells in spleens were determined by B-cell ELISpot of 6 mice per group 
at day 35 and day 56, respectively. Results are indicated as antibody secreting cells (ASC) per 5 x 105 cells. * p 




Superior protection against B. pertussis infection by P.M. compared to S.C. 
omvPV immunization
The colonization of the respiratory tract after intranasal B. pertussis challenge of pulmonary 
immunized mice (P.M. mice), subcutaneously immunized mice (S.C. mice), and non-
immunized control mice (N.I. mice) differed substantially. Lungs, trachea, and noses of N.I. 
mice were heavily colonized by B. pertussis after a challenge. The highest numbers of colony 
forming units were found 7 days post challenge (p.c.) (Figure 1B-D). In contrast, B. pertussis 
was mostly cleared from lungs of P.M. mice already 2 days p.c., whereas bacteria from lungs 
of S.C. mice were cleared 5 days later (Figure 1B). In the trachea of both S.C. and P.M. mice, 
bacteria were mostly cleared 7 days p.c. (Figure 1C). In the nose, no complete clearance of 
B. pertussis was observed in the P.M., S.C., and N.I. mice within 28 days p.c. However, the 
number of bacteria in P.M. mice was significantly lower than in N.I. mice on day 70 (Figure 1D). 
Together, these data show that P.M. immunization with omvPV induced enhanced protection 
against B. pertussis infection compared to S.C. immunization.
IgG antibody responses
B. pertussis-specific antibodies are important contributors to pertussis immunity [34] and 
currently IgG serology still is the gold standard in pertussis vaccine research. The IgG (subclass) 
levels were determined after P.M. and S.C. immunization. Both immunization routes induced 
high and comparable levels of anti-OMV IgG antibodies in serum, but with significantly higher 
levels after P.M. immunization on day 56 (Figure 2A). S.C. immunization elicited already 
anti-Prn IgG antibodies after primary immunization, while these were observed only after a 
booster immunization in P.M. mice (Figure S1A).
The IgG subclasses distribution induced by P.M. and S.C. immunization were comparable for 
OMV-specific responses (Figure 2B). The primary immunization stimulated production of IgG1 
antibodies, while the booster vaccination promoted the formation of IgG3 antibodies. For Prn-
specific responses, booster P.M. immunization led to more IgG2a/b than S.C. immunization, 
while IgG1 still was the predominant subclass for both immunization routes (Figure S1B). 
The immunogenic proteins to which the anti-OMV antibodies are directed were identified 
(Figure 2E and Figure S3A-B). On 2DEWB, twelve and seventeen immunogenic pertussis 
proteins were detected after P.M. and S.C. immunization, respectively (Figure 2E and Table 
S1). Spots showing high staining intensities in both groups corresponded with BP3755, Vag8, 
BrkA, and U2. Antibodies against ahcY, also visible at 55 kDa on 1DEWB (Figure S3B), and 
ompA(2) were solely induced by P.M. immunization, whereas antibody formation against 
ompA(1), U5, bfrG, GroEI, purH, U3, and U4 were only found after S.C. immunization. 
Additionally, anti-LPS antibodies (10 kDa) were observed after booster vaccination in both 
immunization groups (Figure S3B). Notably, following omvPV immunization via either route, 
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no IgG antibodies could be detected that were directed against Ptx, FHA, and Fim2/3 (data 
not shown), the antigens present in acellular pertussis vaccines in addition to Prn. Altogether, 
the systemic anti-OMV IgG response and subclass distribution after both P.M. and S.C. 
immunization were comparable and could not explain the increased protection of P.M. mice 
following challenge.
IgM antibody responses
Next, IgM antibodies were determined in sera from P.M. and S.C mice. IgM antibodies were 
only found directed against OMV and were induced significant on day 14 in P.M. mice. For both 
immunization routes, booster vaccination resulted in enhanced IgM antibody levels (Figure 
2C). Similar to the findings for IgG, the level of anti-OMV IgM was significantly increased in 
P.M. versus S.C. immunized mice on day 56 (Figure 2C).
IgA antibody responses
IgA antibodies were found exclusively in P.M. mice, both in serum (Figure S2A-B) and lungs 
(Figure 2D and S1D). Serum IgA antibodies were directed against OMV and Prn, but not against 
other antigens present in acellular vaccines (Figure S2A-E). The specificity of pulmonary IgA 
was determined by immunoblotting and subsequent mass spectrometric identification of 
immunogenic proteins. The anti-OMV antibodies in the lungs were directed against Vag8 and 
LPS (Figure 2E, S3A, and S3C).
Pulmonary and systemic B-cell responses
The effect of the immunization route on the numbers of B. pertussis-specific plasma cells was 
investigated in cell suspensions from lungs, peripheral blood, and spleen. At the peak of the 
plasma cell response on day 35, anti-OMV and anti-Prn IgG-secreting cells were detected in 
the lungs of P.M. mice only (Figure 2F and S1D). However, in blood and spleen of S.C. and 
P.M. mice similar and modest numbers of IgG-secreting cells were found (Figure 2F and S1D). 
In addition, anti-OMV and anti-Prn IgA-secreting cells were detected in the lungs, spleen and 
blood, exclusively after P.M. immunization (Figure 2F and S1D).
Anti-OMV IgG-producing memory B-cells were measured in the spleen of P.M. and S.C. mice 
on day 56, with a trend towards higher numbers after P.M. immunization (Figure 2G). In 
contrast, anti-OMV IgA-producing memory B-cells could not be detected at all (Figure 2G). 
The Prn-specific memory B-cell responses on day 56 showed a similar trend as was found 
for the OMV-specific responses (Figure S1G). Thus, these data show that both S.C. and P.M. 
immunization elicited IgG-producing plasma and memory B-cells, while P.M. immunization 
also evoked IgA-producing plasma cells.
Pulmonary T-cell responses
Pulmonary B. pertussis-specific T-cell responses were investigated by analyzing cytokine 
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levels in the culture supernatants of lung cells that were restimulated with OMVs in vitro. 
Moderate IL-5 and vigorous IL-17A responses were detected after P.M. immunization only 
(Figure 3A). To investigate whether these cytokines were produced by CD4+ T-cells, single 
cell analysis by ICS was performed on these cultured cells. Only P.M. immunization induced 
OMV-specific IL-17A-producing CD4+CD44+ T-cells in the lungs (Figure 3B). No OMV-specific 
IFNγ-producing and IL-5-producing CD4+CD44+ T-cells could be detected by ICS in the lungs of 
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Figure 3 - Pulmonary and systemic B. pertussis OMV-specific T-cell responses induced by P.M. and S.C. omvPV 
immunization. (A) IL-5 and IL-17A levels in 3 day culture supernatant of lung cells, isolated on day 56, after in 
vitro stimulation with OMVs as determined by MIA. Results in pg/ml are corrected for the background level 
(IMDM complete medium control) and are given as mean ± SD of 6 mice per group. (B) Percentage of IL-
17-producing CD4+CD44+ T-cells in the lungs, harvested on day 28 and day 56, as measured by ICS and flow 
cytometry after in vitro stimulation for 4 days with OMVs. (C) Flow cytometry for expression of CD103 on gated 
CD4+CD44+ T-cells in the lungs on day 56. (D) Frequency of Prn10-24-specific CD4
+ T-cells in blood determined 
directly ex vivo on day 28 and day 56 using a tetramer staining and flow cytometry. (E) Magnitude of the 
systemic OMV-specific CD4+ T-cell response after in vitro stimulation with OMV for 4 days was determined using 
ICS on splenocytes, calculated as the total percentage cytokine (IL-5, IFNγ, and IL-17A)-producing CD4+CD44+ 
T-cells. (F) Percentage IL-5-, IFNγ-, and IL-17-producing cells of CD4+CD44+ T-cells of spleens harvested on day 38 
and day 56 and stimulated in vitro for 4 days with OMVs. Results of each analysis are given of 6 mice per group. 
(G) Distribution of Th subsets based on IL-5 (Th2), IFNγ (Th1), and IL-17A (Th17) production, as determined by 
ICS and flow cytometry. * p ≤ 0.05 versus naive mice; # p ≤ 0.05 versus S.C. mice.
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Recently, it has been demonstrated that tissue-resident memory T-cells are important in 
the protection against respiratory pathogens [35]. Expression of CD103, a marker for tissue-
resident memory T-cells, was determined on the OMV-specific IL-17A-producing CD4+CD44+ 
T-cells, which were solely detected in P.M. mice. Of these cells, 57 ± 24 percent expressed 
CD103 (data not shown). Moreover, an increased percentage of pulmonary CD103+CD4+ 
T-cells was detected in P.M. mice on day 56 compared to both S.C. and naive mice (Figure 3C). 
In conclusion, only P.M. immunization elicited pulmonary tissue-resident Th17 CD4+ T-cells.
Magnitude of the systemic CD4+ T-cell response
The magnitude of the Prn10-24-specific CD4
+ T-cell response was determined ex vivo using 
tetramers specific for this immunodominant I-Ad restricted T-cell epitope of Prn in BALB/c 
mice. No Prn10-24-specific CD4
+ T-cells were detected in the dLN, bronchial and inguinal for P.M. 
and S.C. mice, respectively, on day 28 and day 56 (data not shown). However, Prn10-24-specific 
CD4+ T-cells were observed in blood of exclusively P.M. mice on day 56 (Figure 3D).
Furthermore, the magnitude of the CD4+ T-cell response was investigated by determining 
the total percentage of B. pertussis-specific cytokine-producing (IFNγ, IL-5, or IL-17A) CD4+ 
T-cells. Both P.M. and S.C. immunization induced a significant increase of OMV- and Prn-
specific cytokine-producing CD4+CD44+ T-cells already on day 28 (Figure 3E and S4B). On day 
56, a significantly higher percentage of these cells was detected after P.M. compared to S.C. 
immunization.
The effect of the immunization route on the Th-subset differentiation was determined. 
Analysis of cytokine levels in the culture supernatants of OMV-stimulated splenocytes 
revealed increased production of Th2 cytokine IL-4 and IL-5 after S.C. immunization, while 
the level of IL-13 was comparable after S.C. and P.M. immunization on day 28 and day 56 
(Figure S5A-B). Stimulation of splenocytes with OMVs led to a high background production 
of Th1 cytokines IFNγ and TNFα of naive mice, possibly due to the presence of LPS in the 
OMVs (Figure S5A-B). Increased production of IFNγ by splenocytes from S.C. mice on day 28 
and from P.M. on day 56 was still observed (Figure S5A-B). In addition, increased production 
of IL-17A and IL-10 was found by splenocytes of P.M. mice compared to S.C. mice on day 
56. ICS analysis showed a significantly increased percentage of OMV-specific IFNγ-producing 
CD4+CD44+ T-cells after P.M. immunization on day 28 (Figure 3F, left panel). OMV-specific IL-
5-producing CD4+CD44+ T-cells were detectable in P.M. and S.C. mice on day 28 and day 56. 
Notably, the percentage was significantly higher after S.C. immunization on day 56 (Figure 
3F, middle panel). Significant OMV-specific IL-17A-producing CD4+CD44+ T-cells were induced 
after S.C. immunization on day 56. Notably, significantly higher percentages of these cells 
were detected after P.M. immunization at both day 28 and day 56 (Figure 3F, right panel). A 
similar trend for Prn-specific CD4+CD44+ T-cells were observed as the OMV-specific CD4+CD44+ 
T-cells (Figure S4B).
The distribution of OMV- and Prn-specific CD4+CD44+ T-cells, based on the production of 
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IFNγ, IL-5, or IL-17A, indicates that S.C. immunization induced systemically a Th1-dominated 
response on day 28 and a mixed Th1/Th17/Th2 response on day 56 (Figure 3G and S4C). In 
contrast, P.M. immunization induced a mixed Th1/Th17 response on day 28, which shifted 
towards a Th17-dominated response on day 56. In summary, more Th1/Th17-skewed CD4+ 
T-cells were elicited by P.M. compared to S.C. immunization.
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Figure 4 - Pulmonary cytokine responses after P.M. and S.C. omvPV immunization. The concentrations of 
cytokines in lung lysates of immunized mice were analyzed over time by using MIA. The cytokine concentrations 
were measured in the individual lung lysates of 4 mice per time point for P.M. mice and in a pool of the lung 
lysates of 4 mice per time point for S.C. mice.* p ≤ 0.05 versus naive mice (day 0).
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Cytokine profiles
The immunization-induced cytokine profile was determined in the lung lysates as well as 
serum. The largest differences were observed 4 hours post primary immunization (Figures 
4 and 5). Concentrations of IL-6, IL-12p70, G-CSF, GM-CSF, IL-1α, IL-1β, IL-13, IL-15, LIF, CXCL5, 
CCL3, CCL4, CXCL2, CXCL10, CXCL1, CCL2, M-CSF, and TNFα were increased 4 hours post primary 
immunization in the lungs of P.M. mice. A trend towards increased levels of CXCL10, CXCL1, 
CCL2, and M-CSF was observed in the lungs of S.C. mice (Figure 4). At later time points, CXCL9 
and IL-17A were found in P.M. mice on day 2 and day 35, respectively. In serum, increased 
levels of CXCL1, CCL4, TNFα, and IL-10 levels were found in both S.C. and P.M. mice (Figure 
5A). In addition, higher levels of G-CSF, CXCL10, CCL2, CCL5, and IL-5 were detected after S.C. 
compared to P.M. immunization (Figure 5B), whereas the levels of IL-6 were higher in P.M 
mice (Figure 5C). Notably, CXCL1, CCL4, TNFα, G-CSF, CXCL10, CCL2, and IL-6 were found in 
both the lungs and sera of P.M. mice. Altogether, while S.C. induced only a systemic cytokine 
response, P.M. immunization induced a distinct systemic and pulmonary cytokine response.
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Figure 5 - Systemic cytokine responses after P.M. and S.C. omvPV immunization. The concentrations of 
cytokines in serum of immunized mice were analyzed over time by using MIA. (A) Cytokines with comparable 
levels in P.M. and S.C. mice. (B) Cytokines with elevated levels in S.C. compared to P.M. mice. (C) Cytokine with 
elevated level in P.M. compared to S.C. mice. Data is given as mean concentrations for 4 mice per group per 
time point. * p ≤ 0.05 versus naive mice (day 0); # p ≤ 0.05 versus S.C. mice. 
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Transcriptomic signatures in draining lymph nodes
Microarray analysis on bronchial and inguinal dLN from P.M. and S.C. mice, respectively, 
revealed 1921 genes that were differentially expressed (p-value ≤ 0.001, FR ≥ 1.5) over time 
compared to naive mice (Figure 6A). 951 genes were upregulated and 466 downregulated 
solely after P.M. immunization, 211 were upregulated and 145 were downregulated in 
both groups, and 109 were upregulated and 39 were downregulated exclusively after S.C. 
immunization. ORA using DAVID indicated enrichment of 141 GO-BP terms and KEGG pathways. 
A selection of these terms was sorted by the most significant enrichment and included Cell 
cycle, apoptosis, immune response, T-cell activation, and B-cell mediated immunity (Figure 
6B). Cell cycle genes were mainly upregulated in P.M. mice. Innate signatures in the S.C. mice 
mainly involved genes downstream of IFN signaling (Figure 6C).
Genes related to T- and B-cells, based on gene ontology and text mining, are shown in Figures 
6D-E. In total, 50 genes were related to T-cells of which many were associated with distinct 
Th subsets (Figure 6D). Upregulation of most genes occurred 4 hours after immunization 
and from day 7 onwards. More genes were upregulated in P.M. mice than in S.C. mice. The 
upregulated genes in P.M. mice included Th17-associated genes, such as the master regulator 
for Th17 differentiation (Rorc), Hif1a, and Havcr1. The few T-cell related genes exclusively 
expressed in S.C. mice comprised Th1- and Th17-associated genes, such as Irf5, Ccr6, and Syt11. 
Expression of B-cell related genes in S.C. mice mainly occurred on day 7 and day 35 (Figure 
6E). In contrast, in P.M. mice elevated expression of B-cell related genes post primary 
immunization was detected earlier (4 hours) and persisted until day 28. Moreover, a smaller 
number of genes was induced on day 35 by booster immunization in P.M. compared to S.C. 
mice. Expression of Mzb1, Ighm, Igkc, Ighg2b, Jchain, Ighg1, and Aicda suggested antibody 
production and the presence of B-cells in dLN, which was more pronounced in P.M. mice. 
In addition, upregulation of specific B-cell membrane, activation, and homing markers were 
observed. Both immunization routes induced Cxcr5, Cd22, Cd40, and Cd83 expression, while 
exclusively the S.C. route induced Cd19, Cd72, Ccr6, and Siglecg and exclusively the P.M. route 
induced Cd38.
In conclusion, P.M. and S.C. immunization with omvPV evoke distinct innate and adaptive 
responses in the dLN as detected on transcriptome level.
Figure 6 (Right) - Transcriptomic profiles in the draining lymph nodes following P.M. and S.C. omvPV 
immunization. (A-E) Gene expression in P.M. and S.C. mice was compared to naive mice (day 0) (FR ≥ 1.5, 
p-value ≤ 0.001). (A) 1921 genes upregulated (red) or downregulated (green) are visualized in heatmaps (mean 
of n = 3). Genes not surpassing a fold change of 1.5 are shown as basal level (black). The overlap (yellow) and 
the exclusive presence of genes in either the P.M. (blue) or S.C. (orange) immunization groups is depicted next 
to the heatmap. (B) Over-representation analysis on all 1921 genes revealed the involvement of specific GO-BP 
terms with corresponding total amount of genes (blue), upregulated (red) and downregulated (green) genes. 
(C) The 47 genes exclusively found upregulated during the innate response of the S.C. mice were shown in a 
heatmap (left panel) and the genes were compared to the Interferome database to determine involvement 
of the Type I IFN (IFNα and IFNβ) and/or Type II IFN (IFNγ) signaling pathway (right panel). (D) T-cell related 
genes, including association with distinct Th subsets, are depicted for P.M. and S.C. mice. (E) B-cell related 
genes are depicted for P.M. and S.C. mice.
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cell cycle (GO:0007049)   4.61E-45
cell division (GO:0051301)   2.72E-30
M phase (GO:0000279)   2.44E-29
DNA metabolic process (GO:0006259)   1.89E-24
apoptosis (GO:0006915)   2.59E-04
leukocyte activation (GO:0045321)   5.90E-04
lymphocyte activation (GO:0046649)   6.28E-04
immune response (GO:0006955)   1.13E-03
adaptive immune response (GO:0002250)   1.67E-03
regulation of T cell activation (GO:0050863)   3.05E-03
antigen processing and presentation of antigen (GO:0019884)   6.46E-03
immunoglobulin mediated immune response (GO:0016064)   7.78E-03
B cell activation (GO:0042113)   1.07E-02
immune system development (GO:0002520)   1.64E-02
intracellular signaling cascade (GO:0007242)   1.91E-02



































































































































































































Microarray analysis was performed on lung tissue collected during the primary immunization 
and comprised 691 genes that were differentially expressed (p-value ≤ 0.01, FR ≥ 2.0) over 
time compared to naive mice (Figure 7A). The largest dissimilarity was observed 4 hours after 
P.M. immunization as revealed by a principal component analysis (PCA) (Figure 7B). Many 
of these genes were no longer expressed on day 2 and later, while upregulation of other 
genes was observed (Figure 7A), as was also observed in the direction of variance in the PCA 
(Figure 7B). The pulmonary gene expression on day 28 did not return completely to basal 
levels. Notably, also differential gene expression was observed mainly on day 2 in the lungs 
of S.C. mice (Figure 7A-B). ORA (Benjamini < 0.05) on the 691 genes revealed enrichment 
of 127 terms (11 KEGG Pathways, 116 GO-BP terms). A selection is shown in Figure 7C. Genes 
involved in pathogen recognition reflected by expression of PRR genes and members of 
corresponding downstream signaling pathways (inflammasome, TNF, NFκB, and MAPK) and 
effector molecules (e.g. pro-inflammatory responses) (Figure 7C and S6A). Moreover, genes 
involved in innate lymphoid cells (ILCs), CSF-signaling, T-cell activation, humoral response, 
and genes encoding complement, cytokines, cytokine receptors, and membrane markers 
were upregulated (Figure 7C and S6B).
The transcriptomic signatures obtained after P.M. immunization in the lungs (691 genes) were 
compared to the dataset of gene expression profiles (558 genes) discovered in the lungs 
of mice after experimental B. pertussis infection in a previous study [7]. In total, 98 genes 
were found in both datasets. A gene-function network analysis investigating the involvement 
of genes in modules PRR-signaling, acute phase, cytokine response, humoral response, 
and T-cell responses, showed differences between both datasets (Figure 7D). Notably, the 
infection dataset comprised more genes related to the modules acute phase and humoral 
response, whereas the P.M. immunization dataset included more genes related to cytokine 
response and PRR-signaling. Only a few shared genes (27 genes) were directly connected 
to the investigated modules. However, by using the STRING database many shared genes 
Figure 7 (Right) - Pulmonary transcriptomic profiles following P.M. and S.C. omvPV immunization. (A-C) Gene 
expression was compared to naive mice (day 0) (FR ≥ 2.0, p-value ≤ 0.01). (A) 691 genes upregulated (red) or 
downregulated (green) are visualized in heatmaps (mean of n = 3 for P.M. mice and n = 1 (pool of 3 mice) for 
S.C. mice). Genes not surpassing a fold change of 2.0 are shown as basal level (black). (B) Principal component 
analysis (PC1 and PC2) shows the (dis)similarity of the five time points for both P.M. and S.C. mice. (C) ORA on 
691 genes uncovered the involvement of specific GO-BP terms and KEGG pathways with corresponding total 
amount of genes (blue), upregulated (red) and downregulated (green) genes. (D-E) Pulmonary transcriptomes 
were compared after P.M. immunization and a B. pertussis infection [7]. (D) A gene-function network analysis 
showing the connection of genes, expressed within 28 days after P.M. immunization or infection, to a specific 
module (blue line) based on involvement in acute phase, cytokine response, humoral response, pathogen 
recognition receptor (PRR) signaling, and T-cell responses. Genes that were expressed in both datasets (shared, 
triangle, purple), exclusively expressed in infected mice (circle, green), or exclusively expressed in P.M. mice 
(circle, red) are depicted. Additional, indirect linkage of shared genes with other genes in the network (grey 
line) by using the STRING database are shown. (E) For infected mice (9 time points) and P.M. mice (6 time 
points) an average fold ratio (FR) (expressed as LN-transformed numbers) was calculated to determine the 
expression intensity and kinetics for each module corresponding to those included in the network analysis.
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regulation of interleukin-6 production (GO:0032675)   6.16E-03


















































































regulation of phagocytosis (GO:0050764)   4.78E-02
immune response (GO:0006955)   7.88E-21
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adaptive immune response (GO:0002250)   3.09E-06
cell activation (GO:0001775)   1.15E-05
Chemokine signaling pathway (mmu04062)   2.90E-05
innate immune response (GO:0045087)   6.96E-05
apoptosis (GO:0006915)   1.22E-04
acute inflammatory response (GO:0002526)   1.73E-04
positive regulation of tumor necrosis factor production (GO:0032760)   6.32E-04
cell cycle (GO:0007049)   1.54E-03
Complement and coagulation cascades (mmu04610)   1.82E-03
p53 signaling pathway (mmu04115)   2.69E-03
Apoptosis (mmu04210)   4.87E-03
Cell cycle (mmu04110)   4.94E-03
T cell activation (GO:0042110)   5.10E-03
B cell mediated immunity (GO:0019724)   6.06E-03
pattern recognition receptor signaling pathway (GO:0002221)   1.20E-02
Toll-like receptor signaling pathway (mmu04620)   1.28E-02
angiogenesis (GO:0001525)   1.59E-02
immunoglobulin mediated immune response (GO:0016064)   1.70E-02
acute-phase response (GO:0006953)   2.21E-02






























(42 genes) could be indirectly linked to the modules by their interaction with other genes in 
the network. A comparison of intensity and kinetics of the average gene expression of each 
module revealed that P.M. immunization induced faster and more intense expression of all 
modules than infection (Figure 7E). In conclusion, both P.M. immunization and B. pertussis 
infection induced genes involved in PRR-signaling, acute phase, cytokine response, humoral 
response, and T-cell responses, yet with different intensity and kinetics. Moreover, the genes 
included in these modules are distinct for P.M. immunization and infection.
In vivo recall response after B. pertussis challenge
After unraveling the immune status of both of P.M. and S.C. mice on day 56, we determined 
the recall responses after an intranasal B. pertussis challenge. The serum anti-OMV IgG 
levels decreased after the challenge in P.M. and S.C. mice (Figure 8A). The challenge of 
non-immunized (N.I.) mice developed anti-OMV IgG and IgM, but the IgG levels remained 
lower compared to immunized mice (Figure 8A). For anti-Prn IgG levels a similar trend was 
observed after challenge (Figure S1A). However, no anti-Prn IgM was detected in any of the 
mice (data not shown). Further, no detectable levels of IgG and IgM to Ptx, FHA, or Fim2/3 
were observed (data not shown). The challenge did not substantially alter the IgG subclass 
distribution of the anti-OMV and anti-Prn serum IgG response in P.M. and S.C. mice, present 
on day 56 (Figure 2B and S1B), since the IgG1 subclass remained dominant in both groups 
on day 84 (Figure 8B and S1B). However, a distinct distribution was found in challenged N.I. 
mice, since the IgG2b subclass response was more prominent in this group (Figure 8B and 
S1B). Enhanced serum IgA antibodies specific for OMV, Prn, and Fim2/3 were present in all 
challenged mice, whereas serum anti-Ptx and anti-FHA IgA were absent (Figure S2A-E). The 
pulmonary anti-OMV IgA antibody levels in P.M. mice remained high after the challenge, while 
in S.C. and N.I. mice these antibodies could only be detected on days 70 and day 84 (Figure 
Figure 8 (Right) - In vivo recall response after B. pertussis challenge of P.M., S.C. and N.I. mice. (A) Serum 
anti-OMV IgG antibodies (left panel), IgM antibodies (middle panel), and pulmonary anti-OMV IgA antibodies 
(right panel) determined in time after B. pertussis challenge on day 56 using MIA. Results are expressed as 
fluorescence intensities (FI) of 4 mice per group per time point. * p ≤ 0.05 versus levels on day 56; # p ≤ 0.05 
versus S.C. mice; + p ≤ 0.05 versus N.I. mice. (B) Distribution of the anti-OMV IgG subclasses on day 84. (C-D) 
Numbers of OMV-specific IgG- and IgA-secreting plasma cells (C) and memory cells (D) in spleens on day 84, 
as determined by B-cell ELISpot of 6 mice per group. (E) Cytokine levels in 3 day culture supernatant of lung 
cells, isolated on day 84, after in vitro stimulation with OMVs, as determined by MIA. Results in pg/ml are 
corrected for the background level (IMDM complete medium control) and are given as mean ± SD of 6 mice 
per group. (F) Percentage of IL-17-producing CD4+CD44+ T-cells in the lungs, harvested on day 84, as measured 
by ICS and flow cytometry after in vitro stimulation for 4 days with OMVs. (G) Magnitude of the systemic OMV-
specific CD4+ T-cell response on day 84 after in vitro stimulation with OMV for 4 days, as determined by ICS 
on splenocytes and calculated as the total percentage cytokine (IL-5, IFNγ, and IL-17A)-producing CD4+CD44+ 
T-cells. (H) Distribution of Th subsets based on IL-5 (Th2), IFNγ (Th1), and IL-17A (Th17) production on day 84, 
as determined by using ICS and flow cytometry. * p ≤ 0.05 versus naive mice; # p ≤ 0.05 versus S.C. mice; + p 
≤ 0.05 versus N.I. mice. (I) The characteristics of the adaptive immune response obtained by primary (day 28) 
and booster (day 56) P.M. omvPV immunization in comparison to primary B. pertussis infection on day 28 and 
56 are summarized. ‡ Obtained from a previous study [36]. N.D. = not determined.
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8A). The same trend was observed for pulmonary anti-Prn IgA levels (Figure S1C). In addition, 
no pulmonary anti-Ptx and anti-FHA IgA antibodies were detected after challenge (data not 
shown), while pulmonary anti-Fim2/3 IgA antibodies were found in S.C. and N.I. mice on day 
84 (Figure S2F). Anti-OMV IgA antibodies were only detected in nose lavages of P.M. mice 4 
hours after challenge, which were most likely induced by the earlier immunization (Figure 
S7A). These nasal IgA antibodies were directed against Vag8 (Figure S3D) and Prn (Figure 
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S7B). The challenge led to enhanced anti-OMV IgA antibodies in all groups on day 84 (Figure 
S7A). In addition to higher anti-Vag8 IgA levels, the challenge induced anti-LPS antibodies in 
the P.M. and S.C. mice, but not in the N.I. control mice (Figure S3D). Furthermore, nasal anti-
Prn, -Ptx, and -FHA IgA levels were significantly increased in S.C. mice following challenge 
(Figure S7B-D). Significantly higher anti-Fim2/3 IgA antibody concentrations were detected 
in N.I. mice on day 84 as compared to 4 hours after challenge, with the same trend in both 
immunized groups, but not significant (Figure S7E).
The numbers of anti-OMV IgG- and IgA-secreting plasma cells in the spleen of S.C. and P.M. 
mice were comparable and significantly higher than the numbers in N.I. mice on day 63 (Figure 
8C). Furthermore, high numbers of anti-OMV IgG-producing memory B-cells were present in 
the spleen of P.M., S.C., and N.I. mice compared to the numbers in naive mice (Figure 8D). 
Moreover, higher numbers were induced by P.M. than S.C. immunization. In contrast, even 
after challenge, anti-OMV IgA-producing memory B-cells were not detected in any of the 
groups (Figure 8D). The Prn-specific antibody-secreting cells and memory B-cell responses 
showed a similar trend as found for the OMV-specific responses, except that no Prn-specific 
IgG-producing memory B-cells could be detected in challenged N.I. mice (Figure S1F-G).
Investigation of the culture supernatants of OMV-stimulated cells from the lungs showed 
IL-4 production solely by cells from S.C. mice (Figure 8E). In contrast, lung cells from all 
three challenged groups produced IL-5 and IL-17A, although IL-17A secretion by P.M. mice 
was significantly increased as compared to S.C. and N.I. mice (Figure 8E). However, a trend 
towards a higher percentage of OMV-specific IL-17A-producing CD4+CD44+ T-cells was 
observed in the lungs after challenge in P.M. compared to S.C. or N.I. mice (Figure 8F). Similar 
results were found after Prn stimulation, except that IL-17A-producing CD4+CD44+ T-cells 
were not detectable in N.I. mice (Figure S4C). OMV- and Prn-specific IFNγ- and IL-5-producing 
CD4+CD44+ T-cells were absent in the lungs of all challenged groups (data not shown). 
Systemic T-cell responses, as detected by ICS, showed a higher magnitude, as calculated by 
the total percentage of B. pertussis-specific cytokine-producing (IFNγ, IL-5, or IL-17A) splenic 
CD4+ T-cells, in P.M. compared to S.C. and N.I. mice (Figure 8G). Moreover, distinct Th subset 
distributions were observed in S.C. and P.M. mice after challenge (Figure 8H). In S.C. mice, 
the pre-challenge Th response (Figure 3F) underwent a shift towards a Th17 response at the 
expense of the Th1 response. Notably, the Th2 component remained responsible for a quarter 
of the Th response. In P.M. mice, the Th response was not altered after challenge with little or 
no Th2 component (Figure 8H).
The systemic and local adaptive immune responses after a primary (day 28) and booster (day 
56) P.M. immunization were schematically summarized and compared with those induced 
by a primary B. pertussis infection on day 28, obtained in this study, and day 56, obtained in 
our previous study [36]. The comparison demonstrated that the adaptive immune responses 
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were comparable after P.M. omvPV immunization and a B. pertussis infection (Figure 8I). 
Notably, there were however quantitative differences as the systemic IgG levels were higher 
after P.M. immunization compared to infection while pulmonary IgA levels were enhanced 
upon infection on day 28.
Collectively, the data of the in vivo recall responses indicate that the systemic and local 
memory B- and T-cell responses after P.M. versus S.C. omvPV-immunized mice were different 
in function and magnitude. The systemic ratio of the Th subsets and the IgA response induced 




Pulmonary immunization induces local immunity important for protection as was 
demonstrated for several respiratory pathogens [11-13]. In this study, the immune responses 
evoked by pulmonary and subcutaneous immunization of an omvPV were compared in 
detail. Pulmonary immunization provided superior protection against B. pertussis challenge 
over the subcutaneous route. A systems biology approach revealed innate and adaptive 
immune signatures associated with this superior protection. The pulmonary gene expression 
and cytokine profiles exclusively evoked by P.M. immunization revealed omvPV recognition 
by PRRs, induction of pro-inflammatory and IL-17 effector cytokines, and IgA responses. 
Furthermore, in dLNs of S.C. mice, genes downstream of IFN signaling were expressed, while 
in dLNs of both P.M. and S.C. mice genes involved in the production of IgG were expressed. 
Moreover, based on gene expression, Th17-cells were detected in the dLNs of P.M. mice. 
The systemic cytokines, however, most were higher after S.C. immunization. Although 
both P.M. and S.C. immunization induced strong systemic adaptive immune response, P.M. 
immunization evoked higher IgM levels, IgG levels, and CD4+ T-cell responses. Moreover, 
the induced Th subsets differed, since P.M. immunization led to a mixed Th1/Th17, yet Th17 
dominated, response, whereas S.C. immunization led to a mixed Th1/Th2/Th17 response. 
More importantly, P.M. immunization elicited a robust mucosal adaptive immune response 
as indicated by the presence of IgA antibodies, IgA- and IgG-producing plasma cells, and Th17 
differentiated CD4+ T-cells in the lungs of mice.
An overview of the main findings is presented in Figure 9 and discussed in detail hereafter. 
During the innate phase, expression of genes associated with pathogen recognition and the 
PRR downstream-signaling cascade were detected in the lungs of P.M. mice, which included 
TLRs, MyD88, NFκB, and pro-inflammatory cytokines (Figure 9A). This demonstrates that 
the omvPV is sensed in the lung by TLR4, based on the expression of Lbp and Cd14, and by 
TLR2 on innate cells, which is similar to the recognition of wPV and whole bacteria [37-39]. 
Interestingly, also enhanced expression of Tlr7 and Nlrp3 was observed indicating activation 
of intracellular PRRs by omvPV. The expression of pro-inflammatory cytokines, such as Il1b, 
Il6, and Cxcl10, was also detected in the lungs on protein level. Multiple known IL-17 effector 
cytokines [8, 40] were measured in the lungs of P.M. mice, including CXCL1, CXCL2, CCL2, 
G-CSF, GM-CSF, and TNFα. These IL-17 effector cytokines facilitate, together with IL-1β and 
IL-6, a Th17-differentiating environment. This was reflected by the presence of Th17 cells in 
the dLN, based on expression of Rorc, Hif1a, and Havcr1. Moreover, Th17 cells were detected 
in the spleen and more importantly in the lungs on single cell level, suggesting induction 
of both systemic and tissue-resident cells. In addition, the presence of CCL3, CCL4, CXCL10, 
and IL-12p70 in the lungs promotes differentiation towards Th1 cells [41, 42]. Indeed Th1 
differentiation was promoted, since Th1 cells were detected systemically on single cell level. 
A Th1/Th17 response is favorable for providing protection against B. pertussis infection [5, 7, 
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8] and additionally, the presence of tissue-resident T-cells in the lungs might even enhance 
protection [35]. The humoral response after P.M. immunization was characterized by 
pulmonary expression of IgA-related genes and the IgA transporter (Pigr) and the subsequent 
IgA presence in lungs and serum. In line with these findings, IgA-producing plasma cells were 
detected in spleen, blood, and lungs. Homing of these cells to the lungs may be enabled by 
CCR9, in our dataset found on gene expression level, which expression on IgA-producing 
memory B-cells is a mucosal homing marker. Furthermore, high serum IgG levels in P.M. 
mice corresponded with specific gene expression (Ighg1, Igh2b, and Jchain) of IgG-producing 
plasma cells in the dLN, and with detected IgG-producing plasma cells on single cell level in 
spleen, blood, and lungs. In addition, IgG-producing memory B-cells were detected in spleens 
of P.M. mice. Interestingly, pulmonary expression of Nfil3 and early expression of Rorc in the 
dLN suggest involvement of ILCs in the immune response upon P.M. immunization. Nfil3 is an 
ILC marker and Rorc is expressed by the ILC3 subset [43].
After S.C. immunization, omvPV is most likely sensed in a similar manner as after P.M. 
immunization, mainly by TLR2 and TLR4, although this was not investigated at the injection 
site in this study. The strong systemic cytokine response demonstrated a Th1- (CCL4, CCL5, 
and CXCL10), Th2- (IL-5 and CCL2), and Th17-differentiating (CXCL1, G-CSF, IL-6, and TNFα) 
environment, which was later reflected by presence of splenic Th1, Th2, and Th17 cells on 
single cell level (Figure 9B). Moreover, the induction of Th1 cells was linked to the early 
expression of genes downstream of IFN signaling found in the dLN [44]. The source of the 
early IL-5 production might be ILC2s [43], suggesting the involvement of these cells after 
S.C. omvPV immunization. Furthermore, the expression of B-cell markers (Cd19 and Cd22) in 
addition to immunoglobulin-related genes (Igh2b, Jchain, and Ighg1) revealed the presence 
of IgG-producing plasma cells in the dLNs. Subsequently, IgG-producing plasma cells were 
detected on single cell level in spleen and blood. Additionally, S.C. omvPV immunization led 
to IgG-producing memory B-cells in the spleen and high serum IgG levels.
Based on the IgA responses, three interesting observations were revealed. First, full 
clearance of B. pertussis from the nose was not achieved despite the presence of anti-Vag8 
IgA antibodies in the nose lavage in P.M. mice. This suggests that under the conditions used 
in our study with respect to vaccine and challenge dose, anti-Vag8 IgA induction in the nose 
alone may not be sufficient for prevention of nasal B. pertussis colonization. Second, 28 days 
after B. pertussis challenge, nasal anti-LPS IgA antibodies were detected in P.M. and S.C. mice, 
but not in non-immunized (N.I.) mice. Also, a lack of OMV-specific IgA-secreting plasma cells 
in N.I. mice after challenge was observed. Because no IgA response was detectable before 
challenge in S.C. mice, it was expected that challenge of S.C. and N.I. mice would evoke a 
similar IgA response. This faster induction of IgA responses in S.C. compared to N.I. mice may 
indicate the presence of low numbers of LPS-specific IgA-producing memory B-cells in S.C. 
mice stimulated upon a challenge. Third, large numbers of IgA-secreting plasma cells were 
present in the spleen 7 days post P.M. booster vaccination (day 35). However, IgA-producing 
239
Pulmonary administration of an outer membrane vesicle pertussis vaccines
7
memory B-cells were non-detectable on day 56. Nonetheless, the recall of memory B-cells 
in response to infection led to a rapid increase in numbers of IgA-secreting plasma cells in 
the spleen (day 63). This suggests that IgA-producing memory B-cells may not reside in the 
spleen but elsewhere, presumably as tissue-resident IgA-producing memory B-cells in the 
mucosa [45]. Since IgA responses may contribute to protection against B. pertussis infection, 
these different aspects of the IgA responses require further investigation.  
The immunity induced by P.M. immunization with an omvPV substantially resembles the 
infection-induced immunity, still considered as benchmark for optimal immunity. Interestingly, 
P.M. immunization with omvPV confers sterilizing immunity to a similar extent as is observed 
for infection-induced immunity in mice and baboons [5, 7, 8]. After both P.M. immunization 
and B. pertussis infection, a strong IgG response is induced. Furthermore, circulating and 
pulmonary IgA-producing B-cells were detected after P.M. immunization, leading to the 
production of mucosal IgA. This IgA was mainly directed against Vag8 as was observed 
after a challenge of mice with B. pertussis [36]. Moreover, both after P.M. immunization 
and B. pertussis infection, the CD4+ T-cell responses, pulmonary and systemically, are Th17 
dominated [5, 7, 8, 36].
Remarkably, there were also differences between P.M. immunization and infection-induced 
immunity. Serum IgG responses were already higher after primary P.M. immunization 
compared to B. pertussis infection on day 28. Moreover, increased IgG levels were found 
after booster immunization compared to the levels observed 56 days after infection [36]. 
Moreover, the omvPV vaccination in general evoked a distinct IgG subclass response 
compared to infection, which was partly caused by high anti-LPS IgG3 induction after 
the booster vaccination. IgG subclass distribution is thought to be indirect evidence for 
Th responses [46-48]. In our study the Th responses are not mirrored in the IgG subclass 
responses, since the Th responses are comparable after P.M. immunization and infection, 
while the IgG subclass distribution is distinct. Given that both S.C. and P.M. administration 
of omvPV result in an equal IgG subclass response, suggests that the differences compared 
to infection are probably caused by the vaccine composition and vaccination scheme rather 
than administration route. Furthermore, this study and our previous study [9] demonstrate 
that the antigen specificity of the serum IgG induced by P.M. immunization differs from 
infection, most likely due to distinct antigen composition. Whereas omvPV contains only 
outer-membrane and periplasmic proteins, live bacteria are comprised of additional cytosolic 
proteins and are capable of de novo production and secretion of antigens, such as Ptx [9]. 
Pulmonary IgA levels on day 28 induced by infection were higher compared to primary P.M. 
immunization. Booster P.M. immunization equalized the IgA levels with those after infection 
on day 56 [36].
Furthermore, with respect to cytokine profiles, P.M. immunization leads to faster and more 
intense pulmonary and serum cytokine production as compared to infection. However, higher 
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cytokine levels were expected during B. pertussis infection because of a prolonged antigen 
exposure [7] and a higher antigen dose compared to P.M. immunization with non-replicating 
omvPV. Weaker cytokine responses upon an infection might be explained by the immune 
evasion strategies of B. pertussis [49], such as dampening of host cytokine responses [50]. 
Extensive comparison of early pulmonary transcriptomic profiles induced by P.M. vaccination 
obtained from this study and those induced by B. pertussis infection [7] demonstrated that 
although both responses included genes involved in acute phase, PRR-signaling, cytokine 
responses, humoral response and T-cell responses, these responses comprised distinct genes. 
Moreover, P.M. immunization leads to faster and more intense pulmonary gene expression, 
which is in line with the cytokine profiles.
Together, the comparison of omvPV-induced immunity through P.M. administration and 
infection-induced immunity revealed overall comparability, notwithstanding some distinct 
innate responses.
Another advantage of pulmonary immunization, besides the induction of mucosal immune 
responses resembling that induced by B. pertussis infection, is that P.M. vaccine administration 
is needle-free. Currently, no pulmonary vaccines are licensed and only a few mucosal vaccines 
have been approved for human use. These include nasal vaccine against influenza virus 
and oral vaccines against poliovirus, rotavirus, Salmonella typhi, and Vibrio cholerae [51]. 
Pulmonary vaccine administration in humans is in early clinical development. Both powder 
inhalers [52] and fluid, nebulized vaccines are clinically tested, the latter in infants of 9 months 
of age [53]. Nasal vaccine administration might also be an option and may be suitable for 
infants. Intranasal immunization with an omvPV is also feasible since it provides protection 
against B. pertussis infection [14]. In addition, nasal immunization has been shown to result 
in IgA antibodies not only in the nasal cavity, but also lower in the respiratory tract [51, 54]. 
However, in depth analysis of the immune response induced by nasal immunization route in 
the context of pertussis is required.
In conclusion, this study showed that an omvPV can elicit superior local and systemic 
immunity against B. pertussis infection, with a similar type of adaptive immune response as 
induced by infection, by administering the vaccine pulmonary instead of subcutaneously. 
Therefore, pulmonary immunization may be key to the development of novel candidate 
pertussis vaccines. Further, in addition to serology, the gold standard in pertussis research, a 
systems biology approach is invaluable in order to unravel and understand the immunological 
signatures underlying the vaccine-induced immunity. In turn, this facilitates a rational choice 
for a vaccine candidate and route of administration, mitigating the risk of failure in the late-
stage of development. 
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Supplementary information
Figure S1 - Prn-specific B-cell responses induced by P.M. and S.C. omvPV immunization. (A-C) Serum anti-Prn 
IgG antibodies (A), IgG subclass distribution (B), and pulmonary anti-Prn IgA antibodies (C) were determined in 
immunized mice using MIA. Results are expressed as fluorescence intensities (FI) of 4 mice per group per time 
point. * p ≤ 0.05 versus naive mice (day 0); # p ≤ 0.05 versus S.C. mice; + p ≤ 0.05 versus N.I. mice. (D-E) Numbers 
of Prn-specific IgG- and IgA-secreting plasma cells (n = 6) in (D) lungs, blood, and spleens on day 35 and in (E) 
spleens (n = 4) on day 63. (F) Numbers of Prn-specific IgG- and IgA-producing memory cells were determined in 
spleens (n = 6) on day 56 and 84. *p ≤ 0.05 versus naive mice; # p ≤ 0.05 versus S.C. mice; +p ≤ 0.05 versus N.I. 
mice. N.D = not detected.
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Figure S2 - Serum IgA levels against OMV, Prn, Ptx, FHA and Fim2/3 and pulmonary anti-Fim2/3 IgA induced by 
P.M. and S.C. omvPV immunization. (A-E) The levels of IgA antibodies directed against (A) OMV, (B) Prn, (C) 
Ptx, (D) FHA, and (E) Fim2/3 were determined in serum on day 28 and day 56 (vaccine-induced) and on day 84 
(infection-induced) in naive, S.C., P.M., and N.I. mice. * p ≤ 0.05 versus naive mice; # p ≤ 0.05 versus S.C. mice; 
+ p ≤ 0.05 versus N.I. mice. (F) The levels of pulmonary anti-Fim2/3 IgA following challenge were determined 
in S.C., P.M. and N.I. mice. Results are expressed as fluorescence intensities (FI) of 4 mice per group per time 
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Figure S3 - Specificity of antibodies induced by P.M. and S.C. omvPV immunization. (A) Specificity of IgG and 
IgA in respectively serum and lung lysates of S.C. and P.M. mice on day 56 was determined using 2DEWB. Figure 
represents one blot for each condition. Individual spots with corresponding protein ID, as determined by LC-
MS, are depicted. (B-D) Antibody specific as determined by 1DEWB  for serum IgG (B) and pulmonary IgA (C) 
on day 28, 56, and 84 and nasal IgA (D) 4 hours and 28 days (day 84) after challenge. Identification of bands 
representing GroEL, LPS, Vag8, ahcY, and two unidentified antigens (U1-2) are shown. As a control a Coomassie 
staining (Com) was performed on the 1DE gel to stain the B. pertussis proteins.
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Figure S4 - Pulmonary and systemic Prn-specific T-cell responses induced by P.M. and S.C. omvPV immunization. 
(A) Magnitude of the Prn-specific CD4+ T-cell response on day 28, 56, and 84 after in vitro stimulation with 
Prn for 4 days was determined using ICS and calculated as the total percentage cytokine (IL-5, IFNγ, and IL-
17A)-producing CD4+CD44+ T-cells. (B) Percentage IL-5-, IFNγ-, and IL-17-producing cells of CD4+CD44+ T-cells of 
spleens harvested on day 38 and day 56 and stimulated in vitro for 4 days with Prn. Results of each analysis 
are given of 6 mice per group. (C) Distribution of Th subsets based on IL-5 (Th2), IFNγ (Th1), and IL-17A (Th17) 
production as determined using ICS and flow cytometry. * p ≤ 0.05 versus naive mice; # p ≤ 0.05 versus S.C. 
mice; + p ≤ 0.05 versus S.C. mice.
Figure S5 - Cytokine levels in supernatants of OMV stimulated splenocytes. (A-B) The presence of cytokines in 
day 3 culture supernatants of splenocytes collected on (A) day 28 and (B) day 56 was tested using a multiplex 
assay. Results in pg/ml are corrected for the background level (IMDM complete medium control) and are given 


























































































































































































































































































































Figure S6 - Pulmonary transcriptome following P.M. immunization. (A-B) Differential upregulated (red) or 
downregulated (green) gene expression of P.M. mice (mean of n  =  3) compared to naive mice (day 0) (FR ≥ 
2.0, p-value ≤ 0.01). Genes not surpassing a fold change of 2.0 are shown as basal level (black). (A) Genes are 
depicted involved in pathogen recognition, such as the inflammasome and the pathogen recognition receptor 
(PRR)-, TNF-, NFκB-, and MAPK-signaling pathways and pro-inflammatory responses. (B) Genes are depicted 
involved in ILCs, CSF-signaling, T-cell activation, humoral response, and complement in addition to genes 
encoding for cytokines, cytokine receptors, and membrane markers.
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Figure S7 - IgA responses in the nose lavages of P.M., S.C., and N.I. mice. IgA antibodies specific for OMV (A), 
Prn (B), Ptx (C), FHA (D), and Fim2/3 (E) were determined in the nose lavage of P.M., S.C., and I.N. mice 4 hours 
after B. pertussis challenge (d56-4h) and at day 84. Results are expressed as fluorescence intensities (FI) of 4 
mice per group per time point. * p ≤ 0.05 versus levels on d56-4h; # p ≤ 0.05 versus S.C. mice; + p ≤ 0.05 versus 
N.I. mice.
Table S1 Immunogenic proteins determined by LC/MS of excised spots found by immunoblotting of 2DE gels










60kD chaparonine Q7W0M8 GroEl 57.4 5.2 69 33
adenosylhomocysteinase Q7VUL8 ahcY 51.6 6.1 53 20
autotransporter Q79GN7 vag8 94.8 6.8 41 27
bifunctional purine 
biosynthesis protein Q7VTU1 purH 55.8 6.3 36 16
BrkA autotransporter (1) Q45340 BrkA 103.3 7.1 30 21
BrkA autotransporter (2) Q45340 BrkA 103.3 7.1 18 14
chaperonine protein HtpG Q7W0M8 htpG 71.1 5.2 65 39
dihidrolipoyl dehydrogenase Q7VZ16 odhL 50.1 6.8 61 25
outer membrane protein A (1) Q7VZG6 ompA 21.0 8.7 17 3
outer membrane protein A (2) Q7VZG6 ompA 21.0 8.7 35 5
pertactin autotransporter P14283 prn 93.4 9.2 28 16
probable tonB dependent 
receptor P81549 BfrD 79.3 8.2 58 37
putative outer membrane 
protein Q7VT02 BP3755 23.0 9.2 26 5
Virulence factors putative 
positive transcription regulator P0A4H2 bvga 22.9 8.4 78 14
a) Proteins in excised gel spots identified by LC–MS analysis.
b) Accession numbers of proteins and corresponding ID provided by uniprot (http://www.uniprot.org).
c) Molecular weight (Mw) and isoelectric point (pI) are calculated based on protein sequence.
d) Percentage of a protein sequence covered by identified peptides from the corresponding protein and the 
number of peptides assigned with high confidence.
S.C. P.M. N.I.
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Abstract
Respiratory infection with Bordetella pertussis leads to severe effects in the lungs. The 
resulting immunity and also immunization with pertussis vaccines protects against disease, 
but the induced type of immunity and longevity of the response are distinct. In this study the 
effect of priming, either by vaccination or infection, on a subsequent pathogen encounter 
were studied. To that end, three post-challenge transcriptome datasets of previously primed 
mice were combined and compared to the responses in unprimed control mice. In total, 205 
genes showed different transcription activity. A co-expression network analysis assembled 
these genes into 27 clusters, combined into six groups with overlapping biological function. 
Local pulmonary immunity was only present in mice with infection-induced immunity. 
Complement-mediated responses were more prominent in mice immunized with an outer 
membrane vesicle pertussis vaccine than in mice that received a whole-cell pertussis vaccine. 
Additionally, 46 genes encoding for secreted proteins may serve as markers in blood for 
the degree of protection (Cxcl9, Gp2, Pla2g2d), intensity of infection (Retnla, Saa3, Il6, Il1b), 
or adaptive recall responses (Ighg, C1qb). The molecular signatures elucidated in this study 
contribute to better understanding of functional interactions in challenge-induced responses 
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Introduction
Whooping cough, caused by Bordetella pertussis is an endemic disease with considerable health 
impact [1, 2]. Several vaccines against B. pertussis are marketed or under development. These 
include whole-cell pertussis vaccine (wPV), acellular pertussis vaccine (aPV), live-attenuated 
pertussis vaccine (BPZE1), and vaccines based on outer membrane vesicles (omvPV) [3-6]. 
These vaccines are very different with regard to concept (whole-cell inactivated, subunit, live 
attenuated), composition and route of immunization. Although all vaccines confer protection 
in the mouse challenge model [3-7], the type and level of immunity is different [3-7]. This 
difference in immunity leads to distinct pulmonary immune responses upon subsequent B. 
pertussis encounter [7, 8].
Analysis of different transcriptome datasets is a tool for unbiased investigation of biological 
processes. It has been used to compare for instance the immune responses induced by different 
vaccines to identify universal vaccine-induced signatures [9-11]. Previously, differences in 
pulmonary gene expression  of mice immunized with omvPV or wPV [7], and mice receiving 
a primary infection [8] were elucidated. However, the pulmonary transcriptome datasets 
obtained by challenge experiments may contain potential gene markers related to pertussis 
immunity. The identification of those markers may contribute to better understanding of 
pertussis immunity and as read-out in a human challenge model [12].
We performed an meta-analysis of pulmonary transcriptome datasets obtained after a B. 
pertussis challenge in mice with a different pertussis immune status. These included mice 
with infection-induced immunity, wPV-immunized mice (wPV-mice), omvPV-immunized mice 
(omvPV-mice), and non-immunized mice (N.I. mice) as control [7, 8]. The molecular signatures 
were characterized with special attention for secreted proteins, since these markers could 
potentially be useful for monitoring immune responses in blood samples to determine 
degree of protection, intensity of infection, or promptness of adaptive recall responses for 





We used gene expression datasets from four B. pertussis challenge experiments in mice. These 
included data from challenge studies performed 56 days after the primary immunization or 
infection [7, 8]. We included mice with (i) infection-induced immunity, mice immunized twice 
with (ii) wPV or (iii) omvPV, and (iv) non-immunized mice (Figure 1A). 
Gene expression analysis
The flow diagram showing all stages of the gene expression analysis and the selection 
criteria is shown in Figure 1B. For all datasets, we included five time points: 56 days post 
primary infection (p.i.) or immunization, but before challenge (D0), and 4 hours, 2 days, 7 
days and 14 days post intranasal B. pertussis challenge (p.c.). Gene expression profiles of non-
challenged and non-immunized mice were used as a control. In each of the four experiments, 
differentially expressed genes (DEGs) were identified by using previously described methods 
[13, 14], namely a one-way ANOVA at a stringency value of p ≤ 0.001 and an absolute Fold 
Ratio (FR, i.e. challenge response to the control group) ≥ 2.0. Data for the combined set of 
DEGs (across time points in one study) were merged. This set of DEGs was further refined by 
(i) identifying DEGs that differed by a FR ≥ 2.0 across studies at one time point; (ii) excluding 
genes that are not protein-coding (mainly genes annotated by NCBI as “gene model” or 
“hypothetical gene”); and (iii) excluding genes with batch-to-batch variation between arrays 
in the control groups. 
Functional analysis
For the resulting datasets, a co-expression network was created, based on the Euclidean 
distance between their overall response patterns across all groups and time points. Genes 
were connected in a network if their co-expression similarity fell in the top 1% of overall most 
similar responses. Additionally, remaining genes were connected to genes with the most 
similar response over time in order to include each gene in the network. Further functional 
analysis and identification of genes that encode for secreted proteins based on the Uniprot-
term ‘secreted’ were performed by using DAVID [15]. 
Data visualization
Data were visualized using Adobe Illustrator CC 2015, Cytoscape (version 2.8.3) (www.
cytoscape.org), R (www.r-project.org), Genemaths XT (Applied Maths, St-Martens-Latem, 
Belgium), and Venny (http://bioinfogp.cnb.csic.es/tools/venny/index.html). 
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Figure 1 - Design and method used in this study. Four transcriptome datasets were included obtained after a 
B. pertussis challenge in the lungs of non-immunized mice, mice with infection-induced immunity, and mice 
immunized subcutaneously (S.C.) with omvPV or wPV. (A) The immunization and challenge scheme of these 
datasets is shown. The source of these datasets in the corresponding chapters of this thesis is depicted. (B) 
The different steps of the meta-analysis and criteria used are described and linked to the figures and tables in 
this chapter.
Relation of signatures to immune status
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Figure 2 - Venn diagram. The overlap of differentially expressed genes between four datasets obtained from 
lungs of mice at different time points after B. pertussis challenge is depicted.
Results and Discussion
Identification of gene expression signature clusters
The pulmonary transcriptomes of four individual B. pertussis challenge experiments were 
merged. The immunization and B. pertussis challenge scheme of these studies is shown in 
Figure 1A. Individual datasets revealed 975 DEGs (FR ≥ 2.0, p ≤ 0.001) in one or more datasets 
(Figure 2). In total, 627, 256, 169 and 280 genes were included in the non-immunized, 
omvPV-immunized and wPV-immunized mice, and mice with infection-induced immunity, 
respectively. Subsequently, we identified DEGs (FR ≥ 2.0, p ≤ 0.001) between the datasets 
for each time point. This second round of identifying DEGs between studies, combined with 
a ‘cleanup’ by exclusion of functionally less relevant genes, i.e. hypothetical or non-protein 
coding genes (Figure 1), left 205 genes for further analysis (Table 1). Co-expression patterns 
for these 205 genes were determined and visualized in a network analysis (Figure 3). This 
analysis split the 205 genes into 27 signature clusters (A-AA) ranging in size from 2 to 75 genes 
(Table 1). The average gene expression was calculated for each gene cluster and visualized in 
a heatmap (Figure 4).
Function of clusters and relation to pertussis-vaccinated background
To determine the function of the individual clusters, an overrepresentation analysis was 
performed using DAVID. The different clusters were combined to six groups with overarching 
biological functions (group I-VI) (Figure 3 and 4). From these molecular signatures, we 
additionally identified the genes that encode for secreted proteins. Because they may 
serve as markers that can be analyzed in blood and could be interesting candidates for later 
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application in human studies. In total, 46 genes were identified to code for secreted proteins, 
which were present in the different groups, except for group III (Figure 5). Gene expression 
of clusters and single genes were compared with the number of colony forming units (cfu) 
in the lung (Figure 4 and 5) which were determined previously in primed and unprimed mice 
[7, 8].
At this point, we are able to isolate different molecular signatures from this analysis 
based on the gene expression kinetics. First, (i) signatures of local immunity induced by 
the primary vaccination or infection that are still active or present in the lungs on D0, just 
before challenge. Second, (ii) signatures of infection intensity. The N.I. mice have the highest 
number of bacteria in the lungs on 7 days p.i. whereas these are cleared faster in primed 
Table 1 - Detailed information on the 27 gene clusters.
Clusters Number of genes Included genes
A 75
Abcf1, Abhd8, Agap3, Amotl2, Arap1, Arhgef40, Atp9a, B4galnt1, Cenpb, Cldn3, Cnp, Cpsf1, Cyp2s1, 
D17H6S56E-5, Dctn1, Ddr1, Egln2, Fasn, Flii, Lbp, Gadd45g, Gclc, Get4, Gpr56, Grn, Gstm1, Hgs, Hspb1, 
Itga3, Itga7, Itih4, Keap1, Kif1c, Lrp10, Mgll, Mmrn2, Nfe2l1, Os9, Pard6b, Parm1, Pex14, Piezo1, 
Pip4k2c, Pkm, Plbd2, Pnpla2, Por, Ralgds, Rbm19, Relb, Rftn1, Rgp1, Rgs12, Rnh1, Rptor, Rrp1, Rsph1, 
Rusc2, Sbno2, Sdc3, Sec61a1, Sema3b, Sh3tc1, Slc3a2, Spint2, Sqstm1, Stab1, Tap2, Tgm2, Tmbim6, 
Tnip1, Ucp2, Vars, Vpreb3, Zbtb7a
B 5 Crip2, Hdac5, Isyna1, Lrg1, Plxnb2
C 4 Prpf8, Psap, Psmd3, Shisa5
D 4 Cyba, Ehd1, Mvp, Myh14
E 2 Hadha, Man2b1
F 10 Ccl19, Ciita, Cxcl12, Cxcr2, Fam26f, Gm12407, Plbd1, Reg3g, Rrm2, BC048546
G 8 Cd74, H2-Ab1, H2-D1, H2-DMa, H2-Eb1, H2-K1, Nup62-il4i1, Steap4
H 7 Bpifb1, Cp, Cxcl17, Ltf, Prom1, Scgb3a1, Tmc5
I 5 Cdhr1, Clca4, Pglyrp1, Ubd, 4833428L15Rik
J 3 Ccar1, Gbp10, Gbp6
K 2 Iigp1, Mki67
L 2 Ccna2, Ckap2
M 10 Basp1, C1qb, Cd177, Cxcl13, Gm9758, Gp2, Pla2g2d, Speer4b, Speer4c, Speer4e
N 6 Ccl20, Ighg, Igj, Igk, Igkv4-59, Igkv8-30
O 5 Igh-VJ558, Ighm, Igkc, Igkv4-53, Pigr
P 4 C3, C4a, C4b, Tnfaip2
Q 4 Ccl8, Cxcl9, Retnla, Saa3
R 4 Cfb, Clca3, Lcn2, Tff2
S 14
Ank3, BC117090, Bcl2a1a, Bcl2a1b, Bcl2a1c, Bcl2a1d, Cd209f, Cxcl5, Fpr2, Mmp3, Rorc, Scel, Tspan2, 
A130040M12Rik
T 7 Chil3, Ear1, Ear10, Ear12, Ear2, Ear3, Rnase2a
U 6 Aif1, H2-Aa, H2-Ea-ps, Ms4a7, S100a4, Serpina3g
V 3 Ccl17, Clec4n, 2900060B14Rik
W 3 Ctss, Fcgr2b, Wfdc17
X 4 Agr2, Cxcl11, Igtp, Timp1
Y 3 Cd14, Cxcl2, Fgg
Z 3 Ccl2, Il1b, Il6
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Figure 3 (Left) - Network analysis. The 205 differentially regulated genes formed 27 clusters (A-AA). According 
to overlap in function, the clusters were subsequently combined in six groups (I-VI).
mice (Figure 4 and 5). Therefore the kinetics and/or intensity of gene expression of acute 
phase and pro-inflammatory proteins that are secreted during colonization could indicate 
the intensity of infection in the mouse model. Finally, (iii) signatures of recall responses 
of adaptive immunity. These are expressed earlier (within 2 days p.c.) in immunized mice, 
but are absent or expressed later on (7-14 days p.i.) in N.I. mice. The different, groups (I-VI), 
clusters (A-AA), and genes encoding secreted proteins will be described hereafter.
Group I - Innate activation
Clusters A-E were combined to group I and comprised genes involved in general immune 
responses or related to macrophages and T-cell activation. These clusters were exclusively 
upregulated in the lungs of N.I. mice and mice with infection-induced immunity mice 4 
hours p.c. Cluster A is the largest cluster, with 75 genes, and included genes involved in cell 
activation (Relb, Gadd45g, Lbp, Sbno2). Lipopolysaccharide binding protein (Lbp) is involved in 
recognition of LPS. Moreover, two integrins (Itga3, Itga7) were detected in this group, which 
are cell membrane proteins but not specific for immune cells.
Group II – Pulmonary bridging phase
Clusters F-I are part of group II that was enriched for antigen processing and presentation. 
These clusters were induced 7-14 days p.c. in N.I. mice, whereas these clusters were constantly 
expressed in mice with infection-induced immunity. Cluster G more specifically included 
genes involved in MHC signaling (H2-Ab1, H2-D1, H2-DMa, H2-Eb1, H2-K1). Additionally, group 
II contains genes coding for proteins that are secreted. These are expressed earlier in mice 
with infection-induced immunity compared to the  mice receiving a vaccination (Cxcl12, Cxcl17, 
Ccl19, Pglyrp1) (Figure 5). Cxcl17 is a mucosal cytokine that attracts lung macrophages [16].
Group III – Cell cycle and tissue remodeling
Group III comprised genes of clusters J-L, associated with the cell cycle, which were only 
upregulated 7-14 days p.c. in N.I. mice. This group was marked by high activation of the cell 
proliferation marker Mki67. In addition, this group comprised of interferon-induced GTPases 
such as Gbp6 and Gbp10, which are involved in the innate response to protect against a 
bacterial infection [17] and Iigp1. Activation of these genes solely in N.I. mice suggests 
enhanced lung cell proliferation as a result of lung tissue damage. Therefore, the absence of 
this gene expression signature in protected mice might indicate less collateral lung damage 
as a result of a B. pertussis challenge and, accordingly, suggests that recall responses of the 
adaptive immune system are sufficient.
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Figure 4 - Comparison of pulmonary gene expression profiles following a B. pertussis challenge in mice 
with different pertussis immunity background. Averaged fold changes of 27 clusters (A-AA) of infected 
non-immunized mice and challenged mice with infection-induced immunity, omvPV-immunization, or wPV-
immunization background are depicted in a time course. Additionally, six groups (I-VI) with similarity in function 
are shown. The moment at which the B. pertussis infection or challenge was performed is depicted as well as the 
log10 number of colony forming units (cfu) for each time point post challenge as determined previously [7, 8].
Group IV – Mucosal and systemic adaptive recall responses
Clusters M-R were part of group IV of which the genes encode proteins with immunological 
functions, such as immunoglobulins, complement factors and acute inflammatory proteins. 
Clusters N-O both contain genes involved in antibody production. Cluster N is related to IgG 
production and more active in the lungs of mice with infection-induced immunity compared 
to omvPV- and wPV-immunized mice. Previously, we showed that pertussis immunization 
leads to higher total IgG levels compared to infection [18]. The higher expression of these 
genes in the lungs may suggest that the mice with infection-induced immunity have higher 
numbers of lung-resident IgG-producing B-cells, especially in combination with the co-
clustering of these genes with Ccl20 that attracts CCR6⁺ B-cells. The genes (Pigr, Igh-VJ558) 
in cluster O are specifically related to IgA-production [19] and were strongly upregulated in 
mice with infection-induced immunity from 4 hours to 14 days p.c. This suggests that mice 
with infection-induced immunity have more intense and faster antibody production in the 
lungs compared to subcutaneously immunized mice. This was also shown at the functional 
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Figure 5 - Genes encoding for secreted proteins. Genes encoding for secreted proteins were retrieved from 
DAVID and illustrated as heatmap for the four pulmonary transcriptome datasets. The genes are clustered 
according to prevalence in the six function groups (I-VI), which is shown on the left. The moment at which the B. 
pertussis infection or challenge was performed is depicted as well as the log10 number of colony forming units 
(cfu) for each time point post challenge as determined previously [7, 8]. 
[8] and absence in wPV-mice and omvPV-mice [7]. Local stimulation of the immune system 
might be critical because the induction of antibody-related genes (Iga, Pigr) and mucosal IgA 
may lead to better protection. Cluster P contains three members of the complement system 
(C3, C4a, C4b). Members of complement systems (C1qb, Cfb, C3, C4a, C4b) were expressed 
most profound in the lungs of mice with infection-induced immunity and to a lesser extent 
in omvPV-immunized mice. Interestingly, these genes were hardly expressed in the lungs 
of wPV-immunized mice (Figure 5). This suggests that complement-mediated responses, 
which may contribute to clear B. pertussis from the lungs [20], are more prominent in omvPV-
immunized mice. Cluster Q showed most pronounced expression in N.I. mice 7-14 days p.c., 
but was also present in wPV-mice 7 days p.c. In omvPV-mice and mice with infection-induced 
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Saa3, part of the acute phase response, Cxcl9, that attracts CXCR3⁺ cells, a chemoattractant 
(Ccl8), and resistin-like molecule α (Retnla) that is important in lung pathology [21]. Notably, 
the expression of Saa3 and Retnla follow the number of cfu in the lungs (Figure 5). Mice with 
infection-induced immunity show a limited induction of gene expression for Saa3 and Retnla, 
which also peaks early, already 2 days p.c. In addition, they show the fastest lung clearance 
[8, 18]. On the contrary, the wPV-mice and N.I. mice showed later and more intense gene 
expression in accordance with prolonged lung clearance. The omvPV-mice revealed earlier 
expression compared to wPV-mice and N.I. mice conforming to the lower inflammatory 
responses observed in omvPV-immunized mice [7]. Both Saa3 and Retnla encode for secreted 
proteins (Figure 5) and can therefore serve as a predictor of infection intensity when measured 
in blood.
Group V – Vaccine-primed innate responses
Cluster S-W were part of group V, which included genes associated with myeloid cells. These 
clusters were mainly upregulated in omvPV-mice 4 hours p.c. and in wPV-mice 7 days p.c. In 
cluster S, which is moderately expressed in omvPV-mice and wPV-mice, four members were 
identified belonging to the B cell leukemia/lymphoma 2 related proteins (Bcl2a1a, Bcl2a1b, 
Bcl2a1c, Bcl2a1d), a pathogen recognition receptor (Fpr2), a C-type lectin receptor (Cd209f), 
and matrix metallopeptidase 3 (Mmp3). Additionally, Cxcl5, a neutrophil attractant, was highly 
expressed before the challenge in the lungs of omvPV-mice and wPV-mice (Figure 5). Notably, 
this cluster also included the retinoic acid receptor (RAR)-related orphan receptor C (Rorc) 
that is essential for Th17 cell differentiation [22]. Cluster T included five members (Ear1, Ear2, 
Ear3, Ear10, Ear12) of the eosinophil-associated, ribonuclease A family. Cluster V was intensely 
upregulated in omvPV-mice 4 hours p.c. It contained Ccl17, and dendritic cell specific Clec4n. 
Together, these clusters represent an influx or higher proliferation of myeloid cells and DCs 
that are most profound in the omvPV-mice.
Group VI – Inflammation
Finally, cluster X-AA formed group VI that was enriched for the GO-term inflammatory 
response. Cluster Y was mainly upregulated 4 hours p.c. This was most intense in non-
immunized mice and the lowest in omvPV-mice. This cluster contained the CD14 marker (Cd14) 
that is involved in LPS recognition, a neutrophil attractant (Cxcl2), and fibrinogen (Fgg), which 
is an important attenuator of LPS-mediated responses [23]. Cluster Z included Ccl2 and the 
pro-inflammatory cytokines Il6 and Il1b that were strongly induced in the N.I. mice and not 
in the three immunized groups. This indicates that previous exposure to either a vaccine 
or infection prevents induction of these pro-inflammatory markers in the lungs upon a B. 
pertussis challenge. Therefore, the presence of these signatures may serve as a marker for 
mice being unprotected against pertussis (Figure 5). Finally, cluster AA was only present in 
wPV-immunized mice.
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Conclusions
This meta-analysis revealed molecular signatures specific for immune responses against 
pertussis. The signatures were measured in the lungs of mice that were previously exposed 
to either pertussis vaccination or infection. Comparison of the gene expression profiles in the 
lung of differently treated mice revealed that:
• Infection, but not subcutaneous vaccination, leads to induction of local immunity in the 
lungs. This local immunity is characterized by enhanced IgA production and involvement 
of ‘trained’ pulmonary innate cells [8].
• Responses to pertussis challenge in the lungs of omvPV-mice and wPV-mice were similar 
in nature, but the omvPV-mice respond slightly faster.
• Complement-mediated responses are more prominent in omvPV-immunized mice than 
in wPV-mice.
• Genes with unknown function (Speer4b, Speer4c, Speer4e) were associated with genes 
with well-known function (C1qb, Cd177) based on their co-expression, providing insight 
into their potential immunological functions.
• Genes of potentially secreted proteins were identified of which some may serve as 
markers in blood for analysis of degree of protection (Cxcl9, Gp2, Pla2g2d), intensity of 
infection (Retnla, Saa3, Il6, Il1b), or adaptive recall responses (Ighg, C1qb). This analysis 
can be performed by using an ELISA or multiplex immunoassay and for instance applied 
as readout in a human challenge model [12].
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About the cover: Mount Fitz Roy ("Cerro Chalten"), seen from the Lagoon de los Tres, located in the Los Glaciares National 
Park in Patagonia on the border of Chile and Argentina. With a height of 3,405 metres, sheer  mountain face, and harsh weather 
conditions it is considered one of the world's most difficult mountains to climb. In 2016, René attended the 11th International 
Bordetella Symposium that was held in Buenos Aires, Argentina.
CHAPTER 9







In this thesis a systems vaccinology approach is described to deepen knowledge of the 
immune responses evoked by different pertussis vaccines and compare this with a Bordetella 
pertussis infection since the latter induces robust, sterilizing immunity in the lungs of mice. 
We unraveled distinct immunity profiles elicited by different pertussis vaccines that were 
accompanied by various molecular signatures.
The immunological processes occurring during a B. pertussis infection are analyzed in 
detail and described in Chapter 2. Numerous new responses were identified within the 
innate, bridging and adaptive phases. These include extended duration of innate (cytokine) 
responses well into the second week of the infection. Since infection-induced immunity 
confers sterilizing immunity and provides preferable adaptive immunity against B. pertussis, 
it is used as benchmark throughout the thesis.
Infection-induced immunity is further investigated in Chapter 3. Here, mice with infection-
induced immunity were challenged with a second infection. The molecular background of 
these mice revealed high activity of innate immune cells that specifically reside in the lungs. 
We suggest that these innate immune cells may represent ‘trained’ innate immunity [1, 2]. This 
included for instance gene markers for M-cells (Gp2, Umod). Additionally, the early expression 
of Thy1 and Il7r and IL-5 secretion in the lungs suggested presence of innate lymphoid cells 
(ILCs) [3]. ILCs but also NK-cells are associated with ‘trained’ innate immunity [4].
The candidate vaccine of interest in this thesis is outer membrane vesicle pertussis 
vaccine (omvPV). This is a complex vaccine, containing hundreds of protein antigens. The 
immunogenicity of the individual antigens was assessed by immunoproteomic profiling anti-
sera by using 2-D electrophoresis, Western blotting, and mass spectrometry (Chapter 4). The 
omvPV elicits a broader subclass distribution than whole-cell pertussis (wPV) and acellular 
pertussis (aPV) vaccines and most immunogenic antigens were Vag8, BrkA and LPS (Table 1).
In Chapter 5 the immunogenicity of omvPV is compared with wPV, probably the most 
potent pertussis vaccine currently on the market, after subcutaneous immunization. OmvPV 
immunized mice developed higher systemic IgG titers and cleared bacteria slightly faster than 
wPV immunized mice from the lungs. Both groups evoked a mixed Th1/Th2/Th17 response 
(Table 1). The omvPV induced significantly lower systemic pro-inflammatory cytokine 
responses than wPV. The transcriptome showed that many genes expressed in the spleen 
were markers for the activation of IFN-signaling pathways and involvement of myeloid cells, 
such as neutrophils. Additionally, the omvPV-response comprised upregulation of genes with 
anti-inflammatory functions such as Fpr2 [5] and Steap4 [6].
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Chapter 6 addresses immunological responses evoked by aPV. The CD4+ T-cell response 
induced by aPV is Th2-dominated. Previously it was shown that supplementing aPV with with 
a non-toxic toll-like receptor 4 (TLR4) ligand, Lpxl1, leads to the formation of Th1/Th17 cells 
instead of strictly Th2 cells [7]. We isolated these CD4+ T-cells and analyzed the transcriptome, 
which unraveled distinct molecular signatures between both groups. The addition of Lpxl1 to 
the aPV leads to upregulation of cytokines and transcription factors specific for Th1 and Th17 
cells, such as Ifng and Il17a. Additionally, upregulation of less familiar Th1-associated genes, 
such as Havcr2, Ccl5, and Cxcl9, were detected.
Since infection induces robust immunity, including strong local IgA and Th17 responses, 
mice were immunized with the vaccine candidate omvPV by the pulmonary route (Chapter 
7). Indeed, pulmonary administration of omvPV induced superior protection comparable 
as caused by infection and better than subcutaneously administered omvPV. The bacterial 
clearance rate from the lungs was reduced from 7 days to 2 days (Table 1). The pulmonary 
route elicited increased levels of systemic IgG antibodies, IgG-producing plasma cells, memory 
B-cells, and Th17-cells. More importantly, pulmonary immunization but not subcutaneous 
injection led to the presence of IgA antibodies, IgA-producing plasma cells and Th17-cells 
in the lungs. These adaptive responses were preceded by distinct serum and pulmonary 
cytokine profiles and transcriptome profiles in the dLN and lungs. The activation of TLRs and 
the downstream signaling pathways were detected in the lungs of pulmonary immunized 
mice. Signatures of ILC3s expressing Rorc [8] and IL-5-secreting ILC2s may correlate with the 
more dominant Th17 response after pulmonary immunization and systemic Th2 response 
after subcutaneous immunization respectively.
In Chapter 8, an in silico analysis was performed, which compared the transcriptome profiles 
of the lungs of mice with a different immune status after they received a B. pertussis challenge. 
This revealed 27 gene clusters with distinct patterns between immunized mice and non-
immunized mice. The molecular patterns in the lungs of mice with infection-induced immunity 
revealed more specific markers of local immunity, which were absent in the mice that were 
systemically immunized with omvPV or wPV. This supported the importance of induction of 
local immunity. Specific molecular signatures that encode secreted proteins were detected 
that may serve as potential markers in blood for analysis of degree of protection (Cxcl9, Gp2, 






• The application of systems vaccinology in pertussis research revealed molecular 
signatures of pathogen-recognition, inflammatory responses, involvement and 
interaction of immune cells. The comprehensive dataset provided insight into the 
construction of immunity against B. pertussis.
• Infection-induced responses confer sterilizing protection that is caused by systemic 
immunity but more importantly by mucosal IgA, Th1/Th17 responses, and ‘trained’ innate 
immune cells in the lungs (Chapters 2 and 3).
• The omvPV elicits a broad and balanced immunoproteomic profile that differs from 
the profile induced by aPV, wPV, and infection with respect to antibody levels, antigen 
specificity, and subclass distribution (Chapter 4).
• Subcutaneous immunization of omvPV confers equal efficacy in mice but with a lower 
inflammatory response compared to wPV (Chapter 5).
• Addition of a non-toxic TLR4 ligand to aPV dampens the formation of Th2 cells and 
stimulates Th1/Th17 cells (Chapter 6).
• In contrast to subcutaneous immunization, the pulmonary administration of omvPV leads 
to superior protection in mice that is similar to the protection conferred by infection-
induced immunity (Chapter 7).
• Distinct kinetics and intensity of innate immune responses between pulmonary omvPV 
immunization and B. pertussis infection lead to similar adaptive immunity (Chapter 7).
• Th17 and mucosal IgA are important contributors to enhanced pertussis immunity and 
hallmarks of responses evoked by both pulmonary administration of omvPV and B. 




The world is currently facing resurgence of pertussis [9-11] caused by pathogen adaptation 
and waning immunity [12]. This situation calls for re-evaluation of pertussis vaccines.
(i) Immunity induced by infection and pulmonary omvPV immunization
Infection-induced immunity in humans remains for 4-20 years [13] or even 50 years [14]. 
Immunity induced by marketed pertussis vaccines wanes after 4-12 years [13, 14]. In Chapter 
2 we showed that infection-induced immunity confers sterilizing immunity in the lungs of 
mice, which is consistent with the findings found in two studies with mice and baboons 
[15, 16]. The results in this thesis indicate that systemic IgG, and mucosal IgA (Chapters 3 
and 4), Th17 cells in the lungs (Chapters 2, 3 and 7), and prolonged activity of pulmonary 
innate cells such as alveolar macrophages, M-cells and goblet cells (Chapter 3) contribute 
to robust protection against B. pertussis. The induction of local immune responses might 
improve vaccine-elicited immunity in a similar way. Indeed, pulmonary administration of 
omvPV led to faster clearance of B. pertussis after intranasal challenge than subcutaneous 
immunization (Chapter 7). The clearance is comparable to infection-induced immunity 
(Chapter 2). Although both immunization routes for omvPV induced strong systemic adaptive 
immune response, pulmonary immunization evoked a robust mucosal adaptive immune 
response that included IgA antibodies, IgA- and IgG-producing plasma cells, and Th17 cells 
in the lungs of mice. These findings as well as transcriptome analysis in the lungs suggest 
that infection and pulmonary immunization of omvPV confer comparable immunity (Table 1), 
yet with different intensity and kinetics. The responses were more intense and faster in the 
pulmonary immunized mice. Like other studies [15-18], our findings stress the importance of 
local induction of Th17 cells and induction of mucosal IgA in the lungs for optimal pertussis 
immunity. The molecular signatures of Chapters 2, 3 and 7 provide insight in the underlying 
mechanisms preceding these adaptive responses. Infection-induced immunity (Chapter 3) 
and omvPV immunization (Chapter 7) showed markers of innate lymphoid cells (ILCs) that 
have important functions in orchestrating immunity i.e. by directing the Th-subset distribution 
[19]. Furthermore, the B. pertussis infection and the pertussis immunization studies (Chapters 
2, 3, 5 and 7) demonstrated the involvement of the CCR6/CCL20 pathway [20], important 
for attracting B-cells [21] and Th17 cells [22, 23] towards the lung. Finally, infection-induced 
immunity involved CXCR6+ T-cells that could serve as lung protection marker as was shown 
for mycobacterium tuberculosis [24].
(ii) Outer membrane vesicle vaccine
OmvPV contain hundreds of protein antigens with membrane proteins Vag8 and BrkA as 
main components (Chapter 3). In Chapter 5, we confirmed the protective capacity after 
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autocleavage [25], resulted in dose reduction from 4 µg to 1 µg total protein content, with 
a comparable lung clearance rate of 7 days (Chapter 7)(Table 1). Remarkably, pulmonary 
immunization of omvPV-P93 caused lung clearance in only 2 days after challenge (Chapter 7), 
comparable to infection-induced immunity (Chapter 2). Furthermore, omvPV induce higher 
serum IgG levels after subcutaneous immunization than aPV and wPV (Chapter 3). The omvPV 
induced antibodies of all IgG subclasses directed against a broad range of antigens, e.g. Vag8 
and BrkA. Apart from anti-protein responses, omvPV induced anti-LPS IgG3 antibodies that 
are bactericidal [26, 27]. Strong antibody responses against antigens that cause complement 
evasion by B. pertussis, such as Vag8 [28], may be beneficial as well as the broad subclass 
distribution that facilitates formation of antibodies with different functions [29].
The omvPV contains several intrinsic pathogen-associated molecular patterns (PAMPs) like 
LPS and bacterial DNA although less than wPV (Chapter 3). This presence of LPS in omvPV 
may still be a concern given its relation to adverse effects induced by wPV [30-33]. In Chapter 
5, we demonstrate that the omvPV induces less systemic pro-inflammatory cytokines such as 
IL-6 and IL-1β, than wPV. These inflammatory responses caused by immunization are often 
related to adverse effects like fever [30-33]. Especially, the lower levels of IL-1β are preferable 
in relation to the rare induction of neurological effects by wPV [32]. However, the question 
remains whether the lower IL-1β induction by omvPV in mice is also observed in humans. 
Whereas the induction of pro-inflammatory cytokines is already reduced significantly 
compared to wPV, the remaining LPS contributes to Th1/Th17 skewed responses [34, 35] that 
are considered optimal for pertussis immunity [15, 16, 36]. Indeed, subcutaneous immunization 
with omvPV led to a mixed systemic Th1/Th2/Th17 response as seen in Chapter 5 and Chapter 
7, whereas pulmonary immunization even led to a more Th17-dominated systemic response. 
In addition, the pulmonary immunization conferred lung-resident Th17 cells (Chapter 7). 
Vesicles are nanoparticles, which enables better uptake by DCs, in contrast to the larger 
whole-cell particles [37]. Additionally, the size [38] and cationic charge [39] of vesicles might 
be optimal to stimulate mucosal immune responses. This is in line with the mucosal immunity 
obtained after pulmonary immunization of omvPV (Chapter 7).
Further molecular engineering may optimize the use of omvPV as vaccine candidate. For 
instance, if necessary, PAMPs such as LPS can be modified to balance adjuvant activity and 
undesired inflammatory responses. Moreover, the presence of particular pertussis antigens 
can be increased as was shown for Prn [25] or even constructions can be made that allow 
heterologous antigen expression of different pathogens [40] as combination vaccine.
(iii) Preferred composition of pertussis vaccines
Based on the results described in this thesis we can speculate on the components that should 
be in the pertussis vaccine. The presence of LPS in pertussis vaccines will remain a point of 
debate. It is associated with adverse effects, but also acts as an adjuvant. As discussed above, 




indicate fewer adverse effects. Interestingly, a booster immunization with omvPV and wPV 
and a second infection of B. pertussis induced high levels of anti-LPS IgG3 (Chapters 3, 4, 5 and 
7) that have bactericidal activity [26, 27]. The IgG3 subclass suggests that these antibodies are 
mainly formed in a T-cell independent manner [41]. Additionally, LPS as adjuvant improves the 
Th1/Th17 balance [34, 35] (Chapters 3, 4, 5 and 7). Interestingly, addition of the LPS-derivative 
Lpxl1 to aPV caused a shift from a strong Th2-dominated response towards an additional 
profound Th1/Th17 response [7]. In Chapter 6, we confirmed these Th1/Th17 responses on 
molecular level specifically in isolated CD4+ T-cells. These studies confirm the importance of 
LPS as an adjuvant.
We demonstrated that B-cell and T-cell responses directed against multiple other antigens, 
i.e. Vag8 and BrkA, in omvPV and wPV contribute to protection against B. pertussis (Chapters 
5 and 7). The small numbers of antigens in aPV stimulates vaccine-induced adaptation as was 
recently demonstrated by increased circulation of Prn-deficient strains [42, 43]. This suggests 
that Prn should be replaced, or that additional antigens should be added to the aPV. According 
to our results and those of others, possible candidate antigens would be adenylate cyclase 
toxin-hemolysin (Act) [44], BrkA [45], BvgA, TCF, and Vag8 [28, 46]. However, addition of 
antigens would further increase the cost of the aPV and more importantly would probably 
not improve the Th-balance. Changing the Th-response could be overcome by addition or 
replacement of the adjuvant in the aPV [7, 47]. Antibody responses against B. pertussis should 
preferably be directed against antigens such as Ptx, FHA, Vag8, BrkA because they have 
immune evasive properties [28, 48]. In addition, the IgG subclass distribution should be broad 
to fight the bacteria on multiple fronts through direct killing or with help of phagocytes.
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Chapter 9
Summarizing conclusion and perspectives
This thesis demonstrated the advantage of a systems vaccinology approach [49] in early 
vaccine development. Numerous molecular signatures were identified that are involved in 
pertussis immunization and B. pertussis infection. The next step is to confirm the functionality 
of these molecular signatures in relation to pertussis immunity in dedicated knockout studies. 
Furthermore, upcoming systems vaccinology pillars such as microRNAs [50], unbiased 
proteomics, and investigating purified cell populations [51], can be explored. Finally, new 
initiatives should be sought for more effective and faster retrieval of functional annotation of 
data from public databases.
Effective pertussis immunity comprises of systemic humoral and cellular responses that consist 
of memory B-cells, plasma cells that produce a broad IgG subclass response, and antigen-
specific Th1/Th17-cells against multiple antigens. We demonstrated the importance of local 
immunity in the lungs, which should include IgA-producing memory B-cells and widespread 
IgA in the mucosa in addition to lung-resident memory Th17-cells. To limit vaccine-induced 
selection a broad antibody and preferably T-cell specificity directed against a combination 
of the following antigens is probably important; Ptx, Vag8, Prn, FHA, Fim2, Fim3, BrkA, LPS, 
BvgA, and TCF. Additionally, the induction of ‘trained’ innate immune cells, such as ILCs and 
NK-cells in the lungs may contribute to optimal pertussis immunity.
Re-introduction of wPVs in high-income countries in not expected, as it requires engineered 
strains that are less reactogenic with consistent expression of virulence factors. Altering 
current aPVs by changing adjuvants and/or antigens, i.e. Vag8, BrkA, are plausible options for 
increased efficacy of these vaccines. However, this most likely would only partly solve current 
problems, such as vaccine-induced pathogen evolution, waning immunity, and continued 
transmission in the vaccinated population [12, 52]. Third-generation pertussis vaccines like 
live-attenuated vaccine (BPZE1) [53] and omvPV, the latter especially in combination with 
mucosal immunization, confer better immunity profiles compared to wPVs and aPVs, at 
least in mice. The broad antigen content, intrinsic adjuvants, ideal presentation form as 
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Roodgedrukte woorden zijn opgenomen in de verklarende woordenlijst.
Kinkhoest
Kinkhoest is een luchtweginfectie die wordt veroorzaakt door de gram-negatieve bacterie 
Bordetella pertussis. B. pertussis werd in 1906 ontdekt en geïsoleerd door de Bordet en 
Gengou. Een infectie met B. pertussis komt in de natuur alleen voor bij mensen. Hoewel de 
ziekte vóórkomt bij alle leeftijdsgroepen, lopen pasgeborenen het grootste risico. Bepalen 
of iemand kinkhoest heeft is erg lastig aangezien in het vroege stadium van de infectie vaak 
alleen een milde hoest aanwezig is en geen koorts. In een latere fase van de infectie nemen de 
klachten toe met overgeven, ademnood en intensief hoesten, hetgeen bij baby’s uiteindelijk 
kan leiden tot de dood. Deze intensieve hoest houdt een lange tijd aan. Daarom noemen de 
Chinezen het de “hoest van 100 dagen”.
Kinkhoest epidemiologie
Kinkhoest is een ziekte die voorkómen kan worden door vaccinatie. Vaccinatie tegen 
kinkhoest vanaf 1940 heeft wereldwijd geleid tot een drastische afname van het aantal 
kinkhoestgevallen. Volgens een schatting van de Wereld Gezondheidsorganisatie voorkomt 
vaccinatie tegen kinkhoest circa 700.000 sterfgevallen per jaar. Volgens de huidige schattingen 
ontvangt 86% (115 miljoen) van alle kinderen drie kinkhoestvaccinaties. Ondanks deze hoge 
vaccinatiegraad komt kinkhoest nog steeds voor en zijn er regelmatig grote uitbraken. Ook 
in Nederland is het aantal gevallen van kinkhoest de afgelopen jaren drastisch gestegen (Zie 
Hoofdstuk 1, Figuur 2A). Mogelijke oorzaken zijn verandering van de circulerende stammen, 
maar ook de beperkte beschermingsduur van de huidige kinkhoestvaccins.
Kinkhoestbacterie
De kinkhoestbacterie wordt omgeven door een binnenmembraan en buitenmembraan. Het 
binnenmembraan omsluit het cytoplasma. De ruimte tussen het binnen- en buitenmembraan 
wordt het periplasma genoemd. Elk compartiment (cytoplasma, periplasma, binnen- en 
buitenmembraan) bevat unieke eiwitten met verschillende functies (Zie Hoofdstuk 1, Figuur 
1A). Zo zijn er eiwitten in de buitenmembraan die helpen bij het hechten aan de mucosa. 
Andere eiwitten worden tijdens een infectie uitgescheiden, zoals pertussis toxine (Ptx). 
Onderzoek heeft tevens laten zien dat verschillende eiwitten van B. pertussis in staat zijn om 
het immuunsysteem van de gastheer te onderdrukken of omzeilen, waardoor de bacterie 






Momenteel zijn verschillende kinkhoestvaccins op de markt. Daarnaast worden nieuwe, 
betere kinkhoestvaccins ontwikkeld. Een belangrijk gegeven is dat al deze vaccins verschillen 
in hun samenstelling.
Het eerste kinkhoestvaccin dat op de markt kwam, bestond uit geïnactiveerde bacteriën 
(whole cell pertussis vaccin, wPV). Momenteel ontvangt naar schatting 75% van de 
wereldbevolking dit vaccin. Omdat wPV bestaat uit de volledige gedode bacterie bevat het veel 
verschillende antigenen. Hierdoor werken deze vaccins goed, maar gaat vaccinatie met wPV 
vaak gepaard met bijwerkingen zoals lokale zwelling op de plaats van injectie en koorts. Deze 
bijwerkingen lijken in ernst toe te nemen met het aantal vaccinaties en met de leeftijd waarop 
gevaccineerd wordt. Vandaar dat vaccinatie met wPV wordt afgeraden bij jongvolwassenen 
en volwassenen. Dit heeft geleid tot de vraag naar veiligere kinkhoestvaccins.
Deze vraag naar veiliger kinkhoestvaccins heeft de ontwikkeling gestimuleerd van accelulaire 
pertussis vaccins (aPV). Deze vaccins bestaan uit één tot vijf gezuiverde eiwitten van de 
kinkhoestbacterie, die aan aluminiumzouten worden geadsorbeerd (Zie Hoofdstuk 1, Figuur 
1B). Het aluminiumzout is een hulpstof die het immuunsyteem prikkelt tot een betere reactie 
tegen de antigenen. In Nederland is het wPV in 2005 vervangen door een aPV met drie 
componenten. Deze vaccins geven tijdelijk een goede bescherming, maar recent onderzoek 
laat zien dat de beschermingsduur van aPVs maar beperkt is. De kosten van deze vaccins 
zijn hoog waardoor veel ontwikkelingslanden niet in staat zijn deze vaccins te gebruiken. 
De meest recente strategie met aPVs is maternale vaccinatie, waarbij zwangere vrouwen 
worden gevaccineerd waardoor kinkhoest-specifieke antistoffen worden overgedragen aan 
het ongeboren kind. Deze strategie is vooral gericht om de baby’s in de eerste maanden van 
hun leven te beschermen tegen een kinkhoestinfectie.
Een van de vaccins die momenteel in ontwikkeling is, is een levend verzwakt kinkhoestvaccin. 
Dit vaccin bestaat uit levende bacteriën die in staat zijn om te delen maar dusdanig zijn 
aangepast dat een individu er niet ziek van wordt. Anders dan de huidige vaccins op de 
markt wordt dit vaccin via de neus (intranasaal) toegediend. In een muizenmodel geeft een 
eenmalige dosis van dit vaccin goede bescherming tegen een infectie. De ontwikkeling van 
dit vaccin is momenteel in de vroege klinische fase.
Een ander kinkhoestvaccin, het outer membrane vesicle pertussis vaccin (omvPV) dat 
momenteel in ontwikkeling is, bestaat uit buitenmembraan vesicles (outer membrane 
vesicles, OMVs). OMVs zijn blaasjes, zogenaamde vesicles, die zijn afgesnoerd van de 
buitenmembraan van de bacterie (Zie Hoofdstuk 1, Figuur 1C). Deze OMVs zijn ongeveer 10x 
kleiner dan de bacterie en bevatten voornamelijk eiwitten uit de buitenmembraan en lipiden, 
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zoals het immuunstimulerende lipopolysaccharide (LPS). OMVs worden van nature ook 
aangemaakt door bacteriën voor overdracht van stoffen tussen de bacteriën maar ze kunnen 
ook het immuunsysteem afleiden tijdens een infectie. Het omvPV is een vaccin dat centraal 
staat in dit proefschrift.
Vaccinatie en het immuunsysteem
Vaccinatie is een van de succesvolste medische interventies ter voorkoming van 
infectieziekten. Jaarlijks worden hierdoor miljoenen levens gered en een enorme ziektelast 
voorkomen. Anders dan bij therapeutische medicijnen, zijn vaccins tegen infectieziekten 
preventief en beschermen dus tegen een toekomstige infectie. Tijdens de vaccinatie wordt 
als het ware een infectie nagebootst met een veilig product. Het immuunsysteem bestaat 
o.a. uit vele soorten cellen met specifieke functies. De wijze waarop het immuunsysteem op 
een vaccin reageert, is voor een groot gedeelte afhankelijk van de componenten die zich in 
een vaccin bevinden, maar ook welke immuuncellen worden geactiveerd. Kennis over het 
vaccin en de interactie met het immuunsysteem van de gastheer zijn daarom van cruciaal 
belang om tot een effectief vaccin te komen.
Het immuunsysteem van de gastheer is onder te verdelen in twee gedeeltes. Het aangeboren 
immuunsysteem, dat snel reageert en als functie heeft om als eerste pathogenen te 
herkennen en uit te schakelen via b.v. fagocyterende cellen. Cellen van het aangeboren 
immuunsysteem hebben sensoren (PRRs) voor moleculen (PAMPs) die uniek zijn voor 
microben. Een voorbeeld van een PAMP voor B. pertussis is het hierboven genoemde LPS dat 
herkend wordt door Toll-like receptor 4 (TLR4). Na herkenning gaan deze cellen cytokines 
produceren, die vervolgens andere immuuncellen naar de plek van infectie sturen. Vaccins 
moeten in het algemeen deze stimulatoren ook bevatten om goed te kunnen werken. Deze 
toevoegingen worden adjuvantia genoemd. Echter, wanneer deze signalen te intens zijn, 
kunnen bijwerkingen, zoals koorts optreden. Bij vaccinatie is het daarom van belang dat deze 
signalen gereguleerd worden.
Naast het aangeboren immuunsysteem bestaat het adaptieve immuunsysteem dat bestaat 
uit immuuncellen zoals B-cellen en T-cellen. De antigeen-presenterende cellen (APCs), 
onderdeel van het aangeboren immuunsysteem, nemen het pathogeen of het vaccin op 
en selecteren bepaalde stukken die ze gaan presenteren aan B-cellen en T-cellen. B-cellen 
maken antistoffen zoals immunoglobuline G (IgG) of IgA terwijl cytotoxische T-cellen cellen 
kunnen opruimen die besmet zijn of tot kankercel zijn getransformeerd. Daarnaast spelen 
T-helper (Th) cellen, een belangrijke rol bij een goede bescherming tegen pathogenen zoals 
kinkhoestbacterieen. Th-cellen produceren cytokines op het moment dat ze het antigeen 
herkennen. Aan de hand van de cytokine productie worden ze getypeerd, b.v. Th1, Th2, 




















Hoewel de meeste vaccins goed werken, is het werkingsmechanisme vaak slechts ten dele 
bekend. Daarnaast zijn er veel infectieziektes waar nog geen vaccins voor bestaan. Soms zijn 
verbeterde vaccins nodig. Het ontwikkelen en verbeteren van vaccins is tijdrovend en kostbaar. 
Een nieuwe strategie in biologisch onderzoek dat zich richt op het zo volledig mogelijk 
ontrafelen van biologische responsen kan de kans op succesvolle vaccinontwikkeling vergroten. 
Binnen het vaccinonderzoek wordt deze aanpak ‘systeemvaccinologie’ genoemd. Hierbij wordt 
de immuunrespons na vaccinatie tot in detail geanalyseerd. Daarbij worden de verschillende 
lagen van het immuunsysteem onderzocht met diverse technieken. Zo wordt er gekeken naar 
de expressie van genen, productie van eiwitten of de betrokkenheid van bepaalde cellen (Zie 
Hoofdstuk 1, Figuur 3). Tijdens dit onderzoek worden grote hoeveelheden data gegenereerd die 
met bio-informatica wordt geanalyseerd met als doel verbanden te leggen tussen vaccinatie en 
de immuunrespons. Met deze informatie kan de werking van vaccins beter begrepen worden. 
Ook kan de aanpak van ‘systeemvaccinologie’ de ontwikkeling van nieuwe vaccins bevorderen.
Dit proefschift
In dit proefschrift hebben we ‘systeemvaccinologie’ toegepast om een gedetailleerd beeld te 
schetsen van de immuunrespons na vaccinatie met verschillende kinkhoestvaccins in vergelijk 
met een kinkhoestinfectie in een muizenmodel.
In Hoofdstuk 2 is de immuunrespons onderzocht die plaatsvindt tijdens een B. pertussis infectie 
in onbeschermde muizen. Het doorlopen van een kinkhoestinfectie is uiteraard geen reële 
vaccinatiestrategie maar voorgaand epidemiologisch onderzoek laat zien dat mensen na een 
kinkhoestinfectie langer beschermd zijn dan na vaccinatie met de huidige vaccins. Terwijl de 
immuniteit van kinkhoestvaccins afneemt na 4 tot 12 jaar, blijft de immuniteit na infectie 4 tot 
20 jaar aanwezig. Daarnaast wordt in dit proefschrift een kinkhoestinfectie gebruikt om de 
mate van bescherming geïnduceerd door verschillende vaccins te bepalen in het muizenmodel. 
Het geldt dus als een soort van benchmark. In deze studie hebben we verschillende processen 
geïdentificeerd en aan elkaar gekoppeld die plaatsvinden in de verschillende fases van de 
immuunrespons na een primaire kinkhoestinfectie.
In Hoofdstuk 3 zijn vervolgens de verschillen in de immuunrespons onderzocht bij muizen, 
die al eerder een infectie hebben doorlopen (dus goed beschermd zijn) en bij onbeschermde 
muizen. De beschermde muizen hebben immuniteit opgebouwd die bestaat uit voornamelijk 
Th17 cellen en specifieke antistoffen in het bloed en lokaal in de longen. Opmerkelijk is dat er 
ook cellen uit het aangeboren immuunsysteem in de longen gevonden werden in beschermde 
muizen. Dit betreft goblet cellen, M-cellen en alveolaire macrofagen. Dit geeft aan dat ook 
cellen van het aangeboren immuunsysteem in de longen mogelijk getraind worden door de 
eerste kinkhoestinfectie en bijdragen aan de goede bescherming.
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Het omvPV is een kandidaat vaccin dat centraal staat in dit proefschrift. In Hoofdstuk 
4 wordt aangetoond dat het omvPV net als het wPV een complex vaccin is dat bestaat uit 
honderden eiwitten, en dus potentiele antigenen. In deze studie zijn muizen gevaccineerd 
met omvPV. Vervolgens hebben we met een combinatie van verschillende methodes, zoals 
2D-elektroforese, Western blot en massaspectrometrie bepaald tegen welke antigenen uit de 
OMVs de in het bloed aanwezige antistoffen gericht zijn. Dit is vergeleken met muizen die zijn 
gevaccineerd met een aPV of wPV, of muizen die een infectie hebben doorlopen. De resultaten 
laten niet alleen zien dat de vaccinsamenstelling bepaalt tegen welke eiwitten antistoffen 
worden gemaakt, maar ook invloed heeft op het antistof subtype. Deze antistof subtypes 
hebben een eigen functie bij de bescherming tegen kinkhoest. De resultaten van de studie 
laten zien dat vaccinatie met omvPV leidt tot een breed antistofprofiel tegen antigenen als 
Vag8, BrkA en LPS, maar tevens uit alle subtypes bestaat. In tegenstelling daarmee staat het 
aPV dat weliswaar hoge antistofniveaus tegen de drie antigenen FHA, Prn en Ptx induceert, 
maar die zijn alleen van het IgG1 subtype. Dit geeft mogelijk aan dat door het opwekken van 
verschillende IgG subtypes met meerdere functies, het omvPV een bredere type bescherming 
geeft.
In Hoofdstuk 5 is de immuunrespons na vaccinatie met omvPV verder vergeleken met die 
na vaccinatie met een wPV. Het wPV geeft bescherming maar is ook geassocieerd met 
bijwerkingen. In deze studie laten we zien dat het omvPV een gelijke bescherming biedt tegen 
een kinkhoestinfectie met dezelfde type T-cellen en een hoger antistofniveau als het wPV. 
Maar wat opmerkelijk en belangrijker is, is dat na omvPV vaccinatie minder cytokines worden 
geproduceerd die geassocieerd worden met bijwerkingen. Daarnaast werden er op het niveau 
van genexpressie, genen geïdentificeerd met anti-inflammatoire functies na vaccinatie met 
omvPV.
Naast de specifieke antistoffen wordt er steeds meer aandacht geschonken aan T-cellen en 
specifiek de CD4⁺ T-cellen, bij de bescherming tegen kinkhoest. De CD4⁺ T-cel respons  na 
aPV vaccinatie wordt gedomineerd door het Th2 type. In Hoofdstuk 6 is het adjuvant Lpxl1 
toegevoegd aan het aPV om te bepalen welke invloed dit heeft op de type T-cellen en welke 
genen hierbij tot expressie komen in de T-cellen. Lpxl1 is een niet-toxisch LPS die bindt aan TLR4 
op immuuncellen die de richting van het immuunsysteem bepalen. Na vaccinatie zijn de T-cellen 
geïsoleerd uit muizen om vervolgens de genexpressie profielen te vergelijken met muizen die 
alleen met aPV zijn gevaccineerd. De resultaten van deze studie laten zien dat er meer genen, 
zoals transcriptiefactoren en cytokines tot expressie komen die geassocieerd worden met 
Th1 en Th17 cellen. Daarnaast werden andere minder bekende genen gevonden die gekoppeld 
kunnen worden aan de Th1/Th17 respons. Deze studie laat tevens zien dat het aanpassen van 


















De verschillende kinkhoestvaccins die onderhuids worden ingespoten geven dus allen een 
ander type immuniteit. Een overeenkomst is echter dat ze geen van alle lokale immuniteit 
opwekken in de luchtwegen, zoals dat wel het geval is na een kinkhoestinfectie. In 
Hoofdstuk 7 is daarom bepaald of de toedieningsroute van het omvPV invloed heeft op 
het type immuniteit en de mate van bescherming. Het omvPV werd pulmonaal, diep in de 
longen, toegediend en de immuunrespons werd in detail vergeleken met de onderhuidse 
toediening. De muizen die pulmonaal waren gevaccineerd met omvPV waren in staat om 
een kinkhoestinfectie in 2 dagen te klaren, terwijl dat na onderhuidse toediening 7 dagen 
duurde. In deze studie hebben we tevens laten zien dat beide toedieningsroutes leiden tot 
de inductie van systemische immuniteit, maar dat alleen de pulmonale toediening leidt tot 
lokale immuniteit. Deze lokale immuniteit in de long bestaat uit specifieke IgA antistoffen en 
Th17 cellen.
In Hoofdstukken 2, 3 en 5 is de genexpressie gemeten in de longen tijdens het doorlopen van 
een kinkhoestinfectie bij muizen met een verschillende vaccinatieachtergrond. In Hoofdstuk 
8 is een meta-analyse uitgevoerd op deze datasets. Hierdoor waren we in staat om specifieke 
genen te groeperen en te koppelen aan immunologische functies die gelokaliseerd zijn in de 
long. Daarnaast zijn genen beschreven die mogelijk in het bloed gemeten kunnen worden om 
bijvoorbeeld de mate van bescherming te meten of de intensiteit van de infectie.
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Conclusie en vooruitblik
In dit proefschrift wordt met de toepassing van ‘systeemvaccinologie’ geprobeerd een 
onderbouwing te geven voor de kenmerken waaraan een verbeterd kinkhoestvaccin moet 
voldoen. We hebben laten zien dat de diverse kinkhoestvaccins maar ook de kinkhoestinfectie 
een andere type immuunrespons opwekken en dat ook de mate van bescherming varieert in 
een muizenmodel. Er zijn daarnaast verschillende nieuwe markers (genen, eiwitten, cellen) 
geïdentificeerd als onderdeel van de immuunrespons van de gastheer die door vaccinatie 
met verschillende kinkhoestvaccins en een kinkhoestinfectie worden aangemaakt. We 
hebben in dit proefschrift nog niet specifiek kunnen kijken naar de rol van deze markers 
bij de bescherming tegen kinkhoest. Daarom zou een volgende stap in het onderzoek zich 
kunnen richten op infectie- of vaccinatie-experimenten waarbij specifieke markers worden 
uitgeschakeld om zo de rol van deze specifieke marker te ontrafelen.
Effectieve volwaardige immuniteit tegen kinkhoest bestaat uit systemische humorale en 
cellulaire immuunresponsen. Mogelijk dient deze immuniteit te bestaan uit B-geheugencellen 
en plasmacellen die IgG antistoffen maken van verschillende subtypen tegen meerdere 
antigenen maar ook antigeen-specifieke Th1/Th17 cellen. Wij hebben daarnaast laten zien 
dat de ontwikkeling van lokale immuniteit in de luchtwegen een belangrijke toevoeging is 
aan de bescherming tegen een B. pertussis infectie. Mogelijk dient dit te bestaan uit IgA-
producerende B-geheugencellen en IgA antistoffen in de mucosa en Th17 cellen die zijn 
gelokaliseerd in de longen. Het in dit proefschrift beschreven onderzoek geeft aanwijzingen 
dat een goed beschermend vaccin antistoffen en T-cellen moet opwekken tegen de volgende 
antigenen: Ptx, Vag8, Prn, FHA, Fim2, Fim3, BrkA, LPS, BvgA en TCF. In ieder geval hebben 
beschermde muizen immuunresponsen gevormd tegen deze antigenen.
De herintroductie van wPVs in hoge-inkomenslanden is onwaarschijnlijk, omdat dit vaccin 
veel bijwerkingen geeft. Door de bacteriën genetisch aan te passen, bijvoorbeeld genen 
betrokken bij de LPS synthese, kunnen bijwerkingen van wPVs verminderd worden. Het 
aanpassen van de huidige aPVs is ook een mogelijkheid om de werkzaamheid van de vaccins 
te verbeteren. Bijvoorbeeld door het adjuvans te veranderen of het vaccin uit te breiden 
door andere gezuiverde kinkhoesteiwitten toe te voegen. De aanpassingen zullen de huidige 
problemen met kinkhoestvaccinatie wellicht niet volledig oplossen, waaronder de beperkte 
beschermingsduur, de kinkhoesttransmissie door gevaccineerden en de genetische adaptatie 
van de kinkhoestbacterie. De ontwikkeling van een volgende generatie kinkhoestvaccins, 



















Verklarende woordelijst bij Nederlandse samenvatting
Aangeboren
immuunsysteem




Afweersysteem dat wordt verworven door het trainen van naïeve adaptieve 
immuuncellen d.m.v. blootstelling aan antigenen. Bij een tweede blootstelling aan 
hetzelfde antigeen, kan een getrainde adaptieve immuuncel sneller reageren.
Adjuvantia Stof die het aangeboren immuunsysteem kan stimuleren.
Adsorberen Hechten van moleculen aan het oppervlak van een vaste stof of vloeistof.
Alveolaire macrofagen Long-specifieke macrofagen (fagocyten).
Antigeen-presenterende 
cellen
Immuuncel van het aangeboren immuunsysteem dat antigenen van een pathogeen 
opneemt en presenteert aan cellen van het adaptieve immuunsysteem.
Antigenen Macromoleculen, vaak eiwitten  waar het immuunsysteem op reageert.
Antistof Eiwit, gemaakt door een B-cel, dat een antigeen kan herkennen en het onschadelijk 
kan maken.
Antistof subtype Bij de muis zijn de IgG antistoffen onderverdeeld in 4 subtypen (IgG1, IgG2a, 
IgG2b, IgG3). Elk subtype heeft een eigen functie zoals binding van pathogenen of 
interactie met complement en Fc-receptoren.
B-cellen Immuuncellen die antistoffen kunnen produceren.
B-geheugencellen B-cellen die antistoffen produceren en een lange levensduur hebben.
Cytokines Eiwitten die worden geproduceerd tijdens een immuunrespons en als 
boodschapper fungeren om cellen te beïnvloeden of op afstand aan te trekken.
Cytoplasma De ruimte binnen de binnenmembraan m.u.v. de celkern.
Cytotoxische T-cellen T-cellen met de CD8 receptor op het oppervlak. Binden aan cellen die geïnfecteerd 
zijn door een pathogeen en zorgen dat deze cellen doodgaan.
Fagocytose Het omsluiten en afbreken van een pathogeen door fagocyterende cellen.
Goblet cellen Epitheelcel die slijm produceert.
Gram-negatieve bacterie Bacterie met een binnen- en buitenmembraan. De buitenmembraan bestaat uit 
een combinatie van eiwitten en lipopolysaccharide.
Immunoglobuline Antistof. Er bestaan meerdere types waaronder IgG, voornamelijk aanwezig in het 
bloed en IgA,  voornamelijk in de mucosa.
Lokale immuniteit Afweer die specifiek aanwezig is op een bepaalde plek in het lichaam zoals bijv. 
de longen.
Lipopolysaccharide LPS; moleculen in de buitenmembraan van gramnegatieve bacteriën die bestaan 
uit lipiden en polysaccharide (koolhydraten).
Massaspectrometrie Techniek voor het kwantificeren en identificeren van moleculen op basis van 
massa.
M-cellen Microfold cellen; specifieke immuuncellen in het epitheellaag.
Mucosa Slijmvlies.
PAMPs Pathogen-associated molecular patterns; Moleculen van het pathogeen die 



















Periplasma Ruimte tussen de binnen- en buitenmembraan van de bacterie.
Plasmacellen Gedifferentieerde B-cellen die grote hoeveelheden specifieke antistoffen 
produceren maar alleen overleven zolang er antigen aanwezig zijn.
PRRs Pathogen-recognition receptors; Receptoren op en in bepaalde (immuun)
cellen die PAMPs herkennen om vervolgens het aangeboren immuunsysteem te 
activeren.
T-cellen Cellen van het adaptieve immuunsysteem die een onderdeel zijn van de cellulaire 
afweer welke o.a zijn onderverdeeld in T-helper cellen (CD4+) en cytotoxische 
cellen (CD8+).
T-helper (Th) cellen
Th1, Th2 en Th17
T-cellen met de CD4 receptor op het oppervlak. Helpen bijvoorbeeld B-cellen 
en cytotoxische T-cellen. De verschillende type Th-cellen produceren specifieke 
cytokines die belangrijke processen in de immuunrespons beïnvloeden. De Th1-
cellen maken o.a. IFNγ, Th2-cellen maken IL-4, IL-5 en IL-13 terwijl Th17-cellen IL-17 
maken.
Transcriptiefactor Eiwit dat de aanmaak van vele andere eiwitten bepaalt.
Systemische immuniteit Afweer die aanwezig is in de bloedbaan.
Western blot Techniek om de binding van antistoffen aan antigenen zichtbaar te maken.
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